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Abstract 
 
Proteins have the potential to be potent biopharmaceuticals with few side effects 
because of their endogenous specificity. However, the development of therapeutic 
proteins is frequently hindered by aggregation, a phenomenon that can occur at 
every phase of the manufacturing process. Aggregates can elicit immunogenic 
responses in patients, which along with reducing efficacy have the potential to cause 
life-threatening side effects. Lack of knowledge concerning the mechanism or nature 
of the aggregates underlying the immune response to therapeutic proteins means 
that any aggregates in protein drug formulations are a major concern. As a result, all 
aggregates must be removed during manufacturing or protein drugs reformulated to 
prevent aggregation, which are difficult, expensive and time consuming. Therefore, 
preventing therapeutic protein aggregation is paramount and a better knowledge of 
the conformational states involved will enable development of rational strategies to 
inhibit aggregation. 
 
In this study, the folding, dynamics and aggregation of a variant of the 
biopharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) were 
characterised and a subtle conformational change of the native state was elucidated 
in aggregation-prone conditions. Biophysical comparison of the variant C3 relative to 
wild-type G-CSF suggested they possessed similar structures. In addition, 
characterisation of the dependence of G-CSF C3 aggregation on pH, protein 
concentration and the presence of urea concentrations that were too low to cause 
global denaturation revealed the aggregation behaviour of G-CSF C3 to be similar to 
wild-type G-CSF. A change in the environment of the side chain of Tyr86 on helix B 
of G-CSF C3 was identified, along with increased dynamics of the latter half of the 
AB loop that is proximal spatially to Tyr86. Tyr86 is predicted to be intrinsically 
aggregation-prone and is buried in the native conformation, but is hypothesised to 
become exposed by increased mobility of the AB loop, driving aggregation from a 
highly native-like state. 
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Chapter 1 Introduction 
 
1.1 Protein folding 
 
1.1.1 From pathways to funnels and energy landscapes 
 
The information required for a protein to fold into its functional conformation is 
encoded entirely within its amino acid sequence, as originally demonstrated by 
Anfinsen et al.1,2. For proteins that adopt a three-dimensional structure in order to 
function, this native conformation represents the lowest free energy (and therefore 
most stable) structure1,2. However, given the vast array of different conformations 
that can be adopted by a polypeptide in solution, folding to the native state on a 
biologically relevant timescale cannot involve unbiased exploration of all possible 
conformations. Levinthal proposed that this paradox could be solved by proteins 
folding along specific pathways, driven by local interactions that progressively lead 
to forming the native conformation3. 
 
The first pathway proposed to describe general protein folding was the nucleation-
growth model, which involved formation of tertiary structure from a nucleus of 
secondary structure4. From this the framework model emerged to better account for 
the observation of intermediate species, which proposed packing together of 
secondary structure elements into tertiary structures5,6 (Figure  1.1). Analogous to 
this is the diffusion-collision model that suggested diffusion of secondary structure 
elements and their collision to form tertiary structure7. Whereas these models 
specified a hierarchical progression from primary to tertiary structures, the 
hydrophobic collapse model suggested initial collapse of the polypeptide chain due 
to burial of hydrophobic regions, sequestering them from the surrounding solvent 
and guiding the search for the native topology, which was followed by secondary 
structure formation8,9 (Figure  1.1). 
 
Arguably the most successful model for describing the folding of small single domain 
proteins, the nucleation-condensation model emerged as an amalgamation of 
features from the above models10. In this model, the polypeptide chain collapsed 
into a nucleus due to burial of hydrophobic surface, within which local secondary 
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structure was stabilised by long range tertiary interactions. This nucleus represented 
the transition state in the folding pathway, from which the remainder of secondary 
and tertiary structures formed11-14 (Figure  1.1). 
 
 
Figure ‎1.1 Illustrations of some of the early pathways proposed for protein folding. Schematics for the framework5,6, 
hydrophobic collapse
8,9
 and nucleation-condensation
11-14
 model pathways are shown. The entropy of the 
polypeptide decreases as the structural complexity increases from left to right. This figure was reproduced from 
Morris and Searle (2012)
15
.   
 
Pathways such as these considered sequential transitions from denatured to native 
states through defined structures, constituting what is known as the classical view of 
protein folding6. In the ‘new’ view, protein folding is described by funnel-shaped 
energy landscapes, in which an ensemble of structures are populated and parallel 
folding trajectories are simultaneously explored16,17. An energy landscape is the 
internal free energy of each protein conformation as a function of its degrees of 
freedom i.e. the conformational entropy (Figure  1.2). Similar conformations are 
geometrically close to each other on the energy landscape. These conformations 
may be higher in energy than structurally similar conformations, meaning they 
appear as peaks in the landscape, whereas lower energy conformations appear as 
troughs16.  
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Figure ‎1.2 Schematic representations of different protein folding energy landscapes. The denatured state at the top 
of the funnel encompasses a broad ensemble of high energy structures containing both native and non-native 
interactions, whereas the native state at the bottom of the funnel encompasses a narrower range of lower energy 
structures. Native interactions are energetically favoured over non-native interactions, resulting in the protein being 
funnelled towards the native conformation. A smooth energy landscape is shown in A that represents two-state 
folding. The energy landscape shown in B is more rugged due to population of intermediates. This figure was 
reproduced from Bartlett and Radford (2008)
18
. 
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The principle of minimal frustration states that the internal free energy of the protein 
decreases as it adopts conformations that are more native-like. This reduction in 
internal free energy is greater than can be accounted for by chance alone and 
allows the polypeptide to traverse the energy landscape and reach the native 
conformation, overcoming kinetic traps such as intermediates and the reduced 
conformational entropy of the polypeptide19. The reduction in internal free energy 
arises from the formation of native contacts e.g. hydrogen bonds, electrostatic and 
hydrophobic interactions, which are more stabilising than non-native contacts17. The 
final step of folding involves packing of side chains into their unique three-
dimensional structure and exclusion of water from the protein core20. 
 
The importance of native interactions in energy landscape theory means that native 
state topology plays a central role in defining the folding events that occur21. Using 
models of the folding landscape where energetic frustration has been removed, 
structural features of the transition states of proteins have been predicted from their 
native topologies22,23. Such models have also been used to correctly predict folding 
rates24 and the existence of intermediates25 that had previously been determined 
experimentally. The importance of native state topology in defining the folding 
trajectory also helps rationalise the higher folding rates observed for proteins with 
higher degrees of native state complexity, measured by the contact order26, as well 
as the conservation of structural features in the folding mechanisms of protein 
structural families, despite these proteins often exhibiting little sequence similarity27. 
 
Although the native state of proteins represents the minimally frustrated 
conformation19, a degree of local frustration may persist, arising from a particular 
arrangement of amino acids that is energetically unfavourable but may be required 
for function e.g. in an enzyme active site28. As a result, proteins are only marginally 
stable29,30, having evolved to harness the roughness of their energy landscape to 
facilitate dynamic motions between an ensemble of native-like conformations31,32. 
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1.1.2 The role of intermediates in protein folding 
 
The idea of a two-state transition between denatured and native states during 
folding of a protein only really applies to small globular proteins10,33 or may not be 
applicable at all34,35. For proteins greater than 100 amino acids in length, which 
constitutes over 95 % of proteins in the predicted human proteome36, folding 
generally occurs via one or more intermediate states34,37 (Figure  1.2B). Ever since 
the first discovery of on-pathway38 and off-pathway39 intermediates in folding 
reactions it has become apparent that they can represent partially-folded stepping 
stones to the native conformation or misfolded kinetic traps that reduce the 
efficiency of folding40. The energy levels of folding intermediates and their positions 
along a folding trajectory relative to the unfolded, transition and folded states 
determines their ability to be detected in equilibrium and kinetic folding 
experiments34,35 (Figure  1.3). 
 
Partially folded and misfolded intermediates typically expose hydrophobic residues 
and regions of unstructured polypeptide backbone to the solvent that would 
otherwise be buried in the native conformation37, which can promote intermolecular 
interactions and lead to protein aggregation. Like protein folding, aggregation is 
primarily driven by hydrophobic interactions, but in a concentration-dependent 
manner41. The crowded cellular environment, with protein concentrations in the 
cytosol in the region of 300-400 g l-1 42, thus greatly increases the likelihood of 
aggregation, which competes with folding to determine the fate of nascent proteins. 
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Figure ‎1.3 Free energy diagrams for different folding intermediates. In the absence of energetic frustration folding 
from the unfolded (U) to the native state (N) proceeds in a downhill manner
43
 (A). A transition state (TS) barrier 
between the U and N states without population of intermediates (I) results in two-state folding (B). An intermediate 
that is high in energy relative to both the U and N states can be detected by measuring folding and unfolding 
kinetics but not by equilibrium folding studies (C). However, an I state that is higher in energy than the N state but 
lower in energy than the U state and occurs before the rate limiting TS is observable during measurements of 
folding kinetics but not unfolding kinetics or equilibrium folding measurements (D). Conversely, if the same I state 
occurs after the rate limiting TS than it is observable during measurements of unfolding kinetics but not folding 
kinetics
34
 and can also be elucidated from equilibrium and kinetic native state hydrogen/deuterium exchange
35,44
 or 
NMR relaxation-dispersion experiments
45
 (E). An I state that is higher in energy than the U and N states but occurs 
after the rate limiting TS is not observable in kinetic or thermodynamic studies or equilibrium native state 
hydrogen/deuterium exchange experiments but can be probed using kinetic hydrogen exchange
44
 or NMR 
relaxation-dispersion experiments
45
. This figure was redrawn from Brockwell and Radford (2007)
34
.          
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1.1.3 Protein folding in vivo              
 
In the cell, protein folding is aided by molecular chaperones, which are defined as 
proteins that interact with, stabilise or aid another protein in reaching its functional 
conformation without being present in the final structure46. Generally, molecular 
chaperones aid folding through the binding and release of exposed hydrophobic 
surfaces of non-native states, whereby binding of exposed hydrophobic surfaces 
blocks aggregation and release allows folding to occur. These cycles of binding and 
release allow kinetic partitioning of non-native states from folding36. There is also a 
contribution from interactions of the nascent polypeptide chain with the surface of 
the ribosome that helps prevent misfolding and aggregation47,48. In addition, 
reorganisation of non-native disulphide bonds and cis-trans isomerisation of peptide 
bonds involving Pro are catalysed by protein disulphide isomerases and peptidyl 
prolyl isomerases, respectively to aid folding of non-native states to the native 
conformation49.  
 
The action of molecular chaperones during co- and post-translational folding is 
highly organised36, beginning with interactions between the polypeptide chain and 
ribosome-binding chaperones during translation by the ribosome50,51, such as trigger 
factor (TF) in bacteria and the ribosome-associated and nascent-chain-associated 
complexes in eukaryotes (RAC and NAC, respectively)51. After release from the 
ribosome the polypeptide is then bound by chaperones such as the Hsp70 system52. 
If folding is not accomplished by Hsp70, proteins may be passed to chaperonins 
such as GroEL/ES in bacteria53 or TriC in eukaryotes54, which enclose a single 
molecule of non-native protein in their central cavity to prevent aggregation and 
facilitate folding. Misfolded states that cannot be recovered by the molecular 
chaperone network are targeted for degradation by the ubiquitin proteasome system 
(UPS) in eukaryotes55. 
 
Despite the extensive molecular chaperone network, many proteins still aggregate in 
the cell. Disassembly of aggregated proteins is carried out by Hsp70 in combination 
with Hsp110 and Hsp40 in eukaryotes56,57, while in prokaryotes Hsp70 co-ordinates 
with AAA+ ATPase complexes of the Hsp100 family58. After disassembly, misfolded 
non-native states may be targeted for degradation by the UPS, while aggregates 
that cannot be disassembled may be cleared by lysosomal degradation or selective 
autophagy55. 
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1.2 Protein aggregation 
     
1.2.1 Structural features of protein aggregation 
 
Although folding of a protein into its native conformation reduces its propensity to 
aggregate, owing to the burial of hydrophobic surfaces and polypeptide backbone 
away from solvent37, the native conformations of proteins are only marginally 
stable29,30. Consequently, single point mutations or changes in environmental 
conditions e.g. pH, temperature or protein concentration can increase the population 
of partially unfolded intermediate states that may be aggregation-prone59. Partially 
unfolded states are more likely to aggregate than the globally unfolded state 
because of the proximity of hydrophobic residues that creates hydrophobic 
surfaces60. Conversely, natively unfolded proteins have a greater overall charge and 
reduced hydrophobicity, which reduces the likelihood of aggregation along with 
promoting disorder61. The dependency of aggregation on the charge, hydrophobicity 
and secondary structure propensities of an amino acid sequence have resulted in 
the development of many programs designed to predict the aggregation propensity 
of a protein sequence62-66.        
 
Aggregation can result in formation of insoluble aggregates that are amorphous or 
amyloid in nature (Figure  1.4). In contrast to amorphous aggregates, amyloid fibrils 
are highly ordered and incredibly stable structures with a cross β-sheet structure at 
their core that is perpendicular to the axis of the fibril67. Typically, formation of 
amorphous or amyloid aggregates results in increased formation of intermolecular 
β-sheet68. The ordered nature of amyloid aggregates reflects their assembly via a 
nucleation-growth mechanism, where fibril elongation proceeds by addition of 
monomer to an aggregation nucleus. This aggregation nucleus is unstable and so 
represents the rate-limiting step in amyloid fibril formation59.  
 
Amino acid sequences of native proteins appear to exhibit patterns that instil 
resistance to amyloid aggregation, such as avoiding long stretches of consecutive 
hydrophobic residues and patterns of alternating polar and non-polar residues69. 
Other intrinsic features of polypeptide sequences that appear to inhibit amyloid 
formation include conserved positioning of ‘gatekeeper’ Pro70 and Gly71 residues, 
which have a low propensity for β-sheet formation, as well as the inhibiting effect of 
individual charged residues being placed on the edges of aggregation-prone 
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segments72,73. However, polypeptides exhibiting a range of different 
physicochemical properties have been shown to form amyloid74,75, which coupled to 
the high stability of this aggregate has led to the notion of amyloid representing a 
free-energy minimum accessible to all polypeptide chains73.      
 
 
Figure ‎1.4 Schematic representation of protein folding and aggregation energy landscapes. Partially-folded states 
can possess exposed hydrophobic residues and unstructured regions of polypeptide backbone that cause 
aggregation. Chaperones aid the folding of partially folded and misfolded states to the native state through binding 
and release of exposed hydrophobic regions. Binding sequesters exposed hydrophobic residues thus inhibiting 
intermolecular contacts while release allows partially folded states to form intramolecular contacts. Despite the 
action of chaperones, proteins may still aggregate in vivo, resulting in formation of amorphous aggregates or highly 
ordered amyloid fibrils. This figure was reproduced from Balchin, Hartl and Hartl (2016)
36
. 
 
1.2.2 Protein aggregation and disease 
 
Despite the extensive proteostasis network that exists to regulate folding36 (see 
Section  1.1.3), many human pathologies are associated with protein misfolding and 
aggregation74. Some of these diseases are associated with misfolded proteins that 
have escaped the quality control network and exhibit reduced or abolished function, 
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as observed for the cystic fibrosis transmembrane conductance regulator (CTFR) in 
cystic fibrosis76 and p53 in a range of cancers77. Such diseases tend to be 
hereditary as mutations affect the energy landscape of a protein and so can 
increase the population of misfolded states37. More frequently, diseases resulting 
from misfolded species are due to the formation of intractable aggregates41 
(Figure  1.4). 
  
Many of the diseases caused by aggregation are characterised by deposition of 
intra- or extracellular deposits of amyloid fibrils, which build up to form amyloid 
plaques and so are called amyloidoses78. Many neurodegenerative diseases are 
amyloidoses, including Alzheimer’s disease, Parkinson’s disease and Huntington’s 
disease. However, other examples of amyloidoses include type II diabetes, 
haemodialysis related amyloidosis and cataract formation41,74,78. Although 
amyloidoses are characterised by formation of insoluble deposits of amyloid fibrils, 
cellular toxicity in these diseases is believed to be caused by soluble 
oligomers41,79,80, which are thought to promote amyloid formation by exposure of 
hydrophobic regions and unpaired β-strands80. The mechanisms by which 
cytotoxicity is exerted by soluble oligomeric species are uncertain due to the 
difficulties in their characterisation, which results from their instability and structural 
heterogeneity79,80. The cytotoxicity of soluble oligomers has been shown to relate to 
their size and surface hydrophobicity81 and is hypothesised to be caused by 
common structural features82 interacting with cellular components and 
membranes79.      
 
Chaperones have been shown to inhibit various steps of aggregate formation83 
(Figure  1.4) but a decline in the proteostasis network with aging results in reduced 
effectiveness of these quality control systems84. Consequently, amyloidoses such as 
neurodegenerative diseases are becoming increasingly prevalent in aging 
populations74. 
 
Protein aggregation can occur from a myriad of states on the energy landscape. The 
unfolded 40 and 42 residue polypeptides of amyloid beta (denoted Aβ40 and Aβ42, 
respectively), α-synuclein (α-syn) and islet amyloid precursor protein (IAPP or 
amylin) are the causative agents of Alzheimer’s disease, Parkinson’s disease and 
type II diabetes, respectively41,74. Amyloid aggregation of β2 microglobulin (β2m) 
causes haemodialysis related amyloidosis85 and has been shown to occur from an 
acid unfolded state86,87 as well as a native-like intermediate state under physiological 
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conditions88. The F9S mutant of γS-crystallin has also been shown to form amyloid 
aggregates via partial unfolding of the native state89,90, resulting in cataract formation 
in the eye lens91.  
 
Transthyretin (TTR) is a protein that forms amyloid aggregates as a result of subtle 
fluctuations in the native conformation92,93. Pathogenic variants of TTR (V30M and 
L55P) resulting in familial amyloidotic polyneuropathy (FAP)94 have been shown to 
exhibit increased rates of hydrogen exchange of residues in β-strands at the core of 
the native tetramer, suggesting transient partial unfolding, while for a variant of TTR 
associated with suppression of FAP (T119M) the rate of hydrogen exchange for 
these residues was reduced92. The varied amounts of core β-strand exposure 
observed for wild-type and T119M TTR occurred despite the similar structures these 
variants obtained by crystallography95. NMR relaxation-dispersion studies of a 
monomeric form of native TTR (F87M/L110M) at physiological pH also indicated a 
subtle conformational change affecting certain β-strands, which was increasingly 
observed from changes in the contribution of chemical exchange to measured 
transverse relaxation rates in aggregation-prone conditions and largely abolished for 
the T119M suppressor variant93. Overall, these results point to increased dynamics 
of the native conformation of TTR as causing aggregation.                         
 
1.3 Biopharmaceuticals 
 
1.3.1 The rise of biopharmaceuticals 
 
A biopharmaceutical is a medicinal product that is biological in nature and 
manufactured using biotechnology96. Typically, this biotechnology refers to 
recombinant expression in bacterial cells i.e. E. coli or more commonly mammalian 
cells, which are primarily Chinese hamster ovary (CHO) cells97. Like all 
pharmaceutical substances, biopharmaceuticals are designated an International 
Nonproprietary Name (INN) by the World Health Organisation (WHO) as well as 
their trade name given by the manufacturing company98. The vast majority of 
biopharmaceuticals are parenteral products i.e. they must be administered by 
injection99.   
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The vast majority of biopharmaceuticals currently in clinical use are recombinantly 
expressed proteins97,100. Proteins are attractive as therapeutic agents because of 
their inherent specificity, which theoretically means higher efficacy and fewer 
adverse effects compared to small molecule drugs. Additionally, proteins often 
regulate multiple components of a biological process e.g. a signalling pathway, 
which is difficult to mimic using small molecules. Moreover, many diseases relate to 
reduced or eradicated function of a protein due to a genetic mutation, meaning a 
protein drug can provide effective treatment through replacement101. The importance 
of biopharmaceuticals is reflected in the consistent generation of new products for 
clinical use (Table  1.1), targeting a range of disease areas from cancers to 
neurodegenerative and inflammatory diseases102.   
           
Time period Number of product approvals 
Up to 1989 9 
1990-1994 19 
1995-1999 58 
2000-2004 56 
2005-2009 54 
2010-2014 54 
Table ‎1.1 Total numbers of biopharmaceutical products approved for use in the EU and US over time periods from 
1982-2014. This data was reproduced from Walsh (2014)
97
. 
 
Due to the wide range of applications for biopharmaceuticals and the myriad of 
disease areas targeted, these products can be more easily categorised according to 
broad functional classifications101 as shown in Table  1.2. The mechanisms of action 
of biopharmaceuticals by which these functions can be exerted are also shown, 
along with examples of products that act via these mechanisms. 
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Functional 
classification 
Mechanism of 
action 
Example  
(Trade name) 
Function Clinical use 
Enzymatic or 
regulatory activity 
Replacing a 
protein that is 
deficient or 
abnormal 
Insulin
103,104
 
(Humulin®) 
Regulates blood 
glucose 
Diabetes 
mellitus 
Augmenting an 
existing pathway 
Erythropoietin
98
 
(Epogen®) 
Stimulates 
erythropoiesis 
Anaemia 
Providing a novel 
function or activity 
Human 
deoxyribonuclease I
105
 
(Pulmozyme®) 
Degrades DNA in 
pulmonary secretions  
Cystic fibrosis 
(decreases 
respiratory 
tract 
infections) 
Specialised 
targeting activity 
Interfering with a 
molecule or 
organism 
Trastuzumab
106
 
(Herceptin®) 
Binds cell surface 
receptor HER2 to 
control cancer cell 
growth  
Breast cancer 
Delivering other 
compounds or 
proteins 
Denileukin diftitox
107
 
(Ontak®) 
Delivers cytocidal action 
of diphtheria toxin to 
cells expressing  IL-2 
receptor 
Persistent or 
recurrent 
cutaneous T-
cell lymphoma 
Vaccines 
Protecting against 
a deleterious 
foreign agent 
Hepatitis B surface 
antigen
108
 
(Engerix®)  
Non-infectious protein 
on surface of hepatitis B 
virus 
Hepatitis B 
vaccination 
Treating an 
autoimmune 
disease 
Anti-Rh 
immunoglobulin G
109
 
(Rhophylac®) 
Neutralises Rh antigens 
that could elicit anti-Rh 
antibodies in Rh 
negative patients 
Prevention of 
Rh(D) 
immunisation 
in Rh(D) 
negative 
women 
Treating cancer 
Ipilimumab
110,111
    
(Yervoy®) 
Binds cell surface 
receptor CTLA4 to 
upregulate activity and 
proliferation of T-cells 
Late stage 
melanoma 
Diagnostics 
In vivo diagnostics 
Recombinant purified 
protein derivative  
(DPPD)
112
 
Non-infectious protein 
from Mycobacterium 
tuberculosis 
Diagnosis of 
tuberculosis 
exposure 
In vitro diagnostics 
HIV antigens (Enzyme 
immunoassay)
113
 
Detects human 
antibodies to HIV 
Diagnosis of 
HIV 
Table ‎1.2 Functional classifications of biopharmaceuticals. The mechanisms of action of biopharmaceuticals within 
each classification are shown along with examples of products that act by each mechanism. HER2 – human 
epidermal growth factor receptor 2; IL – interleukin; Rh – Rhesus; Rh(D) – Rhesus D antigen; CTLA4 – cytotoxic T-
lymphocyte associated protein 4; HIV – human immunodeficiency virus. This data was reproduced from Leader 
(2008)
101
. 
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1.3.1.1 Insulin 
 
Bacterially expressed human insulin was the first biopharmaceutical produced using 
recombinant DNA technology103, having been approved by the US Food and Drug 
Administration (FDA) as Humulin® in 1982 for the treatment of diabetes mellitus104. 
This was followed by approval of recombinantly expressed human growth hormone 
(hGH) as Protropin® in 1985 for the treatment of dwarfism114. 
 
Recombinant human insulin was also the first biopharmaceutical to be engineered 
for improved therapeutic traits using site-directed mutagenesis100. For instance, 
introducing substitutions that made the protein more resistant to aggregation 
resulted in development of insulin lispro (inversion of Pro28 and Lys29 in B-chain) 
and later insulin aspart (P28A substitution in B-chain) and insulin glulisine (N3K and 
K29E substitutions in B-chain)104, which exhibit faster modes of action as a result of 
these monomeric insulin variants (monomer referring to the native insulin dimer) 
being able to enter the bloodstream sooner after subcutaneous or intramuscular 
administration than wild-type insulin, which forms zinc-bound hexamers in its 
formulation100,104. Interestingly, a slower acting form of insulin (insulin glargine) has 
also been developed by introducing mutations that make insulin more aggregation-
prone under physiological conditions (N21G substitution in A-chain and B-chain 
elongated by two Arg residues). Insulin glargine is soluble in its formulation at pH 4 
but precipitates upon subcutaneous administration. Therefore, aggregated insulin 
must solubilise before it can enter the bloodstream, resulting in slower release of 
monomeric insulin104,115. 
 
1.3.1.2 Monoclonal antibodies (mAbs) 
 
The highest number of biopharmaceutical approvals in more recent years has come 
from mAbs, which have constituted an increasing proportion of the total number of 
biopharmaceuticals approved97 (Table  1.3) and are the most commercially 
successful category of biopharmaceutical (Figure  1.5). The establishment of mAbs 
as the most successful class of biopharmaceutical is largely due to protein 
engineering, which enabled production of mAbs with reduced immunogenicity.                
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Time period Percentage of mAb approvals 
Up to 1989 11 
1990-1994 13 
1995-1999 24 
2000-2004 20 
2005-2009 22 
2010-2014 26.5 
Table ‎1.3 Approvals of mAbs as a percentage of the total number of biopharmaceuticals approved for use in the EU 
and US over time periods from 1982-2014. This data was reproduced from Walsh (2014)
97
.  
            
 
Figure ‎1.5 US sales of different types of biopharmaceuticals in 2012. Sales are shown as billions of US dollars. This 
figure was redrawn from Aggarwal (2014)
102
. 
 
Early mAbs were raised against a target protein in mice, which generated an 
immune response when subsequently used in humans. Protein engineering enabled 
generation of humanised antibodies that were less immunogenic. In humanised 
antibodies, the complementarity determining regions (CDRs) that make up the 
antigen binding site of a mAb (Figure  1.6) are replaced by CDRs from murine 
antibodies that have been generated against a particular target116. As well as 
reducing the immunogenicity of the antibody, molecular grafting of murine CDRs 
onto a human scaffold means that a human Fc region is present (Figure  1.6), which 
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is involved in mediation of effector functions such as the complementation cascade, 
a process that leads to the lysis of antibody-targeted cells by the immune 
system114,117. The Fc region also recruits immune cells for endocytosis and 
subsequent chemical and enzymatic breakdown of CDR-bound soluble 
molecules101. 
 
Later, the binding affinity of mAbs was significantly improved through the use of 
phage display, which involved cloning of genes encoding antibody variable domains 
into the genome of a filamentous bacteriophage. The inserted genes encode the 
variable (V) domains of the heavy (VH) and light (VL) chains of the antibody 
(Figure  1.6) joined by a flexible (Gly4-Ser)3 linker, which is referred to as a single-
chain Fv (scFv). Upon bacterial expression, the scFv is expressed on the N-terminal 
end of the gene III protein of a filamentous phage, resulting in display of the scFv on 
the phage surface that can still bind its target antigen118. Further development of this 
technology enabled display of the entire heavy and light chains making up the Fab 
region of the antibody (Figure  1.6) on the surface of phage119. Due to the high 
affinity of the antibody fragment for its target antigen, antibody fragments on the 
surface of phage can be purified by affinity chromatography using the antigen, along 
with the attached phage containing the DNA encoding this antibody fragment118. 
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Figure ‎1.6 Schematic of an IgG antibody. Immunoglobulin G (IgG) is the major antibody found in serum and is 
made up of two 50 kDa heavy (H) polypeptide chains and two 25 kDa light (L) chains. Disulphide bonds (green) are 
formed between the flexible linker regions of the two heavy chains in the hinge region as well as the constant (C) 
domains of the heavy and light chains. The CH2 domains are glycosylated at Asn297 (blue) and these glycans 
mediate effector functions
120
. The variable (V) domains contain the complementarity determining regions (CDRs), 
which are involved in antigen recognition
117
. CDRs are variable flexible loops that are flanked by relatively 
conserved framework regions made up of β-sheet
116
. The N- and C- termini and CDRs of one heavy and one light 
chain are shown and the Fc, Fab and Fv regions indicated
117
. Linking together the VH and VL domains of the Fv 
region produces a single-chain Fv (scFv) fragment
118
. The crystal structure of the Fab fragment of trastuzumab 
(Herceptin®; PDB 1N8Z
121
) is also shown using the same colour scheme and in the same orientation as the left-
hand Fab region of the schematic. This figure was redrawn from Lee, Perchiacca and Tessier (2013)
120
.  
 
1.3.2 Screening technologies to improve therapeutic properties of proteins 
 
Screening of vast DNA libraries encoding different mutants of a protein is often 
carried out to identify variants with improved therapeutic properties, such as 
increased ligand binding affinity122, increased recombinant expression yield123 or 
reduced aggregation propensity124. These libraries are usually constructed by 
random or saturation mutagenesis, using chemically synthesised DNA 
oligonucleotides and polymerase chain reaction (PCR) and DNA shuffling based 
methods125. In this way, desired properties can be selected for in the absence of 
structural information of the target or therapeutic protein candidate, with repeated 
rounds of selection resulting in directed evolution of a particular desired trait123.  
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1.3.2.1 In-cell screening methods 
 
Yeast cell surface display has been used to screen for proteins with increased 
expression level and enhanced thermal stability. In Saccharomyces cerevisiae, 
proteins with increased aggregation propensity should be removed by the protein 
quality control mechanisms within eukaryotic cells (see Section  1.1.3). As a result, 
proteins with reduced aggregation propensity are selected by the proteostasis 
network for secretion as well as display on the surface of yeast when fused to the 
protein Aga2p found on the cell wall126. Although this method has been used to 
identify variants of single-chain T-cell receptors (scTCRs) with increased secretion 
levels and display on the cell surface, which correlated with improved thermal 
stability in vitro126, yeast cell surface display has also been shown to result in 
selection of variants that were stable as molten globules i.e. lacking a folded 
structure. This suggests that yeast cell surface display does not always select for 
the native conformation of a protein127, which is typically the functional and least 
aggregation-prone state37. 
 
Bacteria have also been used to screen a wide range of variants for improved 
solubility in vivo. An example of this is fusion of variants at their C-terminus to Green 
Fluorescent Protein (GFP). In this construct, GFP only becomes soluble and 
fluorescent if the attached variant is soluble, providing a qualitative readout of 
protein solubility. This has also been shown to correlate with fluorescence intensities 
of fusion proteins when translated using an in vitro protein synthesis system and 
allowed directed evolution of increasingly soluble proteins128.  
 
A potential flaw with this system is that incorporation of GFP may improve the 
solubility of the attached variant, resulting in an inaccurate interpretation of variant 
protein solubility. This has been rectified to an extent by development of a split GFP 
system that involves attaching the C-terminal 15 amino acids of mutated GFP to the 
C-terminus of the variant proteins of interest and co-expressing the remaining 215 
amino acid segment. These fragments of GFP spontaneously reassemble to form 
fluorescent GFP provided that the client protein is soluble, with the 15 amino acid 
tag having less of an effect of altering solubility than full-length GFP129. 
 
Screening of variants fused to GFP for improved solubility in the cytoplasm of E. coli 
relies on the protein possessing no disulphide bonds in its native structure as these 
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cannot form in the reducing environment of the cytoplasm130. Considering the 
importance of disulphide bonds in maintaining the structures of many 
biopharmaceuticals e.g. antibodies120 (Figure  1.6) and four-helical cytokines131 (see 
Section  1.5.1), screening in the cytoplasm of E. coli reduces the utility of such 
systems to biopharmaceuticals.  
 
Development of a screening method for proteins in the periplasm of E. coli has 
enabled the aggregation-propensity of more therapeutically relevant proteins to be 
tested i.e. the disulphide-containing domain antibodies (dAbs) HEL4 and Dp47d, 
which are single VH domains
120. In addition, this screen has been used to investigate 
the aggregation of proteins linked to amyloidoses, namely the disulphide-containing 
protein β2m and the unfolded polypeptides Aβ40, Aβ42, α-syn and IAPP (see 
Section  1.2.2)132.  
 
This screen relies on incorporation of the protein of interest into a loop of TEM-1 β-
lactamase, an enzyme which confers resistance of E. coli to β-lactam antibiotics. If 
the incorporated protein is soluble then the two segments of β-lactamase can fold to 
form the functional enzyme that is able to hydrolyse ampicillin. On the other hand, if 
the protein aggregates than the enzyme will no longer function and the antibiotic 
resistance of the cell is severely reduced132,133. This screen has also been used to 
identify variants of immunity protein 7 (Im7) that increase stability in vivo, which 
correlated with increases in the thermodynamic and kinetic stabilities of these Im7 
variants in vitro133.                      
 
1.3.2.2 Phage display and cell-free screening methods 
 
The in vivo and in vitro aggregation behaviours of proteins are often correlated as 
the cellular screening methods outlined above can be used to differentiate variants 
with low and high solubility in vitro134. However, the recombinant expression level of 
the variants being screened also relates to their transcription and translation 
levels135 as well as their solubility136. Consequently, transcription and translation 
rates will influence the levels of the reporter protein and result potentially in variants 
appearing falsely more or less aggregation-prone. Additionally, the stresses applied 
to variants being screened in a cell are numerous and only qualitatively defined36. 
On the other hand, carrying out screening of DNA libraries outside of a cell allows 
application of more stringent and tightly controlled selection pressures that may be 
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harmful to cells125, thus providing more guidance on protein drug formulations, as 
well as allowing investigation of folding and aggregation properties specifically rather 
than general solubility. Plus, variants can be selected for functional activity through 
the binding affinity to their target118,137,138.        
 
The high in vitro stability of the phage particle to denaturation allows a range of 
defined conditions to be used for selection of variants with increased stability by 
phage display139, such as temperature140-143, chemical denaturation143,144 and 
proteolysis145. Since its initial development (see Section  1.3.1.2), phage display has 
been used to select for aggregation-resistant antibody VH domains, based on 
transient heating of these domains when displayed on the surface of M13 
bacteriophage. Heating for ten minutes at 80 oC resulted in thermal unfolding of VH 
domains but did not affect the phage. After cooling, VH domains were selected by 
binding to protein A on the basis that aggregation-resistant antibodies would refold 
to their native functional conformation upon cooling140,141. This increased resistance 
to heat-induced aggregation was also shown to correlate with improved recombinant 
expression yield of variable domains141.  
 
The development of cell-free based screening technologies has enabled the 
production of even larger libraries of protein variants (1013-1014 proteins in libraries 
produced by cell-free methods compared to 109 for phage display and bacterial 
libraries146) by removing the requirement for transformation of DNA into host cells125. 
These  cell-free screening technologies rely on transcription and translation of DNA 
libraries in vitro, resulting in complexes where the encoding mRNA is attached to the 
protein variant137,138, either via the ribosome in the case of ribosome display137 or via 
puromycin in the case mRNA display138.  
 
In ribosome display, DNA constructs encoding scFv fragments without a stop codon 
were transcribed and translated in vitro, resulting in a complex of DNA, transcribed 
mRNA and translated protein. The temperature was then dropped from 37 to 4 oC 
and magnesium added to stabilise these complexes. Immobilised antigen was then 
used to select for scFv fragments with functional activity, resulting in isolation of this 
scFv along with the mRNA encoding it. Reverse transcription of the mRNA then 
provided the cDNA encoding the scFv, which could potentially be subjected to 
another round of selection for improved binding affinity137,147 and/or thermodynamic 
stability148.  
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Ribosome display has also been used in conjunction with hydrophobic interaction 
chromatography (HIC) matrices149,150 and proteolysis149 to select for variants with 
improved folding i.e. a more compact native conformation with reduced exposure of 
hydrophobic surface. Ribosome display in the presence of dithiothreitol (DTT) and 
HIC matrices was also used to select for the G-CSF variant C3150 used in this study 
(see Section  1.6.4). 
 
In mRNA display, DNA constructs encoding myc epitope peptides of different 
lengths were transcribed in vitro, followed by attachment of the peptidyl acceptor 
antibiotic puromycin151,152 at their 3’ end via an A27 linker region. Translation of these 
mRNA constructs in vitro resulted in covalent attachment of the polypeptide to the 
transcribed mRNA via the puromycin-DNA linker region. The poly-A linker paused 
the ribosome, giving puromycin time to enter the acceptor site (A-site) before 
dissociation of the nascent chain and become covalently linked to the polypeptide. 
Selection of a particular length of amino acid myc peptide was carried out using an 
anti-myc mAb, resulting in isolation of this myc peptide in complex with the encoding 
mRNA, which could then be reverse transcribed as above138.  
 
mRNA display has been used to select for peptides with high binding affinity for the 
signalling protein Gαi1153, which mediates effector functions of cell surface G-
coupled protein receptors (GPCRs)117. Additionally, these peptides have been made 
more resistant to proteolysis by chymotrypsin through mRNA display-mediated 
selection, resulting in an approximate 100-fold increase in their serum half-life154. 
 
Although cell-free libraries allow exploration of a higher amount of protein sequence 
space, the intrinsic instability of mRNA reduces the stringency of selection 
conditions that can be applied to protein variants146. Conversely, phage are resistant 
to denaturation139 and as a result phage display is currently more established as a 
screening technique than cell-free methods146. The different methods that can be 
used for construction and screening of variant protein libraries are summarised 
schematically in Figure  1.7. 
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Figure ‎1.7 Schematic representation of methods used to construct and screen a library of protein variants. In this 
example, the proteins are scFv fragments. A library of DNA constructs encoding different variants of a protein is 
constructed using random or saturation mutagenesis
125
 and must be subsequently transcribed and translated, either 
in vivo or in vitro (A). Protein libraries in cells may be selected for based on survival e.g. variants conferring β-lactam 
antibiotic resistance
132,133
 or their phenotype e.g. GFP fluorescence
128,129
, while protein libraries displayed on the 
surface of phage
118
 or bound in mRNA-ribosome-protein
137
 or mRNA-puromycin-protein
138
 complexes are selected 
based on binding affinity for an immobilised target antigen (B). DNA is subsequently purified from cells or phage 
encoding selected protein variants or reverse transcription polymerase chain reaction (RT-PCR) is used to amplify 
cDNA sequences from mRNA encoding selected protein variants (C). This figure was redrawn from Magliery and 
Regan (2004)
125
. 
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1.4 The problem of aggregation in biopharmaceutical development 
 
1.4.1 Therapeutic protein aggregates cause immunogenic responses  
 
The screening technologies outlined in Section  1.3.2 are often applied to identify 
variants of proteins with improved solubility and/or increased stability e.g. through 
interactions with HIC matrices or resistance to thermally induced aggregation. The 
purpose of this is to reduce the aggregation propensity of protein variants while 
attempting to maintain their functionality, which is inherently difficult given the 
relationship between the marginal stability of the native conformation29,30 and the 
dynamic motions that are required for function31,32. 
 
There are some examples of protein drug formulations where aggregation is 
advantageous, such as in the case of insulin glargine104,115 (see Section  1.3.1). 
However, in the vast majority of protein drug formulations aggregates must be 
avoided due to the immunogenic responses that they elicit in patients. Antidrug 
antibodies (ADAs) that are generated to therapeutic protein aggregates reduce the 
efficacy of the drug and can induce anaphylactic shock, but more worryingly can 
cause immunisation against a patient’s endogenous proteins leading to life-
threatening side-effects155-157. Although all protein drugs have the potential to be 
immunogenic and the factors surrounding their immunogenicity are wide ranging155, 
aggregates are considered to be one of the main causes156,157.  
 
Lack of clarity about the aggregate species responsible for causing immunogenic 
responses156,158 as well as the immunological mechanism that leads to generation of 
ADAs156,157 greatly complicates the issue of aggregates in therapeutic protein 
formulations. Aggregates have been proposed to elicit an immune response via the 
T-cell independent pathway155. In the T-cell dependent pathway, the antigen is 
digested within antigen-presenting cells (APCs) and the resulting peptides are 
displayed on the surface of the APCs via the major histocompatibility complex 
(MHC) Class II molecule. These peptides are recognised by T cells and in turn result 
in activation of B cells, forming antibody secreting plasma B cells that can be short- 
or long-lived. Some B cells also become memory cells upon activation, which react 
rapidly to repeated presentation of the same T-cell epitopes. Conversely, in the T-
cell independent pathway the antigen is endocytosed by peripheral dendritic cells, 
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which migrate to the spleen and present the antigen to B cells in order to activate 
them159.  
 
How aggregates elicit an immune response is unclear. One theory is that 
aggregates display an array of repetitive epitopes on their surfaces resembling that 
of a pathogen, which triggers the action of APCs156. An alternative theory is that 
insoluble aggregates are endocytosed by peripheral dendritic cells in the same way 
as particulate vaccines of an equivalent size (20-200 nm in diameter), resulting in 
digestion of aggregates and their presentation to B cells.  
 
On the other hand, larger aggregates (0.5-5 µm) would be ingested by 
macrophages through phagocytosis or macropinocytosis155,160. After internalisation 
of a captured particulate, phagosomes and macropinosomes mature through fusion 
and fission events with early and late endosomes and lysosomes, which contain 
hydrolytic enzymes and vaculoar H+-ATPases. Maturation of phagosomes and 
macropinosomes thus presumably facilitates digestion of aggregates for liberation of 
antigen, which is transferred to MHC class II molecules via fusion with immature 
dendritic cells. These dendritic cells subsequently mature into APCs and present 
this antigen on their surface to B-cells in order to activate them160.           
 
The resulting ADAs are classified broadly into two types; neutralising and non-
neutralising. Non-neutralising ADAs are those that bind the therapeutic protein but 
do not inhibit its function, which may still affect the efficacy of the drug by altering its 
clearance from the body161. In addition, protein drug aggregates are usually 
significantly less or non-functional, which also reduces the efficacy of the drug162. 
 
Neutralising ADAs bind the therapeutic protein and reduce or abolish its functional 
activity by disturbing interactions with the target protein, meaning they have a 
greater effect of reducing the efficacy of the therapeutic protein161. Crucially, 
neutralising ADAs can also inhibit the function of endogenous proteins, which could 
cause autoimmune diseases155-157. An example of this is pure red cell aplasia 
(PRCA), an anaemia which is thought to be linked to aggregation of recombinant 
human erythropoietin (Eprex®)163. Although the incidence of autoimmune disease 
resulting from therapeutic protein aggregation is rare, the potential for such life-
threatening conditions to result from therapeutic protein aggregates make their 
detection, characterisation and subsequent removal major priorities164.                
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Current studies of the immunogenicity of protein aggregates suggest that insoluble 
aggregates are more immunogenic than soluble aggregates and that smaller 
insoluble aggregates are more immunogenic155. However, a more recent study using 
aggregates of therapeutic antibodies suggested that small native-like oligomeric 
aggregates (<100 nm) elicited a greater immune response than larger non-native 
aggregates (µm diameter) or native monomer, based on measurement of the ADA 
levels in mice after intravenous or subcutaneous administration of aggregates of 
known size and conformation158. 
 
Generally, the potential severity of aggregates is hypothesised to relate to the 
proportion of the native structure that is present, with a balance existing between the 
amount of non-native structure required to elicit an immune response and the 
amount of native structure required to generate epitopes for ADAs that result in their 
cross-reactivity with endogenous proteins155,156.  
 
1.4.2 Protein aggregates are difficult to detect and characterise 
 
The problem of protein drug aggregation is compounded by the huge range of sizes 
that aggregates can adopt and the heterogeneous nature of aggregates in samples. 
Although a range of technologies exist to characterise protein aggregates162,165, 
there is no single technology that can be used to characterise all possible sizes from 
soluble dimers to visually observable precipitates162,166. Examples of the existing 
technologies used for profiling of protein aggregates are shown in Table  1.4. 
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Technique Aggregate size / µm Parameter measured 
Size exclusion chromatography  
(SEC)
167,168
 
0.001-0.05 Molecular mass 
Dynamic light scattering  (DLS)
169
 0.001-5 
Hydrodynamic radius  
(Rh) 
Analytical ultracentrifugation  
(AUC)
169
 
0.001-0.1 Molecular mass 
Asymmetric flow field flow 
fractionation 
(AF4)
169
  
0.001-100 Particle size 
Nanoparticle tracking analysis  
(NTA)
170
 
20-1000 Particle size 
Taylor dispersion analysis  
(TDA)
171
 
0.01-5 
Hydrodynamic radius  
(Rh) 
Resonant mass measurements  
(RMM)
172
 
0.5-5 Particle size 
Polarisation intensity differential 
scattering (PIDS)
173
 
0.04-2 Particle size 
Table ‎1.4 Examples of techniques used for aggregate sizing in protein solutions. Approximate aggregate size 
ranges that can be detected are shown for each technique along with the parameter measured. This data was 
reproduced from Hamrang, Rattray and Pluen (2013)
165
.    
 
The most commonly used method for aggregate profiling in protein drug 
formulations is SEC because of its speed, simplicity, relatively low sample 
requirements and ability to resolve and quantify monomeric and oligomeric 
species167,168. However, there are numerous issues with SEC, such as interaction of 
aggregates with the resin affecting their elution volume or preventing elution entirely, 
as well as changes in the amounts of aggregates resulting from non-specific 
interactions or dilution during the chromatography run168.  As a result of this, 
aggregate profiling in biopharmaceutical formulations is often carried out using 
orthogonal approaches. Techniques typically used alongside SEC include DLS, 
AUC and AF4169, which alone do not provide the same resolution or quantification 
abilities of SEC, but in combination provide validation of results and the ability to 
further resolve larger aggregates162. 
 
Aggregates in the size range of 0.1-10 µm are too small to detect by visual 
inspection (<100 µm) or light scattering but are too large for detection by SEC or 
AUC (Table  1.4). Although this size range of particle can be detected by DLS and 
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AF4, they are not well resolved by these techniques165,174. These potentially 
immunogenic aggregates are typically near the solubility limit and often low in 
concentration, making their detection by the orthogonal methods outlined above 
difficult162.      
 
One technique that may provide greater detection of particles in the 0.1-10 µm 
range is RMM (Table  1.4). This technique uses a suspended microchannel 
resonator (SMR), which consists of a microfluidic channel within a suspended 
cantilever to detect and resolve micron and submicron particles. Particles that flow 
through the channel are detected by causing a momentary change in the resonant 
frequency of the cantilever, which is due to their differing density to the surrounding 
solution. The reliance on density for particle detection in RMM, rather than optical 
properties or Brownian motion in the approaches above, means that this technique 
has the potential for future use in orthogonal approaches to characterise subvisible 
aggregate formation172.                        
 
1.4.3 The manufacturing process promotes therapeutic protein aggregation 
 
The extent of aggregation of biopharmaceuticals can be influenced by a variety of 
factors that can be classified as intrinsic or extrinsic. Intrinsic factors relate to the 
primary, secondary, tertiary and quaternary structures of a protein while extrinsic 
factors refer to the environmental conditions that the protein experiences175. Both of 
these factors can affect the proportions of different conformations accessible to a 
protein, which may have different aggregation propensities as shown in Figure  1.8. 
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Figure ‎1.8 Illustrations for the major pathways of protein aggregation. Pathway 1 shows that aggregation can occur 
from global (1a) or partial unfolding (1b and 1c) of the native state (N), resulting in population of the unfolded (U) or 
intermediate (I) states, respectively. Intermediates resulting from partial unfolding may be on-pathway for folding 
(1b) or misfolded off-pathway (1c) states
40
. Pathway 2 shows that these states can form aggregate (A) by self-
association through noncovalent (2a) or covalent interactions (2b). Pathway 3 shows that aggregation can occur 
through chemically modified species (X) e.g. deamidation or oxidation. For simplicity, all possible sizes and 
morphologies of soluble aggregates are represented by an A state that can further self-associate to form precipitate 
(P)
175
. This figure was redrawn from Wang, Nema and Teagarden (2010)
175
.  
 
During the manufacturing process, biopharmaceuticals are subjected to a range of 
extrinsic factors that can cause aggregation. Consequently, protein aggregation can 
occur at every phase of drug development, from recombinant expression to 
packaging and storage of the final product and administration175. 
 
Recombinant expression of therapeutic proteins may be carried out in bacteria or 
eukaryotic cells, depending on the requirement for disulphide bonds or 
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posttranslational modifications such as glycosylation176. Expression in bacteria often 
leads to formation of insoluble aggregates, termed inclusion bodies. After washing, 
inclusion bodies are largely made up of the recombinantly expressed protein which 
eases purification, but they must be solubilised and refolded to attain the native 
functional conformation. Whereas similar recombinant expression and purification 
protocols may be used for many different proteins, the optimum conditions for 
refolding vary considerably, with inefficient refolding potentially causing 
aggregation177. Purification of recombinantly expressed proteins is required 
regardless of whether they have been refolded, during which they are subjected to 
changes in environmental conditions such as pH, temperature and ionic strength175. 
 
An important step in protein manufacturing is viral inactivation, which may occur 
through exposure to temperatures high enough to cause thermal denaturation of the 
therapeutic protein (as high as 60 oC178) or acidic pH (as low as pH 3.8179). Thermal 
denaturation of proteins occurs through disruption of noncovalent interactions, 
resulting in exposure of hydrophobic surface area to potentially cause 
aggregation178. At temperatures required for viral inactivation the hydrophobic effect 
is increased compared to at room temperature and the diffusion of protein molecules 
by Brownian motion is increased, making intermolecular collisions and aggregation 
more likely180. Changes in pH can affect the type and distribution of charges on 
proteins and so may alter electrostatic interactions in the native conformation as well 
as affecting the overall charge on the native state, which may promote 
aggregation181.  
 
Proteins may be frozen and thawed after production or between different stages of 
the manufacturing process, which can induce aggregation through interactions of 
hydrophobic surfaces with ice-water interfaces. Generally, interactions with surfaces 
promote partial unfolding and increased exposure of hydrophobic surface, which 
upon desorption from the surface can cause protein aggregation182. Aggregation is 
also induced as a result of pH changes caused by crystallisation of buffer 
components during freezing178.  
 
Agitation of protein solutions during manufacturing, storage and administration can 
cause aggregation by exposing proteins to air-water interfaces. The hydrophobicity 
of air relative to water induces enrichment of hydrophobic surfaces of proteins at the 
air-water interface, facilitating their exposure and subsequently initiating 
aggregation175. Generally, surface adsorption can promote protein aggregation182, 
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with the degree of adsorption being dependent on the material of the surface183. 
Shear stress resulting from flow can also expose hydrophobic surfaces on a potein, 
promoting aggregation, although the effect of shear is thought to be less significant 
than (and perhaps dependent on) adsorption at solid-liquid and air-liquid 
interfaces184.     
 
Additionally, due to the long shelf-life required for biopharmaceuticals (at least 18 
months172,175,190) and preparation of multi-dose formulations, many products contain 
antimicrobial preservatives. One of the most commonly used is benzyl alcohol99, 
which has been shown to promote aggregation of therapeutic proteins through 
interaction with partially unfolded states185-188. Even exposure to light/UV radiation 
can promote aggregation, either through direct photo-oxidation or indirect oxidation 
by free radicals189,190.   
 
Lyophilisation (freeze-drying) is commonly used for preparation of solid products, 
which makes them more resistant to the physical and chemical degradation 
processes that occur in solution. However, drying removes part of the hydration 
layer, which can potentially impact the native conformation and promote aggregation 
upon reconstitution178, along with the potential impact of freezing outlined above. 
Additionally, pharmaceutical containers, rubber stoppers, syringes and needles used 
during storage and administration, respectively are often siliconized to provide 
lubrication and a protective coating, but trace amounts of silicone oil can initiate 
protein aggregation due to its hydrophobicity191.               
 
As well as the increased risk of therapeutic protein aggregation through noncovalent 
intermolecular interactions (pathway 2a in Figure  1.8) that may be promoted by 
manufacturing and storage, chemical modification of proteins may also occur that 
promote their aggregation. These may involve formation of chemical cross-links 
between proteins, such as intermolecular disulphide bonds via disulphide 
exchange192 (pathway 2b in Figure  1.8), or could be chemical alterations of proteins 
that increase their aggregation propensity. 
 
Deamidation, glycation and oxidation are examples of chemical modifications that 
have been suggested to promote aggregation (pathway 3 in Figure  1.8). 
Deamidation is the hydrolysis of amide groups on the side chains of Asn and Gln, 
resulting in formation of carboxylic acids and these residues becoming Asp and Glu, 
respectively182. This chemical modification has been linked to the reduced solubility 
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of crystallins in lenses containing cataracts193 and increased crystallin aggregation in 
vitro194. Glycation is the reaction between a carbonyl group of a reducing sugar and 
a basic side chain182 and has been shown to induce amyloid aggregation of 
albumin195. His, Met, Cys, Tyr and Trp side chains are potentially oxidised by 
reactive oxygen species182 and Met oxidation has been shown to alter the structure 
and thermal stability of an IgG as well as increasing its aggregation rate196.  
    
1.4.4 Methods employed to prevent therapeutic protein aggregation        
 
1.4.4.1 Additives 
 
The requirement for a minimum shelf life of 18 months175,178,197 means that the 
potential physical and chemical stresses that can cause biopharmaceutical 
aggregation must be counteracted. Usually, this is attempted through the use of 
excipients/additives that act either to affect the conformational stability of the native 
protein or its colloidal stability i.e. reducing intermolecular interactions that cause 
aggregation178,182.    
 
A common mechanism of action of excipients is stabilisation of the native 
conformation through preferential exclusion of the excipient from the protein 
surface198, exerted by excipients such as sugars, polyols and amino acids178. 
Addition of excipients such as sucrose results in hydration of the protein surface as 
the interaction of the protein with water is increasingly favourable relative to the 
interaction with sucrose. Preferential exclusion of sucrose and hydration of the 
protein surface has a greater destabilising effect on conformations with increased 
exposure of hydrophobic surface area, meaning that the denatured and intermediate 
states are destabilised to a greater extent than the native conformation198.   
 
Arginine is widely used for refolding of proteins from inclusion bodies199-203, owing to 
the ability of this amino acid in particular to suppress aggregation200,201. However, 
the mechanism by which this suppression is achieved is unclear. There is most 
likely a contribution from preferential exclusion of the amino acid from exposed 
hydrophobic surfaces of a protein making the native conformation more 
energetically favourable as outlined above198, but this does not fully account for the 
ability of arginine to suppress aggregation200. Numerous studies have reported the 
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ability of arginine to interact with203 or improve the solubility of201,204 unfolded and 
partially-unfolded states. Interaction of the guanidine group of the arginine side 
chain with tryptophan side chains has been proposed200,205, along with hydrogen 
bonding interactions with the amide backbone during the initial stages of 
folding203,205.    
 
Non-ionic surfactants are commonly used in the pharmaceutical industry to reduce 
surface adsorption and subsequent aggregation of proteins during storage, filtration, 
purification and transportation182. Non-ionic surfactants such as polysorbates act by 
aligning at interfaces to block their interactions with exposed hydrophobic patches of 
proteins206, as well as binding weakly to these patches on proteins to inhibit the 
same interactions207. However, the ability of non-ionic surfactants to inhibit surface 
adsorption of proteins depends on the properties of both the protein solution and the 
surface208. In some cases, non-ionic surfactants have even been shown to promote 
aggregation through partial denaturation209. Ionic surfactants are less commonly 
used due to their ability to interact with polar and non-polar regions of proteins that 
can facilitate denaturation, as in the case of sodium dodecyl sulphate (SDS)206. 
 
The buffer conditions and excipients/additives used in a protein drug formulation are 
generally selected on a trial-and-error basis, often biased by prior knowledge of 
conditions that have worked previously131,210. In addition, use of multiple excipients 
and stabilising agents during protein formulation adds an additional burden during 
characterisation and shelf-life studies197. An alternative route to preventing 
aggregation is through chemical modification of the therapeutic protein.    
 
1.4.4.2 Chemical conjugation 
 
The most common form of chemical conjugation of therapeutic proteins is 
attachment of polyethylene glycol (PEG)211. ‘PEGylation’ has been shown to 
increase the thermal stability of the derivatised protein212 as well as resulting in 
formation of smaller oligomeric species during aggregation213,214. PEGylation was 
initially designed as a method for improving the in vivo half-life of a protein by 
providing a degree of shielding of the attached protein to proteolytic degradation215 
and reducing renal clearance by making the protein larger211. The longer half-life of 
PEGylated protein drugs is beneficial because fewer doses are required, which 
improves patient compliance211. Additionally, the PEG group itself does not elicit an 
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immune response and provides shielding of the protein from interaction with immune 
response elements, reducing the potential immunogenicity of the drug216. However, 
the increased resistance of PEGylated proteins to renal clearance211, proteolysis215 
and clearance by the immune system216 results in increased liver uptake and 
accumulation, which may increase the risk of toxicity217. 
 
Glycosylation is a chemical modification of proteins that occurs naturally. 
Glycosylation has been shown to reduce the occurrence of a range of chemical and 
physical degradation processes218 and is thought to hinder aggregation through 
steric repulsion219,220, as well as increasing the thermodynamic stability of the 
protein219,221. In humans, glycosylation involves attachment of sugars principally on 
the side chains of Asn and Ser/Thr residues (N- and O-linked glycosylation, 
respectively). Not all of the potential glycosylation sites on a protein are occupied, 
which coupled to the variability in the sequence, order and branching of the sugars 
attached results in a huge range of different glycoforms of proteins218.   
 
1.4.4.3 Protein engineering 
 
Protein engineering methods have also been used in an attempt to reduce the 
aggregation tendency of therapeutic proteins. Often this involves screening of vast 
arrays of mutational variants using methods such as those outlined in Section  1.3.2. 
More rational approaches have employed the use of algorithms that predict the 
aggregation propensity of an amino acid sequence62-66 and/or a three dimensional 
structure63. However, these algorithms only consider the native and denatured 
states, whereas partially unfolded intermediates are often more aggregation-prone 
due to localisation of hydrophobic residues into surface exposed patches60. 
 
Protein engineering strategies have been applied successfully to the generation of 
antibodies with reduced aggregation propensities120. The vulnerability of antibodies 
to aggregation is wide-ranging, owing to the aggregation-prone motifs often being 
located in the hypervariable CDRs140. Mutation of CDRs to inhibit aggregation can 
result in significantly reduced binding affinity222, but mutation of residues adjacent to 
CDRs has been shown to significantly reduce aggregation while allowing retained 
functional activity. An example of this is in grafted amyloid-motif antibodies 
(gammabodies), which are dAbs that display hydrophobic segments from Aβ in their 
CDRs. Gammabodies are able to selectively bind Aβ oligomers and fibrils over 
Introduction 
 
35 
 
monomer, enabling targeting of the causative agents of Alzheimer’s disease (see 
Section  1.2.2). However, the exposed hydrophobic segments in the CDRs of 
gammabodies make them highly aggregation-prone. Interestingly, addition of just 
three negatively charged residues near the hydrophobic loops within the CDR of 
gammabodies was shown to suppress aggregation without affecting binding 
activity223. 
 
The variability of the primary structure of CDRs coupled to their role in antigen-
binding makes it unlikely that a general set of mutations will reduce the aggregation 
propensity of all antibodies while allowing functional activity to be retained120. 
Mutations introduced into an antibody may also have different effects on 
aggregation depending on which CDR they are localised to. However, introduction 
of certain mutations at specific positions within CDRs of dAbs that exhibit significant 
sequence diversity has been shown to elicit generic reductions in aggregation 
propensity, which was subsequently applied to the generation of scFv variants 
derived from Herceptin® with improved solubility224. 
 
Studies of full-length IgGs have also targeted the CDRs for mutation in an attempt to 
inhibit aggregation. One study reported a ten-fold increase in solubility of an 
antibody as a result of substituting just three hydrophobic residues for charged 
residues in a CDR. However, mutation of these hydrophobic residues resulted in 
more than a thousand-fold decrease in binding affinity. The aggregation propensity 
of this IgG was also significantly reduced by targeted glycosylation of a neighbouring 
CDR, which resulted in an eight-fold increase in solubility without altering binding225.                    
 
Other studies of IgGs have used atomistic molecular dynamics simulations to 
identify aggregation-prone regions, enabling the solvent exposure of every residue 
to be identified and a spatial aggregation propensity (SAP) to be calculated. 
Crucially, using molecular dynamics simulations helped to reveal regions whose 
solvent exposure is dependent on dynamics and so would not necessarily be 
revealed from analysis of static structures222,226-229. In some cases, the aggregation 
propensity of identified regions was confirmed experimentally by substitution of 
hydrophobic for charged residues and demonstrating reduced aggregation222,227. 
 
The above studies highlight the importance of the dynamics of the native 
conformation in exposure of aggregation-prone regions. However, as mentioned 
previously aggregation is arguably more likely to occur from a partially unfolded 
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state than the native or denatured states, with increased population of partially 
unfolded states potentially resulting from one of the many stresses of the 
manufacturing process outlined in Section  1.4.3. These intermediates may be 
sparsely populated under aggregation-deficient conditions, making them difficult to 
structurally characterise or model in molecular dynamics simulations.  
 
1.5 Four-helical cytokines 
 
1.5.1 The structural superfamily of four-helical cytokines      
 
The four-α-helix bundle is a common structural motif among globular proteins, 
consisting of four α-helices connected by flexible linker regions. These helices are 
commonly connected in an up-down-up-down arrangement, where the C-terminus of 
one helix is connected to the N-terminus of the next helix in the bundle via a short 
unstructured linker region typically less than 10 amino acids (Figure  1.9A and C). 
Alternatively, helices may be connected via long overhand loops that span the 
helical bundle, which are usually longer than 10 residues, enabling connected 
helices to be orientated in the same direction (Figure  1.9B and D). The ‘handedness’ 
of the arrangement of α-helices in a four-helix bundle is determined based on the 
position of helix B relative to helix A (when helix A is pointing upwards from N- to C-
termini; Figure  1.9E)230 or helix C relative to helix A in cases where helix B is directly 
opposite helix A in the bundle (Figure  1.9F).   
 
Connection of helices A and B plus C and D via long overhand loops is observed in 
the structural superfamily of four-helical cytokines, creating an up-up-down-down 
topology. Conversely, the linker connecting helices B and C is shorter, which results 
in neighbouring helices in the bundle being arranged antiparallel to each other 
(Figure  1.9B and D). The structures of many members of this superfamily are 
stabilised by disulphide bonds231. 
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Figure ‎1.9 Schematic representation of different four-helix bundle topologies. Helices are denoted A, B, C and D 
from N- to C- termini and are coloured red, orange, yellow and blue, respectively in two- (A and B) and three-
dimensional (C and D) representations of four-helix bundles of different topologies. A and C represent the 
conventional four-helix bundle topology while B and D represent the topology found in four-helical cytokines. The 
conventional four-helix bundle topology in C is shown from above in E to illustrate the arrangement of helices in a 
left-handed four-helix bundle. Disordered N- and C-termini and loops connecting helices are shown in green, except 
for the AB loop that is shown in pink. The position of this loop relative to the CD loop and helix D is indicative of a 
short- or long-chain four-helical cytokine
231,232
. Arrows indicate the direction of polypeptide chains from N- to C-
termini and dotted lines indicate lines or arrows in the background in three-dimensional representations. This figure 
was redrawn from Presnell and Cohen (1988)
230
.   
    
The structures of members of the four-helical cytokine family are similar despite little 
or no sequence homology232 and the superfamily can be further divided into short-
chain, long-chain and interferon (IFN)/IL-10 families231. Short-chain four-helical 
cytokines comprise on average 140 amino acids, with the four main helices being 
10-20 amino acids in length and may possess antiparallel β-sheet structures formed 
between residues in their AB and CD loops that pack against the core helices in the 
bundle. Long-chain four-helix bundle cytokines comprise on average 180 amino 
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acids, with the four main helices being 20-30 residues and may exhibit some α-
helical structure in the AB loop (coloured pink in Figure  1.9B and D) that does not 
pack against the core helices232,233. Additionally, in short-chain four-helical cytokines 
the AB loop passes under the CD loop and behind helix D while in long-chain four-
helical cytokines the AB loop passes over the CD loop and in front of helix D231,232.  
 
All long-chain four-helical cytokines are monomeric, as are the majority of short-
chain cytokines, with known exceptions being stem cell factor (SCF)234, 
macrophage-colony stimulating factor (M-CSF)235, interleukin 5 (IL-5)236 and fms-like 
tyrosine kinase 3 ligand (Flt3)237. Other than SCF, these dimeric proteins all contain 
disulphide bonds formed between subunits, but the IL-5 dimer has the added feature 
of intertwined helices, whereby helix D of one subunit completes the four-helix 
bundle of the other subunit.   
 
Members of the IFN/IL-10 family233 exhibit structural features of both short- and 
long-chain four-helical cytokines232. For instance, the AB loop passes in front of helix 
D as observed for long-chain four-helical cytokines, whereas the packing angle 
between the AD and BC helices in the bundle more closely resembles that observed 
in short-chain (around 35o) rather than long-chain (around 18o) four-helical 
cytokines231,232. An additional feature characteristic of the IFN/IL-10 family is a short 
helical section in the CD loop that packs against the core helices of the bundle232.  
 
Of the members of this family, IFN-α238 and IFN-β239 are monomeric while IFN-γ240 
and IL-10241 are intertwined dimers. These intertwined dimers are formed by 
exchange of helix D between subunits as observed for IL-5. However, the subunits 
in IFN dimers are packed side-by-side whereas the subunits in dimers of short-chain 
four-helical cytokines (e.g. M-CSF and IL-5) are packed end-to-end. Example 
members from the short-chain, long-chain and IFN/IL10 families are shown in 
Table  1.5 and Table  1.6. 
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Family Protein Monomer/Dimer Function 
Short-chain 
Granulocyte macrophage-
colony stimulating factor 
(GM-CSF) 
Monomer
242
 
Neutrophil and 
macrophage production
243
 
Macrophage-colony 
stimulating factor  
(M-CSF) 
Dimer
b
 
235
 
Macrophage and 
monocyte production
243
 
IL-2 Monomer
244
 
Immune response 
(primarily T-cells)
244
 
IL-4 Monomer
245
 
Immune response 
(primarily B-cells)
246
  
IL-5 Dimer
b,c
 
236
 
Immune response 
(eosinophil specific)
246
  
Fms-like tyrosine kinase 3 
ligand (Flt3) 
Dimer
b
 
237
 
HSC proliferation and 
differentiation
247
 
Stem cell factor  
(SCF) 
Dimer
a
 
234
 
HSC proliferation and 
differentiation
247
 
 
Erythropoietin  
(EPO)* 
Monomer
248,249
 
Erythrocyte 
production
250
 
Long-chain 
Granulocyte-colony 
stimulating factor  
(G-CSF) 
Monomer
251
 
Neutrophil 
production
252
 
Growth hormone  
(GH) 
Monomer
253
 Growth regulation
254
 
IL-6 Monomer
255
 Immune system
255
 
IL-11 Monomer
256
 Platelet production
257
 
Leukaemia inhibitory 
factor  
(LIF) 
Monomer
258
 
Differentiation and 
suppression of leukemic 
cells
259
 
Ciliary neurotrophic factor 
(CNTF) 
Monomer
260
 
Motor neurone 
development
260
 
Oncostatin M  
(OSM) 
Monomer
261
 
Suppression of tumour 
cell proliferation
262
 
Leptin Monomer
263
 Body weight regulation
264
 
Prolactin (PL) Monomer
265
 
Mammalian reproductive 
biology
265
 
Table ‎1.5 Examples of four-helical cytokines from the short- and long-chain families. The native conformations of 
these proteins are either monomeric or dimeric. Dimers formed without or with disulphide bonds between subunits 
are labelled a and b, respectively while dimers formed by intertwining of helices are labelled c. *EPO possesses 
structural features of both short- and long-chain families. Some of the physiological functions of these proteins are 
also shown. HSC – haematopoietic stem cell. This data was reproduced from Hill, Morea and Chothia (2002)
233
. 
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Family Protein Monomer/Dimer Function 
IFN/IL-10 
IFN-α Monomer
238
 
Antiviral, antiproliferative 
and immunomodulatory 
activities
266,267
 
IFN-β Monomer
239
 
IFN-γ Dimer
c
 
240
 
IL-10 Dimer
c
 
241
 
Inhibits synthesis of other 
cytokines e.g. IFN-γ
241
 
Table ‎1.6 Examples of four-helical cytokines from the IFN/IL-10 family. Proteins are labelled as monomeric or 
dimeric as outlined in the legend of Table  1.5. Some of the physiological functions of these proteins are also shown. 
 
1.5.2 Functions and physiological roles of four-helical cytokines 
 
Four-helical cytokines are small secreted proteins that mediate intercellular 
communication in order to help regulate the circulatory system as well as immune 
and inflammatory responses (Table  1.5 and Table  1.6). Cytokines exert their 
functions by binding to receptors on the surface of cells, which trigger receptor 
dimerisation and a subsequent cascade of intracellular signalling reactions. Many of 
these intracellular signalling reactions involve the Janus kinase family of tyrosine 
kinases (Jaks) and transcription factors from the signal transducers and activators of 
transcription (Stats) family268,269. 
 
The majority of four-helical cytokines signal through binding to Type I cytokine 
receptors, which are transmembrane proteins that possess conserved Cys residues 
and a WSXWS motif in their extracellular region. Type II receptors are structurally 
related to Type I receptors but do not possess the WSXWS motif and are only 
bound by four-helical cytokines of the IFN/IL-10 family269. The intracellular portions 
of cytokine receptors are more varied but contain Box1 and Box2 domains, which 
are conserved among Type I receptors252, while a peptide motif within Box1 is 
conserved among Type II receptors270. Signalling by four-helical cytokines is 
complicated by the use of common and ligand-specific subunits in different cytokine 
receptors, allowing some cross-reactivity of cytokines with different receptors269.  
 
Jaks are constitutively associated with Box1 and Box2 domains270,271 and become 
phosphorylated upon formation of a cytokine-receptor complex. Phosphorylation of 
Jaks causes their activation and phosphorylation of Tyr side chains on the 
intracellular portion of the receptor. Signalling proteins with SH2 domains e.g. Stats 
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then bind to these phosphotyrosine motifs and are phosphorylated by Jaks. 
Phosphorylation of Stats promotes their dissociation from the receptor and 
subsequent formation of homo- and heterodimers, which are recruited to the 
nucleus to influence gene expression and ultimately mediate a cellular response e.g. 
proliferation269. As well as promoting a cellular response, Stat signalling also 
increases expression of proteins that are involved in dampening and terminating 
cytokine signalling pathways. These proteins achieve this negative feedback 
regulation of cytokine signalling through inhibition of Jak and Stat activity272 as 
shown in Figure  1.10.   
 
 
Figure ‎1.10 Schematic illustration of four-helical cytokine signalling pathways. Receptor dimerization is induced by 
binding of its four-helical cytokine (red ellipse in a), which causes phosphorylation and subsequent activation of Jaks 
associated with the intracellular domain. Jaks phosphorylate tyrosine side chains on the intracellular region of the 
receptor, resulting in recruitment of Stats that are in turn phosphorylated by Jaks (b). Phosphorylation of Stats 
causes their dissociation and dimerisation (c) and subsequent recruitment to the nucleus to initiate a biological 
response (d). Stat signalling also upregulates expression of proteins from the suppressor of cytokine signalling 
(SOCS) family such as SOCS1, SOCS3 and cytokine-inducible SH2-domain-containing proteins (CIS) (e). SOCS 
proteins suppress signalling by binding to phosphorylated receptors and Jaks to sterically hinder Stat binding (f). 
Upon activation, Jaks also phosphorylate and activate SH2-domain-containing tyrosine phosphatases (SHPs) that 
subsequently dephosphorylate Jaks and receptors (g). Constitutively expressed protein inhibitor of activated Stats 
(PIAS) also bind to phosphorylated Stats to inhibit their signalling. This figure was reproduced from Gadina et al. 
(2001)
269
.  
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1.5.3 Uses of four-helical cytokines as biopharmaceuticals 
 
The role of four-helical cytokines in regulating the proliferation, differentiation and 
activity of cells involved in vital processes such as haematopoiesis and the immune 
and inflammatory responses (Table  1.5 and Table  1.6) makes them very attractive 
as therapeutic agents.  Examples of four-helical cytokines from the IFN/IL-10 and 
short- and long-chain families that are used as biopharmaceuticals are shown in 
Table  1.7 and Table  1.8, respectively. 
    
Protein 
(Expression system) 
INN (Trade name) Clinical use 
IFN-α 
(E. coli) 
IFN-α-2b
266
 
(IntronA) 
Chronic hepatitis B 
Chronic hepatitis C 
A range of lymphomas, melanomas 
and leukaemias 
IFN-α-2a
266
 
(Roferon-A) 
PEG-IFN-α-2b
266
 
(PegIntron®) 
(ViraferonPeg®) 
Chronic hepatitis C 
PEG-IFN-α-2b
131
 
(Sylatron®) 
Melanoma 
PEG-IFN-α-2a
266
 
(Pegasys®) 
Chronic hepatitis B 
Chronic hepatitis C 
Interferon-alfacon-1
266
 
(Infergen®) 
Chronic hepatitis C 
IFN-β 
(E. coli) 
IFN-β-1b
266
 
(Betaseron®) 
Multiple sclerosis 
IFN-β 
(CHO cells) 
IFN-β-1a
266
 
(Extavia®) 
(Avonex®) 
(Rebif®) 
IFN-γ 
(E. coli) 
IFN-γ-1b
267
 
(Actimmune®) 
Chronic granulomatous disease 
Osteopetrosis 
Table ‎1.7 Recombinant human IFNs used as biopharmaceuticals. The international non-proprietary names (INN) 
and trade names of these drugs are shown as well as their clinical uses. The additional letters and numbers used to 
label IFNs indicate different naturally occurring variants that may also be glycosylated to different extents. This data 
was reproduced from Lipiainen et al. (2015)
131
.  
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Protein  
(Expression system) 
INN (Trade name) Clinical use 
G-CSF 
(E. coli) 
Filgrastim
98
 
(Neupogen®) 
Neutropenia 
HSC transplantation 
Chemotherapy-induced neutropenia 
Pegfilgrastim
98
 
(Neulasta®) 
Neutropenia 
Chemotherapy-induced neutropenia 
Lipegfilgrastim
273
 
(Lonquex®) 
Neutropenia 
G-CSF  
(CHO cells) 
Lenograstim
98
 
(Granocyte®) 
Neutropenia 
HSC transplantation 
Chemotherapy-induced neutropenia 
EPO 
(CHO cells) 
Epoetin-α
98
  
(Eprex®) 
(Epogen®) 
(Neorecormon®) 
Chronic kidney disease (CKD) and 
chemotherapy-induced anaemia 
Epoetin-δ
98
 
(Dynepo®) 
Epoetin-β
98
 
(Mircera®) 
Darbopoietin-α
274
 
(Aranesp®) 
GM-CSF 
(E. coli) 
Molgramostim
98
 
(Leucomax®) Bone marrow transplantation 
Chemotherapy-induced neutropenia GM-CSF 
(S. cerevisiae) 
Sargramostim
98
 
(Leukine®) 
IL-2 
(E. coli) 
Aldesleukin
131
 
(Proleukin®) 
Renal cell carcinoma 
Melanoma 
Diphtheria toxin/IL-2  
fusion protein 
(E. coli) 
Denileukin diftitox
107
 
(Ontak®) 
T-cell lymphoma 
IL-11 
(E. coli) 
Oprelvekin
98
 
(Neumega®) 
Chemotherapy-induced 
thrombocytopenia 
SCF  
(E. coli) 
Ancestim
275
 
(Stemgen®) 
Used in conjunction with Filgrastim 
for HSC transplantation 
Table ‎1.8 Recombinant human four-helical cytokines used as biopharmaceuticals. The international non-proprietary 
names (INN) and trade names of these drugs are shown as well as their clinical uses. The different Greek letters 
used to label EPOs indicate different degrees of glycosylation. This data was reproduced from Lipiainen et al. 
(2015)
131
. 
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Four-helical cytokine drug formulations tend to contain very low concentrations of 
the active therapeutic agent (typically <1 mg/ml131) in comparison to other 
biopharmaceutical classes such as mAbs (typically >50 mg/ml120). PEGylation can 
greatly increase the concentration at which the protein can be stored at, for instance 
protein drug formulations of bacterially expressed G-CSF (Filgrastim) are stored at 
0.3-0.6 mg/ml276, while PEGylated G-CSF formulations (Pegfilgrastim and 
Lipegfilgrastim) are stored at 10 mg/ml131,277, with both PEGylated and non-
PEGylated protein drugs being stored under similar conditions131,276,277. PEGylation 
improves the overall solubility and reduces the rate of aggregation of G-CSF, 
although PEGylated G-CSF still aggregates, resulting in formation of smaller soluble 
aggregates214. PEGylated G-CSF also has a longer in vivo half-life than the non-
PEGylated version (3.5 h for Filgrastim277 compared to 27.2 h for Pegfilgrastim and 
32.4 h for Lipegfilgrastim273) due to the generic effects of PEGylating therapeutic 
proteins outlined in Section  1.4.4. 
 
Many four-helical cytokines used as biopharmaceuticals exhibit a range of 
glycosylation patterns, which often confer beneficial properties to the therapeutic 
protein (see Section  1.4.4). For instance, glycosylated G-CSF exhibits increased 
thermal stability and reduced aggregation propensity relative to the non-glycosylated 
protein278, enabling its formulation at neutral pH after reconstitution, as opposed to 
Filgrastim that is formulated at acidic pH131. For the majority of four-helical cytokines 
glycosylation is not required for function, enabling their recombinant expression in E. 
coli (Table  1.7 and Table  1.8).  
 
An exception to this is EPO, which possesses three N-linked glycans that are 
essential for in vivo (but not in vitro) biological activity279,280 and one O-linked glycan 
that is not279. The dependency of the in vivo but not the in vitro biological activity of 
EPO on N-linked glycosylation is most likely due to secretion, as EPO with N-linked 
glycosylation sites removed is secreted less effectively than fully glycosylated 
EPO279. The relationship between the in vivo half-life of EPO and glycosylation has 
enabled generation of a longer acting mutated EPO called Darbopoietin-α, which 
possesses two extra N-linked glycans and as a result exhibits higher potency and a 
three-fold increase in serum half-life compared to recombinant human EPO 
(Epoetin)274. 
 
        
 
Introduction 
 
45 
 
1.6 Granulocyte-colony stimulating factor (G-CSF) 
 
1.6.1 Structure 
 
Human G-CSF (Figure  1.11) is a 19.6 kDa protein consisting of 174 amino acids 
with an O-linked glycan281 attached to Thr133282. The structure of G-CSF is a 
monomeric long-chain four helix bundle with an up-up-down-down arrangement of 
helices, with each α-helix being antiparallel in relation to its neighbouring helices 
and an overall left-handed arrangement of helices in the bundle251,283. There is also 
a short helical segment within the AB loop consisting of a four residue 310 helix 
followed by six residues of α-helix251.  G-CSF contains two native disulphide bonds 
linking Cys36 to Cys42 and Cys64 to Cys74 as well as an unpaired Cys residue at 
position 17284. These disulphide bonds are essential for forming the native functional 
conformation of G-CSF285, whereas Cys17 and O-linked glycosylation are not 
required for function278,281,285.  
 
Structures of bacterially expressed recombinant human G-CSF (rhG-CSF) have 
been obtained free in solution by crystallography (PDB 1RHG251) and NMR (PDB 
1GNC283; Figure  1.11A) and in complex with the principal ligand-binding region of 
the murine G-CSF receptor (PDB 1CD9286) and the entire ligand-binding region of 
the human receptor (PDB 2D9Q287; Figure  1.12A). Heterologous expression of rhG-
CSF in E. coli results in non-glycosylated G-CSF with an additional N-terminal Met 
residue, meaning the molecular mass of bacterially expressed rhG-CSF is 18.8 
kDa281. Due to the mobility of the unstructured regions of rhG-CSF i.e. the N- and C-
termini and the AB and CD loops283,288 there is electron density missing in the 
structure of unbound rhG-CSF obtained by crystallography251, as opposed to the 
solution NMR structure for which the structural arrangement of every residue has 
been resolved283. Therefore, throughout this thesis all structures of rhG-CSF free 
from its receptor are shown using the NMR structure PDB 1GNC283 (Figure  1.11A).  
 
The four main helices of the bundle are rigid while the disordered loops connecting 
them as well as the unstructured N- and C-termini are more flexible and 
mobile283,288. Despite the AB loop of G-CSF C3 being longer than the CD loop 
(residues 42-71 in the AB loop compared to residues 125-144 in the CD loop), the 
CD loop has been shown to be more dynamic than the AB loop. This is most likely 
due to the short helical section in the AB loop plus the two disulphide bonds linking 
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residues Cys37-Cys43 and Cys65-Cys75, which restrain the AB loop by linking 
residues at the N- and C-termini of this loop to helices A and B, respectively288.  
 
 
Figure ‎1.11 Structure of rhG-CSF. Helices A (residues 13-41), B (72-96), C (102-124) and D (145-170) are coloured 
red, orange, yellow and blue, respectively on the structure in A and on the schematic representation of topology in 
B. The short helical section in the AB loop (48-56) is shown in pink. Cys residues and disulphide bonds connecting 
Cys37 with Cys43 and Cys65 with Cys75 are coloured in black and unpaired Cys18 is shown as a black space-
filling model in A. The unstructured N- and C-termini plus AB and CD loops are shown in green. The O-linked 
glycosylation site (Thr134) is shown in light blue in A. This figure was constructed using the structure of G-CSF 
obtained by NMR (PDB 1GNC
283
) in PyMOL
289
.   
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1.6.2 Function and physiological roles 
 
G-CSF is involved primarily in the response to infection252. Levels of G-CSF in 
human serum are normally undetectable or detectable at very low levels (25.3 ± 
19.7 pg/ml) but show a marked increase during infection (731.8 ± 895.0 pg/ml)290. 
The main physiological role of G-CSF is in promoting neutrophil production, 
achieved through stimulating the proliferation of haematopoietic stem cells and their 
differentiation into mature neutrophils, as well as promoting survival of cells 
throughout the neutrophil lineage. G-CSF also enhances key activities of mature 
neutrophils such as superoxide production and phagocytosis252. The physiological 
role of G-CSF and the functional activity of rhG-CSF expressed in bacterial or 
mammalian cells278,281 allow its use as a biopharmaceutical for treating neutropenia, 
often as a result of chemotherapy as well as mobilisation of haematopoietic stem 
cells (HSCs) for transplantation from the bone marrow98 (Table  1.8).  
 
G-CSF exerts its role in combating infection through binding to the G-CSF receptor 
(G-CSFR), which is found on the surface of all cells of the neutrophil lineage252. 
Binding of G-CSF to G-CSFR results in formation of a 2:2 complex286,287 
(Figure  1.12A) that initiates intracellular signalling cascades along multiple 
interconnected pathways252, the best characterised of which are outlined below. G-
CSFR lacks intrinsic kinase activity but receptor binding results in phosphorylation 
and activation of the Jak family kinases Jak1, Jak2 and Tyk2291,292, which along with 
Src kinases Lyn293 and Hck294 are constitutively bound to the Box1 and Box2 
domains of the membrane-proximal region of G-CSFR. Activation of Jak family 
kinases in turn causes phosphorylation and activation of primarily Stat3292 but also 
Stat1 and Stat5 through dimerisation, resulting in formation of Stat3 homodimers 
plus Stat1/Stat3 and Stat3/Stat5 heterodimers295,296. Upon dimerisation, Stat3 is 
recruited to the nucleus to initiate cell proliferation. Activation of Lyn and Hck results 
in phosphorylation and activation of downstream PI3 kinase297, which in turn 
activates Akt298 that is subsequently recruited to the nucleus to initiate cell survival.  
 
In addition to the Box1 and Box2 intracellular domains, phosphorylation of Tyr704 
and Tyr744 at the C-terminal end of the intracellular region of G-CSFR are essential 
for mediating binding and subsequent activation of Stat3299, while phosphorylation of 
Tyr764 is essential for Shc binding and downstream activation of Ras300 that initiates 
proliferation. Tyr729 phosphorylation is also needed for initiating negative signalling 
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pathways to limit the intensity and duration of the neutrophil-promoting signal 
induced by G-CSF. Phosphorylated Tyr729 recruits SOCS3301, which inhibits Stat3 
signalling and is induced within thirty minutes of G-CSF signal initiation302.      
 
 
Figure ‎1.12 Structure of G-CSF in complex with the G-CSF receptor. A 2:2 complex is formed between G-CSF and 
its receptor (G-CSFR) mediated by two sites of interaction (A). The major site of interaction is at site II between 
residues in helices A and C of G-CSF and residues within the ‘bend’ region of the cytokine receptor homologous 
(CRH) domain of the receptor (labelled orange in A). The CRH domain is made up of N- and C-terminal domains 
(BN and BC, respectively). The minor site of interaction is at site III between residues in helix D and the helical 
section of the AB loop of G-CSF and residues in the Ig-like domain of the receptor (labelled purple in A). Interacting 
residues at sites II and III are listed in Table ‎1.9 and are also coloured red and blue, respectively on the structure of 
G-CSF unbound in solution in B (PDB 1GNC
283
) and on the structure of G-CSF bound to its receptor in C (PDB 
2D9Q
287
), both of which were constructed using PyMOL
289
. The structure of G-CSF in 2:2 complex with G-CSFR 
shown in A was reproduced from Tamada et al. (2006)
287
. 
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 G-CSF  G-CSF receptor 
Interaction 
site 
Residue Atom Distance / Å Atom Residue Domain 
Major site 
(site II) 
Lys16 Cγ 3.99 Cδ2 Leu291 
Cytokine 
receptor 
homologous 
(CRH) 
Glu19 
Oε2 2.25* Oη Tyr173 
Oε2 3.47 Cγ1 Ile239 
Oε1 2.58* Nη2 Arg288 
Gln20 Cδ 2.94 Cδ2 Tyr173 
Arg22 
Nε 3.42* O His238 
Nε 3.40* Oδ1 
Asn240 
Lys23 Cβ 3.13 Nδ1 
Leu108 Cβ 3.84 Nη1 
Arg167 Asp109 Oδ1 2.91* Nη1 
Asp112 
Oδ1 2.86* Nη2 
Oδ1 3.12* N Leu172 
Oδ2 3.79 Cδ1 Leu171 
Minor site 
(site III) 
Tyr39 
Cα 3.98 Cζ Phe75 
Ig-like 
O 3.16* Nε2 
Gln91 
Leu41 Cδ2 3.48 Oε1 
Glu46 
Oε2 3.55 Cδ1 
Ile88 
O 3.03* N 
O 3.09* Nε2 
Gln87 Val48 N 3.52* Oε1 
Leu49 
Cβ 2.54 Nε2 
Cδ2 3.70 Cδ1 Trp82 
Ser53 Cβ 3.65 Sγ Cys3 
Phe144 
Cβ 3.44 Oδ1 Asp90 
Cδ1 3.21 Cβ 
Gln91 
Arg147 Nη1 2.86* Oε1 
Table ‎1.9 Amino acid residues of G-CSF and G-CSF receptor that are involved in interactions in the 2:2 ligand-
receptor complex. The distances between interacting atoms on residues are listed, along with whether this 
interaction occurs in site II or III. The domain that the interacting residue belongs to on the receptor is also shown. 
Distances marked with an asterisk indicate hydrogen bond interactions. Interactions at site II are primarily hydrogen 
bonding with some Van der Waals, while interactions at site III are mainly hydrophobic with some hydrogen bonding 
and an aromatic stacking interaction between the side chains of Tyr39 of G-CSF and Phe75 of the receptor. This 
data was reproduced from Tamada et al. (2006)
287
. 
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1.6.3 Current knowledge of the folding and aggregation of G-CSF 
 
Studies of the folding and aggregation behaviours of G-CSF have been carried out 
using bacterially expressed rhG-CSF, which possesses an added N-terminal Met 
residue and lacks O-linked glycosylation. This thesis only concerns bacterially 
expressed rhG-CSF, which is referred to herein as G-CSF.  
 
G-CSF is significantly more aggregation-prone at pH 7 than pH 4185,276,303, despite 
displaying similar thermodynamic stabilities under these conditions (40 and 38 kJ 
mol-1, respectively142,304). Reduced aggregation of G-CSF at pH 4 has been 
suggested to be the result of the side chain of unpaired Cys18 being less reactive at 
acidic pH305. However, a C18A variant has been shown to aggregate to the same 
extent as wild-type G-CSF at pH 7 and 37 oC, albeit at a slower rate142. A more likely 
explanation for the reduced aggregation of G-CSF observed at acidic pH values is a 
greater overall positive charge on the protein (pI of 6.02 predicted from the amino 
acid sequence117), which increases electrostatic repulsion between monomers303.  
 
Equilibrium denaturation of G-CSF at pH 4 in 0-5 M GdnHCl monitored by far-UV 
CD and fluorescence emission suggested a two-state transition between native and 
denatured states. However, studies of the folding and unfolding kinetics of G-CSF at 
pH 4 revealed the population of two intermediate states as shown in Equation  1.1304.  
 
 
U ↔ I1 ↔ I2 ↔ N Equation  1.1 
 
 
The first intermediate state (I1) was inferred from observation of roughly 50 % of the 
expected change in amplitude of the far-UV CD signal at the beginning of 
measurement, while the observed change in the amplitude of the fluorescence 
emission signal matched what was expected. Based on a dead-time of 
approximately 1 ms for the stopped-flow mixing apparatus used by Brems304 in this 
study, it was concluded that I1 represented formation of approximately 50 % of the 
α-helical structure of G-CSF without tertiary structure formation around Trp59 in the 
AB loop or Trp119 on helix C. 
 
The second intermediate state (I2) was detected based on the change in signal 
observed during kinetic refolding experiments having to be fitted using two 
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exponential functions, suggesting two folding reactions were taking place with 
different rate constants, which were denoted the fast and slow reactions. 
Conversely, the change in signal observed during unfolding experiments could be 
fitted using only a single exponential function. The use of W59Q and W119F single-
site G-CSF mutants enabled the change in the environment of Trp119 to be 
attributed to the fast reaction (approximately 20-100 ms), represented by the 
transition from I1 to I2 in Equation  1.1. Completed formation of native α-helical 
structure was also shown to occur during this I1 to I2 transition. The change in the 
environment of Trp59 was attributed to the slow folding reaction (approximately 0.2-
1 s), represented by the transition from I2 to N in Equation  1.1, suggesting Trp59 is 
in a non-native environment in the I2 state but otherwise G-CSF is native. 
 
Interestingly, when refolding was initiated in the presence of final concentrations of 
2-3.5 M GdnHCl the amplitude for the slow folding reaction was increased compared 
to refolding in the presence of GdnHCl concentrations lower than 2 M, suggesting 
increased population of the I2 state in denaturant concentrations too low to cause 
global denaturation304. This could be indicative of partial unfolding of G-CSF.               
 
In the presence of GdnHCl concentrations too low to cause global denaturation at 
pH 7 (1-2.5 M), the rate of G-CSF aggregation has been shown to increase 
significantly. In the presence of these low denaturant concentrations the 
fluorescence emission intensity of G-CSF was significantly increased, suggesting a 
change in the chemical environment of Trp59 and/or Trp119142. This change in 
fluorescence emission intensity in low GdnHCl concentrations was not observed at 
pH 4304, although this is most likely due to the reduced emission intensity of Trp at 
acidic pH that results from quenching306. Through the use of W59Q and W119F 
single-site G-CSF mutants, the increased fluorescence emission intensity of wild-
type G-CSF at pH 7 was revealed to be the result of a change in the environment of 
Trp59142. This indicated a possible conformational rearrangement of the AB loop in 
conditions that promote G-CSF aggregation and has been hypothesised to be the I2 
state observed during kinetic refolding experiments at pH 4142,304 (Equation  1.1). 
 
Characterisation of G-CSF aggregation at pH 7 suggests that aggregation occurs 
from a highly native-like conformation142,185,303,307,308 with the only detected 
conformational change being an altered environment around Trp59142. This 
aggregation-prone conformation has been described as a structurally expanded 
species303,308, which is supported by monitoring of native state hydrogen exchange 
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of G-CSF in the presence of sucrose185,307-309 and benzyl alcohol185,309. G-CSF 
exhibits reduced aggregation at pH 7 in the presence of sucrose185,307,308, which 
coincides with increased protection of residues in the four core helices from 
hydrogen exchange with the solvent182,288-290. Conversely, the aggregation of G-CSF 
is increased at pH 7 in the presence of benzyl alcohol185, with a corresponding 
decrease in protection of the helical core from hydrogen exchange185,309.  
 
This could suggest that the aggregation of G-CSF is the result of a general increase 
in solvent exposure of the core helices, rather than a more subtle conformational 
change of the AB loop. However, sucrose is well known for causing compaction of 
the native conformation of proteins as a result of its preferential exclusion from 
hydrophobic surfaces198, which is the rationale behind its frequent use as an 
excipient in protein drug formulations178. Conversely, benzyl alcohol is commonly 
used as an antimicrobial preservative99 in protein drug formulations and has been 
shown to interact with partially unfolded forms of proteins, resulting in 
aggregation186-188. Therefore, the generally increased and decreased solvent 
exposure of G-CSF observed in the presence of benzyl alcohol and sucrose, 
respectively are to be expected and may not reflect the minimal conformational 
change required to promote G-CSF aggregation.       
 
1.6.4 Generating G-CSF variant C3   
 
To improve the soluble expression level of G-CSF, Buchanan et al.150 generated a 
library of DNA constructs by error-prone PCR, which encoded an array of random 
G-CSF variants. This library was screened using in vitro ribosome display (see 
Section  1.3.2.2), with mRNA-ribosome-G-CSF complexes being incubated in the 
presence of DTT, HIC matrices and KCl. In vitro translation was also carried out in 
the presence of DTT to remove the stabilising effect of disulphide bonds on the 
native conformation.  
 
The rationale behind the screening conditions was that variants with increasingly 
compact and presumably more thermodynamically stable native conformations 
would be able to retain their functional conformation in the presence of DTT. 
Additionally, these variants would exhibit increased protection of hydrophobic 
surface area, making them less reactive towards HIC matrices, while variants with 
significant affinity for HIC matrices were removed at this stage through 
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centrifugation. After the stability selection stage (Figure  1.13D), the remaining 
stabilised variants were tested for functional activity based on binding to a G-CSFR-
Fc fusion (Figure  1.13E). mRNA-ribosome-G-CSF variants that survived both the 
stability and functional selection stages were then isolated using protein G-coated 
magnetic beads and the mRNA encoding these variants was purified and then 
amplified by RT-PCR, potentially to be used in another round of selection 
(Figure  1.13G). The in vitro ribosome display screening process is illustrated in 
Figure  1.13 and the selection conditions used are outlined in Table  1.10. 
 
Round of selection Selection conditions 
1 1 mM DTT 
2 5 mM DTT 
3 10 mM DTT, Phenyl HIC, 0.5 M KCl 
4 10 mM DTT, Octyl HIC, 1 M KCl 
Table ‎1.10 Stability selection conditions used during screening of a G-CSF variant library by in vitro ribosome 
display. All rounds of selection were performed at room temperature. The screening process is illustrated in 
Figure  1.13. This data was reproduced from Buchanan et al. (2012)150. 
 
Introduction 
 
54 
 
 
Figure ‎1.13 Schematic representation of screening a library of G-CSF constructs by in vitro ribosome display. A 
library of DNA constructs encoding G-CSF variants without stop codons (A) was transcribed in vitro. mRNA 
transcripts (B) were translated in vitro in the presence of 1 mM DTT to prevent formation of stabilising disulphide 
bridges. The resulting mRNA-ribosome-G-CSF complexes (C) were incubated in the presence of DTT and HIC 
matrices plus different KCl concentrations (selection conditions outlined in Table  1.10) (D). G-CSF variants that did 
not interact with HIC matrices were then tested for functional activity based on binding to a G-CSFR-Fc fusion (E). 
Stabilised G-CSF variants with retained functional activity were purified in their mRNA-ribosome-protein complex 
and the attached mRNA was purified (F) and used to amplify cDNA encoding these variants by RT-PCR. cDNA may 
then have been used in further rounds of selection (G). This figure was redrawn from Buchanan et al. (2012)
150
.         
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After the four rounds of selection outlined in Table  1.10, 88 variants of G-CSF plus 
the wild-type protein were cloned into E. coli strain HB2151 for periplasmic 
expression. Quantification of expression levels by western blotting revealed two 
variants with significantly increased expression. One of these variants, termed G-
CSF C3, was chosen for expression at 2 l scale and purified along with wild-type G-
CSF by Ni affinity chromatography. Analysis of purifications by SDS-PAGE and 
SEC-HPLC revealed a thousand-fold increase in the yield of monomeric G-CSF C3 
(8 mg per litre of 2× TY broth) relative to the wild-type protein (8 µg per litre of 2× TY 
broth). Moreover, SEC-HPLC revealed purified G-CSF C3 to be largely monomeric, 
while wild-type G-CSF was shown to contain mostly aggregated species. Crucially, 
G-CSF C3 showed equivalent functional activity to wild-type G-CSF in cell 
proliferation assays (EC50 values of 2.6 and 6 µM, respectively). 
 
G-CSF variant C3 contains four substitutions in relation to the wild-type protein, 
these being C18G, W59R, Q71R and F84L. How these mutants cause increased 
expression of soluble G-CSF variant C3 in the periplasm of E. coli has not been 
determined experimentally. However, computational modelling carried out by 
Buchanan et al.150 predicts that the substitutions W59R and Q71R confer a reduced 
aggregation propensity onto G-CSF, which is most likely due to the general reliance 
of aggregation prediction programs on hydrophobicity and charge62-66. The 
aggregation prediction software used by Buchanan et al.150 is found within the Biovia 
(formerly Accelrys) Discovery Studio® package and calculates SAPs222,226-229 (see 
Section  1.4.4.3), in this case using the structure of G-CSF obtained in complex with 
the CRH domain of the murine G-CSF receptor (PDB 1CD9286). 
 
This suggests that the W59R substitution may be linked to the observed increase in 
recombinant expression of soluble protein. Interestingly, Trp59 in the AB loop of G-
CSF has been revealed from fluorescence emission spectra to undergo a change in 
its chemical environment under aggregation-prone conditions, which is hypothesised 
to result from a conformational change in the AB loop. Other than this subtle 
conformational rearrangement, G-CSF is theorised to undergo aggregation from a 
native-like conformation142,185,303,307,308. This suggests a role for the W59R 
substitution found in G-CSF C3 in conferring increased soluble expression possibly 
via reducing aggregation propensity.  
 
Although the C18G substitution was not predicted to affect the aggregation 
propensity from computational modelling, substitution of unpaired Cys18 for Ala has 
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previously been shown to reduce the rate of aggregation of G-CSF, although 
ultimately the C18A G-CSF variant aggregated to the same extent as the wild-type 
protein142. Therefore, the C18G substitution may also be responsible for the 
observed increase in recombinant expression level. 
     
1.7 Objectives of this study 
        
The outline of this study is biophysical characterisation and comparison of G-CSF wt 
and the variant C3 under conditions that favour and disfavour aggregation. The 
objective of this is to elucidate whether G-CSF C3 exhibits reduced aggregation 
compared to G-CSF wt and whether this is responsible for the observed increase in 
the expression level of soluble G-CSF C3. The other key objective is identifying and 
analysing the subtle conformational change that drives G-CSF aggregation. 
 
In Chapter 3, G-CSF wt and C3 are expressed and purified and their structures 
compared, which revealed no significant differences in conformation between the 
two proteins. The work in Chapter 4 shows that G-CSF C3 exhibits similar 
aggregation behaviour to the wild-type protein. The observed similarities in the 
biophysical properties and aggregation behaviour of G-CSF wt and C3, coupled to 
the increased recombinant expression yield of G-CSF C3 led to a change in focus at 
this point to only studying G-CSF C3 under conditions where aggregation is 
favoured and disfavoured.  
 
Biophysical characterisation of G-CSF C3 in Chapter 4 revealed a change in the 
environment of one or more Tyr residues. The conformational change in 
aggregation-prone conditions was further probed at amino acid resolution by NMR in 
Chapter 5, revealing a change in the environment of Tyr86 on helix B. A significant 
increase in the dynamics of the latter half of the AB loop was also revealed by NMR, 
which is proximal to Tyr86. As a result, increased AB loop dynamics is hypothesised 
to expose an intrinsically aggregation-prone region of G-CSF C3 encompassing 
Tyr86, which drives aggregation from a native-like state. 
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Chapter 2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 General chemicals 
 
Purite 18 MΩ distilled water was used in all protocols. 30% (w/v) acrylamide:0.8% 
(w/v) bis-acrylamide and 10 % (w/v) sodium dodecyl sulphate (SDS) were 
purchased from Severn Biotech Ltd., UK. Agar was purchased from Melford 
Laboratories, UK. Ready mixed LB-Broth (Miller) was purchased from Merck, 
Germany. Agarose, L-arginine, dibasic sodium phosphate (Na2HPO4) and 
ethylenediaminetetraacetic acid (EDTA) were purchased from Acros Organics, 
Belgium. Glucose, glycerol, hydrochloric acid (32 % (w/v) HCl), sodium azide, 
sodium chloride (NaCl), sodium hydroxide (NaOH), sucrose and 
tris(hydroxymethyl)aminomethane (Tris) were purchased from Fisher Scientific, UK. 
Carbenicillin disodium salt, dithiothreitol (DTT) and isopropyl β-D-1-
thiogalactopyranoside (IPTG) were purchased from Formedium, UK. 15N ammonium 
chloride (15NH4Cl) and 
13C-glucose were purchased from Cambridge Isotope 
Laboratories, USA. Deuterium oxide (D2O) was purchased from Fluorochem, UK. 8-
anilino-1-napthalenesulphonic acid (ANS), ammonium chloride (NH4Cl), ammonium 
persulphate (APS), benzamidine hydrochloride hydrate, bromophenol blue, 
chloramphenicol, ethanol, ethidium bromide, guanidine hydrochloride (GdnHCl), 
magnesium chloride (MgCl2), magnesium sulphate (MgSO4), monobasic sodium 
phosphate (NaH2PO4), phenylmethanesulphonyl fluoride (PMSF), sodium acetate, 
tetramethylethylenediamine (TEMED), tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP), triton X-100 and urea (BioXtra prep-grade) were purchased from Sigma Life 
Sciences, USA. Urea used for experiments was of 99 % purity or greater and was 
purchased from Acros Organics, Belgium or MP Biomedicals, UK. 
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2.1.2 Molecular biology materials 
 
Synthetic DNA sequences encoding G-CSF wt and C3, codon optimised for E. coli 
expression, were purchased from Eurofins MWG Operon, Germany and inserted 
into the multiple cloning site (MCS) of expression vector pET23a (Novagen) by 
procedures outlined in Section  2.2, creating pET23a_G-CSF_wt and pET23a_G-
CSF_C3. A plasmid map for pET23a_G-CSF is shown in Appendix  7.3 and the DNA 
and amino acid sequences of both G-CSF constructs used for recombinant protein 
expression are shown in Appendices 7.1/7.2 and 7.4/7.5, respectively. The pET23a 
vector used as the backbone contained a gene encoding TonB (pET23a_TonB) and 
was obtained from Sam Hickman, Brockwell lab, University of Leeds.  
   
Q5 High-Fidelity DNA polymerase and Antarctic Phosphatase kits plus all restriction 
enzymes were purchased from New England Biolabs (NEB), USA. T4 DNA ligase, 1 
kbp and 100 bp DNA ladders and 6× loading buffer were purchased from Promega, 
UK. QIAprep Spin Miniprep and QIAquick gel extraction kits were purchased from 
Qiagen, UK. 
 
2.1.3 E. coli strains 
    
E. coli strains BL21(DE3), BL21(DE3) pLysS and XL1-Blue supercompetent cells 
were purchased from Agilent, USA. Stocks of competent cells were prepared from 
these strains, using the CaCl2 method
310, and stored at -80 oC. The genotypes of E. 
coli strains used are shown below: 
 
E. coli XL1-Blue  
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proABlaclq ZΔM15 Tn10 
(Tetr)] 
 
E. coli BL21(DE3)  
F- dcm ompT hsdSB (rB
-, mB
-) gal λ(DE3) 
 
E. coli BL21(DE3) pLysS  
F- dcm ompT hsdSB (rB
-, mB
-) gal λ(DE3) [pLysS (Camr)] 
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2.1.4 Growth media 
 
Transformed E. coli were cultured in Luria-Bertani (LB) medium, containing 25 g of 
ready mixed LB-Broth per litre of water. All media were sterilised before use by 
autoclaving for 20 mins at 120 oC. 100 mg/ml carbenicillin in water was sterilised by 
filtration through a 0.22 µm filter and added to media (after cooling) to a final 
concentration of 100 μg/ml. Chloramphenicol was dissolved in 100% ethanol and 
added to cooled media to a final concentration of 34 μg/ml. For preparation of agar 
plates 15 g of agar was added per litre of LB before autoclaving. 
 
To express 15N and 15N/13C isotopically labelled proteins, cells were grown in M9 
minimal medium. 5× M9 salts were prepared as outlined below and filtered through 
a 0.22 µm filter: 
 
5× M9 salts 
67.8 g of Na2HPO4 
30 g of KH2PO4 
5 g of NaCl 
 
5× M9 salts were then used to make 1 l of 1× M9 minimal medium with water after 
addition of 1 g of NH4Cl (or 1 g of 
15NH4Cl when expressing labelled protein). The 
following filter sterilised supplements were added per litre of M9 minimal medium 
after autoclaving but before adding antibiotics:  
 
Supplements 
2 ml of 1 M MgSO4 
100 µl of 1 M CaCl2 
20 ml of 20 % (w/v) glucose (or 10 ml of 20 % (w/v) 13C-glucose when expressing 
labelled protein) 
 
2.1.5 Protein chemistry materials 
 
SuperdexTM 75 10/300 GL gel filtration and 5 ml HiTrapTM SP HP cation exchange 
columns were purchased from GE Healthcare Bio-Sciences AB, Sweden and were 
attached to an Äkta prime plus pump system, also purchased from GE Healthcare. 
The Gel Filtration Low Molecular Weight Calibration Kit used to calibrate the 
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SuperdexTM 75 10/300 GL gel filtration column was also purchased from GE 
Healthcare. Vivaspin 2 ml and 20 ml centrifugal concentrators with respective 3 and 
5 kDa molecular weight cut off (MWCO) PES membranes were purchased from 
Sartorius Stedim, U.K. All buffers used during protein purification were filtered by 
vacuum filtration using 0.45 μm membrane filters purchased from Millipore, UK. 
Small volumes of buffers used were syringe-filtered using 0.45 μm Minisart 
membrane filters purchased from Sartorius, UK. SnakeSkin Pleated Dialysis Tubing 
with a 3.5 kDa MWCO and ZebaTM Spin Desalting Columns with a 7 kDa MWCO 
were purchased from Thermo Scientific, UK. Small volumes of proteins were 
dialysed using either 250 µl DiaEasyTM Dialyzers with a 6-8 kDa MWCO or 800 µl 
DiaEasyTM Dialyzers with a 3.5 kDa MWCO, both purchased from BioVision, USA. 
10× Tris-Tricine-SDS pH 8.3 cathode running buffer was purchased from Alfa Aesar, 
USA. InstantBlue Coomassie stain was purchased from Expedeon, UK, while Quick 
Coomassie Stain was purchased from Generon, UK. Precision Plus Protein Dual 
Xtra Standard molecular mass marker was purchased from Bio-Rad, USA. 
 
2.2 Molecular biology methods 
 
2.2.1 Agarose gel electrophoresis 
 
Agarose gels were prepared by heating 1.5 % (w/v) agarose in 1× Tris-acetate-
EDTA (TAE) buffer in a 250 ml conical flask until the agarose dissolved. TAE buffer 
was prepared as a 50× stock, containing 121 g Tris, 28.55 ml glacial acetic acid and 
50 ml 0.5 M EDTA (pH 8.0) in 500 ml. Once the agarose had dissolved and cooled 
to approximately 50 oC, ethidium bromide (10 mg/ml in water) was added to a final 
concentration of 1 µg/ml. The gels were then poured into a 12 cm by 15 cm gel tray, 
a comb was inserted, and the gel was allowed to set. DNA samples were diluted 1:5 
with 6× loading buffer. Samples containing 0.1 µg of 1 kbp ladder and 0.13 µg of 
100 bp ladder were also diluted 1:5 with 6× loading buffer and loaded into 
appropriate wells to allow size estimation of DNA within each band. Gel 
electrophoresis was carried out in 1× TAE buffer, running at a constant voltage of 
100 V until the dye front had reached roughly two thirds down the length of the gel. 
The gels were imaged using a UV transilluminator (Syngene). 
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2.2.2 Restriction digests of plasmid DNA 
 
Restriction digests were set up using NdeI and XhoI restriction enzymes in 
combination, or EcoRI in isolation. The composition of a restriction digest mixture is 
shown below: 
- Approx. 1-5 µg of plasmid DNA 
- 1× NEBuffer 4 
- 1× bovine serum albumin (BSA) 
- 5 U each of NdeI and XhoI 
- Made up to a final volume of 50 µl with sterile water  
When using EcoRI the reaction mixture was identical, apart from the absence of 
BSA. The samples were incubated at 37 oC for 1 h. 
  
Where digested plasmid DNA was to be used subsequently for ligation, vector DNA 
was 5’ dephosphorylated by adding 1× Antarctic Phosphatase reaction buffer and 5 
U of Antarctic Phosphatase, followed by incubation at 37 oC for 15 mins. The 
phosphatase was inactivated by incubation at 65 oC for 5 mins. After digestion (or 5’ 
dephosphorylation for vector DNA), the products were separated by agarose gel 
electrophoresis and purified using the QIAquick gel extraction kit (Qiagen) following 
the manufacturer’s instructions.   
 
2.2.3 Ligation of DNA 
 
Ligation reactions were set up using T4 DNA ligase. The composition of a ligation 
reaction mixture is shown below: 
- Approx. 1-2 µg of insert DNA 
- Approx. 300-400 ng of vector DNA 
- 1× T4 DNA ligase buffer 
- 3 U T4 DNA ligase 
- Made up to a final volume of 10 µl with sterile water 
Negative control samples were also set up, containing all components outlined 
above minus insert DNA. The samples were incubated overnight at 4 oC. 
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2.2.4 Transformation of ligations into XL1-Blue supercompetent cells  
 
E. coli XL1-Blue supercompetent cells were thawed on ice from a stock stored at -80 
oC. 1.7 µl of 1.22 M β-mercaptoethanol was added to 100 µl of cells on ice. Cell 
suspensions were gently mixed and incubated on ice for 10 mins. Transformation of 
competent cells was carried out by adding 5 μl of ligation reaction mixture to 100 µl 
cell suspensions, gently mixing and incubating on ice for 30 mins. Cell/DNA 
suspensions were then immersed in a water bath at 42 oC for 45 s, followed by 
incubation on ice for a further 2 mins. 900 µl of sterile SOC medium (without 
antibiotic) was added to cell suspensions, which were then incubated for 1 h at 37 
oC with shaking at 200 rpm. After incubation cells were centrifuged at 1000 rpm for 
10 mins using a Labnet Spectrafuge 24D microcentrifuge and 900 µl of medium was 
discarded. Cell pellets were gently resuspended in the remaining 100 µl of SOC 
medium and plated onto LB agar plates containing 100 µg/ml carbenicillin. 
 
2.2.5 Preparation of plasmid DNA 
 
Plasmid DNA was isolated from 5 ml overnight LB cultures of XL1-Blue cells under 
100 µg/ml carbenicillin selection. DNA was isolated using the QIAprep Spin Miniprep 
Kit (Qiagen) following the manufacturer’s instructions. The concentration of the 
eluted DNA was calculated using an Amersham Biosciences Ultrospec 2100 Pro 
UV/Visible Spectrophotometer, based on A260 values. An A260 value equalling 1 
corresponds to 50 µg/ml of double stranded DNA when the path length is 1 cm. 
 
2.2.6 DNA sequencing 
 
All DNA sequencing was carried out by Beckman Coulter Genomics. T7 promoter 
(5’-TAATACGACTCACTATAGGG-3’) and T7 terminator (5’-
GCTAGTTATTGCTCAGCGG-3’) primers were used for forward and reverse 
sequencing, respectively of pET23a DNA. 
 
 
 
 
 
Materials and Methods 
 
63 
 
2.2.7 Transformation of E. coli strains for protein expression 
 
Competent BL21(DE3) or BL21(DE3) pLysS cells were thawed on ice from a stock 
stored at -80 oC. Transformation of competent cells was carried out by adding 1 μl of 
plasmid DNA at 100 ng/µl to 50 µl of cells on ice. The Cell/DNA suspensions were 
gently mixed and incubated on ice for 30 mins, followed by immersion in a water 
bath at 42 oC for 45 s and incubation on ice for a further 2 mins. 450 µl of sterile LB 
medium (without antibiotic) was added to the cell suspension, which was then 
incubated for 1 h at 37 oC with shaking at 200 rpm. Finally, 100 µl of the suspension 
was plated onto LB agar plates containing 100 µg/ml carbenicillin (and 34 µg/ml 
chloramphenicol for pLysS cells), which were incubated overnight at 37 oC. 
 
2.3 General protein methods 
 
2.3.1 Calculation of protein concentration by ultraviolet (UV) absorption at 
280 nm (A280) 
 
Protein concentration was determined by measuring the absorption of UV light by 
the protein in solution at a wavelength of 280 nm (A280) and using the Beer-Lambert 
Law (Equation  2.1); where A represents absorbance, ε represents the molar 
extinction coefficient, c represents the molar concentration and l represents the path 
length of light in cm. Where necessary, protein solutions were diluted to produce 
A280 values below 1.  
 
 
A = εcl Equation  2.1 
 
The molar extinction coefficients (ε280) of G-CSF wt and C3 unfolded in GdnHCl 
were calculated from their amino acid sequences to be 15460 and 9770 M-1 cm-1, 
respectively, using the Gill and von Hippel Law (Equation  2.2); where n is the 
number of that amino acid in the protein of interest. For proteins unfolded in GdnHCl 
εTrp is 5690 M-1 cm-1, εTyr is 1280 M-1 cm-1 and εCystine is 120 M-1 cm-1 311. 
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εprotein = nTrp. εTrp + nTyr. εTyr + nCystine. εCystine Equation  2.2 
 
The ε280 values for folded G-CSF wt and C3 were determined using 77 and 407 µM 
stocks, respectively. Six-fold dilutions of each G-CSF stock in 20 mM sodium 
phosphate, 20 mM sodium acetate pH 4 were prepared in triplicate, using the same 
buffer with and without 6 M GdnHCl. The A280 values of these solutions were then 
measured and average A280 values calculated for the three G-CSF dilutions with and 
without 5 M GdnHCl. Based on these average A280 values and the ε280 values of 
unfolded G-CSF wt and C3 calculated using the Gill and von Hippel law, ε280 values 
for folded G-CSF wt and C3 of 15981 M-1 cm-1 and 10349 M-1 cm-1 were calculated 
using Equation  2.3.  
 
 
ε280 folded = ε280 unfolded (
average A280 without 5 M GdnHCl
average A280 with 5 M GdnHCl
) Equation  2.3 
 
2.3.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
SDS-PAGE was used to assess protein yield and purity during expression and 
purification. A two-layered system was used, consisting of a stacking gel on top of a 
resolving gel. The composition of these gels is outlined in Table  2.1. Tris-tricine 
buffered SDS-PAGE gels were used.  
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Gel component 
Resolving gel 
volume added / ml 
Stacking gel 
volume added / ml 
30% (w/v) acrylamide:0.8% (w/v) 
bis-acrylamide 
7.5 0.83 
Gel buffer (3 M TrisHCl, 0.3% (w/v) 
SDS pH 8.45) 
5.0 1.55 
Water 0.44 3.72 
Glycerol 2.0 0 
10% (w/v) APS 0.10 0.10 
TEMED 0.010 0.005 
Table ‎2.1 Composition of stacking and resolving gels used to make the two layered gel system for Tris-tricine 
buffered SDS-PAGE. The volumes indicted are sufficient for casting two 8 cm by 10 cm mini-gels using a 1.5 mm 
spacer. 
 
Two glass plates (Atto mini-gel kit) separated by a 1.5 mm spacer were assembled 
and clipped together according to the manufacturer’s instructions. TEMED is the last 
component to be added to the resolving gel mixture, which is then immediately 
poured into the space between the glass plates, up to within 2 cm of the top of the 
glass plates. This is quickly followed by addition of TEMED to the stacking gel, 
which is immediately poured on top of the resolving gel and a comb inserted to 
create wells. Both are allowed to set simultaneously, as the glycerol in the resolving 
gel prevents mixing of the different layers.  
 
Samples were diluted 1:1 with 2× loading buffer (50 mM TrisHCl, 100 mM DTT, 2% 
(w/v) SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol pH 6.8. Gel samples 
were boiled for the 5 mins before loading onto the gel, with 15 µl of boiled sample 
being loaded per well. In addition, 5 µl of Precision Plus Protein Dual Xtra Standard 
molecular mass marker was loaded into another well to aid identification of 
molecular masses of gel bands. For gel electrophoresis, the inner reservoir of the 
gel tank contained cathode buffer (100 mM TrisHCl, 100 mM Tricine, 0.1% (w/v) 
SDS pH 8.3) and the outer reservoir contained anode buffer (400 mM TrisHCl pH 
8.8). The gels were run at a constant current of 30 mA until the samples entered the 
resolving gel, at which point the current was increased to 60 mA. Electrophoresis 
was stopped once the dye front had reached the bottom of the gel and gels were 
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stained with InstantBlue stain or Quick Coomassie Stain. The gels were 
photographed using a UV transilluminator (Syngene).  
 
2.3.3 Trichloroacetic acid (TCA) precipitation 
 
Protein solutions containing 6 M GdnHCl were subjected to TCA precipitation and 
resuspension to allow analysis by SDS-PAGE. Unfolded protein in 6 M GdnHCl was 
diluted two-fold with pre-chilled 40 % (w/v) TCA and vortexed until white precipitate 
was observed, then left on ice for 20 mins. The TCA/protein suspension was 
centrifuged at 13300 rpm for 10 mins using a Labnet Spectrafuge 24D 
microcentrifuge and the supernatant discarded. The resulting pellet was 
resuspended in 1 ml of acetone, which had been stored at -20 oC prior to use and 
then centrifuged as above. After discarding the supernatant this wash step was 
repeated and the resulting protein pellet was dried by boiling briefly in a heating 
block. The dried protein pellet was resuspended in 2× loading buffer.      
 
2.3.4 Mass spectrometry 
 
2.3.4.1 Mass measurement 
 
The molecular masses of expressed and purified G-CSF proteins were measured 
using electrospray ionisation mass spectrometry (ESI-MS). G-CSF samples in 20 
mM sodium phosphate, 20 mM sodium acetate pH 4 were buffer exchanged into 66 
mM ammonium acetate pH 4 using ZebaTM desalting columns with 7 kDa MWCO 
according to the manufacturer’s instructions. Samples of G-CSF were submitted at 
60-80 µM for experiments and analyses carried out by Dr. James Ault in the mass 
spectrometry facility, University of Leeds using a Synapt HDMS instrument 
purchased from Waters, UK. For mass spectra of acid denatured and reduced G-
CSF C3 1 % (v/v) formic acid and 50 % (v/v) acetonitrile were added to samples 
along with 10 mM TCEP by Dr. Ault before analysis.   
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2.3.4.2 Verification of disulphide bond formation 
 
Trypsin digests of G-CSF proteins carried out by Dr. Ault were also analysed using 
ESI-MS, in the presence and absence of a reducing agent to confirm formation of 
the two native disulphide bonds. 50 µl G-CSF samples in 20 mM sodium phosphate, 
20 mM sodium acetate pH 4 at 50 µM were washed twice with 200 µl of 50 mM 
ammonium bicarbonate pH 7, with sample volumes being reduced back to 50 µl 
after washes using Vivaspin 0.5 ml centrifugal concentrators with 3 kDa MWCO 
PES membrane. 20 ng µl-1 of trypsin in 50 mM ammonium bicarbonate pH 7 was 
added to 20 µl of G-CSF sample and incubated with shaking at 37 oC for 18 h. 
Digestion was quenched by addition of 5 µl of formic acid. For reduction TCEP was 
added to a final concentration of 5 mM and incubated at 60 oC for 30 mins before 
ESI-MS analysis.        
 
Enzymatic digests of proteins in SDS-PAGE gel bands were also carried out and 
analysed by Dr. Ault using ESI-MS, in order to sequence and identify the proteins in 
these gel bands. 
 
2.4 Recombinant expression of G-CSF proteins 
 
A single colony of BL21(DE3) or BL21(DE3) pLysS cells freshly transformed with 
pET23a_G-CSF_wt or pET23a_G-CSF_C3 DNA was picked and used to inoculate 
a 250 ml LB culture containing 100 µg/ml carbenicillin (and 34 µg/ml 
chloramphenicol for pLysS cells), which was incubated overnight at 37 oC with 
shaking at 200 rpm. 
 
20 ml of overnight culture was used to inoculate each litre of LB medium in a 2 l 
conical flask, containing 100 μg/ml carbenicillin (and 34 µg/ml chloramphenicol for 
pLysS cells). For recombinant expression of G-CSF proteins in M9 minimal medium, 
10 ml of overnight LB culture was used to inoculate 0.5 l of M9 minimal medium, 
containing 100 μg/ml carbenicillin (and 34 µg/ml chloramphenicol for pLysS cells), in 
a 2 l conical flask. Typically, 11× 1 l of LB medium or 22× 0.5 l of M9 minimal 
medium were used for recombinant G-CSF expression. Cell cultures were incubated 
at 37 oC with shaking at 200 rpm and cell growth was monitored at regular intervals 
by measuring the optical density of cultures at a wavelength of 600 nm (OD600). At 
an OD600 value of approximately 0.6 protein expression was induced by adding 
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sterile filtered IPTG (1 M in water) to a final concentration of 1 mM. After addition of 
IPTG all cultures were incubated for 4 h at 37 oC with shaking at 200 rpm. The cell 
pellets were harvested by centrifugation at 6000 rpm, 4 oC for 15 mins using a 
Beckman Coulter Avanti J-26 XP centrifuge with a pre-chilled JLA 8.1 rotor. Cell 
pellets were stored at -20 oC and the supernatant was treated with Virkon 
disinfectant and discarded. 
 
For expression trials the OD600 was measured at the end of each hour of the 4 h 
post-induction incubation period as well as after overnight incubation. Pellets of 1 ml 
samples of cell culture were harvested by centrifugation for 5 mins at 13300 rpm in a 
Labnet Spectrafuge 24D microcentrifuge at room temperature. Cell pellets were 
stored at -20 oC and the supernatant discarded. Expression levels were determined 
by SDS-PAGE analysis, which involved thawing of cell pellets and subsequent lysis 
by resuspending in 2× loading buffer and boiling for 15 mins. The volume of 2× 
loading buffer used for cell lysis was varied to correct for cell density.   
 
2.5 Purification of G-CSF proteins 
 
2.5.1 G-CSF inclusion body isolation, washing and solubilisation 
 
Cell pellets were thawed and resuspended in lysis buffer (50 mM TrisHCl, 5 mM 
EDTA, 2 mM phenylmethanesulphonyl fluoride (PMSF) and 2 mM benzamidine 
hydrochloride hydrate pH 8) at a ratio of 1 g of cell pellet to 10 ml of buffer and lysed 
by 5× 30 second periods of sonication on ice at 75 % amplitude, using a Sonics 
Vibra-CellTM VCX-130PB sonicator with a 6 mm diameter probe. The cytoplasmic 
inclusion bodies were harvested by centrifugation at 15000 rpm, 4 oC for 30 mins 
using a Beckman Coulter Avanti J-26 XP centrifuge with a JLA 16.250 rotor. 
Inclusion bodies were washed by resuspending in wash buffer 1 (50 mM TrisHCl, 5 
mM EDTA, 1 % (v/v) triton X-100 pH 8) at a ratio of 1 g of inclusion body pellet to 20 
ml of buffer and harvesting inclusion bodies by centrifugation as above. This wash 
step was repeated using wash buffer 2 (50 mM TrisHCl, 5 mM EDTA, 4 M urea pH 
8). Washed inclusion bodies were resuspended in unfolding buffer (50 mM TrisHCl, 
5 mM EDTA, 6 M GdnHCl, 10 mM DTT pH 8) at a ratio of 1 g of inclusion body 
pellet to 5 ml of buffer and left on a platform shaker at room temperature overnight. 
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Resuspended pellet was then centrifuged at 15000 rpm, 4 oC for 1 h using a 
Beckman Coulter Avanti J-26 XP centrifuge with a JA 25.50 rotor. 
 
2.5.2 G-CSF refolding 
 
G-CSF inclusion bodies solubilised in unfolding buffer were diluted ten-fold with 
refolding buffer (50 mM TrisHCl, 5 mM EDTA, 0.9 M L-arginine pH 8) and dialysed 
into 5 l of 20 mM sodium phosphate, 20 mM sodium acetate pH 4. After three 
dialysis changes refolded G-CSF was centrifuged at 15000 rpm for 30 mins as 
above and the supernatant vacuum filtered through a 0.22 µm filter to remove 
precipitated protein. 
 
2.5.3 Cation exchange chromatography 
 
A 5 ml HiTrapTM SP HP cation exchange column was connected to an Äkta prime 
plus pump system at room temperature and washed with five column volumes (CVs) 
of water at a flow rate 5 ml/min to remove the 20 % (v/v) ethanol storage solution. 
The column was then equilibrated with five CVs of 20 mM sodium phosphate, 20 
mM sodium acetate pH 4 through lines A1 and B. Refolded G-CSF was loaded onto 
the column at a flow rate of 5 ml/min through line A1. A gradient of 0-100 % elution 
buffer (20 mM sodium phosphate, 20 mM sodium acetate, 1 M NaCl pH 4) was then 
run over 100 ml at 2 ml/min through line B, with elution monitored by measuring A280 
and 2 ml fractions being collected. Elution traces did not immediately return to zero 
after elution of protein in the peak, resulting in the appearance of an elution peak 
with a long trailing ‘tail’. Fractions in both the ‘peak’ and the ‘tail’ of the elution profile 
were pooled separately based on the results of SDS-PAGE analysis. Both ‘peak’ 
and ‘tail’ fraction pools were desalted by dialysis into 5 l of 20 mM sodium 
phosphate, 20 mM sodium acetate pH 4 at 4 oC. After three dialysis changes G-CSF 
was concentrated using Vivaspin 20 ml centrifugal concentrators with 5 kDa MWCO 
PES membrane until the protein concentration was 2.5-5 mg/ml for G-CSF wt and 8-
10 mg/ml for G-CSF C3. G-CSF proteins were snap frozen as 50-200 µl aliquots in 
1.5 ml Eppendorf tubes using dry ice and ethanol and stored at -80 oC. 
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After assessment of protein purity by SDS-PAGE, aliquots of G-CSF C3 from both 
the ‘peak’ and ‘tail’ elution pools were used for experiments, whereas only aliquots 
of G-CSF wt from the ‘peak’ elution pool were used for experiments. 
 
2.5.4 Size exclusion chromatography (SEC) 
 
Analytical SEC was performed to assess whether G-CSF C3 was monomeric after 
refolding and purification. All buffers and cleaning solutions were filtered and 
degassed by vacuum filtration through 0.22 µm filters before use. A SuperdexTM 75 
10/300 GL gel filtration column was connected to an Äkta prime plus pump system 
at room temperature and washed with one CV of water at a flow rate of 0.5 ml/min to 
remove the 20 % (v/v) ethanol storage solution, followed by one CV of 1 M NaOH 
and another CV of water at the same flow rate to remove any contaminant protein.  
 
The column was then equilibrated with one CV of 20 mM sodium phosphate, 20 mM 
sodium acetate pH 4 through line A1. Aliquots of G-CSF C3 at pH 4 (see 
Section  2.5.3) were thawed and centrifuged for 15 mins at 13300 rpm in a Labnet 
Spectrafuge 24D microcentrifuge at room temperature before injection onto the 
column. 100 µl of G-CSF C3 was injected onto the column at 219 µM through a 500 
µl loop attached to the injection port at the beginning of the run. Protein was eluted 
from the column at a flow rate of 0.5 ml/min and elution was monitored by 
measuring A280, which was set to zero at the beginning of the run. G-CSF C3 was 
also analysed by SEC in the same pH 4 buffer with an additional 200 mM NaCl 
using 100 µl of 208 µM G-CSF C3.   
 
G-CSF C3 was also analysed by SEC in 20 mM sodium phosphate, 20 mM sodium 
acetate, 0.02 % (w/v) sodium azide pH 7 with and without 200 mM NaCl. Aliquots of 
G-CSF C3 at pH 4 (see Section  2.5.3) were thawed and set up for dialysis into 2 l of 
20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 
with two changes at 4 oC. Following dialysis, G-CSF C3 was diluted with the pH 7 
dialysis buffer outlined above with or without an additional 2 M NaCl to final salt 
concentrations of 0 or 200 mM. G-CSF C3 samples in 20 mM sodium phosphate, 20 
mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer with or without 200 mM 
NaCl were centrifuged as above before injection onto the column. 100 µl of 406 and 
443 µM G-CSF C3 were injected onto the column in the presence and absence of 
200 mM NaCl, respectively. Before each experiment, the gel filtration column was 
Materials and Methods 
 
71 
 
washed and cleaned, then equilibrated in the same buffer used to inject G-CSF C3 
onto the column as described above. 
 
Proteins from the Gel Filtration Low Molecular Weight Calibration Kit (GE 
Healthcare) were loaded onto the column in 20 mM sodium phosphate, 20 mM 
sodium acetate, 0.02 % (w/v) sodium azide, 200 mM NaCl pH 7 according to the 
manufacturer’s instructions. A calibration curve for analytical SEC was obtained by 
plotting the ratio of the elution volumes of calibrant proteins (Ve) to the void volume 
(V0) of the column (Ve/V0) against log10 of the molecular masses of calibrant proteins 
in kDa and fitting to a linear function. 
 
2.6 Steady-state spectroscopy 
 
2.6.1 Buffers 
 
All experiments were carried out in 20 mM sodium phosphate, 20 mM sodium 
acetate pH 4, referred to herein as pH 4 buffer, or in 20 mM sodium phosphate, 20 
mM sodium acetate, 0.02 % (w/v) sodium azide pH 7, referred to herein as pH 7 
buffer, unless otherwise stated. For experiments carried out in pH 4 buffer aliquots 
of G-CSF stocks (see Section  2.5.3) were thawed and diluted to the stated protein 
concentrations. For experiments carried out in pH 7 buffer, aliquots of G-CSF stocks 
were thawed and set up for dialysis into 2 l of pH 7 buffer with two changes at 4 oC 
followed by dilution to the protein concentrations stated. Buffers were made 
volumetrically and filtered by vacuum filtration, or syringe filtration for small volumes, 
through 0.22 µm filters. 
 
The ionic strength of a buffer solution is a function of the concentration of all the ions 
present and can be calculated using Equation  2.4; where I represents ionic strength, 
c represents the concentration of ion i and z represents the charge of ion i.   
 
 
I =
1
2
∑ cizi
2 
Equation  2.4 
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Urea concentrations of stock solutions were checked by measuring the refractive 
indices (Ceti refractometer, Belgium) of pH 4 and 7 buffers with and without urea. 
The difference in these refractive indices was then used in Equation  2.5 to calculate 
urea concentration312; where ΔN represents the difference in refractive indices of 
buffer stocks with and without urea. 
 
 
[Urea] = 117.66ΔN + 29.753ΔN2 + 185.56ΔN3 Equation  2.5 
    
2.6.2 Circular Dichroism (CD) spectroscopy 
 
CD spectra were acquired on a ChirascanTM plus CD Spectrometer (Applied 
Photophysics, U.K.) using recording parameters of 1 nm increments, 1 s of 
acquisition per increment and a bandwidth of 2.5 nm at 25 oC. For measurements in 
the far-UV region (190-260 nm) spectra were recorded using 200 µl of sample 
volume in a 1 mm path length quartz cuvette (Hellma), while in the near-UV region 
(250-350 nm) spectra were recorded using 950 µl of sample volume in a 1 cm path 
length quartz cuvette (Hellma). Samples were left to equilibrate in the instrument for 
approximately one minute before acquisition. 
 
Ellipticity values of buffer alone were subtracted from ellipticity values of samples 
containing G-CSF before calculation of molar ellipticity using Equation  2.6; where [θ] 
represents molar ellipticity, θ represents the ellipticity recorded in degrees, c 
represents molar concentration and l represents the path length of light in m. The 
mean residue ellipticity ([θ]MRE) is then calculated by dividing [θ] by the number of 
peptide bonds313. 
 
 
[θ] =
θ
cl
 Equation  2.6 
 
α-helices exhibit characteristic absorption minima at 208 and 222 nm313 and [θ]MRE 
values at these wavelengths can be used to estimate the percentage α-helical 
content using Equation  2.7314 and Equation  2.8315, respectively. 
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At 208 nm % α helix = (
[θ]MRE − 4000
−33000 − 4000
) × 100 Equation  2.7 
 
At 222 nm % α helix = (
[θ]MRE − 3000
−36000 − 3000
) × 100 Equation  2.8 
 
2.6.2.1 Characterisation of native and unfolded G-CSF proteins 
 
Far-UV spectra of folded and unfolded G-CSF proteins in pH 4 and 7 buffers were 
acquired in the absence and presence of 8.1 M urea, respectively. For acquiring 
these far-UV spectra pH 7 buffer without azide was used. Far-UV spectra in pH 4 
buffer were acquired using 5 µM G-CSF wt and 8 µM G-CSF C3, while spectra in 
pH 7 buffer were acquired using 4 µM G-CSF wt and 5 µM G-CSF C3. Far-UV 
spectra acquired in the presence of 8.1 M urea are only shown in the region of 215-
260 nm because data obtained below 215 nm led to excessive dynode voltage (800-
1000 V) caused by the absorbance of signal by urea. 
 
2.6.2.2 Characterisation of G-CSF C3 in sub-denaturing urea concentrations 
 
Far-UV spectra of G-CSF C3 in pH 4 buffer in the presence of 0-3 M urea with 1 M 
increments were acquired using 5-8 µM protein. Far-UV spectra of G-CSF C3 in pH 
7 buffer in the presence of 0, 0.5 and 1-4 M urea with 1 M increments were acquired 
using 7-8 µM protein. These spectra are only shown in the region of 210-260 nm 
because data obtained below 210 nm led to excessive dynode voltage (800-1000 V) 
caused by the absorbance of signal by urea.  
 
Near-UV CD spectra of G-CSF C3 in pH 4 buffer in the presence of 0-3 M urea with 
1 M increments were acquired using 36-52 µM protein. Near-UV spectra of G-CSF 
C3 in pH 7 buffer in the presence of 0, 0.5 and 1-4 M urea with 1 M increments were 
acquired using 45-57 µM protein. 
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2.6.3 Fluorescence emission spectroscopy 
 
Fluorescence emission spectra were acquired on a QM-1 Fluorimeter (Photon 
Technology International, U.K.) using recording parameters of 1 nm increments, 1 s 
of acquisition per increment at 25 oC. Samples were left to equilibrate in the 
instrument for approximately one minute before acquisition.   
 
Fluorescence count values of buffer alone were subtracted from count values of 
samples containing G-CSF. Where necessary, fluorescence count values were 
adjusted to correct for different protein concentrations of samples. 
 
2.6.3.1 Characterisation of native and unfolded G-CSF proteins 
 
All measurements were recorded using 950 µl of sample in a 1 cm path length 
quartz cuvette (Hellma) using excitation and emission slit widths of 1 and 1.5 nm, 
respectively. After excitation at 280 nm emission spectra in the region of 290-400 
nm were acquired for folded and unfolded G-CSF wt and C3 in pH 4 and 7 buffers, 
using the same samples as used in Section  2.6.2.1. For acquiring emission spectra 
of unfolded and reduced G-CSF C3 in pH 4 and 7 buffers 1 mM TCEP was added to 
G-CSF C3 samples in 8.1 M urea and 650 µl of sample used. 
 
2.6.3.2 Characterisation of G-CSF C3 in sub-denaturing urea concentrations 
 
All measurements were recorded using 950 µl of sample in a 1 cm path length 
quartz cuvette (Hellma). For G-CSF C3 samples in pH 4 buffer excitation and 
emission slit widths of 1 nm and 1.5 nm, respectively were used, while for G-CSF 
C3 samples in pH 7 buffer excitation and emission slit widths of 1 nm were used. 
After excitation at 280 nm emission spectra in the region of 290-400 nm were 
acquired for G-CSF C3 in pH 4 buffer in the presence of 0-3 M urea with 1 M 
increments, as well as in pH 7 buffer in the presence of 0, 0.5 and 1-4 M urea with 1 
M increments, using the same samples as used in Section  2.6.2.2. All 
measurements were recorded using 950 µl of sample in a 1 cm path length quartz 
cuvette (Hellma).  
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2.6.3.3 8-anilino-1-napthalenesulphonic acid (ANS) fluorescence    
 
1 ml samples of 250 µM ANS in pH 4 buffer with and without 5 µM G-CSF C3 were 
set up at urea concentrations of 0-1 M with 0.2 M increments and 1-9 M with 1 M 
increments, then incubated at 25 oC overnight in a water bath. 1 ml samples of 250 
µM ANS in pH 7 buffer with and without 2.5 µM G-CSF C3 were also set up at the 
same urea concentrations and incubated at 25 oC overnight.    
 
All measurements were recorded using 500 µl of sample in a 1 cm path length 
quartz cuvette (Hellma). For samples in pH 4 buffer excitation and emission slit 
widths of 0.5 nm and 0.75 nm, respectively were used, whereas for samples in pH 7 
buffer excitation and emission slit widths of 1.5 nm and 2 nm were used. After 
excitation at 389 nm emission spectra in the region of 400-600 nm were acquired for 
samples of 250 µM ANS with and without 5 µM G-CSF C3 in pH 4 buffer in the 
presence of 0-1 M urea in 0.2 M increments and 1-9 M urea in 1 M increments. 
Spectra were also acquired for samples of 250 µM ANS in pH 7 buffer with and 
without 2.5 µM G-CSF C3 in pH 7 buffer in the presence of 0-1 M urea in 0.2 M 
increments and 1-9 M urea in 1 M increments.  
 
2.6.4 Urea denaturation of G-CSF C3 
 
Stocks of 7 µM G-CSF C3 in pH 4 and 7 buffers in 0, 2, 4, 6, 8 and 9 M urea were 
prepared by mixing appropriate amounts of pH 4 and 7 buffers without urea, pH 4 
and 7 buffers with 10 M urea and concentrated G-CSF C3 protein solutions at pH 4 
and 7 as outlined in Table  2.2 and Table  2.3, respectively. These stocks were mixed 
in the correct ratios to prepare 1 ml samples of 7 µM G-CSF C3 at urea 
concentrations of 0-9 M with 0.2 M increments, which were subsequently incubated 
at 25 oC overnight. 
 
 
 
 
 
 
 
Materials and Methods 
 
76 
 
Urea 
concentration of 
stock / M 
Buffer volume 
added / ml 
10 M urea 
volume added 
/ ml 
Volume of 
521 µM G-
CSF C3 
added / ml 
Total 
volume of 
stock / ml 
0 7.9 0 0.1 8 
2 9.45 2.4 0.15 12 
4 7.05 4.8 0.15 12 
6 4.65 7.2 0.15 12 
8 1.875 8 0.125 10 
9 0.35 3.6 0.05 4 
Table ‎2.2 Volumes of pH 4 buffer solution with and without 10 M urea and concentrated protein solution required to 
make 7 µM G-CSF C3 pH 4 stocks for equilibrium denaturation. 
 
Urea 
concentration of 
stock / M 
Buffer volume 
added / ml 
10 M urea 
volume added 
/ ml 
Volume of 
341 µM G-
CSF C3 
protein 
added / ml 
Total 
volume of 
stock / ml 
0 7.84 0 0.16 8 
2 9.36 2.4 0.24 12 
4 6.96 4.8 0.24 12 
6 4.56 7.2 0.24 12 
8 1.8 8 0.2 10 
9 0.4 4.5 0.1 5 
Table ‎2.3 Volumes of pH 7 buffer solution with and without 10 M urea and concentrated protein solution required to 
make 7 µM G-CSF C3 pH 7 stocks for equilibrium denaturation.  
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2.6.4.1 Urea denaturation monitored by fluorescence emission 
 
For each G-CSF C3 sample fluorescence emission intensity was measured using 
950 µl of protein solution in a 1 cm path length quartz cuvette (Hellma) with five 
repeats of 10 s acquisition at 25 oC. Samples were left to equilibrate in the 
instrument for approximately one minute before acquisition. For G-CSF C3 samples 
in pH 4 buffer emission intensity was measured at 301 and 348 nm after excitation 
at 280 nm. For G-CSF C3 samples in pH 7 buffer emission intensity was measured 
at 320 nm after excitation at 280 nm. Emission intensities at 301 nm were measured 
using excitation and emission slit widths of 1 and 2 nm, respectively. Emission 
intensities at 320 and 348 nm were measured using excitation and emission slit 
widths of 1 nm. After measurement of emission intensities samples were recovered 
and incubated at 25 oC overnight.         
 
2.6.4.2 Urea denaturation monitored by far-UV CD 
 
Using the same G-CSF C3 samples as described in Section ‎2.6.4.1 ellipticity 
intensity at 222 nm (θ222) was measured using 200 µl of sample in a 1 mm path 
length quartz cuvette (Hellma) with five repeats of 10 s acquisition and a bandwidth 
of 2.5 nm at 25 oC. Samples were left to equilibrate in the instrument for 
approximately one minute before acquisition. 
 
2.6.4.3 Calculating‎the‎free‎energy‎of‎unfolding‎(ΔGoUN) from urea 
denaturation measurements       
 
Fluorescence emission and θ222 intensities (see Sections ‎2.6.4.1 and ‎2.6.4.2, 
respectively) were plotted against urea concentration and fitted to Equation  2.9, 
which assumes a two-state transition between folded and unfolded states at 
equilibrium; where Sobs is the observed signal and represents either measured 
fluorescence emission or θ222 intensity, a and c are the signals of the denatured and 
native states in the absence of denaturant, respectively, b and d are the 
dependencies of the signal of the denatured and native states, respectively on the 
denaturant concentration, [D] is the denaturant concentration, ΔGUN is the free 
energy of unfolding in the absence of denaturant and MUN is the dependence of 
ΔGUN on the denaturant concentration
312.  
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Sobs =
((a[D] + b)e
(
ΔGUN−MUN[D]
RT ) + (c[D] + d))
(1 + e
(
ΔGUN−MUN[D]
RT ))
 Equation  2.9 
  
Using parameters a, b, c and d derived from Equation  2.9 fluorescence emission 
and θ222 intensities were normalised using Equation  2.10, converting Sobs values into 
fractions of folded protein (frac(F))312.  
 
 
frac(F) =
Sobs − (a[D] + b)
(c[D] + d) − (a[D] + b)
 Equation  2.10 
 
2.7 Aggregation assays 
 
2.7.1 G-CSF C3 aggregation at different protein concentrations 
 
100 µl samples of G-CSF C3 at concentrations of 4.5 and 8.6 mg/ml in pH 4 buffer, 
plus G-CSF C3 at concentrations of 1.7 and 5.5 mg/ml in pH 7 buffer were prepared 
from the stocks described in Section ‎2.5.3 in triplicate in 1.5 ml Eppendorf tubes. 
These samples were centrifuged for 15 mins at 13300 rpm in a Labnet Spectrafuge 
24D microcentrifuge at room temperature. 10 µl of supernatant was removed from 
each sample and diluted with 50 µl of pH 4 or 7 buffer to allow measurement of A280. 
The measured A280 values of triplicate samples were averaged and standard 
deviations calculated for each protein concentration. An absorbance scan across 
wavelengths 190-600 nm was acquired for at least one of each set of triplicate 
samples to ensure measured A280 values were not being affected by light scattering 
from particulates. The solutions were then incubated at 37 oC in a water bath but 
samples were removed at regular intervals for centrifugation and measurement of 
A280 as described above. These periods of centrifugation and measurement of A280 
lasted for approximately 30 mins and were not included in the time course of the 
experiment.  
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Proportions of aggregated G-CSF C3 remaining at these time intervals were 
calculated by subtracting the average A280 measured at a time interval from the 
average A280 measured before incubation at 37 
oC, then dividing this value by the 
average A280 measured before incubation at 37 
oC. Changes in the proportion of 
aggregated G-CSF C3 over time for G-CSF C3 in pH 7 buffer with a starting protein 
concentration of 5.5 mg/ml were fitted to a single exponential decay with a y-axis 
offset, while changes in the proportion of aggregated G-CSF C3 over time for other 
samples were fitted to a linear function. 
   
2.7.2 G-CSF C3 aggregation at different urea concentrations 
 
100 µl samples of 87 µM G-CSF C3 in pH 4 buffer, plus 70 µM G-CSF C3 in pH 7 
buffer at urea concentrations of 0-7 M with 1 M increments were prepared in 
triplicate in 1.5 ml Eppendorf tubes. These samples were centrifuged for 15 mins at 
13300 rpm in a Labnet Spectrafuge 24D microcentrifuge at room temperature. 10 µl 
of supernatant was removed from each sample and diluted with 50 µl of pH 4 or 7 
buffer containing the same urea concentration as the G-CSF C3 sample to allow 
measurement of A280. Measured A280 values were averaged and standard deviations 
calculated for triplicate samples of each protein concentration. An absorbance scan 
across wavelengths 190-600 nm was acquired for at least one of each set of 
triplicate samples to ensure measured A280 values were not being affected by light 
scattering from particulates. Samples were then incubated at 37 oC in a water bath 
but removed at regular time intervals for centrifugation and measurement of A280 as 
described above. These periods of centrifugation and measurement of A280 lasted 
for approximately 30 mins and were not included in the time course of the 
experiment.  
 
Changes in the A280 over time for G-CSF C3 in pH 7 buffer in urea concentrations of 
5-7 M urea with 1 M increments were fitted to a single exponential decay with a y-
axis offset, while changes in the A280 over time for other G-CSF C3 samples were 
fitted to a linear function. Bar graphs showing the fractions of soluble G-CSF C3 
remaining after certain time intervals were calculated by dividing the A280 measured 
at that time interval by the A280 measured before incubation at 37 
oC. For G-CSF C3 
samples in pH 7 buffer at urea concentrations of 0-7 M with 1 M increments, 
fractions of soluble G-CSF C3 were calculated after incubation for 24 h at 37 oC. For 
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G-CSF C3 samples in pH 4 buffer at urea concentrations of 0-7 M urea with 1 M 
increments, fractions of soluble G-CSF C3 were calculated after 27 h at 37 oC.    
 
2.7.3 G-CSF C3 aggregation at different urea concentrations monitored by 
Dynamic Light Scattering (DLS) 
 
Light scattering was measured using a WyattQELSTM module integrated within a 
miniDawnTM TREOS® instrument (Wyatt Technology, USA). All buffers and cleaning 
solutions were filtered and degassed by vacuum filtration through 0.22 µm filter 
membranes before use, as well as being injected into the 0.7 µl flow cell through a 
0.22 µm filter. The flow cell was initially flushed with 10 ml of air followed by 5 ml of 
water by injection through the ‘IN’ port with waste tubing connected to the ‘OUT’ 
port. The flow cell was then washed with 1 ml of 1 M nitric acid followed by 1 ml of 
water by injection through the ‘OUT’ port with waste tubing connected to the ‘IN’ 
port. These wash steps were repeated until the light scattering trace reached a 
baseline, which corresponded to rescaling of the light scattering values to four 
decimal places for at least 5 mins. Before injection of each G-CSF C3 sample the 
flow cell was equilibrated by injection of 1 ml of sample buffer through the ‘OUT’ port 
followed by a five minute delay to ensure the baseline for the light scattering trace 
was maintained.      
 
600 µl samples of 83 and 85 µM G-CSF C3 in pH 4 buffer in the presence and 
absence of 3 M urea, respectively, or 67 and 66 µM G-CSF C3 in pH 7 buffer in the 
presence and absence of 4 M urea, respectively, were prepared in 1.5 ml Eppendorf 
tubes. These samples were centrifuged for 15 mins at 13300 rpm in a Labnet 
Spectrafuge 24D microcentrifuge at room temperature. 10 µl of supernatant was 
removed from each sample and diluted with 50 µl of pH 4 or 7 buffer containing the 
same urea concentration as the G-CSF C3 sample to allow measurement of 
absorbance across wavelengths 190-600 nm. This procedure ensured that 
measurements were not affected by light scattering. At this point, recording of the 
light scattering trace by ASTRA version 6 (Wyatt Technology, USA) was started and 
allowed to proceed for 5 mins before injection of G-CSF C3 samples in order to 
provide a pre-injection baseline. 290 µl of supernatant was injected into the flow cell 
through the ‘OUT’ port for light scattering measurement. Sample injection was 
followed by a five minute delay for recording of light scattering, after which time 1 ml 
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of sample buffer was injected into the flow cell through the ‘OUT’ port. Recording 
was then allowed to proceed for a further 5 mins to provide a post-injection baseline. 
 
The remaining 300 µl of supernatants were incubated at 37 oC in a water bath. After 
24 h, these samples were centrifuged and the supernatants analysed by DLS as 
outlined above.   
 
A three minute interval within each five minute recording of light scattering data was 
chosen for analysis by the ASTRA version 6 software in order to avoid ‘spikes’ in the 
light scattering trace resulting from injections. Light scattering over these time 
intervals was fitted to a second order autocorrelation function (Equation  2.11) in 
ASTRA version 6; where g2(τ) represents the second order autocorrelation function, 
I(t) represents the intensity of scattered light at time t, I(t + τ) represents the intensity 
of scattered light after time delay τ and the brackets (〈 〉) indicate averaging over all 
time316.       
 
 
g2(τ) =
〈I(t)I(t + τ)〉
〈I(t)〉2
 Equation  2.11 
            
The value of g2(τ) obtained from Equation  2.11 was then used in Equation  2.12, 
which assumes the population of the sample is monodisperse in size to obtain the 
decay rate of the autocorrelation function (Γ); where B is the baseline of the 
autocorrelation function at infinite delay and β is the amplitude of the autocorrelation 
function at zero delay316. 
 
 
g2(τ) = B + βe−2Γτ Equation  2.12 
  
The value of Γ obtained from Equation  2.12 was then used in Equation  2.13 to 
obtain the translational diffusion coefficient (Dt) of the species within the sample; 
where q is the magnitude of the scattering vector and is calculated using 
Equation  2.14; where N is the refractive index of the sample, λ is the wavelength of 
the incident light and θ is the angle of the detector relative to the flow cell316. 
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Dt =
Γ
q2
 Equation  2.13 
 
 
q =
4πN
λ
sin (
θ
2
) Equation  2.14 
   
The value of Dt obtained from Equation  2.13 was then used in the Stokes-Einstein 
equation (Equation  2.15) to obtain the hydrodynamic radius (Rh) of the species 
within the sample; where kB is Boltzmann’s constant, T is temperature and η is the 
viscosity of the sample316.  
 
 
Rh =
kBT
6πηDt
 Equation  2.15 
  
Attempting to fit light scattering data for G-CSF C3 samples using Equation  2.12 in 
ASTRA version 6 assumes a monodisperse solution. If there are multiple sizes of 
species present i.e. the sample is polydisperse then each species of a particular 
size will decay at a different rate316. For polydisperse samples, the g2(τ) value 
obtained from fitting of light scattering intensities to Equation  2.11 was used in 
Equation  2.16 to obtain a first order autocorrelation function (g1(τ)); where ζ(τ) is the 
experimental noise after time delay τ. The g1(τ) value is subsequently used in 
Equation  2.17, which is the weighted sum of the exponential decays of each species 
of a different Rh in the population; where G(Γ) is the distribution function of the 
species with different decay rates (Γ) and G(Γ)dΓ is the fraction of the total intensity 
of scattering by each species317.  
 
 
g2(τ) = (g1(τ))2 + 1 + ζ(τ) Equation  2.16 
 
 
g1(τ) = ∫ G(Γ)e−Γτ dΓ Equation  2.17 
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A regularisation analysis318 was then performed by the DYNALS algorithm in ASTRA 
version 6 using the distribution function G(Γ) calculated in Equation  2.17. The 
resulting plot shows the fractional intensity of species with different Rh values
318. 
This regularisation analysis was carried out on all G-CSF C3 DLS samples to give 
an idea of their polydispersity. 
 
Rh values calculated from regularisation analysis of DLS data were used in 
Equation  2.18 to estimate the molecular masses of species, although this assumes 
these species are spherical; where Mr is the molecular mass of the species, ρ is the 
average density of a protein, which is assumed to be 1.37 g cm-3, NA is Avogadro’s 
number and rw is the radius of the hydration layer surrounding the protein, which is 
assumed to be 3.2 Å for one hydration shell319. 
 
 
Rh = √
3Mr
(4πρNA)
+ rw
3
 Equation  2.18 
 
  
2.8 Electron Microscopy 
 
Transmission electron microscope images of aggregates were acquired by Dr. Katie 
Stewart, University of Leeds on a JEOL JEM-1400 transmission electron 
microscope (JEOL Ltd, Japan). Aggregates were prepared as described in 
Section ‎2.9.4 and thawed, then 10 µl of aggregated samples were placed on 
formvar/carbon-coated copper grids (provided by Martin Fuller, Electron Microscopy 
facility, University of Leeds). After 30 s incubation, excess sample was removed by 
blotting with filter paper followed by negative staining with 10 µl of 2% (w/v) aqueous 
uranyl acetate. Grids were imaged after a 30 second drying period. 
 
2.9 Nuclear Magnetic Resonance (NMR) spectroscopy   
 
NMR experiments were carried out in partnership with Dr. Gary Thompson and Dr. 
Arnout Kalverda in the NMR facility, University of Leeds. In particular, transverse 
relaxation experiments, 13C-correlated spectra used for backbone assignment and 
1H-15N SOFAST HMQC spectra used to monitor hydrogen exchange were optimised 
and carried out under the supervision of Dr. Kalverda.   
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NMR spectra were acquired using a Varian Inova spectrometer (Agilent) operating 
at a proton resonance frequency of 600 MHz and equipped with a room temperature 
probe unless otherwise stated. For NMR experiments 10 % (v/v) D2O was added to 
G-CSF samples, resulting in the buffer components in the pH 4 and 7 buffers being 
diluted by 10 %. Spectra were acquired using 300 µl of sample in a Shigemi 
microtube matched to D2O (Sigma Life Sciences, USA) at 25 
oC unless otherwise 
stated. All NMR spectra were processed using NMRPipe320 and analysed using 
CCPN Analysis321.  
 
2.9.1 Backbone assignments by double- and triple-resonance NMR   
 
Multi-dimensional NMR relies on the transfer of magnetisation between nuclei, 
specifically from nuclei with a high gyromagnetic ratio (e.g. 1H) to nuclei with a low 
gyromagnetic ratio such as 15N and 13C. The gyromagnetic ratio of a nucleus is the 
ratio of its magnetic dipole moment to its angular momentum and this ratio governs 
the precession frequency of a nucleus in a magnetic field according to 
Equation  2.19; where ω0 represents the precession frequency of the nucleus i.e. the 
Larmor frequency, γ represents the gyromagnetic ratio and B0 represents the 
magnetic field strength. Consequently, nuclei with a higher γ are more sensitive to 
detection by NMR. Shielding of nuclei from the magnetic field (B0) by local electron 
density alters ω, giving rise to the different chemical shifts observed in NMR spectra.  
 
ω0 = −γB0 Equation  2.19 
 
In two- and three-dimensional NMR, transfer of magnetisation from more to less 
sensitive nuclei is achieved through insensitive nuclei enhancement by polarisation 
transfer (INEPT) radiofrquency pulse sequences322, examples of which can be seen 
within the pulse sequence of the heteronuclear single quantum coherence (HSQC) 
experiment319,323 (Figure  2.1).  
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Figure ‎2.1 A generic pulse scheme for the 1H-15N HSQC experiment. Narrow and wide bars represent 90o and 180o 
pulses, respectively, along x- or y-axes. Δ represents the time delay between pulses and is equal to (4J)
-1
 for the J-
coupling of the nuclei being studied, in this case 
1
H and 
15
N linked by an amine bond. The first INEPT block 
transfers magnetisation from 
1
H to 
15
N nuclei. The chemical shift is then allowed to evolve on the 
15
N nucleus for a 
time period t1, during which time a 180
o
 pulse decouples 
1
H and 
15
N.  A second INEPT block transfers magnetisation 
back from 
15
N to 
1
H nuclei for detection by acquisition of a Free Induction Decay (FID). During acquisition there is 
15
N broadband decoupling to ensure only one peak is observed in the 
1
H-
15
N HSQC spectrum per amine bond
319,323
. 
 
Introduction of nuclei with spin quantum number I = ½ into a magnetic field results in 
alignment of their spins parallel to the magnetic field, either in the same direction 
along the z-axis (corresponding to the low energy +½ or α state) or in the opposite 
direction along the z-axis (corresponding to the high energy –½ or β state). The J-
coupling between two nuclei connected by a covalent bond is the difference in the 
resonance frequency of one nucleus that results from the other nucleus in the bond 
being in the α or β spin state, which is caused by differing interactions of these spin 
states with the local electron density of the bond324. INEPT blocks exploit the J-
couplings of nuclei connected by covalent bonds. Figure  2.2 shows J-couplings for 
covalent bonds commonly used in triple-resonance NMR for backbone assignment. 
 
 
Figure ‎2.2 J-coupling constants for nuclei linked by covalent bonds commonly used for assignment of the 
polypeptide backbone. Frequencies of couplings JNH ~ 91 Hz (yellow), JNCO ~ 15 Hz (green), JCαCO ~ 55 Hz (red), 
JCαCβ ~ 35 Hz and JNCα ~ 7-11 Hz (blue) are depicted
319
. 
Materials and Methods 
 
86 
 
Acquisition of triple-resonance spectra involves the transfer of magnetisation 
between 1H, 15N and 13C nuclei, resulting in an HSQC spectrum with a third 13C 
dimension perpendicular to the 1H-15N plane. For example, an HNCA spectrum 
results in two 13Cα peaks for every backbone amide proton as shown in Figure  2.3. 
Due to the stronger coupling of the amide nitrogen nucleus to the alpha carbon 
nucleus of the same amino acid residue, denoted the i residue, compared to the 
preceding residue, denoted the i-1 residue, an HNCA spectrum contains higher and 
lower intensity peaks for the alpha carbon nuclei of the i and i-1 residues, 
respectively325-327. On the other hand, an HN(CO)CA spectrum only gives a single 
13Cα peak for every backbone amide proton corresponding to the i-1 residue through 
utilisation of the J-coupling between the amide nitrogen and the connecting carbonyl 
group326,328. Thus, HNCA and HN(CO)CA spectra can be used in conjunction to 
distinguish 13Cα peaks belonging to i and i-1 residues as well as link together 
residues based on the amino acid sequence.  
 
The same principle applies to the use of HNCO325,326,329 and HN(CA)CO330 spectra, 
which produce one and two 13CO peaks, respectively with overlapping peaks for the 
carbonyl carbon nucleus of the i-1 residue. Finally, a triple-resonance spectrum that 
produces 13Cα and 
13Cβ peaks such as an CBCA(CO)NH
331 spectrum (Figure  2.3) 
can help provide the identity of amino acid residues, based on the characteristic 
chemical shift values of 13Cα and 
13Cβ peaks for particular residues. 
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Figure ‎2.3 Magnetisation pathways for HNCA, HN(CO)CA and CBCA(CO)NH triple-resonance NMR spectra. 
Chemical shifts are evolved on nuclei in red producing peaks in these spectra, while nuclei in blue are used to 
transfer magnetisation via J-couplings but the chemical shift is not evolved for these nuclei. Double-headed arrows 
in the HNCA
325-327
 and HN(CO)CA
330
 schematics indicate initial excitation of the amide proton, which is subsequently 
transferred to nuclei in red and blue as indicated. Magnetisation is then transferred back to the amide proton for 
detection. Single-headed arrows in the CBCA(CO)NH
331
 schematic indicate excitation of Hα and Hβ protons, which is 
then transferred to nuclei in red and blue as indicated finishing at the amide proton for detection.     
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Backbone assignments of 473 and 176 µM G-CSF C3 were carried out in pH 4 
buffer in the absence and presence of 3 M urea, respectively using the NMR spectra 
and acquisition parameters outlined in Table  2.4 and Table  2.5. Backbone 
assignments of 458 and 208 µM G-CSF C3 were carried out in pH 7 buffer in the 
absence and presence of 4 M urea, respectively using the NMR spectra and 
acquisition parameters outlined in Table  2.6 and Table  2.7.  
 
Parameter HSQC HNCA HN(CO)CA HNCO HN(CA)CO CBCA(CO)NH 
np 2048 2048 2048 2048 2048 2048 
nt 48 16 16 16 32 28 
sw / Hz 7225 9615 9615 9615 9615 9615 
sw (15N) / 
Hz 
1700 1600 1600 2500 1600 1600 
sw (13C) / 
Hz 
N/A 4000 4000 3000 3000 10500 
ni (15N) 256 32 32 32 32 32 
ni (13C) N/A 32 32 32 32 32 
d1 / s 1 0.97 1 0.95 1 1.04 
Acquisition 
time / h 
8.5 21 22 21 43 39.5 
Table ‎2.4 NMR spectra and acquisition parameters used for assignment of 473 µM G-CSF C3 in pH 4 buffer 
without urea. np refers to the number of data points (real+imaginary) acquired along the FID in the directly detected 
dimension; nt refers to the number of transients, meaning the number of scans of each data point along the FID; sw 
refers to the spectral width for detection in the dimension shown; ni refers to the number of increments of the 
evolution time t1 (see Figure ‎2.1), corresponding to the number of FIDs (complex points) recorded in the indirect 
dimensions shown; d1 refers to the time delay after acquisition of the FID to allow recovery of equilibrium 
magnetisation before the pulse sequence is applied.  
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Parameter HSQC HNCA CBCA(CO)NH 
np 2048 2048 2048 
nt 48 16 32 
sw / Hz 7225 9615 9615 
sw (15N) / Hz 1600 1600 1600 
sw (13C) / Hz N/A 4000 10500 
ni (15N) 256 32 32 
ni (13C) N/A 32 32 
d1 / s 1 0.97 1.04 
Acquisition time / h 8.5 21 45 
Table ‎2.5 NMR spectra and acquisition parameters used for assignment of 176 µM G-CSF C3 in pH 4 buffer with 3 
M urea. See the legend of Table ‎2.4 for a description of each parameter. 
     
Parameter HSQC HNCA HN(CO)CA HNCO HN(CA)CO CBCA(CO)NH 
np 2048 2048 2048 2048 2048 2048 
nt 64 32 32 8 64 64 
sw / Hz 7225 9615 9615 9615 9615 9615 
sw (15N) / 
Hz 
1700 1600 1600 2500 1600 1600 
sw (13C) / 
Hz 
N/A 4000 4000 3000 3000 10500 
ni (15N) 232 32 32 32 28 32 
ni (13C) N/A 32 32 36 30 32 
d1 / s 1 0.97 1 1 1 1.04 
Acquisition 
time / h 
10 42 44 12 70.5 90 
Table ‎2.6 NMR spectra and acquisition parameters used for assignment of 458 µM G-CSF C3 in pH 7 buffer 
without urea. See the legend of Table ‎2.4 for a description of each parameter. 
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Parameter HSQC HNCA CBCA(CO)NH 
np 2048 2048 2048 
nt 64 32 32 
sw / Hz 7225 9615 9615 
sw (15N) / Hz 1600 1600 1600 
sw (13C) / Hz N/A 4000 10500 
ni (15N) 232 32 32 
ni (13C) N/A 32 32 
d1 / s 1 0.97 1.04 
Acquisition time / h 10 42 90 
Table ‎2.7 NMR spectra and acquisition parameters used for assignment of 208 µM G-CSF C3 in pH 7 buffer with 4 
M urea. See the legend of Table ‎2.4 for a description of each parameter. 
 
Backbone assignments of amide proton and nitrogen atoms plus alpha, beta and 
carbonyl carbon atoms of G-CSF C3 in pH 4 buffer were aided by previous 
backbone assignments of G-CSF wt by Zink et al.283 and Werner et al.288, which in 
turn assisted assignment of the same atoms of G-CSF C3 in pH 7 buffer. Backbone 
assignments of amide proton and nitrogen atoms of G-CSF C3 in pH 4 and 7 buffers 
in the presence of urea were aided by urea titrations monitored by 1H-15N HSQC 
spectra outlined in Section ‎2.9.3.  
 
Assignments of backbone amide proton and nitrogen atoms of G-CSF wt in pH 4 
buffer were achieved using previous backbone assignments of G-CSF wt by Zink et 
al.283 and Werner et al.288. 111 µM G-CSF wt in pH 4 buffer was used to acquire an 
1H-15N HSQC spectrum for backbone assignment using the parameters outlined in 
Table  2.8. 
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Parameter HSQC 
np 1024 
nt 40 
sw / Hz 8621 
sw (15N) / Hz 1600 
ni (15N) 256 
d1 / s 0.9 
Acquisition time / h 6 
Table ‎2.8 Acquisition parameters for 1H-15N HSQC spectrum used for assignment of 111 µM G-CSF wt in pH 4 
buffer. See the legend of Table ‎2.4 for a description of each parameter. 
 
2.9.2 Comparison of G-CSF‎C3‎from‎‘peak’‎and‎‘tail’‎elution‎pools‎of‎cation‎
exchange chromatography by 1H-15N HSQC spectra 
 
1H-15N HSQC spectra of 173 and 177 µM G-CSF C3 in pH 4 buffer obtained from 
‘peak’ and ‘tail’ elution pools of cation exchange chromatography, respectively (see 
Section ‎2.5.3) were acquired using the parameters outlined in Table  2.9, in order to 
elucidate any structural differences between G-CSF C3 obtained from these 
different elution pools. 
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Parameter HSQC 
np 1024 
nt 16 
sw / Hz 8621 
sw (15N) / Hz 1600 
ni (15N) 256 
d1 / s 0.9 
Acquisition time / h 2.5 
Table ‎2.9 Acquisition parameters for 1H-15N HSQC spectra used for assignment of 173 and 177 µM G-CSF C3 in 
pH 4 buffer obtained from ‘peak’ and ‘tail’ elution pools of cation exchange chromatography. See the legend of 
Table ‎2.4 for a description of each parameter.    
 
2.9.3 Urea titrations of G-CSF C3 monitored by 1H-15N HSQC spectra 
 
1H-15N HSQC spectra of 103 and 81 µM G-CSF C3 in pH 4 and 7 buffers, 
respectively were acquired in the presence of 0-7 M urea with 0.5 M increments. 
Spectra were acquired using the parameters outlined in Table  2.10.  
 
Parameter HSQC 
np 2048 
nt 4 
sw / Hz 9615 
sw (15N) / Hz 1700 
ni (15N) 128 
d1 / s 1 
Acquisition time / mins 20 
Table ‎2.10 Acquisition parameters for 1H-15N HSQC spectra used to monitor urea titration of G-CSF C3. 103 and 81 
µM G-CSF C3 were used in pH 4 and 7 buffers, respectively in the presence of 0-7 M urea with 0.5 M increments. 
See the legend of Table ‎2.4 for a description of each parameter.  
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2.9.4 G-CSF C3 aggregation at different urea concentrations monitored by 
1H-15N HSQC spectra 
 
1H-15N HSQC spectra were acquired using a Varian Inova spectrometer (Agilent) at 
37 oC operating at a proton resonance frequency of 750 MHz and equipped with a 
cryogenic probe. Assignments for backbone amide proton and nitrogen nuclei were 
transferred from 25 to 37 oC by acquisition of 1H-15N HSQC spectra at 3 oC 
temperature intervals within this temperature range. Spectra of 78 and 85 µM G-
CSF C3 in pH 4 buffer in the presence and absence of 3 M urea, respectively, plus 
63 and 65 µM G-CSF C3 in pH 7 buffer in the presence and absence of 4 M urea, 
respectively were acquired using the parameters outlined in Table  2.11. Samples 
were left to equilibrate at each temperature interval for at least 1 h before starting 
acquisition. 
 
Parameter HSQC 
np 2048 
nt 8 
sw / Hz 11962 
sw (15N) / Hz 1971 
ni (15N) 128 
d1 / s 1 
Acquisition time / mins 40 
Table ‎2.11 Acquisition parameters for 1H-15N HSQC spectra used to monitor temperature titration of G-CSF C3. 78 
and 85 µM G-CSF C3 were used in pH 4 buffer in the presence and absence of 3 M urea, respectively, while in pH 
7 buffer 63 and 65 µM G-CSF C3 were used in the presence and absence of 4 M urea, respectively. See the legend 
of Table ‎2.4 for a description of each parameter. 
   
For monitoring of G-CSF C3 aggregation, spectra of 83 and 85 µM G-CSF C3 in pH 
4 buffer in the presence and absence of 3 M urea, respectively, or of 67 and 66 µM 
G-CSF C3 in pH 7 buffer in the presence and absence of 4 M urea, respectively 
were acquired using the parameters outlined in Table  2.12. After an overall 
acquisition period of 24 h at 37 oC samples were snap frozen using dry ice and 
ethanol and stored at -80 oC. The resulting losses of amide proton signals for G-
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CSF C3 aggregation assay samples in pH 7 buffer with and without 4 M urea were 
fitted to a single exponential decay with a y-axis offset using in-house software 
written in Python by Dr. Theodoros Karamanos. Error calculation was performed 
based on the experimental noise determined by CCPN Analysis321.  
 
The amide proton peak intensities from spectra of G-CSF C3 aggregation assays 
carried out in pH 4 buffer with or without 3 M urea could not be fitted to a single 
exponential decay so these data were not included in analysis. However, insoluble 
aggregates from these samples were analysed by electron microscopy (EM), along 
with insoluble aggregates from pH 7 aggregation assay samples (see Section ‎2.8). 
 
Parameter HSQC 
np 2118 
nt 6 
sw / Hz 11962 
sw (15N) / Hz 1971 
ni (15N) 130 
d1 / s 1 
Acquisition time / mins 30 
Table ‎2.12 Acquisition parameters for 1H-15N HSQC spectra used to monitor aggregation of G-CSF C3 at 37 oC. 83 
and 85 µM G-CSF C3 were used in pH 4 buffer in the presence and absence of 3 M urea, respectively, while in pH 
7 buffer 67 and 66 µM G-CSF C3 were used in the presence and absence of 4 M urea, respectively. See the legend 
of Table ‎2.4 for a description of each parameter. 
 
2.9.5 ANS binding to G-CSF C3 monitored by 1H-15N HSQC spectra 
 
1H-15N HSQC spectra were acquired using a Varian Inova spectrometer (Agilent) at 
25 oC operating at a proton resonance frequency of 750 MHz and equipped with a 
cryogenic probe. Spectra of 85 and 65 µM G-CSF C3 in pH 4 and 7 buffers 
respectively, in the presence of 700 µM ANS were acquired using the parameters 
outlined in Table  2.13.  
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Parameter HSQC 
np 2048 
nt 12 
sw / Hz 11962 
sw (15N) / Hz 1971 
ni (15N) 256 
d1 / s 1 
Acquisition time / h 2 
Table ‎2.13 Acquisition parameters for 1H-15N HSQC spectra used to monitor ANS binding of G-CSF C3 at 25 oC. 85 
and 65 µM G-CSF C3 in pH 4 and 7 buffers, respectively in the presence of 700 µM ANS were used. See the 
legend of Table ‎2.4 for a description of each parameter. 
 
2.9.6 Calculating chemical shift perturbations (CSPs) from amide proton 
chemical shifts 
 
CSPs were mainly calculated in order to probe for conformational changes of G-
CSF C3 in pH 4 and 7 buffer upon addition of sub-denaturing urea concentrations, 
as well as assessing structural differences between G-CSF C3 at pH 4 and 7 in the 
absence of urea. 1H and 15N chemical shifts of backbone amide proton and nitrogen 
nuclei for G-CSF C3 at pH 4 in 0, 0.5 and 3 M urea, as well as G-CSF C3 at pH 7 in 
0, 0.5 and 4 M urea were obtained from backbone assignments (see Section ‎2.9.1) 
and urea titrations (see Section ‎2.9.3). CSPs were also calculated to probe for 
conformational changes of G-CSF C3 during temperature titration of 1H-15N HSQC 
spectra from 25-37 oC (see Section ‎2.9.4). In addition, CSPs were calculated to 
determine regions of G-CSF C3 that may be involved in binding to ANS. Changes in 
the chemical shifts of amide protons and nitrogens for G-CSF C3 due to the 
presence of ANS were assessed by acquiring 1H-15N HSQC spectra (see 
Section ‎2.9.5).  
 
The structural similarity between recombinantly expressed G-CSF wt used in this 
study to previous studies of G-CSF wt by NMR was also assessed by calculating 
CSPs. For assessing the structural similarity of G-CSF wt produced in this study to 
protein produced in previous studies of G-CSF wt by NMR, the centres of the 
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nitrogen and proton dimensions of the 1H-15N HSQC spectrum of G-CSF wt were 
adjusted until chemical shifts for the backbone amide nitrogen and proton of Thr2 
matched the chemical shifts reported for this residue by Zink et al.283 and Werner et 
al.288. Thr2 was chosen because this residue is within the unstructured twelve 
residue N-terminal segment, meaning any structural differences between G-CSF wt 
used in this study and wild-type protein used in previous studies would be unlikely to 
affect this residue. CSPs were also used to determine the structural similarity 
between G-CSF wt and C3 at pH 4 prepared in this study.   
 
CSPs were calculated using Equation  2.20; where the scaling factor of 0.14 for 
differences in 15N chemical shifts represents the ratio of the range of 1H chemical 
shifts (in ppm) occupied to the range of 15N chemical shifts (in ppm) occupied332.  
 
 
CSP = √(Δδ1H)2 + (0.14Δδ15N)2 Equation  2.20 
 
 
2.9.7 Hydrogen/deuterium exchange monitored by 1H-15N HSQC spectra 
 
In natively folded proteins exchangeable protons are involved in hydrogen bonding, 
either with the solvent or within the secondary and tertiary structures of proteins. 
Consequently, exchange of these protons with solvent deuterons relies on a 
structural isomerisation represented by Equation  2.21333-335.  
 
 
 
NHclosed ⇌ NHopen ↔ ND Equation  2.21 
   
 
The observed rate constant (kobs) for hydrogen exchange depends on the rates of 
the opening (kop) and closing (kcl) reactions as well as the intrinsic rate of hydrogen 
exchange (kch) according to Equation  2.22
333-335. kch represents the rate of hydrogen 
exchange of the amino acid sequence of the fully unfolded and solvent exposed 
protein. kch is heavily dependent on pH and temperature
335 as well as amino acid 
sequence336, the effects of which have all been quantified precisely allowing 
calculation of kch using freely available computational tools such as CIntX
337.     
kop 
kcl 
kch 
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kobs =
kopkch
(kop + kcl + kch)
 Equation  2.22 
 
For a natively folded protein kop is assumed to be much lower than kcl, meaning 
Equation  2.22 can be simplified to Equation  2.23.  
 
 
kobs =
kopkch
(kcl + kch)
 Equation  2.23 
 
Under conditions where the intrinsic rate of hydrogen exchange is low i.e. kch << kcl 
the value of kobs becomes dependent on the proportion of exchangeable protons that 
are exposed to solvent, which is represented by the opening equilibrium constant 
(Kop) in Equation  2.24. Conversely, when the intrinsic rate is high i.e. kch > kcl 
hydrogen exchange occurs as soon as exchangeable protons become exposed to 
solvent, meaning kobs is only limited by kop (Equation  2.25). Due to the bimolecular 
and unimolecular nature of the exchange mechanisms depicted in Equation  2.24 
and Equation  2.25 they have been termed EX2 and EX1, respectively334. 
 
EX2 kobs = Kopkch Equation  2.24 
 
EX1 kobs = kop Equation  2.25 
 
Buffer components required to prepare 10 ml of pH 4 and 7 buffer were dissolved in 
4 ml of D2O and lyophilised. Buffer components required to prepare 10 ml of pH 4 
buffer with 3.33 M urea and pH 7 buffer with 4.44 M urea were dissolved in 9 ml of 
D2O and lyophilised. After freeze-drying buffer components were resuspended and 
made up to a final volume of 10 ml using D2O and the pD was adjusted to 4.8 or 7.8 
for pH 4 and 7 buffer components, respectively. pD 4.8 and pD 7.8 buffers exhibited 
pH meter readings of 4.4 and 7.4, respectively338. 
 
A concentrated G-CSF C3 pH 4 stock was diluted to a final concentration of 52 µM 
in 500 µl of pD 4.8 deuterated buffer with and without a final urea concentration of 3 
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M, followed by brief manual mixing to initiate hydrogen/deuterium exchange 
reactions. A concentrated G-CSF C3 pH 7 stock was also diluted to a final 
concentration of 52 µM in 300-350 µl of pD 7.8 deuterated buffer with and without a 
final urea concentration of 4 M, followed by brief manual mixing to initiate exchange. 
 
After mixing, hydrogen exchange reaction samples were placed into a Shigemi 
microtube and inserted into the NMR spectrometer. Hydrogen exchange was 
monitored based on measuring peak intensities of amide protons using 1H-15N band-
selective optimised-flip-angle short-transient (SOFAST) HMQC spectra339, the 
parameters of which are outlined in Table  2.14. The dead-time between initiating 
exchange and beginning acquisition was 7-8 mins. In total, spectra of G-CSF C3 
samples in pD 4.8 buffer were acquired over 24 h, while spectra of G-CSF C3 
samples in pD 7.8 buffer were acquired over 15 h.   
 
Parameter pD 4.8 samples pD 7.8 samples 
flip angle 120o 120o 
np 512 512 
nt 24 8 
sw / Hz 8503 8503 
sw (15N) / Hz 1600 1600 
ni 68 60 
d1 / s 0.302 0.248 
Acquisition time / mins 20 5 
Table ‎2.14 Acquisition parameters for 1H-15N SOFAST-HMQC spectra used to monitor amide proton hydrogen 
exchange reactions of G-CSF C3. 52 µM G-CSF C3 was used in pD 4.8 buffer in the presence and absence of 3 M 
urea as well as in pD 7.8 buffer in the presence and absence of 4 M urea. Flip angle refers to the degree of 
inversion of amide protons relative to the z-axis. See the legend of Table ‎2.4 for a description of other parameters.             
 
The resulting loss of amide proton signal was fitted to a single exponential decay 
with a y-axis offset using in-house software written in Python by Dr. Karamanos. 
Error calculation was performed based on the experimental noise determined by 
CCPN Analysis321. Measured rate constants (kobs) were used with intrinsic rate 
constants (kch) calculated using CIntX
337 in Equation  2.26 to calculate protection 
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factors (PFs)335. The ratio of ln(PF) for G-CSF C3 in pD 4.8 and 7.8 buffers to ln(PF) 
in the urea concentrations specified was then calculated to elucidate residues with 
altered solvent exposure upon addition of urea.      
 
 
PF =
kch
kobs
 Equation  2.26 
 
2.9.8 Amide nitrogen transverse relaxation (R2) 
 
Introduction of nuclei with spin quantum number I = ½ into a magnetic field causes 
the energy levels represented by the α and β spin states to be populated according 
to the Boltzmann distribution, resulting in a slightly higher population of spins in the 
α state compared to the β state and causing net magnetisation along the z-axis. 
Excitation of nuclei by application of a radiofrequency pulse disturbs the Boltzmann 
distribution, giving rise to precession of spins perpendicular to the axis of the 
magnetic field in the xy plane. Relaxation encompasses the processes by which the 
Boltzmann distribution of spins is restored, meaning net magnetisation is lost in the 
xy plane and restored along the z-axis. 
 
The three processes by which relaxation occurs are longitudinal and transverse 
relaxation, the rates of which are denoted R1 and R2, respectively and the nuclear 
Overhauser effect (nOe). Longitudinal relaxation is the return of magnetisation to the 
z-axis, while transverse relaxation is the loss of coherence in the xy plane. 
Consequently, R1 determines the time period before nuclei can be excited again by 
a radiofrequency pulse and R2 determines the width of peaks. The nOe is the 
exchange of magnetisation between nuclei through space and is proportional to the 
inverse of the sixth power of the distance between nuclei.   
  
For spin I = ½ nuclei, the two mechanisms by which relaxation occurs are dipolar 
relaxation and chemical shift anisotropy (CSA). Dipolar relaxation arises from the 
interaction of the magnetic field of one spin with another spin. The strength of this 
dipolar coupling is proportional to the gyromagnetic ratios of the interacting nuclei 
and the inverse cube of the distance between nuclei, while it is also affected by the 
direction of the vector connecting the two nuclei relative to the magnetic field. The 
relaxation induced by dipolar coupling is proportional to the square of the dipolar 
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coupling, i.e. to the inverse sixth power of the distance between nuclei. Fluctuations 
of the local magnetic field caused by either molecular tumbling of nuclei in solution 
or protein motions are the cause of dipolar relaxation in proteins. Dipolar relaxation 
also causes transition of spins between α and β states, giving rise to the nOe.   
 
The electronic density around a nucleus, which gives rise to the chemical shift, is not 
spherical (isotropic), but varies as the orientation of the nucleus changes with 
respect to the magnetic field. This phenomenon gives rise to CSA. In solution, fast 
molecular tumbling causes CSA to be rotationally averaged across all possible 
orientations, resulting in a single chemical shift. However, changes in the strength 
and direction of the magnetic field experienced by nuclei caused by molecular 
tumbling cause fluctuations in the local magnetic fields of spins, resulting in 
relaxation.    
 
Dipolar relaxation and CSA are the mechanisms by which longitudinal and 
transverse relaxation occur. However, transverse relaxation is also contributed to by 
spins precessing at different frequencies in the xy plane. This additional contribution 
results in longitudinal and transverse relaxation rates having different dependencies 
on correlation time as depicted in Figure  2.4324.          
 
 
Figure ‎2.4 Variation of the relaxation rate constant (W) with correlation time (τc) for longitudinal and transverse 
relaxation of nuclei. τc is the time taken for the molecule to rotate through one radian. At the point where τc is equal 
to the inverse of the Larmor frequency (1/ω0) the longitudinal rate reaches a maximum but the transverse rate 
continues to increase. This figure is reproduced from Keeler (2005)
324
.   
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Measurement of relaxation properties of proteins typically uses backbone amide 
nitrogen nuclei. The low gyromagnetic ratio of nitrogen (γ = -2.71 × 107 T s-1)319, 
coupled with the high gyromagnetic ratio of proton (γ = 2.67 × 108 T s-1)319, means 
that R1 and R2 relaxation of backbone amide nitrogen nuclei is predominantly due to 
dipole-dipole interactions with the attached proton319,340 and so can be used to 
investigate local fluctuations of the polypeptide backbone. Measured R2 rates may 
also be affected by chemical exchange resulting from larger amplitude protein 
motions341. In order to reduce the contributions of R1 relaxation and chemical 
exchange to measured R2 rates a series of 180
o pulses with set time delays before 
and after each pulse is applied in the indirect dimension, referred to as a Carr-
Purcell-Meiboom-Gill (CPMG) pulse train342,343. The CPMG sequence is 
implemented between the first INEPT block and the t1 evolution period in the indirect 
dimension of the HSQC pulse sequence (see Figure  2.1), keeping spins of nitrogen 
nuclei in the xy plane while decoherence occurs. By varying the number of 
repetitions of the CPMG block time delays of different lengths are created and 1H-
15N HSQC spectra with different amide proton peak intensities are acquired, which 
can be used to calculate R2 rates for each amide nitrogen
341.  
      
162, 151 and 163 µM G-CSF C3 in pH 4 buffer in the presence of 0, 0.5 and 3 M 
urea, respectively and 130, 135 and 134 µM G-CSF C3 in pH 7 buffer in the 
presence of 0, 0.5 and 4 M urea, respectively were used for measuring backbone 
15N R2 rates. Time delays of 16.1, 32.2, 48.4, 64.5, 80.6, 96.7, 112.8 and 129.0 ms 
were used in R2 experiments. Relaxation occuring during these mixing times 
resulted in 1H-15N HSQC spectra with varying amide proton peak intensities, the 
parameters of which are outlined in Table  2.15. Amide proton peak intensities at 
each relaxation delay were fitted to a single exponential decay using in-house 
software written in Python by Dr. Thompson and Dr. Karamanos. Errors were 
calculated as the difference of duplicate peak intensities from the mean intensity 
acquired using relaxation delays of 32.2 and 96.7 ms. Monte Carlo error analysis 
with one thousand steps was performed to calculate the error of the parameters 
obtained from fitting of peak intensities to a single exponential decay. The ratio of R2 
for G-CSF C3 in pH 4 and 7 buffers to R2 in the urea concentrations specified was 
then calculated to elucidate residues with altered dynamics upon addition of urea. 
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Parameter HSQC 
np 2048 
nt 8 
sw / Hz 12019 
sw (15N) / Hz 1600 
ni (15N) / Hz 160 
d1 / s 2.5 
Acquisition time / h 20 
Table ‎2.15 Acquisition parameters for 1H-15N HSQC spectra used to measure backbone 15N R2 rates of G-CSF C3. 
162, 151 and 163 µM G-CSF C3 were used in pH 4 buffer in the presence of 0, 0.5 and 3 M urea, respectively, 
while in pH 7 buffer 130, 135 and 134 µM G-CSF C3 were used in the presence of 0, 0.5 and 4 M urea, 
respectively. See the legend of Table ‎2.4 for a description of each parameter.    
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Chapter 3 Biophysical comparison of the native states of     
G-CSF wt and C3 
 
3.1 Introduction 
 
The variant of G-CSF identified by Buchanan et al.150, termed G-CSF C3, was 
identified by screening a library of G-CSF DNA constructs generated randomly by 
error-prone PCR. Screening consisted of four rounds of in vitro ribosome display, 
with increasingly stringent selection pressures being employed during each round 
(see Section  1.6.4). G-CSF variants remaining after these four rounds of selection 
were subsequently cloned and expressed in the periplasm of E. coli strain HB2151 
along with wild-type G-CSF. One of the variants identified as showing increased 
soluble expression of monomeric protein was G-CSF C3, which was corroborated 
by SDS-PAGE and SEC-HPLC analysis of G-CSF C3 purified from 2 l periplasmic 
expression in parallel with the wild-type protein. G-CSF C3 contains four amino acid 
substitutions relative to wild-type, these being C18G, W59R, Q71R and F84L. 
Despite these substitutions, G-CSF C3 was shown to have equivalent functional 
activity to wild-type G-CSF from cell proliferation assays. Although the substitutions 
W59R and Q71R are predicted to reduce aggregation propensity, based on 
computational modelling of G-CSF with and without the substitutions found in the 
variant C3150, reduced aggregation was not confirmed experimentally. Likewise, 
there have been no attempts to investigate the structure of G-CSF C3 and make 
comparisons of its aggregation behaviour to wild-type G-CSF. 
 
G-CSF proteins used in this study were expressed in the cytoplasm of E. coli, 
resulting in formation of insoluble inclusion bodies. Consequently, after refolding of 
G-CSF proteins from cytoplasmic inclusion bodies and subsequent purification it 
was critical to establish that the functional native conformation of monomeric G-CSF 
had been reached by comparison with previous biophysical studies of wild-type G-
CSF. In this chapter, the expression of G-CSF wt and C3 are described, along with 
their purification and characterisation using a range of biophysical techniques to 
confirm they were correctly folded, as well as providing more structural information 
about the variant C3.  In addition, isotope labelling of G-CSF wt (15N) and C3 
(15N/13C) proteins are described and their purification to allow assignment of 1H-15N 
HSQC spectra. Acquisition and assignment of 1H-15N HSQC spectra allowed higher 
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resolution structural comparison of G-CSF wt and C3 and provided a more reliable 
measure of these proteins having reached their native conformation.  
 
In the following chapter all experiments carried out in pH 4 and 7 buffers were 
performed in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer or 20 
mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 
buffer unless otherwise stated.    
 
3.2 Results                      
 
3.2.1 Recombinant expression of G-CSF proteins 
 
Expression trials of G-CSF C3 in BL21(DE3) and BL21(DE3) pLysS cells were 
carried out to determine which of these E. coli strains would provide the highest 
yield of G-CSF proteins. Competent BL21(DE3) and BL21(DE3) pLysS cells (see 
Section  2.1.3) were transformed with pET23a_G-CSF_C3 (Appendix  7.3) and grown 
on LB and agar plates containing 100 µg/ml carbenicillin (and 34 µg/ml 
chloramphenicol for pLysS cells; see Section  2.2.7). Single colonies were used to 
inoculate 250 ml overnight LB cultures containing 100 µg/ml carbenicillin (and 34 
µg/ml chloramphenicol for pLysS cells), which were incubated at 37 oC with shaking 
at 200 rpm. 20 ml of overnight cultures were used to inoculate 1 l LB expression 
cultures that were subsequently incubated at 37 oC with shaking at 200 rpm. At an 
OD600 of 0.6 protein expression was induced in half of the expression cultures by 
addition of 1 mM IPTG, followed by incubation of both induced and uninduced 
expression cultures for a further 4 h at 37 oC with shaking at 200 rpm. At the end of 
each hour the OD600 was measured and pellets harvested from 1 ml samples of 
expression culture by centrifugation at 13300 rpm for 5 mins at room temperature. 
Cell pellets were lysed by resuspending in appropriate amounts of 2× loading buffer 
to correct for cell density and expression levels analysed by SDS-PAGE 
(Figure  3.1). 
Biophysical comparison of the native states of G-CSF wt and C3 
 
105 
 
 
Figure ‎3.1 Recombinant expression trials of G-CSF C3 in E. coli strains BL21(DE3) and BL21(DE3) pLysS. At an 
OD600 of 0.6 protein expression was induced in half of the expression cultures (I) and the other half were left 
uninduced (U). After induction samples of both induced and uninduced expression cultures of BL21(DE3) (A) and 
BL21(DE3) pLysS (B) cells were harvested at the time periods shown, which included samples taken from cultures 
that had been left overnight (o/n). Samples of cultures from expression trials of G-CSF C3 in BL21(DE3) pLysS cells 
were not taken 3 h after induction. The sizes of protein molecular mass markers are shown on the left in kDa.    
 
Expression trials showed that the highest expression of G-CSF C3 is achieved using 
E. coli strain BL21(DE3) pLysS with induction by addition of 1 mM IPTG, followed by 
incubation for 4 h or overnight at 37 oC with shaking at 200 rpm. Interestingly, 
recombinant protein expression appears to occur regardless of the addition of IPTG 
when E. coli strain BL21(DE3) is used, but when using BL21(DE3) pLysS cells 
expression only occurs after induction with IPTG.  
 
pET vectors are commonly used for recombinant expression due to the high levels 
of mRNA synthesised, typically leading to recombinant protein expression 
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encompassing 40-50% of total cellular protein176,344. High levels of transcription are 
due to incorporation of the target DNA sequence downstream of the promoter for the 
highly processive bacteriophage T7 RNA polymerase. T7 RNA polymerase is not 
endogenous to bacterial chromosomes, meaning it must be supplied during 
recombinant expression. In the case of BL21(DE3) cells, DNA encoding viral T7 
RNA polymerase is integrated into the bacterial chromosome by prophage λDE3, 
under control of the IPTG-inducible lacUV5 promoter344. 
 
Positioning of the T7 polymerase DNA sequence downstream of the lacUV5 
promoter should provide stringent regulation of recombinant protein expression. 
However, high levels of recombinant expression using the pET system without 
inducer have been shown previously for a number of soluble and insoluble proteins 
expressed in LB medium345-348, including G-CSF348. This phenomenon is thought to 
occur when cells cultured in complex media reach the stationary phase and is 
caused by a lack of carbon sources. The lac operon plays an endogenous role in 
carbohydrate scavenging, thus being activated under such nutrient-limited 
conditions in a cAMP-dependent process349.  
 
Presumably, recombinant expression of G-CSF wt and C3 stimulates this nutrient 
limited response and uninduced recombinant protein expression in E. coli 
BL21(DE3) cells. The additional pLysS plasmid found in BL21(DE3) pLysS cells 
encodes bacteriophage T7 lysozyme, which binds T7 RNA polymerase and inhibits 
transcription350. T7 lysozyme thus inhibits transcription by small amounts of T7 RNA 
polymerase that may be expressed by cells, especially in carbon-starved conditions, 
but after induction the expression level of T7 RNA polymerase is greatly increased 
and T7 lysozyme is no longer able to inhibit transcription. This additional regulation 
restores the ability to induce protein expression with IPTG176, as well as improving 
the recombinant expression level of G-CSF C3 (Figure  3.1).              
 
Expression trials of G-CSF wt and C3 using E. coli strain BL21(DE3) pLysS were 
also carried out to assess whether the cytoplasmic expression level of G-CSF C3 is 
higher than wild-type in line with the periplasmic expression levels of these 
proteins150. The results of these expression trials show that the cytoplasmic 
expression level of G-CSF C3 is significantly higher than that of the wild-type protein 
(Figure  3.2).     
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Figure ‎3.2 Recombinant expression trials of G-CSF wt and C3 in E. coli strain BL21(DE3) pLysS. At an OD600 of 0.6 
protein expression was induced and samples of expression cultures were harvested 4 h after induction. The sizes of 
protein molecular mass markers are shown on the left in kDa. 
 
3.2.2 Purification of G-CSF proteins 
 
3.2.2.1 G-CSF inclusion body preparation and solubilisation 
 
G-CSF proteins expressed in the cytoplasm of E. coli form insoluble inclusion 
bodies, evidenced from the appearance of G-CSF in the insoluble fraction of cell 
lysate (Figure  3.3). This is most likely due to the reducing environment of the E. coli 
cytoplasm130, which prevents the formation of the two disulphide bonds needed for 
G-CSF to refold to its native biologically active conformation285. After recombinant 
expression in BL21(DE3) pLysS cells and cell lysis by sonication, G-CSF inclusion 
bodies were harvested by centrifugation at 15000 rpm for 30 mins at 4 oC. Inclusion 
bodes were washed by resuspending in 50 mM TrisHCl, 5 mM EDTA, 1 % (v/v) 
triton X-100 pH 8 (wash buffer 1) to remove cell membranes and harvested by 
centrifugation as above. This wash step was repeated using 50 mM TrisHCl, 5 mM 
EDTA, 4 M urea pH 8 (wash buffer 2) to solubilise contaminant proteins. Finally, G-
CSF inclusion bodies were solubilised by resuspending in 50 mM TrisHCl, 5 mM 
EDTA, 6 M GdnHCl, 10 mM DTT pH 8 (unfolding buffer) and centrifuged as above 
to remove any remaining insoluble material (Figure  3.3).  
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Figure ‎3.3 Inclusion body extraction, washing and solubilisation for G-CSF wt and C3. Cell lysates were centrifuged 
in order to separate pellet (P) and supernatant (S). G-CSF wt (A) and C3 (B) inclusion bodies were subsequently 
washed by resuspending in wash buffers containing 1 % (v/v) triton X-100 and 4 M urea (washes 1 and 2, 
respectively), with G-CSF inclusion bodies being harvested after each wash step. After washing, G-CSF inclusion 
bodies were solubilised and unfolded by resuspending in buffer containing 6 M GdnHCl and 10 mM DTT (unfolded) 
and centrifuged to remove any remaining insoluble material. Dialysis of refolded G-CSF into pH 4 buffer for cation 
exchange resulted in large amounts of aggregate that were removed by centrifugation and filtration. Samples of 
pellet and supernatant from G-CSF C3 after refolding and dialysis are shown in B. The sizes of protein molecular 
mass markers are shown on the left in kDa.  
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3.2.2.2 G-CSF refolding and purification by cation exchange 
chromatography  
 
After solubilising and unfolding G-CSF proteins from inclusion bodies, refolding was 
achieved by ten-fold dilution in 50 mM TrisHCl, 5 mM EDTA, 0.9 M arginine pH 8 
buffer. Arginine has been frequently used for refolding of proteins from inclusion 
bodies199-203, including G-CSF202,203, due its ability to suppress aggregation200,201 (see 
Section  1.4.4.1).  
 
Refolded G-CSF proteins were dialysed into pH 4 buffer for purification by cation 
exchange chromatography, a commonly used final purification step during 
preparation of G-CSF203,348,351,352. However, during dialysis aggregation was 
observed. SDS-PAGE analysis of pellet and supernatant from G-CSF C3 after 
refolding and dialysis revealed this aggregate to be a mixture of G-CSF C3 and 
contaminant proteins (Figure  3.3B). Insoluble aggregates were removed by 
centrifugation at 15000 rpm for 30 mins at 4 oC followed by filtration using a 0.22 µm 
filter before loading onto an SP HP cation exchange column for purification. Ten-fold 
dilution of G-CSF proteins during refolding resulted in large volumes of dilute protein 
solutions, which required loading onto the column through line A1 of an Äkta prime 
plus pump system. The bound protein was eluted from the column over an elution 
gradient of 0-1 M NaCl over 100 ml with 2 ml fractions being collected. The purity of 
eluted G-CSF proteins was determined by SDS-PAGE (Figure  3.4).  
 
Unusually, the elution traces observed for G-CSF proteins during cation exchange 
chromatography did not immediately return to baseline after elution of the main peak 
(Figure  3.4A and B), giving these elution traces the appearance of a ‘peak’ with a 
succeeding ‘tail’. SDS-PAGE analysis shows that G-CSF proteins are the only 
component of elution fractions collected from the peak or tail (Figure  3.4C and D). 
The reason for this tail may be the appearance of G-CSF proteins with different 
degrees of deamidation of glutamine residues276, which would affect the overall 
charge of the protein. Consequently, elution fractions from the peak and tail of cation 
exchange chromatography were pooled separately and desalted by dialysis into pH 
4 buffer. 
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Figure ‎3.4 Cation exchange purification of refolded G-CSF wt and C3. G-CSF proteins were loaded onto an SP HP 
cation exchange column in pH 4 buffer. Approximately 130 ml of G-CSF wt was loaded, although the protein 
concentration was too dilute to measure accurately (A). Approximately 390 ml of G-CSF C3 was loaded at a protein 
concentration of 0.57 mg/ml (B). Loading and elution of protein was followed by measurement of A280 (blue line and 
left hand y-axis of elution traces). Bound protein was eluted from the column using a gradient of 0-100 % elution 
buffer (green line and right hand y-axis of elution traces) applied over 100 ml with 2 ml fractions being collected. 
Elution buffer used was pH 4 buffer with 1 M NaCl. Numbers of elution fractions collected are shown on the top x-
axis and the purity of elution fractions collected in or around the elution peak were assessed by SDS-PAGE for G-
CSF wt (C) and C3 (D). The sizes of protein molecular mass markers are shown on the left in kDa.    
 
Peak pools constituted fractions 16-23 and 27-32 from purifications of G-CSF wt and 
C3, respectively, while tail pools constituted fractions 24-40 and 33-45 from 
purifications of G-CSF wt and C3, respectively (Figure  3.4). After desalting, these 
elution pools were concentrated to 2.5-5 mg/ml for G-CSF wt pools and 8-10 mg/ml 
for G-CSF C3 pools then snap frozen as aliquots of 50-200 µl. The purity of these 
pools was assessed by SDS-PAGE (Figure  3.5).     
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Figure ‎3.5 Purified G-CSF wt and C3 obtained from the ‘peak’ and ‘tail’ portions of cation exchange 
chromatography elution traces. G-CSF wt samples from peak and tail elution pools were analysed at 27 and 25 µM, 
respectively (A). G-CSF C3 samples from peak and tail elution pools were analysed at 36 and 42 µM, respectively 
(B). G-CSF C3 samples from the peak elution pool at pH 4 and 7 were analysed at 50 µM (C). The sizes of protein 
molecular mass markers are shown on the left in kDa.   
 
In all elution pools there appears to be a faint band below the most intense gel band 
corresponding to G-CSF (Figure  3.5). Amino acid sequencing of the protein from 
both faint and strong gel bands by enzymatic digest and electrospray ionisation 
tandem mass spectrometry (ESI-MS/MS), carried out by Dr. James Ault, identified 
them both as G-CSF (results not shown).  Dialysis of a sample of G-CSF C3 in pH 4 
buffer into pH 7 buffer and subsequent analysis by SDS-PAGE did not remove this 
additional faint gel band (Figure  3.5C), suggesting that this band is not caused by 
inefficient reduction of the two disulphide bonds of G-CSF by DTT at pH 4. 
Therefore, this faint extra band observed in SDS-PAGE is most likely the result of a 
small amount of proteolytic degradation276 reducing the mass of the protein. G-CSF 
wt obtained from the tail portion of cation exchange was not pure enough for 
experimental use and so was discarded, while all other aliquots of G-CSF wt and C3 
were sufficiently pure for use in experiments.  
 
The total yields of pure G-CSF wt and C3 were approximately 0.1 and 6.5 mg, 
respectively per litre of LB medium used for expression. Unusually, the total yields of 
pure isotopically labelled G-CSF wt and C3 from expression in M9 minimal medium 
(see Section  2.1.4) were slightly higher than those observed from expression in LB 
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medium, with yields of approximately 0.2 and 9.1 mg per litre of M9 medium used 
for expression of G-CSF wt and C3, respectively.      
 
3.2.3 Mass spectrometry of G-CSF proteins 
 
3.2.3.1 Confirmation of the molecular masses of G-CSF proteins 
 
The molecular masses of purified G-CSF wt and C3 were confirmed by electrospray 
ionisation mass spectrometry (ESI-MS), carried out by Dr. Ault (see Section  2.3.4.1). 
Before analysis by ESI-MS, G-CSF samples were buffer exchanged into 66 mM 
ammonium acetate pH 4, which was calculated to match the ionic strength (I) of the 
pH 4 buffer used in this study (43 mM). G-CSF C3 from the peak and tail elution 
pools of cation exchange were analysed to determine whether there were any 
differences in the molecular masses of G-CSF C3 from these pools. The differences 
between the measured molecular masses of G-CSF wt and C3 obtained from the 
most intense peaks in mass spectra and the molecular masses predicted based on 
amino acid sequence were within the 0.01 % error of mass measurement by ESI-
MS. There appear to be no significant differences between mass spectra obtained 
for G-CSF C3 from the peak or tail of cation exchange chromatography 
(Figure  3.6B-E).  
 
An additional peak corresponding to a species with a molecular mass of 18566 Da 
was observed in the mass spectrum of native G-CSF wt (Figure  3.6A), 
corresponding to removal of the N-terminal Met and Thr residues. This proteolytic 
degradation is also suspected to be responsible for the faint additional gel band 
observed below the main G-CSF gel band in SDS-PAGE analysis (Figure  3.5). 
Mass spectra of native G-CSF C3 produced broad mass distributions, most likely 
the result of ion adducts. The vast majority of these peaks were removed by acid 
denaturation of G-CSF C3 and reduction of disulphide bonds, which was achieved 
by addition of 1 % (v/v) formic acid/50 % (v/v) acetonitrile and 10 mM TCEP, 
respectively before analysis. Mass spectra of acid denatured and reduced G-CSF 
C3 and native G-CSF wt showed four additional peaks that were higher in molecular 
mass than the main G-CSF peak, each separated by approximately 18 Da. These 
peaks were most likely the result of oxidation of the side chains of the four Met 
residues in G-CSF276.       
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Figure ‎3.6 Confirmation of the molecular masses of G-CSF wt and C3 by ESI-MS. Mass spectra are shown as the 
mass of species in Da plotted against percentage intensity, where the most intense peak is normalised to 100 %. 
Mass spectrometry of native G-CSF wt was carried out at 79 µM (A), while native G-CSF C3 was analysed at 69 
and 83 µM for peak (B) and tail (C) samples, respectively in 66 mM ammonium acetate pH 4 buffer (I = 43 mM) by 
Dr. Ault. Mass spectra of acid denatured and reduced G-CSF C3 peak and tail samples are shown in D and E, 
respectively. Peaks with masses closest to the predicted mass of G-CSF wt and C3 are highlighted in red.   
    
3.2.3.2 Confirmation of native disulphide bond formation in G-CSF proteins 
 
ESI-MS analysis of G-CSF C3 revealed a 4 Da increase in molecular mass upon 
reduction (Figure  3.6B-E), corresponding to the reduction of the two disulphide 
bonds found in native G-CSF C3. The measured molecular mass of native G-CSF 
wt was also consistent with the formation of these two disulphide bonds 
(Figure  3.6A). To confirm the two disulphide bonds had formed between Cys 
residues 37-43 and 65-75 found in native G-CSF, trypsin digests were carried out by 
Dr. Ault (see Section  2.3.4.2) and the results analysed by ESI-MS in the presence 
and absence of 5 mM TCEP (Figure  3.7 and Figure  3.8). Before digestion, G-CSF 
samples were buffer exchanged into 50 mM ammonium bicarbonate pH 7. 
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The theoretical m/z values of peptides containing disulphide bonds predicted to 
result from digestion of G-CSF wt with trypsin were used to identify peaks in mass 
spectra caused by disulphide linked peptides. These predicted m/z values were 
calculated from isotopically averaged molecular masses of peptides and their 
charge states (Figure  3.7C). In the absence of a reducing agent, the mass spectrum 
of G-CSF wt contained peaks with m/z values corresponding to disulphide 
containing peptides, which are highlighted in Figure  3.7A. Upon addition of TCEP 
four of these peaks were no longer observed, suggesting that they represent 
species containing disulphide bonds. However, two of these peaks remained after 
addition of TCEP, highlighted in red on Figure  3.7B. The m/z values of these peaks 
suggest reduction of one of the two disulphide bonds in this peptide (Figure  3.7C). 
Peaks for fully reduced peptides of digested G-CSF wt were not observed in mass 
spectra. 
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Figure ‎3.7 Trypsin digest of G-CSF wt analysed by ESI-MS to confirm the presence of native disulphide bonds 
Cys37-Cys43 and Cys65-Cys75. Mass spectra are shown as the mass-to-charge ratio (m/z) plotted against intensity 
in arbitrary units. Digested G-CSF wt samples were analysed at 50 µM in 50 mM ammonium bicarbonate pH 7 
buffer (I = 65 mM) in the absence (A) or presence (B) of 5 mM TCEP (blue and red, respectively) by Dr. Ault. Peaks 
with measured m/z values corresponding to peptides containing disulphide bonds are highlighted as outlined in C. 
The predicted m/z values of these peptides are also shown in C, along with their charge states and amino acid 
sequences. Peaks for fully reduced peptides were not observed in mass spectra and so are not listed in C.    
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G-CSF C3 contains two extra Arg residues compared with wild-type G-CSF, owing 
to the amino acid substitutions W59R and Q71R. Consequently, there are two more 
trypsin cleavage sites in G-CSF C3 than wild-type. The resulting disulphide 
containing peptides of G-CSF C3 were smaller than those found in G-CSF wt, which 
appeared to make them more amenable to analysis by ESI-MS based on the 
intensities of peaks observed in Figure  3.8 compared to Figure  3.7.  
 
The smaller peptides of G-CSF C3 containing disulphide bonds were visible both in 
oxidised and reduced forms (Figure  3.8A, B, E and F). The narrow m/z ranges over 
which these smaller peptides are shown in Figure  3.8A, B, E and F means that 
peaks resulting from incorporation of 13C at natural abundance were observed. 
Predicted m/z values of peptides containing oxidised and reduced Cys residues 
were calculated using monoisotopic molecular masses when peaks resulting from 
13C isotope distribution could be observed, whereas for peptides detected over wider 
m/z ranges (where isotope distributions could not be resolved) predicted m/z values 
were calculated using isotopically averaged molecular masses (Figure  3.8G).  
 
The larger of the two peptides linked by a disulphide bond between Cys65 and 
Cys75 was no longer detectable when this disulphide linkage was broken as shown 
in Figure  3.8C and D, which were acquired before and after treatment with 5 mM 
TCEP, respectively. Interestingly, peaks with masses corresponding to the smaller 
peptide in the Cys65-Cys75 disulphide linked species were observed both in the 
absence and presence of TCEP (Figure  3.8E and F, respectively). This is most likely 
due to the formation of Cys65-Cys65 disulphide bonds during the trypsin digest that 
were reduced by TCEP.     
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Figure ‎3.8 Trypsin digest of G-CSF C3 analysed by ESI-MS to confirm the presence of native disulphide bonds 
Cys37-Cys43 and Cys65-Cys75. Mass spectra of peptides containing disulphide linked and reduced Cys37 and 
Cys43 residues are shown in A and B, respectively. The mass spectrum of peptides linked by a disulphide bond 
between Cys65 and Cys75 is shown in C. After reduction with TCEP the larger of these peptides is no longer 
observed (D) but the smaller peptide is still detected (F). The mass spectrum of peptides linked by a disulphide 
bond between Cys65 residues is shown in E. Mass spectra are shown as the mass-to-charge ratio (m/z) plotted 
against intensity in arbitrary units. Digested G-CSF C3 samples were analysed at 50 µM in 50 mM ammonium 
bicarbonate pH 7 buffer (I = 65 mM) in the absence or presence of 5 mM TCEP (blue and red, respectively) by Dr. 
Ault. Peaks with measured m/z values corresponding to peptides containing disulphide bonds are highlighted as 
outlined in G. The predicted m/z values of these peptides are also shown in G, along with their charge states and 
amino acid sequences. Peaks for the peptide containing reduced Cys75 were not observed in mass spectra and so 
are not listed in G. 
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3.2.4 Analytical size exclusion chromatography (SEC) of G-CSF C3 
 
Analytical SEC was used to ensure purified G-CSF C3 was monomeric under the 
buffer conditions used for experiments in this study. The low yield from expression 
and purification of G-CSF wt, coupled with the high protein concentrations required 
for analytical SEC (at least 1 mg/ml) meant that only G-CSF C3 was analysed.  
 
G-CSF C3 was loaded onto a SuperdexTM 75 10/300 GL gel filtration column via a 
500 µl loop attached to the injection port of an Äkta prime plus pump system and 
elution monitored over roughly one column volume. G-CSF C3 chromatography runs 
were carried out in pH 4 and 7 buffers in the presence and absence of 200 mM 
NaCl, but calibrants were only run at pH 7 in the presence of 200 mM NaCl in 
accordance with the manufacturer’s instructions (Figure  3.9).  
 
Elution traces of G-CSF C3 at pH 7 show two peaks, the elution volumes of which 
correspond to monomeric and dimeric G-CSF C3 as revealed by the calibration plot. 
Observations of dimeric species have also been reported for G-CSF wt307,308, 
although the role of dimeric G-CSF in aggregation is uncertain. Dimeric G-CSF has 
been proposed as an on-pathway species to aggregation307, but also as an 
indistinguishable mixture of on-pathway dimer that leads to irreversible aggregation 
and off-pathway dimer that exists in equilibrium with native monomer303,308. 
 
Unusually, G-CSF C3 at pH 4 elutes from the gel filtration column after a larger 
elution volume than predicted from its molecular mass. Addition of 200 mM NaCl 
decreases the observed elution volume of G-CSF C3, suggesting that there may be 
nonspecific adhesion of G-CSF C3 to the gel filtration column at pH 4. However, 
even in the presence of 200 mM NaCl the elution volume of G-CSF C3 is 
significantly larger at pH 4 than monomeric G-CSF C3 at pH 7. Considering the 
calibrant proteins have not been analysed by SEC at pH 4, it is not clear whether the 
different elution volumes observed for G-CSF C3 at pH 4 and 7 are due to the 
biophysical properties of the protein or the gel filtration column.           
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Figure ‎3.9 Analytical SEC of G-CSF C3. 100 µl of each G-CSF C3 sample was injected onto the column via a 500 
µl loop attached to the injection port of an Äkta prime plus pump system. 406 and 443 µM G-CSF C3 were used in 
20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM) with or 
without 200 mM NaCl, respectively (purple and blue, respectively) , while 208 and 219 µM G-CSF C3 were used in 
20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 mM) with or without 200 mM NaCl, 
respectively (red and orange, respectively). Chromatograms show A280 over roughly one column volume after 
injection of protein onto the column (A). The elution volumes of calibrant proteins (traces not shown in A) were used 
to produce a calibration plot, showing the ratio of the elution volumes of calibrant proteins (Ve) to the void volume 
(V0) of the column (Ve/V0) against log10 of the molecular masses of calibrant proteins in kDa fitted to a linear function 
(B). Calibration values for major peaks in the elution traces are coloured in the same way as the elution traces, while 
values for minor peaks in the elution traces of G-CSF C3 in pH 7 buffer in the presence and absence of 200 mM 
NaCl are shown in dark and light green, respectively.          
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3.2.5 Characterising and comparing the secondary structures of G-CSF wt 
and C3 using far-UV circular dichroism (CD) 
 
Far-UV CD was used to characterise and compare the secondary structures of G-
CSF wt and C3. CD measures the differential absorption of left and right circularly 
polarised components of plane-polarised light by chiral groups. In proteins, one such 
chiral group are peptide bonds arranged in secondary structures, which exhibit 
distinct far-UV CD spectra. For example, α-helical structures exhibit characteristic 
absorption minima at 208 and 222 nm313. 
 
Far-UV CD spectra of G-CSF wt and C3 at pH 4 and 7 exhibit absorption minima at 
209 and 221 nm, confirming they are both predominantly α-helical. Upon addition of 
8.1 M urea these absorption minima are lost due to unfolding of secondary structure 
(Figure  3.10). 
  
 
Figure ‎3.10 Far-UV CD spectra of G-CSF wt and C3 folded and unfolded. Spectra of G-CSF wt were acquired 
using protein concentrations of 5 and 4 µM in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 
mM) and 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM), 
respectively (red and orange, respectively), while spectra of G-CSF C3 were acquired using protein concentrations 
of 8 and 5 µM in pH 4 and 7 buffers, respectively (blue and green, respectively). pH 7 buffer without azide was used 
for acquiring spectra to avoid noise caused by absorbance of signal by azide. Spectra of folded (F) and unfolded (U) 
proteins are represented by solid and dashed lines, respectively, with spectra of unfolded proteins being acquired in 
the presence of 8.1 M urea. Mean residue ellipticity ([θ]MRE) values acquired at wavelengths below 215 nm are not 
shown for unfolded samples due to excessive dynode voltage (800-1000 V) caused by the absorbance of signal by 
urea.     
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The mean residue ellipticity ([θ]MRE) at 208
314 and 222315 nm can be used to estimate 
the percentage of secondary structure that is α-helical in folded proteins. [θ]MRE 
values at 208 and 222 nm for G-CSF wt at pH 7 give estimations of 59 and 56 % α-
helical structure, respectively. The percentage α-helical content of G-CSF wt at pH 7 
has previously been reported as 59 % based on the [θ]MRE value at 208 nm
353. G-
CSF C3 at pH 7 is estimated to possess 60 and 58 % α-helical structure based on 
[θ]MRE values at 208 and 222 nm, respectively, suggesting that the secondary 
structures of G-CSF wt and C3 are similar at pH 7. G-CSF wt at pH 4 has estimated 
α-helical content of 64 and 59 % based on [θ]MRE values at 208 and 222 nm, 
respectively, which is comparable to the 61 % α-helical content reported 
previously353. Interestingly, G-CSF C3 at pH 4 possesses estimated 70 and 66 % α-
helical content based on calculations using [θ]MRE values at 208 and 222 nm, 
respectively, which is notably higher than the estimated α-helical content of the wild-
type protein. However, other previous studies of G-CSF wt have estimated α-helical 
percentages of 75354 and 69276 % at pH 4.5, based on the [θ]MRE value at 208 nm, 
making it difficult to determine whether the difference between estimated α-helical 
percentages of G-CSF wt and C3 at pH 4 observed in this study is significant.   
 
3.2.6 Characterising and comparing the tertiary structures of G-CSF wt and 
C3 using fluorescence 
 
Fluorescence emission spectra of G-CSF wt and C3 were studied to allow 
comparison of their tertiary structures. The amino acids Trp, Tyr and Phe are 
intrinsically fluorescent, but the higher quantum yield and extinction coefficient of 
Trp, coupled with the sensitivity of Trp fluorescence to the chemical environment 
make this residue the most useful reporter of changes in tertiary structure355. Due to 
the large dipole moment of Trp356 the fluorescence emission energy is sensitive to 
the polarity of the environment. When buried within the hydrophobic core of the 
protein interior the wavelength at which the maximum intensity of fluorescence 
emission is observed is typically 335 nm357, but when exposed to solvent this 
wavelength is red-shifted to 355 nm and a decrease in intensity is usually 
observed355.  
 
The intensity of Trp fluorescence emission may be reduced by quenching from other 
proximal amino acid side chains. Lys and Tyr side chains quench by excited-state 
proton transfer and Gln, Asn, Glu, Asp, His and cysteine/cystine side chains quench 
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by excited-state electron transfer. Additionally, Asp, Glu and His side chains are 
better able to quench tryptophan fluorescence when protonated358-360. Excited-state 
proton transfer over an intermediate pH range (4-11) involves transfer of a proton 
from the donor to the C2, C4 or C7 positions of the indole ring361-364 of Trp and is 
assumed to be dependent on the orientation of donor and acceptor groups359. 
Conversely, excited-state electron transfer occurs from the indole ring to an 
acceptor358,360,365,366 and can theoretically occur over distances as great as 10 Å and 
is less dependent on orientation359.  
 
The fluorescence emission spectra shown in Figure  3.11 have been corrected for 
protein concentration, such that any differences in the intensities of spectra are due 
to fluorescence properties of G-CSF proteins. Generally, spectra of G-CSF wt are 
more intense than G-CSF C3 due to the extra Trp residue found in the wild-type 
protein.  
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Figure ‎3.11 Fluorescence emission spectra of G-CSF wt and C3 folded and unfolded. Spectra of G-CSF wt were 
acquired using protein concentrations of 5 and 4 µM in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 
buffer (I = 43 mM) and 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I 
= 80 mM), respectively (A/red and B/orange, respectively), while spectra of G-CSF C3 were acquired using protein 
concentrations of 8 and 5 µM in pH 4 (C) and 7 (D) buffers, respectively (blue and green, respectively). 
Fluorescence emission intensities have been corrected for the different protein concentrations used. pH 7 buffer 
without azide was used for acquiring spectra because the same samples were also used for acquiring far-UV CD 
spectra (see the legend of Figure ‎3.10). Spectra of folded (F) and unfolded (U) proteins are represented by solid 
and dashed lines, respectively, with spectra of unfolded proteins being acquired in the presence of 8.1 M urea. 
 
Spectra of G-CSF wt and C3 at pH 7 show emission maxima at 336 and 335 nm, 
respectively (Figure  3.11B and D). Upon addition of 8.1 M urea a red-shift in the 
wavelength of maximum emission is observed to 346 nm, indicating solvent 
exposure of Trp due to unfolding of tertiary structure. The spectra of G-CSF wt and 
C3 at pH 4 (Figure  3.11A and C) exhibit emission intensities around 335 nm far 
lower than the intensities observed for emission of G-CSF wt and C3 around this 
same wavelength at pH 7. This is indicative of Trp fluorescence quenching and has 
been reported previously for G-CSF wt at pH 4306.  
 
The emission intensities of spectra of G-CSF wt and C3 at pH 4 are highest at 
wavelengths of 329 and 300 nm, respectively (Figure  3.11A and C), which is most 
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likely due to the W59R substitution found in G-CSF C3. As well as removal of a Trp 
residue contributing to reduced emission intensity around 335 nm, Trp59 has been 
proposed to be involved in quenching Tyr fluorescence306. Consequently, removal of 
Trp59 brings about a shift in the wavelength of maximum emission observed in the 
spectrum of G-CSF C3 compared to the wild-type protein at pH 4 to 300 nm, which 
is characteristic of Tyr fluorescence emission367. Addition of 8.1 M urea results in a 
red-shift in the wavelength of maximum emission observed to 347 and 346 nm for 
G-CSF wt and C3, respectively at pH 4. This red-shift is accompanied by an 
increase in emission intensity owing to the removal of Trp fluorescence quenching 
caused by G-CSF unfolding.  
 
Intriguingly, an increase in the overall emission intensity is observed in the unfolded 
spectrum of G-CSF wt at pH 7 (Figure  3.11B), while a decrease in the emission 
intensity is observed in the unfolded spectrum of G-CSF C3 at pH 7 (Figure  3.11D). 
This would suggest quenching of Trp59 occurs at both pH 4 and 7 in G-CSF wt, 
which is removed upon unfolding. Again, this may be due to energy transfer 
between Trp59 and a proximal Tyr side chain in the wild-type protein306. The 
structure of G-CSF wt suggests the pH independent quenching of Trp59 
fluorescence is most likely due to the proximal side chain of Tyr86 (Figure  3.12A). 
On the other hand, quenching of Trp119 fluorescence only occurs at acidic pH and 
is most likely due to the proximal side chain of His80 (Figure  3.12B). 
 
 
Figure ‎3.12 Proximity of Trp side chains in G-CSF wt to amino acid side chains suspected to be involved in Trp 
fluorescence quenching. The indole nitrogen atom of Trp59 is 5.7 Å away from the oxygen atom in the phenol side 
chain of Tyr86 (A). The indole nitrogen atom of Trp119 is 5.8 Å away from the deprotonated nitrogen atom of the 
imidazole side chain of His80 that becomes protonated at acidic pH (B). Distances in Å are shown for atoms 
connected by yellow dotted lines. This figure was constructed using the structure of G-CSF wt (PDB 1GNC
283
) in 
PyMOL
289
.  
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Unusually, the spectra of unfolded G-CSF wt at pH 4 and 7 exhibit different 
intensities (Figure  3.11A and B), a phenomenon which is also observed for G-CSF 
C3 (Figure  3.11C and D). To determine if this is due to disulphide bonds still being 
present in urea denatured G-CSF proteins, 1 mM TCEP was added to G-CSF C3 
samples unfolded in 8.1 M urea at pH 4 and 7 and fluorescence emission spectra 
acquired (Figure  3.13). Reduction of disulphide bonds in G-CSF C3 causes these 
spectra to overlay around wavelengths associated with Trp fluorescence (around 
345 nm), suggesting that the difference in intensities of spectra of unfolded and 
oxidised G-CSF wt and C3 seen in Figure  3.11 is likely due to disulphide bonds, 
which are effective quenchers of Trp fluorescence359.  
 
Reduction of disulphide bonds also causes a difference in intensity around 
wavelengths associated with Tyr fluorescence (around 300 nm) as shown in 
Figure  3.13, which may be due to the pH dependence of Tyr fluorescence. In the 
ground state, the pKa of the phenolic hydroxyl group of Tyr is 10, but in the excited 
state the pKa of this group decreases to approximately 4-5. Ionisation of the phenolic 
side chain of Tyr causes tyrosinate formation and a red-shift of the wavelength at 
which maximum emission is observed to 340 nm367. Therefore, a higher population 
of tyrosinate side chains compared to tyrosine side chains in the unfolded and 
reduced G-CSF C3 sample at higher pH could be responsible for the reduced 
intensity observed around 300 nm. The expected increase in fluorescence emission 
at 340 nm as a result of tyrosinate formation in the higher pH sample is most likely 
obscured by Trp fluorescence.      
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Figure ‎3.13 Fluorescence emission spectra of unfolded and reduced G-CSF C3. Spectra of G-CSF C3 were 
acquired using protein concentrations of 8 and 5 µM in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 
buffer (I = 43 mM) and 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I 
= 80 mM), respectively (blue and green, respectively) in the presence of 8.1 M urea and 1 mM TCEP. Spectra were 
acquired after addition of TCEP without readjustment of pH. Fluorescence emission intensities have been corrected 
for the different protein concentrations used. pH 7 buffer without azide was used for acquiring spectra because the 
same samples were also used for acquiring far-UV CD spectra (see the legend of Figure ‎3.10). 
 
3.2.7 Nuclear Magnetic Resonance (NMR) spectroscopy of G-CSF proteins 
 
The 1H-15N heteronuclear single quantum coherence (HSQC) spectrum provides a 
peak for every amide proton of a protein, allowing high resolution structural 
comparison of G-CSF wt and C3. For NMR experiments 10 % (v/v) D2O was added 
to G-CSF samples, resulting in 10 % dilution of pH 4 and 7 buffer components. 
Consequently, all NMR experiments were carried out in 18 mM sodium phosphate, 
18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer or 18 mM sodium phosphate, 18 
mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 buffer unless 
otherwise stated. 
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3.2.7.1 Comparing G-CSF C3 from the peak and tail of cation exchange 
chromatography using 1H-15N HSQC spectra 
 
1H-15N HSQC spectra were used to probe for differences in G-CSF C3 obtained 
from the peak or tail portions of the elution trace from cation exchange 
chromatography. Spectra acquired using the same parameters, with very similar 
concentrations of G-CSF C3 from peak and tail samples in the same buffer 
conditions revealed no differences between protein acquired from the peak or tail of 
cation exchange chromatography (Figure  3.14). 
 
 
Figure ‎3.14 1H-15N HSQC spectra of G-CSF C3 from peak and tail samples. Spectra were acquired using 173 and 
177 µM 
15
N G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I = 39 mM) 
from the peak (blue) and tail (orange) of cation exchange chromatography, respectively. Spectra were acquired at 
25 
o
C using a spectrometer operating at a proton resonance frequency of 600 MHz. 
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3.2.7.2 Assignment of 1H-15N HSQC spectra 
 
From assignment of the 1H-15N HSQC spectra of G-CSF proteins at pH 4 the 
positions of 160 non-proline residues were identified, but peaks for Ser97 and the N-
terminal Met residue could not be assigned. The N-terminal residue is often not 
observable in 1H-15N HSQC spectra due to rapid exchange with the solvent, while 
the peak for Ser97 is presumed to be too broad for detection or overlapping with 
other peaks. The 1H-15N HSQC spectrum of G-CSF wt at pH 4 was assigned based 
on previous assignments of wild-type protein (Figure  3.15), in which assignments of 
Ser97 and the N-terminal Met residue were also not reported283,288.  
 
Despite G-CSF C3 only containing four substitutions relative to the wild-type protein, 
the 1H-15N HSQC spectrum of G-CSF C3 was too different from the spectrum of 
wild-type G-CSF to allow assignment from reported assignments of wild-type protein 
alone283,288. Therefore, 1H-15N HSQC spectra for G-CSF C3 at pH 4 and 7 were 
assigned using HNCA, HN(CO)CA, CBCA(CO)NH, HNCO and HN(CA)CO triple-
resonance spectra. Example strips from HNCA, HN(CO)CA and CBCA(CO)NH 
spectra are shown in Figure  3.16. At pH 4, all non-proline residues in G-CSF C3 
were assigned apart from Ser97 and Met1 (Figure  3.17), while at pH 7 Thr2, His44 
and Ala144 also could not be assigned. These peaks may be lost at higher pH due 
to a higher rate of exchange with the solvent causing broadening. Alternatively, 
these peaks may be broadened as a result of changes in local polypeptide dynamics 
or conformational exchange brought about by this pH change.      
 
1H-15N HSQC spectra of G-CSF wt and C3 at pH 4 both possess some residues that 
exhibit two or more resonances. These satellite peaks are observed for residues in 
unstructured regions of G-CSF around Pro residues and have been attributed to 
slow conformational exchange resulting from cis-trans isomerisation of peptide 
bonds with Pro residues288. In addition, extra peaks are observed around some Gln 
residues in G-CSF wt and C3 e.g. Gln33 and Gln174, which most likely correspond 
to deamidation of Gln residues. Tables of assignments for amide proton and 
nitrogen atoms of G-CSF wt at pH 4 and G-CSF C3 at pH 4 and 7, as well as alpha, 
beta and carbonyl carbon atoms of G-CSF C3 at pH 4 and 7 are shown in 
Appendices 7.6-7.8.    
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Figure ‎3.15 1H-15N HSQC spectrum of wild-type G-CSF assigned at pH 4. The spectrum was acquired using 111 
µM 
15
N G-CSF wt in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I = 39 mM) and 
assigned using previous assignments
283,288
. Peaks labelled with an apostrophe indicate satellite peaks, while peaks 
labelled with an asterisk indicate peaks suspected to result from deamidation of Gln residues. The region 
highlighted in the dotted square in A is shown magnified in B. Unlabelled peaks correspond to side chains or noise. 
The spectrum was acquired at 25 
o
C using a spectrometer operating at a proton resonance frequency of 600 MHz 
equipped with a room temperature probe. 
Biophysical comparison of the native states of G-CSF wt and C3 
 
130 
 
 
Figure ‎3.16 Example strips of HNCA, HN(CO)CA and CBCA(CO)NH spectra used for assignment of the 1H-15N 
HSQC spectrum of G-CSF C3. HNCA (blue), HN(CO)CA (red) and CBCA(CO)NH (green) spectra were acquired 
using 473 µM 
13
C 
15
N G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I 
= 39 mM). Peaks are shown for assignment of residues T134-M138 of G-CSF C3 and a pink dotted line is drawn to 
indicate linking of Cα atoms of sequential residues along the backbone. Numbers at the top of each strip indicate the 
strip number and numbers at the bottom of each strip (within each strip) indicate the nitrogen chemical shift in ppm. 
The nitrogen chemical shift axis is perpendicular to the proton and carbon chemical shift axes. Peaks labelled with 
an apostrophe are satellite peaks. Spectra were acquired at 25 
o
C using a spectrometer operating at a proton 
resonance frequency of 600 MHz equipped with a room temperature probe.   
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Figure ‎3.17 1H-15N HSQC spectrum of G-CSF C3 assigned at pH 4. The spectrum was acquired using 473 µM 13C 
15
N G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I = 39 mM) and 
assigned using HNCA, HN(CO)CA, CBCA(CO)NH, HNCO and HN(CA)CO triple-resonance spectra. Peaks labelled 
with an apostrophe are satellite peaks, while peaks labelled with an asterisk indicate peaks suspected to result from 
deamidation of Gln residues. The region highlighted in the dotted square in A is shown magnified in B. Unlabelled 
peaks correspond to side chains or noise. The spectrum was acquired at 25 
o
C using a spectrometer operating at a 
proton resonance frequency of 600 MHz equipped with a room temperature probe. 
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3.2.7.3 Comparing the structures of G-CSF wt and C3 using chemical shift 
perturbations (CSPs) 
 
To determine the structural similarity of G-CSF wt prepared in this study to wild-type 
protein used in previous NMR studies CSPs were calculated from amide proton and 
nitrogen chemical shifts (see Section  2.9.6). A CSP is the Euclidean distance 
between two peaks and so can provide a measure of how different the chemical 
environments of a particular residue are under different conditions. CSPs were 
calculated using the assignments of G-CSF wt at pH 4 from this study and previous 
assignments of the wild-type protein from studies by Zink et al.283 and Werner et 
al.288 (Figure  3.18A and B, respectively). 
 
1H-15N HSQC spectra of G-CSF wt in this study were acquired in 18 mM sodium 
phosphate, 18 mM sodium acetate pH 4 buffer at 25 oC, while spectra in the study 
by Zink et al.283 were acquired in 50-60 mM sodium phosphate pH 3.5 buffer at 27 
oC. CSPs for the majority of residues of G-CSF wt used in this study in relation to G-
CSF wt used by Zink et al.283 are equal to or lower than 0.1 (Figure  3.18A), 
suggesting that there are only small differences between G-CSF wt prepared in this 
study with previous preparations. Additionally, the residues that exhibit greatest 
CSPs are distributed throughout the protein rather than being clustered in certain 
structural segments, suggesting that these differences are likely the result of the 
different buffer conditions and temperature used in this study rather than differences 
in the conformations of G-CSF wt used in these studies. 
 
Spectra in the study by Werner et al.288 were acquired in 50 mM deuterioacetic acid 
pH 3.9 buffer at 30-32 oC. Again, these are different buffer conditions and 
temperatures to those used for acquiring 1H-15N HSQC spectra of G-CSF wt in this 
study and this is reflected in the small CSPs observed for most residues of G-CSF 
wt used in these studies (Figure  3.18B). However, large CSPs are observed for 
residues Leu15, Lys17, Leu19, Glu20 and Gln21, which is probably due to the C18S 
substitution found in the G-CSF protein used by Werner et al.288. Significantly large 
CSPs are also observed for Ile118 (coloured red in Figure  3.18B) and other proximal 
residues in the amino acid sequence, which is most likely due to the proximity of 
these residues to Cys18 in the tertiary structure of G-CSF.  
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Figure ‎3.18 CSPs for previous assignments of G-CSF wt relative to assignments of G-CSF wt used in this study. 
Previous assignments used were from Zink et al.
283
 (A) and Werner et al.
288
 (B). Horizontal lines show the mean, 
mean + σ and mean + 2σ CSP values. Orange and red bars correspond to residues exhibiting CSPs greater than 
the mean + σ and mean + 2σ, respectively. A secondary structure schematic is shown above for reference. Right: 
Residues with significant CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same 
colour scheme, constructed using PyMOL
289
. Red residues are also labelled.       
 
CSPs were also used to compare the structures of G-CSF wt and C3 at pH 4. 
Unsurprisingly, the largest CSPs for G-CSF C3 relative to wild-type are the four 
substitutions C18G, W59R, Q71R and F84L, along with some neighbouring residues 
of these substitutions (Figure  3.19). In particular, substitution of Cys for Gly brings 
about a large CSP, due to the lower characteristic chemical shift value of amide 
nitrogen atoms of Gly residues. Significant CSPs are also observed for Val154 and 
His157, which is most likely due to the proximity of these residues to the W59R 
substitution site in the tertiary structure of G-CSF. Therefore, an effect of the W59R 
substitution on the local conformation of G-CSF in the region of the latter half of the 
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AB loop and the section of helix D containing Val154 and His157 cannot be ruled 
out. A large CSP is also observed for Leu169, which is proximal to the C18G 
substitution. Apart from around the sites of these four substitutions, CSPs 
throughout the protein appear to be of a similarly low amplitude, suggesting no 
conformational differences between G-CSF wt and C3 beyond the local 
environments of these four substitutions.      
 
 
Figure ‎3.19 CSPs for G-CSF wt relative to the variant C3 at pH 4. Horizontal lines show the mean, mean + σ and 
mean + 2σ CSP values. Orange and red bars correspond to residues exhibiting CSPs greater than the mean + σ 
and mean + 2σ, respectively. A secondary structure schematic is shown above for reference. Right: Residues with 
significant CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, 
constructed using PyMOL
289
. Red residues are also labelled. 
 
Assignment of the 1H-15N HSQC spectra of G-CSF C3 at pH 4 and 7 enabled CSPs 
to be calculated for G-CSF C3 under these different conditions. Many of the largest 
CSPs are observed for His residues and their neighbouring residues (Figure  3.20). 
This is due to the protonation of His side chains that occurs at pH 4 but not at pH 7. 
G-CSF possess five His residues, which are located at positions 44, 53, 80, 157 and 
171 in the amino acid sequence. Unfortunately, His44 could not be assigned in the 
1H-15N HSQC spectrum of G-CSF C3 at pH 7, along with Thr2 and Ala144, 
presumably because these peaks are broadened at higher pH or overlap with other 
peaks in the spectrum. 
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Figure ‎3.20 CSPs for G-CSF C3 at pH 4 relative to G-CSF C3 at pH 7. Horizontal lines show the mean, mean + σ 
and mean + 2σ CSP values. Orange and red bars correspond to residues exhibiting CSPs greater than the mean + 
σ and mean + 2σ, respectively. A secondary structure schematic is shown above for reference. Right: Residues with 
significant CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, 
constructed using PyMOL
289
. Red residues are also labelled.  
 
Interestingly, Arg59 exhibits a large CSP, despite there being no nearby His 
residues in the amino acid sequence. The structure of G-CSF wt shows that the side 
chains of His53 and His157 are in close proximity to each other and the side chain 
of Arg59 (Figure  3.21). Therefore, protonation of His53 and His157 side chains most 
likely causes electrostatic repulsion between these residues and Arg59 around the 
short helical section of the AB loop, possibly affecting the local structure in this 
region. Other than in this region and around other His residues, CSPs throughout 
the protein sequence are of a similarly low magnitude, suggesting no significant 
differences in the conformation of G-CSF C3 beyond the local environment of His 
residues at pH 4 and 7. 
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Figure ‎3.21 Proximity of the side chains of His53, His157 and Arg59 in G-CSF C3. The deprotonated imidazole 
nitrogen atom from the side chain of His53 is 4.6 Å away from the equivalent atom of His157 and 6.5 Å away from 
the closest nitrogen atom of the guanidine group in the Arg59 side chain. The deprotonated imidazole nitrogen atom 
from the side chain of His157 is 4.8 Å away from the closest guanidine nitrogen atom of the Arg59 side chain. 
Although shown deprotonated in this figure, these imidazole nitrogen atoms are protonated at acidic pH. Distances 
in Å are shown for atoms connected by yellow dotted lines. This figure was constructed using the structure of G-
CSF wt (PDB 1GNC
283
) in PyMOL
289
. To create this figure Trp59 in the G-CSF wt structure has been mutated to an 
Arg residue.       
         
3.3 Discussion 
 
Recombinantly expressed and purified human G-CSF must reach its native 
conformation in order to function as a biopharmaceutical. Since the purpose of this 
study is to investigate the aggregation of G-CSF as a biopharmaceutical it was 
imperative to establish that the native conformation had been reached under the 
conditions that would be used to study aggregation. Additionally, aggregation of G-
CSF is thought to occur from a native-like state142,303,307,308, meaning biophysical 
characterisation of the native conformation was essential to probe for subtle 
changes that may be linked to aggregation. Investigation into the structure of G-CSF 
C3 and subsequent comparison to wild-type may also help to rationalise the vast 
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increase in expression level of soluble G-CSF C3 when expressed in the periplasm 
of E. coli150.  
 
As well as confirming the correct molecular masses of G-CSF proteins prepared in 
this study (Figure  3.6), ESI-MS was used to show that disulphide bonds linking 
residues Cys37-Cys43 and Cys65-Cys75 had formed (Figure  3.7 and Figure  3.8). 
These disulphide bonds are required for G-CSF wt to form its native conformation285.    
 
Far-UV CD spectra of G-CSF wt and C3 showed that these proteins have an 
estimated 59 % and 60 % α-helical structure, respectively at pH 7 (Figure  3.10), 
which matches the percentage of α-helical structure reported previously for G-CSF 
wt353. The estimated percentages of α-helical structure for G-CSF wt and C3 at pH 4 
are 64 % and 70 %, respectively. Previously, G-CSF wt had been reported to have 
an estimated 61 % α-helical structure at pH 4353, which is similar to G-CSF wt used 
in this study but not the variant C3, suggesting G-CSF C3 may be slightly more α-
helical than wild-type. However, other previous studies have reported estimated 
percentages of 75354 and 69276 % α-helical structure for G-CSF wt at pH 4.5, making 
it unclear whether the differences in percentage α-helical structure estimated for G-
CSF wt and C3 at pH 4 are significant.    
 
Fluorescence emission spectra of G-CSF wt and C3 showed Trp fluorescence 
quenching at pH 4 (Figure  3.13A and C). This has been reported previously for G-
CSF wt306 and shows that Trp119 is in a similar chemical environment in G-CSF wt 
and C3, with quenching most likely the result of protonation of the proximal side 
chain of His80 (Figure  3.12B). In addition, there is additional Trp fluorescence 
quenching observed for G-CSF wt at pH 7 that is not observed for G-CSF C3 
(Figure  3.11B and D). This is evident from the increase in fluorescence intensity of 
emission spectra of G-CSF wt at pH 7 upon unfolding, plus the intensity of emission 
spectra of G-CSF C3 at pH 7 decreasing upon unfolding. This quenching has been 
attributed to Tyr residues306 and must involve Trp59 as this Trp residue is 
substituted to Arg in G-CSF C3. Substitution of Trp59 for Arg also causes an 
increase in Tyr fluorescence intensity for G-CSF C3 compared to wild-type protein at 
pH 4, suggesting quenching of Tyr fluorescence by Trp side chains. The structure of 
G-CSF wt suggests that quenching of Trp59 fluorescence is caused by the side 
chain of Tyr86 (Figure  3.12A). Overall, fluorescence emission spectra suggest that 
the G-CSF wt used in this study possesses similar tertiary structure around Trp 
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residues to G-CSF wt studied previously by fluorescence306 and that G-CSF C3 
possesses a similar tertiary structure around Trp119. 
 
Assignments of amide proton and nitrogen atoms of G-CSF wt from 1H-15N HSQC 
spectra allowed calculation of CSPs, providing high resolution structural comparison 
of G-CSF wt prepared in this study to previous studies of G-CSF wt by NMR 
(Figure  3.18). The results suggest that there is little difference between G-CSF wt 
prepared in this study and G-CSF wt prepared in previous studies, with differences 
suspected to be the result of the different buffer conditions and temperatures used 
for acquisition of spectra, as well as the C18S substitution found in the G-CSF 
protein used by Werner et al.288.  
 
CSPs of G-CSF C3 relative to the wild-type protein at pH 4 suggest that there is no 
observable difference in conformation beyond the four substitutions found in the 
variant C3. However, residues Val154 and His157 around the W59R substitution 
exhibit higher CSPs than residues throughout the rest of G-CSF C3, despite not 
being close in amino acid sequence to the site of this substitution, meaning a local 
structural difference around this region in G-CSF C3 compared to the wild-type 
protein cannot be excluded (Figure  3.19). Additionally, CSPs calculated for G-CSF 
C3 at pH 4 relative to G-CSF C3 at pH 7 imply a possible difference in local 
structure around the short helical section of the AB loop (Figure  3.20), likely due to 
electrostatic repulsion between the Arg59 side chain and the side chains of His53 
and His157 that are protonated at pH 4 but not at pH 7 (Figure  3.21).     
 
The W59R substitution is located in the loop connecting helices A and B in G-CSF. 
This AB loop has been hypothesised to undergo rearrangement under aggregation-
prone conditions, promoted by the addition of GdnHCl concentrations that are too 
low to cause global denaturation of the protein at pH 7142. Rearrangement of the AB 
loop was identified from a change in the fluorescence intensity of Trp59 in low 
GdnHCl concentrations, while the remainder of G-CSF was shown to be native-
like142. Under less aggregation-prone conditions at pH 4, a conformation of G-CSF 
wt with fully formed native α-helical structure but non-native fluorescence of Trp59 
has also been identified as a late stage kinetic folding intermediate304. Therefore, 
substitution of Trp59 in the AB loop in G-CSF C3 could alter the local structure of 
this loop without affecting the global conformation, instilling a reduced propensity for 
aggregation. Alternatively, substitution of uncharged residues for charged residues 
in this region may disturb a hydrophobic aggregation interface or simply increase 
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electrostatic repulsion between G-CSF molecules, thus hindering aggregation 
without affecting the structure of the AB loop. 
 
Substitution of the unpaired Cys18 residue for Gly in G-CSF C3 may also contribute 
to reduced aggregation propensity by preventing intermolecular disulphide bond 
formation, without affecting the overall conformation of G-CSF. Substitution of 
Cys18 for Ala has been shown to slow the rate of G-CSF aggregation and prevent 
formation of disulphide cross-linked aggregates, although ultimately wild-type and 
C18A proteins were reported to aggregate to the same extent142. Considering the 
variant C3 was identified from screening of a randomly generated library of G-CSF 
DNA constructs, it is possible that not all of the four substitutions contribute to the 
observed increase in soluble expression level of G-CSF C3 relative to the wild-type 
protein. This could account for the incorporation of the F84L substitution in the 
variant C3 as there is no reported involvement of this residue in G-CSF aggregation. 
 
Although it has been suggested that the observed increase in expression of soluble 
G-CSF C3 is due to reduced aggregation propensity relative to wild-type, this has 
not been confirmed experimentally. This assumption is supported by the reduced 
aggregation propensity predicted around substitutions W59R and Q71R, based on 
computational modelling of G-CSF wt and C3150. However, given that aggregation is 
commonly driven by hydrophobic interactions, it is unsurprising that these 
substitutions are predicted to reduce aggregation propensity, particularly W59R. 
Additionally, the cytoplasmic expression level of G-CSF C3 is higher than wild-type 
(Figure  3.2), even though expression of G-CSF in the cytoplasm yields insoluble 
inclusion bodies due to the inability to form disulphide bonds130. In turn, this 
suggests that the heterologous expression levels of G-CSF wt and C3 in E. coli 
contribute significantly to the improved expression of soluble G-CSF C3 in the 
periplasm relative to wild-type protein150, as opposed to only being the result of the 
hypothesised reduced aggregation propensity of G-CSF C3. 
 
In the early stages of this study, recombinant expression of G-CSF wt and C3 was 
carried out in the periplasm of E. coli using pCANTAB6, a MedImmune in-house 
vector provided by Dr. Andrew Buchanan (MedImmune, UK). The realtive yields of 
G-CSF wt and C3 from periplasmic expression reflected the yields reported by 
Buchanan et al150 (results not shown). However, analysis of the molecular mass of 
G-CSF C3 purified from the periplam by ESI-MS (carried out by Dr. Ault) revealed 
cleavage of the N-terminal Thr residue. More importantly though, expression in 
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pCANTAB6 resulted in the addition of 26 extra residues at the C-terminus of G-CSF 
proteins, encoding Myc and hexahistidine tags as well as linker residues between 
and on either side of these detection motifs that are encoded by pCANTAB6. These 
tags are not present in commercially available formulations of G-CSF and could 
have affected the folding, dynamics and aggregation of G-CSF proteins. Therefore, 
untagged G-CSF was chosen for this study in order to reflect more closely G-CSF 
as it is found in biopharmaceutical formulations used clinically.      
 
The recombinant expression level of G-CSF C3 is dramatically higher than the wild-
type protein, regardless of whether these proteins are expressed in their soluble 
native forms in the periplasm150 or as insoluble aggregates in the cytoplasm of E. 
coli (Figure  3.2). This would suggest that the higher expression yield of G-CSF C3 is 
related to the transcription and/or translation rates of these proteins. Although 
degradation by proteases also affects the recombinant expression level of soluble 
proteins, proteins in inclusion bodies are generally protected from this176. 
Theoretically, the transcription rates of G-CSF wt and C3 DNA constructs should be 
comparable due to their incorporation into the same vector.  
 
The translation rates of mRNA transcripts can be affected by differential usage of 
codons in prokaryotic and eukaryotic cells. Rarely used codons have fewer cognate 
tRNAs, which slow the rate of translation368. Stalling is amplified in regions where 
rare codons are clustered and can cause amino acid substitutions and deletions, as 
well as premature termination of translation due to ribosome dissociation369. 
However, clustering of rare codons at 5’ ends of mRNA transcripts has been 
suggested to destabilise mRNA secondary structure, which helps to expose the 
ribosome binding site and translation start codon370. 
 
mRNA secondary structures are related to the proportions of purine and pyrimidine 
bases in DNA sequences. A decrease in GC content at the 5’ end of DNA encoding 
G-CSF has been shown to improve recombinant expression in E. coli, which has 
been hypothesised to be the result of reduced secondary structure371. However, A/U 
rich regions are recognised by the protein bS1, found in the 30S ribosomal 
subunit372. bS1 is thought to facilitate unfolding of secondary structure and 
incorporation of mRNA in the mRNA channel of the 30S subunit373,374, which may 
also account for a general increase in recombinant expression of DNA sequences 
with reduced GC content at their 5’ ends in E. coli375. Previous studies have 
rationalised improved recombinant expression of G-CSF in E. coli from replacement 
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of rare codons at the 5’ end of DNA sequences with more commonly used codons, 
although this also resulted in a reduction in GC content376,377.  
 
G-CSF wt and C3 DNA constructs used by Buchanan et al.150 have 18 % and 21 % 
rare codons, respectively, while the DNA constructs used in this study are made up 
of 16 % and 17 % rare codons, respectively. The DNA sequences of the constructs 
used in this study show similar distributions of rare codons (Figure  3.22), while the 
DNA sequences used by Buchanan et al.150 are 99 % identical (Figure  3.23), 
suggesting that the notable difference in expression levels of these G-CSF proteins 
is not due to rare codons. Additionally, DNA constructs used by Buchanan et al.150 
and in this study have GC contents of 66 % and 58 %, respectively. Alignments of 
these DNA sequences reveal no obvious differences in the distribution of purines 
and pyrimidine bases between G-CSF wt and C3 DNA constructs, suggesting that 
the translation efficiencies of these mRNA transcripts would be similar. 
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1   ATGACTCCTC TCGGTCCTGC ATCTAGCCTT CCGCAAAGCT TCCTGCTGAA        wt  
         |  ||  |  |      |  |  |                         
1   ATGACCCCGT TAGGCCCTGC CTCCTCTCTT CCGCAATCCT TCCTGCTGAA        C3 
 
51  GTGCCTTGAA CAGGTCCGCA AAATCCAGGG TGATGGCGCT GCCCTGCAGG        wt 
    ||    |                                |      |     | 
51  AGGCCTGGAA CAGGTGCGCA AAATCCAGGG TGATGGTGCA GCACTGCAAG        C3 
 
101 AGAAACTGTG TGCGACCTAC AAACTGTGCC ATCCGGAAGA ACTGGTGCTG        wt 
        |                                       |      | 
101 AGAAGCTGTG TGCGACCTAC AAACTGTGCC ATCCGGAAGA GCTGGTGTTG        C3 
 
151 TTGGGCCACT CTCTGGGCAT TCCGTGGGCA CCCCTGAGTA GCTGTCCATC        wt 
    |       |   |     |       | |            |         | 
151 CTCGGCCATA GCCTGGGTAT TCCGCGTGCA CCCCTCAGCA GCTGTCCGTC        C3 
 
201 CCAAGCCCTG CAATTAGCCG GCTGCTTATC GCAGCTGCAC TCAGGACTCT        wt 
    |  |   | |  | | |      |   |     |              
201 ACAGGCGTTA CGTCTGGCCG GTTGCCTTAG TCAGCTGCAC TCTGGACTGT        C3 
 
251 TCCTGTATCA GGGCCTGTTA CAGGCGTTAG AGGGGATTTC CCCGGAACTG        wt 
                   | || |   |   | |   | 
251 TGCTGTATCA GGGGTTACTC CAAGCCCTGG AAGGCATTTC GCCGGAACTG        C3 
 
301 GGTCCCACAC TCGATACGCT TCAGTTGGAT GTTGCGGACT TTGCAACCAC        wt 
         |                |        |         |      | 
301 GGTCCAACTC TGGATACGCT GCAGTTGGAC GTTGCGGATT TTGCCACGAC        C3 
 
351 CATCTGGCAG CAGATGGAGG AACTGGGGAT GGCACCAGCG TTGCAACCGA        wt 
                              |                 | 
351 CATCTGGCAG CAGATGGAGG AACTTGGCAT GGCTCCAGCG CTGCAACCCA        C3 
 
401 CGCAAGGTGC GATGCCGGCC TTTGCGAGTG CCTTTCAGCG TCGTGCTGGA        wt 
     |     |   |     |         |            |   |     | 
401 CACAAGGGGC AATGCCTGCG TTTGCTTCAG CGTTTCAACG GCGTGCGGGA        C3 
 
451 GGTGTACTCG TGGCTTCACA TCTGCAGTCG TTCCTGGAAG TGAGCTATCG        wt 
      |         |  |      ||                          
451 GGCGTACTGG TTGCCAGTCA CTTGCAGAGC TTCCTCGAAG TCTCGTATCG        C3 
 
501 CGTTCTGCGC CATTTGGCGC AACCG                                   wt 
       || |       | |  |   | 
501 CGTGTTACGC CATCTTGCTC AGCCG                                   C3 
 
Figure ‎3.22 Alignment of DNA sequences of G-CSF wt and C3 used for cytoplasmic expression. Rare codons were 
identified using E. coli Codon Usage Analyzer 2.1
378
 and are highlighted in cyan. Codons encoding different amino 
acids in G-CSF wt and C3 are highlighted in red. Rare codons encoding different amino acids in G-CSF wt and C3 
are highlighted in green. All other nucleotide variations between G-CSF wt and C3 DNA sequences are silent and 
not highlighted. Vertical lines indicate sites where purine bases have been swapped for pyrimidine bases or vice 
versa. The nucleotide at the beginning of each line is numbered on the left. 
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1   ACCCCCCTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTG        wt  
                                                        | 
1   ACCCCCCTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGGG        C3  
 
51  CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA        wt 
 
51  CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA        C3 
 
101 AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC        wt 
 
101 AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC        C3 
 
151 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCAGCT GCCCCAGCCA        wt 
 
151 GGACACTCTC TGGGCATCCC CAGGGCTCCC CTGAGCAGCT GCCCCAGCCA        C3 
 
201 GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC        wt 
            |                                         | 
201 GGCCCTGCGG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTCTCC        C3 
 
251 TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATCTCCCC CGAGTTGGGT        wt 
 
251 TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATCTCCCC CGAGTTGGGT        C3 
 
301 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT        wt 
 
301 CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT        C3 
 
351 CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC        wt 
 
351 CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC        C3 
 
401 AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG        wt 
 
401 AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG        C3 
 
451 GTCCTGGTTG CCTCCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT        wt 
         | 
451 GTCCTAGTTG CCTCCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT        C3 
 
501 TCTACGCCAC CTTGCCCAGC CC                                      wt 
 
501 TCTACGCCAC CTTGCCCAGC CC                                      C3 
 
Figure ‎3.23 Alignment of DNA sequences of G-CSF wt and C3 used for periplasmic expression. DNA sequences of 
G-CSF wt and C3 were provided by Dr. Andrew Buchanan (MedImmune, UK). DNA encoding the signal sequence 
that is cleaved after protein translocation into the periplasm is not shown. Rare codons were identified using E. coli 
Codon Usage Analyzer 2.1
378
 and are highlighted in cyan. Codons encoding different amino acids in G-CSF wt and 
C3 are highlighted in red. Rare codons encoding different amino acids in G-CSF wt and C3 are highlighted in green. 
All other nucleotide variations between G-CSF wt and C3 DNA sequences are silent and not highlighted. Vertical 
lines indicate sites where purine bases have been swapped for pyrimidine bases or vice versa. The nucleotide at 
the beginning of each line is numbered on the left. 
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The translation efficiency of mRNA transcripts can also be affected by the 
physicochemical properties of amino acids on the peptidyl-tRNA and aminoacyl-
tRNA135. During catalysis of peptide bond formation the aminoacyl-tRNA and 
peptidyl-tRNA are incorporated in the A- and P- sites of the ribosome, respectively. 
Incorporation of the aminoacyl-tRNA in the A-site is achieved through base-pairing 
of the mRNA codon encoding a particular amino acid in the A-site with the antisense 
codon of the tRNA that is covalently attached to that amino acid. After peptide bond 
formation the deacylated tRNA is transferred from the P-site to the E-site for release 
from the ribosome117,135.  
 
The rate of the peptidyl transfer step of translation is most often limited by 
incorporation of the aminoacyl-tRNA in the A-site of the ribosome and is not usually 
affected by the rate of the peptide bond forming reaction itself379. However, Pro is 
both a poor acceptor group to peptide bond formation when incorporated in the A-
site380,381 and a poor donor group when incorporated in the P-site382,383, meaning this 
residue greatly reduces the rate of peptide bond formation. The reason for this is 
unclear, but is thought to be due to the steric properties of Pro and its orientation in 
the peptidyl transfer centre of the ribosome384. Translation is also often slowed at 
clusters of Arg and Lys residues, most likely owing to the interaction of positively 
charged segments of nascent peptide with the negatively charged walls of the 
ribosome exit tunnel385. Gly residues can also slow the rate of peptide bond 
formation, although the reason for this observed effect is unclear. Rather than being 
due to the physiochemical properties of Gly, the effect of this residue has been 
hypothesised to be the result of base-pairing of codons encoding Gly with the anti-
Shine-Dalgrano sequence found in the 16S rRNA of the ribosome386, which normally 
binds the Shine-Dalgrano sequence of mRNA transcripts for initiation of 
translation117. 
 
Considering that G-CSF C3 has two more Arg residues and one more Gly residue 
than wild-type protein, the effect of these substitutions may be to slow the translation 
rate. Additionally, the W59R substitution found in the variant C3 results in the amino 
acid sequence GIPRAP, which contains many residues that could stall translation. 
Consequently, this section of the amino acid sequence may stall translation of G-
CSF C3 to a greater extent than wild-type protein, although intuitively reducing the 
rate of translation should not increase the recombinant expression level of G-CSF 
C3. 
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The effects of local translation kinetics on protein folding and aggregation are 
complex and wide ranging and may have implications on recombinant protein 
expression135. Translation kinetics have been shown to affect the folding of newly 
synthesised proteins through interaction with the ribosome surface47 and exit 
tunnel387, as well as modulating the proportions of co- and post-translational 
folding388. Co-translational folding can result in stabilisation of intermediates through 
interactions with the ribosome that would otherwise be less populated during post-
translational folding47,387, which can even affect the energy landscape of proteins 
after dissociation from the ribosome389. Stabilisation of such intermediates by the 
ribosome can also act to protect polypeptides from misfolding and aggregation47,48.  
 
Presumably, the effect of translation kinetics on the folding of G-CSF wt and C3 
cannot account for the observed increase in heterologous expression of G-CSF C3 
compared to the wild-type protein, as this effect is observed whether these proteins 
are expressed as insoluble aggregates in the cytoplasm (Figure  3.2) or soluble 
native protein in the periplasm of E. coli150. Therefore, no obvious link can be drawn 
between the translation rates of G-CSF wt and C3 and their vastly different 
recombinant expression levels in E. coli.  
             
A detailed investigation of the many factors surrounding the recombinant expression 
of G-CSF wt and C3 in E. coli is beyond the scope of this thesis. Next, the focus of 
the work moved to analysis of the aggregation behaviour of G-CSF C3 and its 
comparison with the wild-type protein in Chapter 4. Furthermore, investigation of the 
structure and dynamics of G-CSF C3 at amino acid resolution by NMR in Chapter 5 
helps to elucidate subtle changes to the native conformation that are likely to be 
linked to aggregation. Due to the poor yield from expression and purification of G-
CSF wt (maximum yields of 0.1 and 0.2 mg/l were obtained from recombinant 
expression in LB and M9 media, respectively),  experiments in these chapters were 
carried out using G-CSF C3 only and compared to published studies of G-CSF wt 
aggregation when possible. For these experiments, G-CSF C3 obtained from the 
peak and tail of cation exchange chromatography were used as no significant 
differences in the purities or structures of these samples could be detected from 
analysis by SDS-PAGE, ESI-MS or 1H-15N HSQC spectra. Overall, the work in this 
chapter has shown that G-CSF wt prepared in this study is structurally similar to 
wild-type G-CSF prepared in previous studies and there are no observable 
differences between the native conformations of G-CSF wt and C3. 
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Chapter 4 Characterising the aggregation properties of        
G-CSF C3 
 
4.1 Introduction 
 
The reason for the thousand-fold increase in the yield of soluble G-CSF C3 from the 
E. coli periplasm in relation to the wild-type protein is unclear, but it has been 
suggested to be the result of the reduced aggregation of G-CSF C3 relative to the 
wild-type protein. This hypothesis arose from computational modelling of G-CSF 
with and without the substitutions found in the variant C3, which suggests reduced 
aggregation propensity around substitutions W59R and Q71R150. This hypothesis 
was tested further here by investigating the relative aggregation properties of G-CSF 
wt and C3 using other protein aggregation prediction programs (Figure  4.1). Since 
G-CSF has been reported to form amorphous aggregates308 and aggregates that 
bind the fluorescent dye Thioflavin-T307, a long used indicator of amyloid 
formation390, a range of prediction programs were utilised to cover both amorphous 
and amyloid aggregation.         
 
Although G-CSF C3 is predicted to be less aggregation-prone than wild-type G-
CSF, this had not previously been investigated experimentally. In this chapter, the in 
vitro aggregation of G-CSF C3 is characterised in terms of its dependence on 
protein concentration, pH and urea concentration. In its drug formulation as 
Filgrastim, G-CSF wt is stored at pH 4 with excipients because wild-type G-CSF 
aggregates less readily at acidic pH values compared to pH values above 5185,276,303, 
whereas at physiological pH at 37 oC G-CSF wt has been shown to aggregate 
readily within hours142,185,214,307,308,391. Therefore, all aggregation assays are carried 
out at pH 4 and 7. Aggregation assays of G-CSF C3 at pH 7 are carried out at 
similar protein concentrations to assays carried out previously for wild-type G-CSF 
to allow comparison142,185,214,308. Aggregation assays of G-CSF C3 are also carried 
out using different urea concentrations to establish whether the rate of aggregation 
would accelerate in the presence of denaturant concentrations too low to cause 
global denaturation of the protein, as observed for aggregation of wild-type G-CSF 
in the presence of different GdnHCl concentrations142. 
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Equilibrium denaturation analyses of G-CSF C3 are also carried out at pH 4 and 7 in 
urea to measure the thermodynamic stability of the native state under conditions 
used to study aggregation, as well as to probe for additional conformations that may 
be populated at urea concentrations at which aggregation is accelerated. From 
these analyses urea concentrations are identified at pH 4 and 7 that accelerate 
aggregation but do not cause global unfolding. In addition, curvature in the pre-
transition baselines of some of the equilibrium curves measured by intrinsic 
fluorescence reveal a change in the fluorescence properties of G-CSF C3 in low 
urea, which are further investigated by near-UV CD in this chapter and NMR in 
Chapter 5. Additionally, the ANS binding properties of G-CSF C3 are investigated in 
different urea concentrations to probe for exposure of hydrophobic surfaces in 
aggregation-prone conditions.               
 
In the following chapter all experiments carried out in pH 4 and 7 buffers are 
performed in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer or 20 
mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 
buffer unless otherwise stated. For NMR experiments 10 % (v/v) D2O was added to 
G-CSF samples, resulting in 10 % dilution of pH 4 and 7 buffer components. 
 
4.2 Results 
 
4.2.1 In silico prediction of the aggregation of G-CSF wt and C3 
 
The protein aggregation prediction program Aggrescan62 predicts generic 
aggregation propensity from an amino acid sequence. The scores attributed by 
Aggrescan62 represent the experimental aggregation propensity of each amino acid 
when used to replace Phe19 of the 42 residue amyloid-β peptide (Aβ42). Phe19 is 
located within the aggregation-prone central hydrophobic cluster. The aggregation 
propensity of each amino acid was determined from the fluorescence emission 
intensity of variants of Aβ42 fused to Green Fluorescent Protein (GFP) when 
expressed in the cytoplasm of E. coli, relative to the emission intensity of wild-type 
Aβ42 fused to GFP. Scores for G-CSF are averaged over seven residues (three 
either side of the residue being scored) to produce an ‘a4v’ score. Residues with 
positive scores are predicted to promote aggregation while residues with negative 
scores are predicted to promote solubility62. 
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CamSol63 can be used to predict the intrinsic solubility of an amino acid sequence, 
also providing a measure of generic aggregation propensity. Predictions are based 
on the charge, hydrophobicity and secondary structure propensity of amino acids. 
These scores are then averaged over a seven residue window and adjusted for 
patterns of alternating hydrophobic and hydrophilic residues, as well as the 
gatekeeping effect exerted by individual charges. Regions with scores below -1 are 
predicted to be poorly soluble while regions with scores above 1 are predicted to be 
significantly soluble63.  
 
CamSol63 can also be used to predict the surface solubility of a protein structure, 
based on projection of intrinsic solubility scores onto a protein surface. The intrinsic 
solubility score of a residue is averaged over residues within a radius of 8 Å that are 
not contiguous in sequence. As well as considering the proximity of residues on the 
protein surface, this projection also takes into account solvent accessible surface 
area. This means that hydrophobic residues buried in the protein interior for 
example will produce significantly negative intrinsic solubility scores, but will likely 
appear neutral in solubility scores corrected for protein structure63.          
 
Zyggregator64 is very similar to CamSol63 in the sense that amyloid aggregation 
propensity is predicted from an amino acid sequence based on the charge, 
hydrophobicity and secondary structure propensity of amino acids and that scores 
are adjusted for patterns of alternating hydrophobic and hydrophilic residues and the 
gatekeeping effect of individual charges64. The key difference between the 
Zyggregator64 and CamSol63 algorithms is that different secondary structure 
propensities are employed for Gly and Pro residues, which discourage β-sheet 
formation and so help prevent amyloid formation, but have little affect on general 
solubility63,392. Therefore, the different secondary structure propensities used for Gly 
and Pro in the Zyggregator64 algorithm help specify prediction of amyloid formation. 
Scores are inverted in the Zyggregator64 program relative to CamSol63 because the 
former predicts aggregation propensity while the latter predicts solubility, meaning 
Zagg scores above 1 indicate regions that are predicted to promote amyloid 
aggregation64.  
 
TANGO65 calculates the propensities for formation of α-helix, β-sheet, β-turn, α-
helical aggregate and β-sheet aggregate from an amino acid sequence, based on a 
Boltzmann distribution of these states. The TANGO65 method assumes that the 
main secondary structure of β-sheet aggregate is β-strand, that the regions involved 
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in aggregation are fully buried away from solvent and that residues with 
complementary charges in a particular window will promote aggregation, while net 
charge on the polypeptide or net charges within two residues of the prediction 
window disfavour aggregation65. Intermolecular β-sheet structure is a common 
feature of both amorphous and amyloid aggregates68, meaning TANGO65 predicts 
the generic β-sheet aggregation propensity of an amino acid sequence. Amino acid 
sequence lengths of five residues or more with a β-sheet aggregation propensity 
above 5 % are predicted to be involved in forming β-sheet aggregates65.  
 
Both Aggrescan62 and CamSol63 predict reduced aggregation propensity as a result 
of the W59R substitution found in G-CSF C3 (Figure  4.1A and B/C, respectively), 
although the predicted effect of this mutation is lessened in structurally corrected 
solubility scores (Figure  4.1C), suggesting Trp59 in G-CSF wt may be at least 
partially protected from solvent. The Q71R substitution found in the variant C3 is 
also predicted by CamSol63 to reduce the aggregation propensity of G-CSF, based 
on intrinsic and structurally corrected solubility scores (Figure  4.1B and C, 
respectively). These predictions are in agreement with the computational modelling 
carried out previously for G-CSF with and without the substitutions found in the 
variant C3150. However, the changes in solubility predicted by CamSol63 for these 
substitutions using the structure of G-CSF wt are within the confidence limits of -1 
and 1 for prediction of residues that promote aggregation and solubility, respectively 
(Figure  4.1C), suggesting that these substitutions may not be significant in reducing 
aggregation of the native conformation of G-CSF.  
 
Interestingly, the C18G mutation is predicted to reduce the aggregation propensity 
of G-CSF by Aggrescan62 and CamSol63 (Figure  4.1A and B/C, respectively), even 
though these programs do not take into consideration the propensity for 
intermolecular disulphide bond formation between unpaired Cys residues. 
Furthermore, the effect of this substitution spans the -1 confidence limit of CamSol63 
predictions both in intrinsic and structurally corrected solubility score profiles 
(Figure  4.1B and C, respectively). The C18G substitution is also predicted to reduce 
the propensity for amyloid aggregation of G-CSF, based on the Zagg score predicted 
by Zyggregator64 in this region dropping below the confidence limit of 1 
(Figure  4.1D). This suggests that the reduced secondary structure propensity of Gly 
compared to Cys results in a reduced predicted propensity for both amorphous and 
amyloid aggregation. 
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The F84L substitution appears to have a more significant impact of reducing the 
predicted propensities for forming amyloid and β-sheet aggregates, predicted by 
Zyggregator64 and TANGO65 in Figure  4.1D and E, respectively, than reducing the 
general aggregation propensity of G-CSF, as predicted by Aggrescan62 and 
CamSol63 in Figure  4.1A and B/C, respectively. Although reductions in aggregation 
propensity are predicted by Aggrescan62 and CamSol63 as a result of the F84L 
substitution, Leu84 is still predicted to be a residue that promotes aggregation of G-
CSF, based on the scores attributed to this residue and the thresholds for 
aggregation prediction of these programs. Conversely, the F84L substitution results 
in Zagg scores for residues in this region dropping closer to the confidence limit of 1, 
suggesting that this reduction may be more significant in terms of the predicted 
propensity for amyloid aggregation (Figure  4.1D). Additionally, TANGO65 predicts a 
large reduction in the β-sheet aggregation propensity as a result of the F84L 
substitution, although the propensity for forming β-sheet aggregate in the region 
around Leu84 is still above the 5 % threshold (Figure  4.1E). 
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Figure ‎4.1 Aggregation prediction scores for G-CSF wt and C3. Scores for G-CSF wt are shown as solid lines, while 
scores for G-CSF C3 are shown as dashed lines. Where applicable, scores have been calculated for G-CSF wt and 
C3 at pH 4 (red) and 7 (blue). a4v scores calculated by Aggrescan
62
 to be above and below 0 indicate residues 
predicted to promote aggregation and solubility, respectively in vivo
62
 (A). CamSol
63
 solubility scores above 1 
indicate residues predicted to increase solubility, while scores below -1 indicate residues predicted to decrease 
solubility and so promote aggregation
63
 (B and C). CamSol
63
 solubility scores corrected for structure were calculated 
using the G-CSF wt structure (PDB 1GNC
283
), with residues being mutated in PyMOL
289
 for calculation of G-CSF C3 
solubility scores (C). Zagg scores calculated by Zyggregator
64
 to be above 1 indicate residues predicted to promote 
amyloid formation
64
 (D). TANGO
65
 predicts the percentage propensity for β-sheet aggregation, whereby sequences 
of five residues or more exhibiting percentages above 5 % are predicted to be involved in forming β-sheet 
aggregates
65
 (E). 
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4.2.2 Characterising the dependence of G-CSF C3 aggregation on pH and 
protein concentration      
 
The dependence of G-CSF C3 aggregation on pH and protein concentration was 
characterised using 100 µl samples of G-CSF C3 set up in triplicate in 1.5 ml 
Eppendorf tubes and incubated quiescently at 37 oC. G-CSF C3 samples were 
incubated in pH 4 buffer at protein concentrations of 4.5 and 8.6 mg/ml, while G-
CSF C3 samples in pH 7 buffer were set up using protein concentrations of 1.7 and 
5.5 mg/ml. At regular time intervals, samples were centrifuged at 13300 rpm for 15 
mins at room temperature and the A280 value of the supernatant measured. A280 
values were averaged across triplicate samples and standard deviations of mean 
A280 values used as errors. Mean A280 values measured after time intervals of 
incubation at 37 oC were normalised to the mean A280 value measured before 
incubation at 37 oC to produce proportions of aggregated G-CSF C3 (Figure  4.2).      
 
Protein aggregation assays show lower proportions of aggregated G-CSF C3 in pH 
4 buffer compared to pH 7 buffer, suggesting G-CSF C3 is less aggregation-prone 
at pH 4. This is emphasised by the aggregation profiles of 8.6 mg/ml G-CSF C3 in 
pH 4 buffer and 1.7 mg/ml G-CSF C3 in pH 7 buffer, which appear similar even 
though the G-CSF C3 sample at pH 4 has a five-fold higher protein concentration 
(Figure  4.2). Reduced aggregation of G-CSF C3 at acidic compared to neutral pH 
agrees with previously reported aggregation behaviour for the wild-type protein at 
acidic and neutral pH185,276,303.  
 
Reduced aggregation of G-CSF wt at acidic pH has been suggested to be the result 
of increased electrostatic repulsion between G-CSF molecules, caused by a greater 
overall positive charge of G-CSF at acidic compared to neutral pH303. Considering 
the pI values of G-CSF wt and C3, which are predicted from their amino acid 
sequences to be 6.02 and 6.67, respectively117, it is likely that the reduced 
aggregation of G-CSF C3 at pH 4 compared to pH 7 is also due to an overall greater 
positive charge on G-CSF C3 molecules at the lower pH causing electrostatic 
repulsion.    
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Figure ‎4.2 Aggregation assays for G-CSF C3 at different protein concentrations. Assays were set up using G-CSF 
C3 at protein concentrations of 1.7 and 5.5 mg/ml (orange and red, respectively) in 20 mM sodium phosphate, 20 
mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM), while protein concentrations of 4.5 and 8.6 
mg/ml (purple and blue, respectively) were used in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I 
= 43 mM). During centrifugation and measurement timing was suspended, meaning the x-axis in this figure 
represents the time samples were incubated at 37 
o
C. Error bars represent the standard deviation of the mean A280 
value measured across triplicate samples. Proportions of aggregated G-CSF C3 from the 5.5 mg/ml sample were 
fitted to a single exponential decay function with a y-axis offset, while proportions of aggregated G-CSF C3 for all 
other samples were fitted to a linear function.       
 
Surprisingly, the time courses of aggregation of G-CSF C3 samples in pH 7 buffer at 
1.7 and 5.5 mg/ml shown in Figure  4.2 appear comparable to those observed for 
wild-type G-CSF in 100 mM MOPS pH 7 buffer at 1 and 5 mg/ml142. The ionic 
strengths of 100 mM MOPS at pH 7 and the pH 7 buffer used in this study are 
calculated to be 39 and 80 mM, respectively. These different buffer conditions used 
may affect G-CSF aggregation, for instance the aggregation of G-CSF at acidic pH 
has been reported to be dependent on ionic strength303. However, the percentage of 
aggregated protein for 1.7 mg/ml G-CSF C3 in pH 7 buffer after 68 h of incubation at 
37 oC was 41 %, which is comparable to the approximate 35-40% aggregated 
protein observed after 3 days incubation at 37 oC for 1.5 mg/ml G-CSF wt in 10 mM 
sodium phosphate, 150 mM NaCl pH 7 buffer185,308, even though this buffer has a 
higher ionic strength than the pH 7 buffer used in this study.  
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The percentage of aggregated protein for 5.5 mg/ml G-CSF C3 in pH 7 buffer after 
44 h incubation at 37 oC was 38 %, which is significantly lower than the approximate 
50 % aggregated protein observed after 2 days incubation at 37 oC for 5 mg/ml G-
CSF wt in 100 mM MOPS at pH 7142, as well as the 53 % aggregated protein 
reported after 2 days incubation at 37 oC for 5 mg/ml G-CSF wt in 100 mM sodium 
phosphate pH 6.9 buffer214. However, after 68 h incubation at 37 oC the percentage 
of aggregated protein for 5.5 mg/ml G-CSF C3 in pH 7 buffer was 49 %, suggesting 
that G-CSF C3 ultimately aggregates to the same extent as the wild-type protein at 
pH 7, albeit at a slower rate. This effect could be attributed to substitution of the 
unpaired Cys residue in G-CSF, which has been shown previously to slow the rate 
of aggregation at pH 7, although ultimately aggregation was reported to occur to the 
same extent as wild-type G-CSF142.  
 
Ultimately, G-CSF C3 appears to aggregate at a slower rate at higher protein 
concentrations than wild-type G-CSF but aggregates to the same extent (i.e. similar 
concentration of soluble protein at the end-point) as the wild-type protein and more 
generally, it appears that G-CSF aggregation at neutral pH does not depend on ionic 
strength. 
 
4.2.3 Characterising the dependence of G-CSF C3 aggregation on urea 
concentration           
 
Protein aggregation assays to characterise the denaturant dependence of G-CSF 
C3 aggregation were set up in the same way as assays used to characterise the 
dependence of G-CSF C3 aggregation on pH and protein concentration (see 
Section  4.2.2), although in this case mean A280 values were plotted against time 
rather than being converted into proportions of aggregated protein, to allow 
comparison with aggregation assays carried out by Raso et al.142 in the presence of 
denaturant. 70 and 87 µM G-CSF C3 in pH 7 and 4 buffers, respectively were 
incubated quiescently at 37 oC in the presence of 0-7 M urea with 1 M increments, 
with triplicate samples being set up at each urea concentration (Figure  4.3). 
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Figure ‎4.3 Aggregation assays for G-CSF C3 at different urea concentrations. Assays were set up using 70 and 87 
µM G-CSF C3 in 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 
mM) and 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 mM), respectively (A and B, 
respectively) in the presence of 0 (black), 1 (cyan), 2 (pink), 3 (purple), 4 (orange), 5 (blue), 6 (red) and 7 M (green) 
urea. During centrifugation and measurement timing was suspended, meaning the x-axis in this figure represents 
the time samples were incubated at 37 
o
C. Error bars represent the standard deviation of the mean A280 value 
measured across triplicate samples. A280 values for G-CSF C3 pH 7 samples in the presence of 5, 6 and 7 M urea 
were fitted to a single exponential decay function with a y-axis offset as shown in A, while A280 values for all other 
samples were fitted to a linear function.  
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The greatest amounts of G-CSF C3 aggregation in pH 7 buffer are observed in the 
presence of 5, 6 and 7 M urea. Interestingly, the amount of G-CSF C3 aggregation 
is highest in 6 M urea (Figure  4.3A). This is analogous to the effects of 2, 2.5 and 
3.5 M GdnHCl on the amount of G-CSF wt aggregation at pH 7 reported previously, 
in which the highest amount of aggregation is observed in 2.5 M GdnHCl142. This 
suggests that the effect of denaturant on the aggregation of G-CSF C3 is similar to 
the effect on the wild-type protein, possibly indicating a common aggregation 
mechanism. 
 
The relative rates of G-CSF C3 aggregation in these different urea concentrations 
are difficult to interpret because the curves plateau at different A280 values 
(Figure  4.3A), which is an effect not observed for G-CSF wt aggregation in the 
presence of GdnHCl over a similar timescale142. The reason for the seemingly varied 
endpoints of G-CSF C3 aggregation in different urea concentrations is unclear, but 
may be due to the overall charge of GdnHCl that is absent for urea affecting 
aggregation. Alternatively, removal of the unpaired Cys in G-CSF C3 may affect the 
aggregates formed, as aggregates of wild-type G-CSF have previously been shown 
to be disulphide cross-linked, whereas aggregates of a C18A G-CSF variant are not 
disulphide cross-linked142.  
 
Interestingly, addition of 3, 4 and 5 M urea also appears to increase the amount of 
G-CSF C3 aggregation observed in pH 4 buffer (Figure  4.3B), although to a lesser 
extent than observed in pH 7 buffer (Figure  4.3A). Quantification of the aggregation 
of G-CSF wt in the presence of denaturant at pH 4 has not previously been 
reported, meaning it is unknown whether the effect of denaturant on G-CSF C3 
aggregation at pH 4 is also exhibited by the wild-type protein. The greatest amount 
of G-CSF C3 aggregation in pH 4 buffer appears to be in the presence of 4 M urea, 
while at higher urea concentrations less aggregation is observed (Figure  4.3B). This 
is similar to the effect of 6 M urea on G-CSF C3 aggregation in pH 7 buffer relative 
to 7 M urea (Figure  4.3A), suggesting that there may be a common structural 
change occurring at pH 4 and 7 in certain urea concentrations that promotes 
aggregation, while at higher urea concentrations global unfolding occurs and the 
unfolded state is solubilised. Interestingly, a subtle conformational change has been 
suggested to cause aggregation of G-CSF wt in 1.5-2.5 M GdnHCl, revealed by a 
change in the fluorescence properties of Trp59 in the AB loop142.    
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4.2.4 Measuring the thermodynamic stability of G-CSF C3 
 
Equilibrium denaturation analyses of G-CSF C3 were carried out to measure the 
thermodynamic stability of the protein at pH 4 and 7. Additionally, these analyses 
provided a measure of the thermodynamic stability in the presence of urea 
concentrations that have been shown to promote protein aggregation (Figure  4.3). 
Equilibrium denaturation of G-CSF C3 was carried out at 25 oC to allow better 
comparison of the free energies of unfolding (ΔGoUN) obtained for G-CSF C3 to 
those reported for wild-type G-CSF at 20 oC at pH 4304 and at 25 oC at pH 7142. In 
addition, aggregation of G-CSF wt has been shown to occur less readily at 25 oC 
compared to at 37 oC185,307, meaning ΔGoUN values obtained for G-CSF C3 at 25 
oC 
were less likely to be affected by aggregation.  
 
Equilibrium denaturation of G-CSF C3 involved setting up samples of 7 µM G-CSF 
C3 in pH 4 and 7 buffers in the presence of 0, 2, 4, 6, 8 and 9 M urea, which were 
subsequently mixed in the correct ratios to produce 1 ml samples of 7 µM G-CSF 
C3 in 0-9 M urea with 0.2 M increments in 1.5 ml Eppendorf tubes (see 
Section  2.6.4). These 1 ml samples were incubated at 25 oC overnight and used the 
next day to measure fluorescence emission intensity at 25 oC. The fluorescence 
emission intensity of the pH 7 samples was measured at 320 nm, while the emission 
intensity of pH 4 samples was measured at 301 and 348 nm. Intensities at different 
wavelengths were monitored during equilibrium denaturation of G-CSF C3 at pH 4 
and 7 due to the different fluorescence emission spectra observed for folded G-CSF 
C3 at pH 4 and 7 (see Section  3.2.6). After measurement samples were returned to 
incubation at 25 oC and left overnight again. The next day samples were used to 
measure ellipticity at 222 nm at 25 oC by far-UV CD. 
 
The resulting observed signal intensities were fitted to Equation  2.9 and the 
parameters from these fits were used in Equation  2.10 to normalise the observed 
signal intensities, by converting them into the fraction of folded G-CSF C3 (see 
Section  2.6.4.3), according to the linear-extrapolation method of analysing 
equilibrium denaturation data312. 
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Figure ‎4.4 Equilibrium denaturation analyses of G-CSF C3 overlaid with fractions of soluble G-CSF C3 calculated 
from aggregation assays. Equilibrium denaturation of G-CSF C3 in 20 mM sodium phosphate, 20 mM sodium 
acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM; blue data points in A) and 20 mM sodium phosphate, 20 
mM sodium acetate pH 4 buffer (I = 43 mM; red and orange data points in B) is shown on the left hand y-axis and 
was monitored by measuring ellipticity at 222 nm (open data points) and intrinsic fluorescence emission intensity at 
320 nm (blue closed data points), 301 nm (orange closed data points) and 348 nm (red closed data points) at 25 
o
C. 
Fractions of soluble G-CSF C3 remaining after incubation of 70 µM G-CSF C3 in pH 7 buffer for 24 h at 37 
o
C in the 
presence of 0-7 M urea with 1 M increments (blue bars in A), as well as after incubation of 87 µM G-CSF C3 in pH 4 
buffer for 27 h at 37 
o
C at the same urea concentrations (red bars in B) are shown on the right hand y-axis.      
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Equilibrium denaturation curves for G-CSF C3 in pH 4 and 7 buffers showed 
concurrent loss of secondary and tertiary structure by urea that fitted well to a 
reversible co-operative transition, although only in urea concentrations of 2-9 M in 
pH 7 buffer (Figure  4.4A) and 1-9 M in pH 4 buffer (Figure  4.4B). Significant 
increases in ellipticity and fluorescence emission intensity at 320 nm were observed 
for G-CSF C3 in pH 7 buffer upon increasing the urea concentration from 0-2 M 
(Figure  4.4A), as well as in fluorescence emission intensity at 301 nm observed for 
G-CSF C3 in pH 4 buffer (Figure  4.4B). Consequently, these data obtained for 0-2 M 
urea at pH 7 and 0-1 M urea at pH 4 were not included in fitting of the observed 
signal intensities to Equation  2.9 in order to calculate ΔGoUN values
312.     
 
The increases in ellipticity and fluorescence emission intensities observed for G-
CSF C3 suggest a conformational change of the protein at urea concentrations that 
are too low to cause global unfolding, which could be linked to aggregation. 
Therefore, the secondary and tertiary structures of G-CSF C3 in pH 7 buffer in the 
presence of urea concentrations up to 4 M, as well as in pH 4 buffer in the presence 
of urea concentrations up to 3 M were further investigated by far- and near-UV CD 
(see Sections  4.2.7 and  4.2.9, respectively), intrinsic fluorescence emission (see 
Section  4.2.8) and later by NMR (see Chapter 5). 
 
ΔGoUN and MUN values, representing the free energy of unfolding and the 
dependence of this free energy on denaturant concentration, respectively312, 
obtained for G-CSF C3 in pH 4 and 7 buffers are shown in Table  4.1. The ΔGoUN 
value calculated for G-CSF C3 in pH 7 buffer from fluorescence measurements in 2-
9 M urea of 40.0 kJ mol-1 is similar to the ΔGoUN value reported for wild-type G-CSF 
in 100 mM MOPS pH 7 buffer with 0-5 M GdnHCl at 25 oC (40.2 kJ mol-1)142. 
Although the ΔGoUN value calculated for G-CSF C3 in pH 7 buffer from far-UV CD 
measurements is only 36.1 kJ mol-1, the relatively large error on this value makes it 
unclear whether this is significantly different to the value reported for the wild-type 
protein.  
 
The ΔGoUN value calculated for G-CSF C3 in pH 4 buffer from fluorescence 
measurements at 348 nm in 0-9 M urea of 37.0 kJ mol-1 is also similar to the ΔGUN 
value reported for wild-type G-CSF in 20 mM sodium acetate, 20 mM MES, 50 mM 
Tris pH 4 buffer with 0-5 M GdnHCl at 20 oC (37.7 kJ mol-1)304. ΔGoUN values 
calculated for G-CSF C3 in pH 4 buffer from fluorescence measurements at 301 nm 
in 1-9 M urea and far-UV CD measurements in 0-9 M urea are 35.7 and 35.4 kJ mol-
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1, respectively, which are lower than the value reported for wild-type G-CSF but are 
within the relatively small error margins of these calculations, suggesting that they 
are not significantly different from the value reported for the wild-type protein. 
Overall, these results suggest that the thermodynamic stability of G-CSF C3 is 
similar to wild-type G-CSF at pH 4 and 7.             
 
 pH 7 pH 4 
 
Ellipticity 
222 nm 
Fluorescence 
320 nm 
Ellipticity 
222 nm 
Fluorescence 
301 nm 
Fluorescence 
348 nm 
ΔGoUN 
/ kJ 
mol-1 
36.12 ± 
5.7 
40.00 ± 4.9 
35.36 ± 
2.8 
35.70 ± 2.5 36.97 ± 3.1 
MUN / 
kJ 
mol-1 
M-1 
6.21 ± 1.0 6.80 ± 0.8 6.90 ± 0.6 7.04 ± 0.5 7.32 ± 0.6 
Table ‎4.1 Free energies of unfolding (ΔGoUN) and the dependencies of these free energies on denaturant 
concentration (MUN) calculated for G-CSF C3. Values were calculated from equilibrium denaturation analyses of 7 
µM G-CSF C3 carried out in 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 
buffer (I = 80 mM) and 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 mM), monitoring 
ellipticity and fluorescence at the wavelengths shown. ΔG
o
UN and MUN values and errors were obtained from fitting of 
observed signal intensities to Equation ‎2.9 (see Section ‎2.6.4.3) shown in Figure ‎4.4.   
 
Equilibrium denaturation analyses of G-CSF C3 in pH 7 and 4 buffers are shown in 
Figure  4.4A and B, respectively overlaid with fractions of soluble G-CSF C3, which 
were calculated using the mean A280 values shown in Figure  4.3. Mean A280 values 
measured after incubation of 70 µM G-CSF C3 in pH 7 buffer in the presence of 0-7 
M urea for 24 h at 37 oC (Figure  4.3A), as well as incubation of 87 µM G-CSF C3 in 
pH 4 buffer in the presence of 0-7 M urea for 27 h at 37 oC (Figure  4.3B) were 
divided by mean A280 values measured for the same samples before incubation at 
37 oC. Overlaying the fractions of soluble and folded G-CSF C3 reveals urea 
concentrations at pH 4 and 7 at which aggregation occurs but global unfolding does 
not, these being 3 and 4 M urea at pH 4 and 7, respectively.  
 
As well as enabling investigation of the thermodynamic stability of G-CSF C3, 
equilibrium denaturation analysis has allowed a more precise definition of the 
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conditions in which aggregation is favoured and disfavoured. Therefore, many of the 
experiments performed in the remainder of this study are carried out in 0-3 M urea in 
pH 4 buffer and 0-4 M urea in pH 7 buffer.  
 
4.2.5 Characterising insoluble G-CSF C3 aggregates using Electron 
Microscopy (EM)  
 
EM images of G-CSF C3 aggregates were collected to determine whether they were 
amorphous or amyloid in nature (Figure  4.5). For aggregation assays in pH 7 buffer 
G-CSF C3 was used at 67 and 66 µM in the presence and absence of 4 M urea, 
respectively, while for assays in pH 4 buffer G-CSF C3 was used at 83 and 85 µM in 
the presence and absence of 3 M urea, respectively. 300 µl aggregation assays 
were set up in a 1.5 ml Eppendorf tube and then transferred to a Shigemi tube, 
which was subsequently incubated quiescently at 37 oC for 24 h in an NMR 
spectrometer to monitor HSQC peak intensities (see Section  2.9.4). After 24 h, each 
sample was transferred to 1.5 ml Eppendorf tubes and snap frozen, followed by 
storage at -80 oC. Samples were later thawed and 10 µl transferred to 
formvar/carbon-coated copper grids for imaging by Dr. Katie Stewart (see 
Section  2.8). 
 
Surprisingly, G-CSF C3 aggregates formed at pH 4 and 7 appear to have different 
morphologies (Figure  4.5). Generally, aggregates formed at pH 7 appear 
amorphous in nature (Figure  4.5A-D), whereas aggregates formed at pH 4 more 
closely resemble protofibrils (Figure  4.5E-H), species that are considered to be late-
stage intermediates in amyloid fibril formation79. In particular, G-CSF C3 aggregates 
formed at pH 4 in the presence of 3 M urea appear to be largely protofibrillar in 
nature (Figure  4.5G and H). EM images also suggest that there are mixtures of 
amorphous and protofibrillar species in the same aggregation assay samples at pH 
7 (Figure  4.5D) and 4 (Figure  4.5E and F), which may account for the observation of 
amorphous aggregates by EM308 and aggregates that bind Thioflavin-T formed by 
wild-type G-CSF at pH 779,307. 
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Figure ‎4.5 EM images of G-CSF C3 aggregates. Two images are shown for each aggregation assay sample. 
Images A/B and C/D show aggregates formed in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) 
sodium azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) in the absence or presence of 4 M urea, respectively and 
images E/F and G/H show aggregates formed in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O 
pH 4 buffer (I = 39 mM) in the absence or presence of 3 M urea, respectively. EM grids for imaging were prepared 
and imaged by Dr. Stewart. Scale bars represent 500 nm.  
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4.2.6 Characterising soluble G-CSF C3 aggregate formation using Dynamic 
Light Scattering (DLS) 
 
DLS involves measurements of light scattering intensity by particles over a range of 
time periods. The intensity of scattered light is constantly fluctuating due to 
Brownian motion of the particles in solution, provided a monochromatic light source 
is used and the wavelength of light is larger than the particle size. Light scattering 
intensities over time are then fitted to a second order auto-correlation function 
shown in Equation  2.11 (see Section  2.7.3), in order to calculate a hydrodynamic 
radius (Rh) for the particles. This correlation function relates the scattering intensity 
at the beginning of measurement to the scattering intensity after a time delay (τ). As 
τ becomes greater there is less correlation between the scattering intensities 
observed at the start of measurement and the scattering intensities after the time 
delay τ, meaning the correlation function decreases. Smaller particles move faster 
and so cause the correlation function to decay at a higher rate, whereas larger 
particles move slower and so cause a slower rate of decay316. 
 
For a population of species with a monodisperse size the decay rate of the 
correlation function can be calculated using a single exponential decay function i.e. 
Equation  2.12 (see Section  2.7.3), whereas for populations of species where a 
range of particle sizes is present each species has its own exponential decay rate, 
meaning attempting to calculate the decay rate of the correlation function using a 
single exponential decay function becomes less accurate316. For polydisperse 
samples, decay rates for each species of a different size are calculated using a 
summation of the single exponential decay functions of each of the species based 
on the weighting of these differently sized species i.e. Equation  2.17317. The decay 
rates of autocorrelation functions are then used in Equations 2.13-2.15 to calculate 
Rh values
316. 
 
To provide an indication of the polydispersity of the sample a regularisation analysis 
can be carried out, based on the distribution function calculated from Equation  2.17. 
The resulting plot shows the fractional scattering intensity by each species of a 
particular Rh value
318. All of the above calculations are performed by ASTRA 6 
software. The Rh values for the different species identified can then be used to 
estimate their molecular mass from Equation  2.18 (see Section  2.7.3), although this 
assumes the particles are spherical319. 
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For DLS measurements, 600 µl samples of G-CSF C3 were set up in 1.5 ml 
Eppendorf tubes, using 66 and 67 µM G-CSF C3 in pH 7 buffer in the presence and 
absence of 4 M urea, respectively and 83 and 85 µM G-CSF C3 in pH 4 buffer in the 
presence and absence of 3 M urea, respectively. After centrifugation at 13300 rpm 
for 15 mins at room temperature 290 µl of supernatant was used for DLS 
measurement (see Section  2.7.3). The remainder of the supernatant was incubated 
quiescently at 37 oC for 24 h, after which time the sample was centrifuged and DLS 
characterisation repeated.  
 
The correlation functions and regularisation analyses are shown for G-CSF C3 
aggregation assays at pH 7 and 4 monitored by DLS (Figure  4.6 and Figure  4.7, 
respectively). The correlation function plots show the results of attempting to fit the 
autocorrelation values to a single exponential decay function (Figure  4.6A/B and 
Figure  4.7A/B), while regularisation analyses show the results of fitting the 
autocorrelation values to a summation of the exponential decay functions of each 
species detected with a different Rh. The output of the regularisation analysis is the 
fractional intensity of each species with a distinguishable Rh (Figure  4.6C/D and 
Figure  4.7C/D). This cannot be used to quantify the amount of each species present 
due to the intensity of scattering being proportional to the sixth power of the radius 
of the particle. Moreover, in order for two species of different sizes to be separated 
their Rh values must vary by at least a factor of five
316. 
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Figure ‎4.6 Aggregation assays of G-CSF C3 at pH 7 with or without 4 M urea monitored by DLS. Assays were set 
up in 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM) using 
67 and 66 µM G-CSF C3 in the absence (A, C and E) or presence (B, D and F) of 4 M urea, respectively and then 
incubated quiescently at 37 
o
C for 24 h. DLS analysis of samples before and after incubation at 37 
o
C for 24 h are 
shown in black and red. The change in the autocorrelation functions over time in the absence or presence of 4 M 
urea are shown fitted to single exponential decay functions in A and B, respectively, while regularisation analyses of 
the changes in the autocorrelation functions over time in the absence or presence of 4 M urea are shown in C and 
D, respectively. The Rh values of peaks and peak widths in the regularisation analysis in the absence or presence of 
4 M urea are shown in E and F, respectively, along with the percentage of area under each peak. These details are 
not shown for peaks that account for less than 5 % of the area occupied.    
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Figure ‎4.7 Aggregation assays of G-CSF C3 at pH 4 with or without 3 M urea monitored by DLS. Assays were set 
up in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 mM) using 85 and 83 µM G-CSF C3 in 
the absence (A, C and E) or presence (B, D and F) of 3 M urea, respectively and then incubated quiescently at 37 
o
C for 24 h. DLS analysis of samples before and after incubation at 37 
o
C for 24 h are shown in black and red. The 
change in the autocorrelation functions over time in the absence or presence of 3 M urea are shown fitted to single 
exponential decay functions in A and B, respectively, while regularisation analyses of the changes in the 
autocorrelation functions over time in the absence or presence of 3 M urea are shown in C and D, respectively. The 
Rh values of peaks and peak widths in the regularisation analysis in the absence or presence of 4 M urea are shown 
in E and F, respectively, along with the percentage of area under each peak. These details are not shown for peaks 
that account for less than 5 % of the area occupied. 
 
The variation in the correlation function over time can be fitted more accurately to a 
single exponential decay function when fewer species of different Rh values are 
present in solution, as shown from DLS measurements of G-CSF C3 at pH 7 in the 
absence or presence of 4 M urea (Figure  4.6A and B, respectively). In the absence 
of urea, the correlation function for G-CSF C3 at pH 7 decays more rapidly and 
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reaches a baseline after a shorter time period (Figure  4.6A) compared to G-CSF C3 
in the presence of 4 M urea (Figure  4.6B), indicating that the species formed in the 
absence of urea are smaller and so cause less light scattering.  
 
After incubation at 37 oC the correlation functions for G-CSF C3 at pH 7 without urea 
show slightly increased deviation from the fit at early time periods (Figure  4.6A), 
suggesting formation of species of a wider range of Rh values, which is also 
reflected in the increased width of the main peak in the regularisation analysis 
(Figure  4.6C and E). Rh values and ranges of the most intense peak equate to 
estimated molecular masses of 3.4-13.9 and 4.9-45.4 kDa before and after 
incubation at 37 oC, respectively (Figure  4.6E), suggesting that within this peak is 
monomeric G-CSF C3, as well as a greater proportion of oilgomeric forms of G-CSF 
C3 after incubation at 37 oC. 
 
In the presence of 4 M urea at pH 7, regularisation analysis shows that species with 
larger Rh values are observed and a wider range of Rh values is occupied 
(Figure  4.6D and F), suggesting formation of larger soluble G-CSF C3 aggregates 
as a result of adding 4 M urea. Interestingly, even before incubation at 37 oC there 
appear to be large soluble G-CSF C3 aggregates present in 4 M urea, but after 
incubation at 37 oC the distribution is shifted towards species with higher Rh values 
(Figure  4.6D and F), implying formation of larger soluble aggregates. Due to the 
wide ranges of Rh values occupied by peaks in the presence of 4 M urea 
(Figure  4.6F), estimated molecular masses of species have not been calculated. 
 
Surprisingly, incubation of G-CSF C3 at pH 4 for 24 h at 37 oC in the absence of 
urea appears to result in formation of aggregates with larger Rh values compared to 
incubation of G-CSF C3 at pH 7 in the absence of urea (Figure  4.7C and 
Figure  4.6C, respectively), implying formation of larger soluble G-CSF C3 
aggregates at pH 4. This is in contrast to the increased formation of insoluble 
aggregates observed for G-CSF C3 at pH 7 compared to at pH 4, which is apparent 
even when higher protein concentrations are used at pH 4 (Figure  4.2).  
 
The formation of soluble G-CSF C3 aggregates at pH 4 without urea after incubation 
at 37 oC reduces the accuracy of a fit of the change in correlation function over time 
to a single exponential decay and results in a slower rate of decay (Figure  4.7A). 
This is also reflected in the regularisation analysis, which shows an increase in the 
width and area of the second peak after incubation at 37 oC (Figure  4.7C). There is 
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also a corresponding decrease in the area of the first peak due to incubation at 37 
oC, although the width of this peak remains largely unchanged (Figure  4.7E) and 
corresponds to estimated molecular mass ranges of 6.3-49.0 and 5.0-52.1 kDa.  
 
In the presence of 3 M urea at pH 4, the change in correlation function over time 
appears to fit better to a single exponential decay function after incubation of G-CSF 
C3 for 24 h at 37 oC (Figure  4.7B), suggesting that the population of species in 
solution becomes less disperse in size. Additionally, the decay in the correlation 
function occurs after a longer time period, implying larger species are present.  
 
Regularisation analysis shows that, after incubation of G-CSF C3 at pH 4 in the 
presence of 3 M urea for 24 h at 37 oC, there is a shift in the distribution from 
population of the lower to the higher Rh peak (Figure  4.7D and F), implying 
increased formation of soluble aggregates. The peak of higher Rh value is also 
present before incubation at 37 oC (Figure  4.7D and F), suggesting soluble 
aggregates of G-CSF C3 are present at pH 4 in the presence of 3 M urea and 
incubation at 37 oC results in continued formation of these aggregates. This is 
similar to the effect of 4 M urea on G-CSF C3 aggregation at pH 7 observed from 
DLS measurements (Figure  4.6D and F). The estimated molecular masses of 
species in the lower Rh peak before incubation at 37 
oC are 13.9-92.4 kDa, 
suggesting monomeric G-CSF C3 is within this peak. However, the wide ranges of 
Rh values occupied by other peaks in the presence of 3 M urea (Figure  4.7F) means 
that estimated molecular masses of species have not been calculated.          
 
4.2.7 Probing for changes in secondary structure of G-CSF C3 in 
aggregation-prone conditions using far-UV CD 
 
Far-UV CD was used to probe for changes in the secondary structure of G-CSF C3 
in the presence of urea concentrations that are too low to cause global denaturation 
at 25 oC. The spectra of G-CSF C3 at pH 7 in the presence of 0-4 M urea exhibit 
absorption minima at 221-222 nm (Figure  4.8A), indicative of predominantly α-
helical structure313. In addition, the intensities of these spectra are similar, 
suggesting no significant change in the α-helical content of G-CSF C3 upon addition 
of urea.  
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Spectra of G-CSF C3 at pH 4 in the presence of 0-3 M urea are also similar in terms 
of their shapes and intensities, showing absorption minima at 221 nm (Figure  4.8B). 
The spectrum of G-CSF C3 at pH 4 in the absence of urea is more negative at this 
absorption minimum than in the presence of all concentrations of urea, but is also 
more negative across all wavelengths at which ellipticity was measured. This would 
suggest unusually high intensities exhibited by the buffer blank that were subtracted 
from the intensities measured in this spectrum, possibly due to light scattering. 
Overall, these spectra suggest that there is no significant change in the secondary 
structure of G-CSF C3 in urea concentrations that favour or disfavour aggregation. 
 
Equilibrium denaturation analysis of G-CSF C3 carried out at pH 7 and monitored by 
far-UV CD spectroscopy suggested an increase in the ellipticity measured at 222 nm 
between urea concentrations of 0-2 M (Figure  4.4A). However, acquisition of far-UV 
CD spectra of G-CSF C3 over wavelengths of 210-260 nm suggests no significant 
change in ellipticity at 222 nm in the presence of 0-4 M urea (Figure  4.8A). The 
increase in signal intensity observed over 0-2 M urea in the equilibrium curve 
obtained using far-UV CD for G-CSF C3 at pH 7 is most likely being accentuated by 
linear extrapolation of the pre-transition baseline, which has been carried out during 
fitting of intensities measured over 2-9 M urea in order to calculate ΔGoUN and MUN 
values312 (see Section  2.6.4.3). Consequently, linear extrapolation of the pre-
transition baseline may be giving a false impression of the extent of the change in 
ellipticity at 222 nm observed in 0-2 M urea in Figure  4.4A. 
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Figure ‎4.8 Far-UV CD spectra of G-CSF C3 at different urea concentrations. Spectra of G-CSF C3 in 20 mM 
sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM) were acquired in the 
presence of 0 (black), 0.5 (green), 1 (red), 2 (blue), 3 (pink) and 4 M (orange) urea using 7-8 µM G-CSF C3 (A), 
while spectra of G-CSF C3 in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 mM) were 
acquired in the presence of the same urea concentrations, excluding 0.5 and 4 M urea, using 5-8 µM G-CSF C3 (B). 
A horizontal dotted line is drawn at zero ellipticity. [θ]MRE values acquired at wavelengths below 210 nm are not 
shown due to excessive dynode voltage (800-1000 V) caused by the absorbance of signal by urea.       
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4.2.8 Probing for changes in the tertiary structure of G-CSF C3 in 
aggregation-prone conditions using fluorescence 
 
Intrinsic fluorescence emission spectra of G-CSF C3 were used to probe for 
changes in the environment of Trp and Tyr residues upon addition of urea 
concentrations that are too low to cause global denaturation at 25 oC. The emission 
spectra of G-CSF C3 at pH 7 show increases in intensity across all wavelengths as 
the urea concentration is raised from 0 to 2 M and to a lesser extent from 2 to 4 M 
(Figure  4.9A). The wavelengths at which maximum emission is observed remain at 
334-335 nm in the presence of 0-4 M urea. This emission wavelength is 
characteristic for a Trp side chain that is buried within a hydrophobic environment357. 
This suggests that the increased intensity in the fluorescence emission spectra of G-
CSF C3 at pH 7 in 0-4 M urea could be due to a change in the environment of Trp 
side chains that is not accompanied by an increase in solvent exposure. 
Alternatively, the increased emission intensity observed could be caused by a 
change in the environment of one or more of the three Tyr side chains in G-CSF C3, 
as the wavelength at which maximum emission intensity is observed for Tyr side 
chains does not vary with solvent exposure367. 
 
Emission spectra of G-CSF C3 at pH 4 show a significant increase in intensity after 
adding 1 M urea, but at higher urea concentrations smaller increases are observed 
(Figure  4.9B). Again, the increase in emission intensity is not accompanied by a 
change in the emission maxima, which remain at 299-301 nm. An emission 
maximum at 303 nm is characteristic of Tyr fluorescence, although the wavelength 
of maximum emission of Tyr is not affected by the degree of solvent exposure367. 
The blue-shift in the fluorescence emission maximum of G-CSF C3 at pH 4 
compared to pH 7 is due to quenching of Trp119 fluorescence, most likely caused 
by ionisation of the proximal side chain of His80 (Figure  3.12B). The increase in 
fluorescence emission intensity of G-CSF C3 at pH 4 around 300 nm suggests a 
change in the environment of one or more of the three Tyr side chains, although the 
reduced intensity of Trp at pH 4 due to quenching makes it unclear whether a 
change in the environment of Trp side chains is also occurring upon addition of 
urea.      
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Figure ‎4.9 Fluorescence emission spectra of G-CSF C3 at different urea concentrations. Spectra of G-CSF C3 in 
20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM) were 
acquired in the presence of 0 (black), 0.5 (green), 1 (red), 2 (blue), 3 (pink) and 4 M (orange) urea using 7-8 µM G-
CSF C3 (A), while spectra of G-CSF C3 in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 
mM) were acquired in the presence of the same urea concentrations, excluding 0.5 and 4 M urea, using 5-8 µM G-
CSF C3 (B). Fluorescence emission intensities have been corrected for the different protein concentrations used.   
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Equilibrium denaturation analysis of G-CSF C3 at pH 7 showed an increase in the 
fluorescence emission intensity measured at 320 nm between urea concentrations 
of 0-2 M (Figure  4.4A). Acquisition of fluorescence emission spectra of G-CSF C3 
over wavelengths of 290-400 nm revealed a dramatic increase in emission intensity 
observed across all wavelengths as a result of increasing the urea concentration 
from 0 to 2 M, which is larger than the increase observed from 2 to 4 M 
(Figure  4.9A). In turn, this suggests that the inability to fit fluorescence emission 
intensities recorded in 0-2 M urea to a two-state transition between native and 
unfolded states is due to population of one or several additional conformations.  
 
Equilibrium denaturation analysis of G-CSF C3 at pH 4 showed an increase in the 
fluorescence emission intensity measured at 301 nm between urea concentrations 
of 0-1 M, but not when measured at 348 nm (Figure  4.4B). Fluorescence emission 
spectra of G-CSF C3 acquired over wavelengths of 290-400 nm revealed a large 
increase in emission intensity around 300 nm upon addition of 1 M urea, but little 
change around 330-340 nm (Figure  4.9B). Again, this suggests that the inability to fit 
fluorescence emission intensities recorded at 301 nm in 0-1 M urea to a two-state 
transition is due to population of one or multiple additional conformations, which may 
possess an altered conformation around one or more of the three Tyr side chains of 
G-CSF C3. Due to Trp fluorescence quenching of G-CSF C3 at pH 4, it is unclear 
whether there may also be an altered conformation around Trp119 in this state.       
 
4.2.9 Probing for changes in the tertiary structure of G-CSF C3 in 
aggregation-prone conditions using near-UV CD    
 
CD can be used to characterise the tertiary structure of a protein as well as its 
secondary structure by measuring in the near-UV region of the spectrum. The 
chirality of aromatic side chains that arises from their arrangement in asymmetric 
environments within a folded protein results in the differential absorption of left and 
right circularly polarised components of plane-polarised light, which can be 
measured by CD. The intensity of this CD signal is reduced for more mobile 
aromatic side chains313. Typically, Phe side chains exhibit their absorbance 
maximum between 255-270 nm, Trp side chains exhibit a peak at 290 nm and often 
some absorbance at 290-305 nm and Tyr side chains are observed as an 
absorption minimum around 275-282 nm393. The CD signal observed in the near-UV 
region is far less intense than that observed in the far-UV region because of the 
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relative amounts of aromatic side chains and peptide bonds, meaning higher protein 
concentrations are needed for recording near-UV CD spectra313. 
 
To probe for tertiary structure changes in G-CSF C3 in urea concentrations that are 
too low to globally denature the protein at 25 oC, near-UV CD spectra were acquired 
in pH 7 buffer using 45-57 µM protein in the presence of 0-4 M urea, while in pH 4 
buffer spectra were acquired using 36-52 µM protein in the presence of 0-3 M urea 
(Figure  4.10A and B, respectively).     
 
The near-UV CD spectra of G-CSF C3 at pH 7 and 4 show an increased absorption 
signal in the region around 275 nm upon addition of urea (Figure  4.10A and B, 
respectively), suggesting a change in the environment of one or more of the three 
Tyr side chains. Although there are slight increases in negativity for absorption 
around 255 and 290 nm upon adding urea, indicative of Phe and Trp side-chains, 
respectively, these changes are significantly smaller in magnitude than the 
increased negativity observed around 275 nm, suggesting that they are largely due 
to the change observed around 275 nm.  
 
A change in the environment of Tyr side chains most likely also accounts for the 
increased fluorescence emission intensity observed for G-CSF C3 at pH 7 and 4 
upon adding urea (Figure  4.9A and B, respectively). Interestingly, the absorption 
minima at 275 nm observed in the near-UV CD spectra become more negative in 
the presence of urea (Figure  4.10), implying Tyr side chains are becoming less 
mobile as a result of the conformational change occurring. This would suggest that 
Tyr side chains are not becoming more solvent exposed as a result of adding urea.    
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Figure ‎4.10 Near-UV CD spectra of G-CSF C3 at different urea concentrations. Spectra of G-CSF C3 in 20 mM 
sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 mM) were acquired in the 
presence of 0 (black), 0.5 (green), 1 (red), 2 (blue), 3 (pink) and 4 M (orange) urea using 45-57 µM G-CSF C3 (A), 
while spectra of G-CSF C3 in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 buffer (I = 43 mM) were 
acquired in the presence of the same urea concentrations, excluding 0.5 and 4 M urea, using 36-52 µM G-CSF C3 
(B). 
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4.2.10 Assessing the structural integrity of G-CSF C3 between 25 and 37 oC        
 
Comparison of the secondary and tertiary structures of G-CSF C3 in the presence 
and absence of urea was carried out at 25 oC, revealing a change in the 
environment of one or more of the three Tyr side chains. Additionally, equilibrium 
denaturation analyses were used to calculate the thermodynamic stability of G-CSF 
C3 at 25 oC, as well as relating the fractions of native G-CSF C3 at 25 oC to the 
fractions of soluble G-CSF C3 calculated from aggregation assays carried out at 37 
oC. Relating the conformational change observed at 25 oC to the increased 
aggregation observed for G-CSF C3 at pH 7 in the presence of 4 M urea and at pH 
4 in the presence of 3 M urea at 37 oC relies on there being no conformational 
change of G-CSF C3 between 25 and 37 oC.  
 
To probe for conformational changes over this temperature range, 1H-15N HSQC 
spectra of G-CSF C3 in pH 7 buffer with or without 4 M urea were acquired at 
temperatures of 25-37 oC with 3 oC increments, using protein concentrations of 65 
and 63 µM in 0 and 4 M urea, respectively (Figure  4.11A and Figure  4.12A). 1H-15N 
HSQC spectra of G-CSF C3 in pH 4 buffer with or without 3 M urea were acquired 
over the same temperatures, using protein concentrations of 85 and 78 µM in 0 and 
3 M urea, respectively (Figure  4.13A and Figure  4.14A). This temperature titration of 
1H-15N HSQC spectra also allowed assignments of backbone amide protons to be 
transferred from 25 to 37 oC for aggregation assays, monitored by changes in 
HSQC peak intensity (see Chapter 5). 
 
Chemical shifts of backbone amide proton and nitrogen nuclei were used to 
calculate CSPs (see Section  2.9.6) for G-CSF C3 at 25 oC relative to 37 oC 
(Figure  4.11B-Figure  4.14B). The CSPs observed are small in amplitude and are 
due to the movement of peaks in the proton dimension of 1H-15N HSQC spectra 
upfield towards the proton resonance frequency of water (Figure  4.11A-
Figure  4.14A), which is calculated to be 4.75 and 4.63 ppm at 25 and 37 oC, 
respectively, at pH 5.5. Although the proton resonance frequency of water will vary 
with pH, this variation is only 0.02 ppm per pH unit, smaller than the variation 
caused by temperature319. CSPs were not calculated for Ile96 from 1H-15N HSQC 
spectra of G-CSF C3 at pH 4 or 7 due to overlap of the HSQC peak for this residue 
with peaks for the side chains of Gln, Arg and Lys residues (Figure  3.17A), which 
made the peak for Ile96 difficult to track over different temperatures.   
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Figure ‎4.11 Thermal titration of G-CSF C3 at pH 7 without urea from 25 to 37 oC monitored by 1H-15N HSQC 
spectra. Spectra of 65 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium 
azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) were acquired at 25 (purple), 28 (blue), 31 (teal), 34 (orange) and 37 
o
C (red) (A). CSPs were calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 at 25 
and 37 
o
C (B). Horizontal lines show the mean, mean + σ and mean + 2σ CSP values. Orange and red bars 
correspond to residues exhibiting CSPs greater than the mean + σ and mean + 2σ, respectively. A secondary 
structure schematic is shown above for reference. Right: Residues with significant CSPs are shown mapped onto 
the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, constructed using PyMOL
289
. Red 
residues are also labelled. Spectra were acquired using a spectrometer operating at a proton resonance frequency 
of 750 MHz equipped with a cryogenic probe. 
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Figure ‎4.12 Thermal titration of G-CSF C3 at pH 7 with 4 M urea from 25 to 37 oC monitored by 1H-15N HSQC 
spectra. Spectra of 63 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium 
azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) were acquired in the presence of 4 M urea at 25 (purple), 28 (blue), 
31 (teal), 34 (orange) and 37 
o
C (red). Extra peaks on the right hand side of the spectrum due to urea are labelled 
(A). CSPs were calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 at 25 and 37 
o
C 
(B). Horizontal lines show the mean, mean + σ and mean + 2σ CSP values. Orange and red bars correspond to 
residues exhibiting CSPs greater than the mean + σ and mean + 2σ, respectively. A secondary structure schematic 
is shown above for reference. Right: Residues with significant CSPs are shown mapped onto the structure of G-
CSF wt (PDB 1GNC
283
) using the same colour scheme, constructed using PyMOL
289
. Red residues are also 
labelled. Spectra were acquired using a spectrometer operating at a proton resonance frequency of 750 MHz 
equipped with a cryogenic probe. 
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Figure ‎4.13 Thermal titration of G-CSF C3 at pH 4 without urea from 25 to 37 oC monitored by 1H-15N HSQC 
spectra. Spectra of 85 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 
buffer (I = 39 mM) were acquired at 25 (purple), 28 (blue), 31 (teal), 34 (orange) and 37 
o
C (red) (A). CSPs were 
calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 at 25 and 37 
o
C (B). Horizontal 
lines show the mean, mean + σ and mean + 2σ CSP values. Orange and red bars correspond to residues exhibiting 
CSPs greater than the mean + σ and mean + 2σ, respectively. A secondary structure schematic is shown above for 
reference. Right: Residues with significant CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) 
using the same colour scheme, constructed using PyMOL
289
. Red residues are also labelled. Spectra were acquired 
using a spectrometer operating at a proton resonance frequency of 750 MHz equipped with a cryogenic probe. 
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Figure ‎4.14 Thermal titration of G-CSF C3 at pH 4 with 3 M urea from 25 to 37 oC monitored by 1H-15N HSQC 
spectra. Spectra of 78 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 
buffer (I = 39 mM) were acquired in the presence of 3 M urea at 25 (purple), 28 (blue), 31 (teal), 34 (orange) and 37 
o
C (red) (A). CSPs were calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 at 25 
and 37 
o
C (B). Horizontal lines show the mean, mean + σ and mean + 2σ CSP values. Orange and red bars 
correspond to residues exhibiting CSPs greater than the mean + σ and mean + 2σ, respectively. A secondary 
structure schematic is shown above for reference. Right: Residues with significant CSPs are shown mapped onto 
the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, constructed using PyMOL
289
. Red 
residues are also labelled. Spectra were acquired using a spectrometer operating at a proton resonance frequency 
of 750 MHz equipped with a cryogenic probe. 
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The migration of peaks towards the water resonance frequency with increasing 
temperature is observable in the 1H-15N HSQC spectra of G-CSF C3 at pH 4 and 7 
both in the presence and absence of urea (Figure  4.11A-Figure  4.14A) and is due to 
an increase in the hydrogen exchange rate of amide protons with water protons in 
the solvent335. The change in hydrogen exchange rate also affects the amide 
nitrogen chemical shift, causing movement of HSQC peaks in the nitrogen 
dimension as well as proton. This accounts for the largest CSPs mainly being 
observed for amide protons of residues in unstructured regions of G-CSF C3, which 
are more often involved in hydrogen bonds with water molecules than other 
residues. As well as depending on buffer conditions such as pH and temperature335, 
the rate of hydrogen exchange also depends on the amino acid sequence336, which 
accounts for differences in CSPs observed for residues that are close together in the 
amino acid sequence. 
 
CSPs could not be calculated from 1H-15N HSQC spectra of G-CSF C3 at pH 7 for 
Phe145 in the absence or presence of 4 M urea (Figure  4.11B and Figure  4.12B, 
respectively), as the peak for this residue is broadened beyond detection at 37 oC. 
In the absence of urea, CSPs could not be calculated for Ser67, Gln68 and Leu72 
for G-CSF C3 at pH 7 (Figure  4.11B) because these residues are also broadened 
beyond detection at 37 oC. Broadening of these residues could suggest changes in 
their dynamics at higher temperature at pH 7 that are affecting their longitudinal and 
transverse relaxation rates (see Section  2.9.8). CSPs also could not be calculated 
for residue Glu46 of G-CSF C3 at pH 4 in the presence of 3 M urea (Figure  4.14B), 
as this residue is too broad for detection at 25 oC but is observable at 37 oC, again 
implying a possible change in the dynamics of this residue at higher temperature 
under these conditions. 
 
Overall, thermal titration of G-CSF C3 from 25 to 37 oC monitored using 1H-15N 
HSQC spectra suggests no conformational changes as a result of this temperature 
increase, based on calculation of CSPs. This supports the notion of a change in the 
environment of one or more Tyr side chains observed in sub-denaturing urea 
concentrations at 25 oC as being potentially linked to G-CSF C3 aggregation at 37 
oC, which is promoted in sub-denaturing urea concentrations. 
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4.2.11 Investigating exposed hydrophobic surfaces of G-CSF C3 by 8-anilino-
1-napthalenesulphonic acid (ANS) fluorescence  
 
The fluorescence emission properties of ANS depend on the polarity of the 
environment surrounding the dye. In water, the maximum emission intensity of ANS 
fluorescence is observed at 505 nm394. However, upon increased hydrophobicity of 
the environment around the dye e.g. due to binding to a hydrophobic protein 
surface, the fluorescence quantum yield increases significantly. For instance, the 
quantum yield of ANS increases from 0.004 to 0.75 upon binding to BSA in water395. 
The increase in fluorescence emission intensity is accompanied by a blue-shift in 
the wavelength at which the maximum emission intensity is observed to around 480 
nm396.  
 
The increased fluorescence emission intensity and blue-shift in the wavelength of 
maximum emission upon increased hydrophobicity of the environment around ANS 
has led to its use in identifying partially folded states of proteins, including not only 
the population of equilibrium and kinetic intermediates355 and molten globule 
states394 in protein folding, but also amorphous aggregates394 and oligomeric 
species that represent early-stage intermediates in amyloid fibril formation79. ANS 
has also been used to assess the surface hydrophobicity of native proteins and is 
generally used to probe for exposed hydrophobic surfaces394.  
 
Although commonly used to probe for exposed hydrophobic surfaces, the dominant 
mechanism of ANS binding to protein surfaces is thought to be electrostatic, 
specifically through ion pairing between the negatively charged sulphonate group 
and positively charged side chains of Arg, Lys and His at acidic pH397-399. There are 
also most likely complementary interactions such as van der Waals or hydrophobic 
interactions that help stabilise binding398,399. Binding of ANS to Arg and to a lesser 
extent Lys side chains has been shown to cause an increase in fluorescence 
emission intensity and a blue-shift in the wavelength of maximum emission, 
although these changes are lower in magnitude than those brought about by binding 
to hydrophobic surfaces and have been demonstrated using at least ten thousand-
fold molar excesses of single Arg or Lys amino acids to ANS, or the use of poly-Arg 
or poly-Lys peptides398. Generally, ANS binding to protein surfaces through 
electrostatic interactions will not cause the characteristic increase in fluorescence 
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intensity and blue-shift in the wavelength of maximum emission unless also 
accompanied by a change in the hydrophobicity of the environment of the dye397,398. 
            
ANS fluorescence of G-CSF C3 in the presence and absence of urea was used to 
probe for changes in the amount of exposed hydrophobic surface area that may 
provide interfaces for protein aggregation. 250 µM ANS was incubated with 2.5 µM 
G-CSF C3 in pH 7 buffer, or 5 µM G-CSF C3 in pH 4 buffer, in the presence of 0-7 
M urea. Urea concentrations of 0-1 M were used at 0.2 M increments, as well as 1-7 
M at 1 M increments. 1 ml samples were set up in 1.5 ml Eppendorf tubes and 
incubated quiescently at 25 oC overnight and fluorescence emission spectra 
acquired at 25 oC the next day (Figure  4.15).  
 
ANS fluorescence emission spectra in pH 7 buffer in 0-7 M urea with or without G-
CSF C3 appear similar (Figure  4.15A and C, respectively), suggesting no change in 
the polarity of the environment around ANS as a result of adding G-CSF C3. 
Although there are slight differences in the emission intensities of ANS with or 
without G-CSF C3 at a wavelength of 475 nm in 0.2-1 M urea (Figure  4.15E), these 
differences are smaller than the characteristic changes in fluorescence emission 
associated with a change in the hydrophobicity of the environment of ANS395,396, 
suggesting no interaction of ANS with exposed hydrophobic surfaces of G-CSF C3. 
 
ANS fluorescence emission spectra in pH 4 buffer with G-CSF C3 show higher 
intensities and are blue-shifted compared to spectra acquired without G-CSF C3 
(Figure  4.15B and D, respectively), implying increased hydrophobicity of the 
environment of ANS in the presence of G-CSF C3. Intriguingly, the intensity of 
emission of ANS with G-CSF C3 at 475 nm decreases dramatically as the urea 
concentration increases from 0-1 M and then appears to remain low up to urea 
concentrations of 7 M (Figure  4.15F), even though ANS has been demonstrated to 
bind to proteins at higher urea concentrations399. This implies reduced 
hydrophobicity of the environment around ANS in the presence of G-CSF C3 at 
higher urea concentrations and perhaps contrasts with the increased aggregation of 
G-CSF C3 observed at higher urea concentrations, which is assumed to be due to 
increased exposure of hydrophobic surface area.  
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Figure ‎4.15 ANS fluorescence emission spectra at different urea concentrations with or without G-CSF C3. Spectra 
of 250 µM ANS in 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide pH 7 buffer (I = 80 
mM) were acquired with (solid lines in A) or without (dashed lines in C) 2.5 µM G-CSF C3 in the presence of 0 
(black), 0.2 (red), 0.4 (orange), 0.6 (yellow), 0.8 (green), 1 (teal), 2 (blue), 3 (navy blue), 4 (purple), 5 (violet), 6 
(magenta) and 7 M (pink) urea. Spectra of 250 µM ANS in 20 mM sodium phosphate, 20 mM sodium acetate pH 4 
buffer (I = 43 mM) were acquired with (solid lines in B) or without (dashed lines in D) 5 µM G-CSF C3 in the 
presence of the same urea concentrations. The fluorescence intensity at a wavelength of 475 nm in different urea 
concentrations is shown for ANS samples with or without G-CSF C3 (red and black, respectively) at pH 7 (E) and 4 
(F).   
 
Incubation of G-CSF C3 with ANS in pH 4 buffer in the absence of urea resulted in 
protein precipitation. In the presence of urea concentrations above 1 M insoluble 
aggregates could not be observed, suggesting that formation of G-CSF C3 
aggregates with ANS incorporated may account for the increased hydrophobicity in 
the environment around the dye. 
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4.3 Discussion 
 
Despite the reduced aggregation propensity predicted for G-CSF C3 compared to 
the wild-type protein (Figure  4.1), the aggregation behaviours of these two proteins 
appear to be similar. Aggregation of G-CSF C3 at pH 4 requires higher protein 
concentrations to cause comparable rates of aggregation to those observed at pH 7 
during quiescent incubation at 37 oC (Figure  4.2), suggesting that G-CSF C3 is less 
aggregation-prone at pH 4. This matches the reported behaviour for wild-type G-
CSF in that it is less aggregation-prone at acidic pH185,276,303 e.g. in its formulation 
buffer as Filgrastim276, but aggregates readily at physiological pH and 
temperature142,185,214,307,308,391. Additionally, the proportions of aggregated G-CSF C3 
at pH 7 at 1.7 mg/ml after certain time periods of incubation at 37 oC (Figure  4.2) 
were similar to proportions of aggregated protein present after incubation of 1142 and 
1.5185,308 mg/ml G-CSF wt under the same conditions for similar time periods (see 
Section  4.2.2).  
 
The proportion of aggregated G-CSF C3 at 5.5 mg/ml after 68 h quiescent 
incubation at pH 7 and 37 oC was 49 % (Figure  4.2), which is very similar to 
reported values around 50 % of aggregated wild-type G-CSF at 5 mg/ml incubated 
for 48 h under the same conditions142,214. This suggests that although the rate of 
aggregation of 5.5 mg/ml G-CSF C3 may be slower than 5 mg/ml wild-type G-CSF 
at pH 7, ultimately these proteins will aggregate to the same extent. A similar effect 
has previously been observed as a result of substitution of the unpaired Cys18 
residue, which reduced the rate of aggregation but ultimately aggregated to the 
same extent as wild-type G-CSF142. Therefore, the slower rate of G-CSF C3 
aggregation relative to wild-type G-CSF may be the result of the C18G substitution. 
 
Aggregation of G-CSF C3 at pH 4 and 7 appears to be accelerated by addition of 
urea concentrations that are too low to cause global unfolding (Figure  4.3A and B, 
respectively). The effect of adding 5, 6 and 7 M urea on the rate of G-CSF C3 
aggregation at pH 7 (Figure  4.3A) is similar to the effect of 2, 2.5 and 3.5 M GdnHCl 
on the rate of aggregation of wild-type G-CSF at pH 7142, in the sense that the 
fastest rates of G-CSF wt and C3 aggregation are observed in the presence of 2.5 
M GdnHCl and 6 M urea, respectively. At higher denaturant concentrations the rates 
of G-CSF wt and C3 aggregation are reduced again, presumably due to 
solubilisation of the unfolded state.  
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Interestingly, addition of sub-denaturing urea concentrations also appears to 
increase the rate of G-CSF C3 aggregation at pH 4 (Figure  4.3B), but to a lesser 
extent than observed at pH 7 (Figure  4.3A). The denaturant dependence of G-CSF 
wt aggregation at pH 4 has not been reported, so it is unknown whether the wild-
type protein would also exhibit increased aggregation at acidic pH in the presence of 
denaturant.  
 
Surprisingly, the morphologies of G-CSF C3 aggregates formed at pH 4 and 7 
appear very different (Figure  4.5). G-CSF C3 aggregates formed at pH 7 appear to 
be largely amorphous in the absence (Figure  4.5A and B) or presence (Figure  4.5C 
and D) of 4 M urea, while aggregates at pH 4 appear to more closely resemble 
protofibrils i.e. late-stage intermediates in amyloid fibril formation79 (Figure  4.5E-H), 
particularly when formed in the presence of 3 M urea (Figure  4.5G and H). 
Consequently, it is unclear whether the lower rate of aggregation of G-CSF C3 
observed at pH 4 (Figure  4.3B) relative to at pH 7 (Figure  4.3A) in the presence of 
sub-denaturing urea concentrations is entirely due to electrostatic repulsion between 
G-CSF C3 monomers at acidic pH, or is affected by the different morphology of 
aggregates formed at acidic and neutral pH (Figure  4.5). 
 
Aggregation assays of G-CSF C3 at pH 7 in the presence of different urea 
concentrations appear to result in different end-points of aggregation, based on 
different plateaus of A280 values over time during aggregation assays (Figure  4.3A). 
Conversely, aggregation assays of G-CSF wt at pH 7 in the presence of different 
GdnHCl concentrations appear to progress towards the same end-point142. The ionic 
strength of the buffer used does not appear to affect the rate of aggregation of G-
CSF wt at neutral pH in the absence of denaturant, based on comparison of wild-
type G-CSF aggregation assays in different studies using similar protein 
concentrations but buffers of different ionic strengths142,185,308. However, the overall 
charge of GdnHCl that is absent from urea could be affecting the size of the 
aggregates formed.  
 
EM images show that aggregation of G-CSF C3 at pH 7 in the presence of 4 M urea 
results in mixtures of amorphous and protofibrillar aggregates (Figure  4.5D), while 
G-CSF C3 aggregates formed in the absence of urea appear to be entirely 
amorphous (Figure  4.5A). This could mean that the aggregation assays for G-CSF 
C3 carried out in different urea concentrations result in different proportions of 
aggregates of different sizes being formed, which in turn lead to different end-points 
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of aggregation assays because larger aggregates will pellet more easily 
(Figure  4.3A). Conversely, aggregation assays for G-CSF wt carried out in different 
GdnHCl concentrations could result in aggregates of the same size or simply larger 
aggregates, owing to a possible effect of electrostatic interactions on the size of 
aggregates formed, meaning these aggregation assays lead to the same end-point. 
Unfortunately, the size of G-CSF wt aggregates formed in the presence of 
denaturant has not been reported, meaning this hypothesis cannot be confirmed.  
 
Equilibrium denaturation analyses of G-CSF C3 at pH 4 and 7 at 25 oC are shown in 
Figure  4.4A and B, respectively overlaid with the fractions of soluble G-CSF C3 
remaining after incubation of G-CSF C3 at pH 4 and 7 at 37 oC in the presence of 0-
7 M urea, which were calculated from the aggregation assays shown in Figure  4.3. 
Overlaying of the fractions of folded and soluble G-CSF C3 revealed urea 
concentrations at which G-CSF C3 appears to be native but insoluble aggregates 
are formed (4 M urea at pH 7 and 3 M urea at pH 4, Figure  4.4A and B, 
respectively). Moreover, DLS analysis of aggregation assays revealed that soluble 
G-CSF C3 aggregates form more readily at pH 7 in the presence of 4 M urea and at 
pH 4 in the presence of 3 M urea, even before incubation of samples at 37 oC 
(Figure  4.6 and Figure  4.7, respectively). Therefore, many subsequent experiments 
were performed in urea concentrations of 0-4 M at pH 7 and 0-3 M at pH 4.  
 
Equilibrium denaturation analyses of G-CSF C3 at pH 4 and 7 at 25 oC were also 
used to calculate ΔGoUN and MUN values (Table  4.1), representing the free energy of 
unfolding and the dependence of this free energy on denaturant concentration, 
respectively312. ΔGoUN values for G-CSF C3 at pH 4 and 7 were calculated to be 
37.0 and 40.0 kJ mol-1, respectively from fluorescence emission measurements at 
348 and 320 nm, respectively, which are similar to ΔGUN values reported for wild-
type G-CSF of 37.7 kJ mol-1 at pH 4 at 20 oC304 and 40.2 kJ mol-1 at pH 7 at 25 
oC142, suggesting G-CSF C3 has a similar thermodynamic stability to the wild-type 
protein at pH 4 and 7.  
 
ΔGoUN and MUN values could only be calculated for G-CSF C3 at pH 7 using 
fluorescence emission intensities and ellipticities measured in 2-9 M urea due to the 
significant increases in signal observed in urea concentrations up to 2 M 
(Figure  4.4A). Far-UV CD spectra of G-CSF C3 at pH 7 in 0-4 M urea did not reveal 
any significant change in ellipticity in the presence of urea (Figure  4.8A), suggesting 
that the increased ellipticity observed during equilibrium denaturation analysis of G-
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CSF C3 at pH 7 in 0-2 M urea may be exaggerated by linear extrapolation of the 
pre-transition baseline of this equilibrium curve (Figure  4.4A). Conversely, 
fluorescence emission spectra of G-CSF C3 at pH 7 in 0-4 M urea showed an 
increase in intensity across all wavelengths measured in urea concentrations of 0-2 
M and to a lesser extent 2-4 M (Figure  4.9A), corroborating the increase in 
fluorescence emission intensity observed during equilibrium denaturation analysis of 
G-CSF C3 at pH 7 in 0-2 M urea (Figure  4.4A).  
 
Equilibrium denaturation analysis of G-CSF C3 at pH 4 revealed significant 
increases in the fluorescence emission intensity at 301 nm in urea concentrations up 
to 1 M (Figure  4.4B), which prevented use of these intensities in calculation of ΔGoUN 
and MUN values. However, fluorescence emission intensities measured at 348 nm 
and ellipticities did not show any significant change in urea concentrations that are 
too low to cause global denaturation (Figure  4.4B). Fluorescence emission spectra 
of G-CSF C3 at pH 4 in 0-3 M urea showed an increase in intensity around 300 nm 
but no significant change around 345 nm. This would suggest a change in the 
environment of one or more of the three Tyr side chains in G-CSF C3 at pH 4 upon 
addition of urea, although Trp fluorescence quenching is observed for G-CSF C3 at 
pH 4 (Figure  3.11C), making it difficult to determine if a change in the environment 
of Trp119 was also occurring as a result of adding urea. 
 
Near-UV CD spectra were used to further probe the changes in tertiary structure 
observed by fluorescence emission spectra in sub-denaturing urea concentrations. 
Near-UV CD spectra of G-CSF C3 at both pH 7 and 4 showed increased negativity 
in the region around 275 nm upon addition of urea (Figure  4.10A and B, 
respectively), indicative of a change in the environment of Tyr side chains. 
Conversely, far-UV CD spectra of G-CSF C3 at pH 7 and 4 in different urea 
concentrations did not reveal any significant change in ellipticity in the presence of 
urea (Figure  4.8A and B, respectively), suggesting no detectable changes in the 
secondary structure of G-CSF C3 upon addition of urea. A change in the 
environment of one or more of the three Tyr side chains of G-CSF C3 upon addition 
of urea concentrations that are too low to cause global denaturation is most likely 
also responsible for the increases in fluorescence emission intensity observed in 
spectra of G-CSF C3. 
 
The biophysical experiments that revealed a change in the environment of Tyr side 
chains of G-CSF C3 in sub-denaturing urea concentrations were carried out at 25 
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oC, whereas aggregation assays showing increased aggregation of G-CSF C3 in the 
presence of sub-denaturing urea concentrations were carried out at 37 oC. Thermal 
titrations of G-CSF C3 at pH 7 in the absence or presence of 4 M urea (Figure  4.11A 
and Figure  4.12A respectively) and at pH 4 in the absence or presence of 3 M urea 
(Figure  4.13A and Figure  4.14A respectively) monitored by 1H-15N HSQC spectra 
were carried out to ensure there are no significant conformational differences 
between G-CSF C3 at 25 and 37 oC. Calculation of CSPs revealed only small 
changes in proton and nitrogen chemical shifts (Figure  4.11B-Figure  4.14B), 
attributable to the increased hydrogen exchange rate of amide protons with solvent 
protons at higher temperatures335. This supports the theory that a change in the 
environment of Tyr side chains of G-CSF C3 detected at 25 oC is linked to 
aggregation at 37 oC in sub-denaturing urea concentrations.  
 
In the study by Raso et al.142, wild-type G-CSF showed accelerated aggregation in 
the presence of 1.5 M GdnHCl at pH 7 and has been reported to exhibit increased 
fluorescence emission under these conditions, which has been attributed to a 
conformational change of the AB loop altering the environment of the Trp59 side 
chain. Trp59 was identified as the source of increased wild-type G-CSF 
fluorescence by sequentially substituting each of the two Trp residues using W59Q 
and W119F mutants142, the former of which should exhibit the same fluorescence 
emission spectra as G-CSF C3 based on the number and location of aromatic 
residues in these proteins. However, the G-CSF W59Q mutant (G-CSF C3 
analogue) was not reported to exhibit increased emission intensity in the presence 
of sub-denaturing GdnHCl concentrations142. This would suggest that the W59R 
substitution found in G-CSF C3 is causing the increased fluorescence emission 
intensity observed in sub-denaturing urea concentrations and may be linked to a 
conformational change of the AB loop.  
 
Fluorescence emission spectra of folded and unfolded G-CSF wt showed quenching 
of Trp fluorescence at neutral and to a far greater extent acidic pH (Figure  3.11B 
and A, respectively). The structure of G-CSF wt suggests that quenching of Trp 
fluorescence at neutral pH is most likely due to the proximity of the side chains of 
Trp59 and Tyr86 (Figure  3.12A). Therefore, the increased fluorescence emission of 
Trp59 in wild-type G-CSF observed by Raso et al.142 upon addition of 1.5 M GdnHCl 
at pH 7 is most likely due to an increase in distance between the side chains of 
Trp59 and Tyr86, which could lessen the quenching effect of Tyr86 on Trp59 
fluorescence emission.  
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This could mean that the increased fluorescence emission intensity of G-CSF C3 
observed in low urea concentrations is due to reduced quenching of Tyr86 by Arg59, 
implying a change in the environment of the Tyr86 side chain in low urea 
concentrations that may be linked to aggregation. However, changes in the 
environments of the side chains of Tyr40 and Tyr166 may not have been detected 
by Raso et al.142 as this study was primarily focussed on changes in the environment 
of Trp residues of wild-type G-CSF under conditions that promote aggregation. The 
conformational change undergone by G-CSF C3 in aggregation-prone conditions is 
probed at amino acid resolution by NMR in Chapter 5 in order to identify the Tyr 
residue or residues that may be linked to promoting G-CSF C3 aggregation. 
 
ANS fluorescence emission in the presence of G-CSF C3 was investigated over a 
range of urea concentrations to probe for exposure of hydrophobic surfaces that 
could act as aggregation interfaces. The fluorescence emission spectra of ANS with 
or without G-CSF C3 at pH 7 were similar in 0-7 M urea (Figure  4.15A and C, 
respectively), suggesting no interaction of ANS with hydrophobic surfaces.  
 
The fluorescence emission spectra of ANS with G-CSF C3 at pH 4 in the absence of 
urea were significantly more intense than spectra of ANS alone at pH 4 
(Figure  4.15B and D, respectively) and the wavelength at which maximum emission 
intensity was observed was blue-shifted in the presence of G-CSF C3. This 
suggests a change in the hydrophobicity of the environment around ANS in the 
presence of G-CSF C3 at pH 4, which was not observed in the presence of urea 
concentrations of 1 M and above. However, protein precipitation was observed 
when G-CSF C3 was incubated with ANS at pH 4 in the absence of urea but not in 
the presence of urea concentrations above 1 M urea, suggesting that the change in 
hydrophobicity of ANS may be due to incorporation of ANS into aggregates.  
 
There is no change in ANS fluorescence at pH 7 with or without G-CSF C3, which 
coupled with the structural similarity of G-CSF C3 conformations at pH 4 and 7, 
shown by CSPs calculated from 1H-15N HSQC spectra (Figure  3.19), suggests that 
ANS binding at pH 4 is driven by electrostatic interactions between the negatively 
charged sulphonate group and positively charged side chains, which is the dominant 
mechanism of ANS binding to protein surfaces397-399. This binding event may then 
promote aggregation by neutralising a positive charge on the surface of G-CSF C3 
and adding a hydrophobic naphthalene group, whereby incorporation of ANS into 
aggregates causes the changes in ANS fluorescence emission spectra that are 
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characteristic of a change in the polarity of the environment of ANS. ANS has also 
previously been shown to accelerate aggregation of a therapeutic protein, although 
aggregation was attributed to an increase in hydrophobic interactions between ANS 
and the protein at aggregation-prone temperatures, compared to predominantly 
electrostatic interactions at lower temperatures187.   
 
Reduced binding of ANS to G-CSF C3 at pH 4 upon addition of urea could be due to 
a conformational change that disturbs an exposed positively charged surface that 
binds ANS, which in turn may help elucidate conformational changes in urea that 
promote G-CSF C3 aggregation. In addition, the hypothesised positively charged 
surface that may be neutralised upon ANS binding could be responsible for reducing 
the aggregation propensity of G-CSF C3 at acidic pH in the absence of ANS. For 
these reasons ANS binding by G-CSF C3 merited further investigation by NMR in 
Chapter 5.    
 
In Chapter 5, the conformational changes of G-CSF C3 that may promote 
aggregation are characterised at amino acid resolution by NMR. In addition, the 
dynamics of G-CSF C3 are investigated under conditions that favour and disfavour 
aggregation through measurement of transverse relaxation rates. Hydrogen 
exchange NMR is also used to probe for changes in solvent exposure of residues in 
the presence and absence of urea concentrations that promote aggregation, along 
with aggregation assays during which 1H-15N HSQC peak intensities are monitored 
over time in an attempt to identify aggregation interfaces. ANS binding is also further 
investigated by NMR to probe for conformational changes that disturb ANS binding 
and could be linked to aggregation.  In summary, the work in this chapter showed 
that G-CSF C3 exhibits similar aggregation behaviour to the wild-type protein and 
aggregation may be linked to a change in the environment of one or more of the 
three Tyr side chains found in G-CSF C3. 
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Chapter 5 Elucidating the conformational changes that 
promote G-CSF C3 aggregation 
 
5.1 Introduction 
 
The work presented in Chapter 4 showed that aggregation of G-CSF C3 at 37 oC is 
promoted in urea concentrations that are too low to cause global denaturation. In 
these sub-denaturing urea concentrations a change in the environment of Tyr40, 
Tyr86 and/or Tyr166 has been suggested by near-UV CD and fluorescence 
emission spectra (Figure  4.10 and Figure  4.9, respectively). Previously, a study of 
the aggregation of wild-type G-CSF at 37 oC had revealed a change in the 
fluorescence properties of Trp59 as being potentially linked to increased 
aggregation in sub-denaturing GdnHCl concentrations at pH 7 and 25 oC142.  
 
The proximity of the side-chains of Trp59 and Tyr86 (Figure  3.12A) suggests that 
the increased fluorescence emission intensity of Trp59 is most likely due to reduced 
quenching by Tyr86, resulting from the conformational rearrangement of the AB loop 
proposed by Raso et al.142, which would increase the distance between these side-
chains. A conformation of wild-type G-CSF with native α-helical structure, but non-
native Trp59 fluorescence, has also been identified during a study of wild-type G-
CSF folding at pH 4 and 25 oC and proposed as a late stage kinetic folding 
intermediate304. This suggests that a conformational change in the AB loop of G-
CSF C3 could be responsible for the changes in near-UV CD and fluorescence 
emission spectra observed in the presence of low urea concentrations but, more 
importantly, could be linked to aggregation. However, previous studies of G-CSF wt 
folding and aggregation were largely focussed on studying the changes in the 
environments of Trp59 and Trp119 side chains, and hence changes in the 
environment of Tyr40, Tyr86 and/or Tyr166 may not have been detected. 
 
In this chapter, conformational changes of G-CSF C3 in sub-denaturing urea 
concentrations are characterised at amino acid resolution by monitoring urea 
titrations by 1H-15N HSQC spectra and calculation of CSPs. The dynamics of 
residues of G-CSF C3 are also investigated in urea concentrations that favour and 
disfavour aggregation by transverse relaxation rates (R2) of backbone amide 
nitrogen nuclei. In addition, hydrogen-deuterium exchange is used to the measure 
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dynamics of G-CSF C3 residues over a longer timescale (minutes and hours) and to 
probe for regions of increased solvent exposure in aggregation-prone conditions. 
Identification of aggregation interfaces by monitoring peak intensities in 1H-15N 
HSQC spectra during G-CSF C3 aggregation assays in the presence and absence 
of urea is also described.  
 
ANS was used in Chapter 4 in an attempt to reveal exposure of hydrophobic 
surfaces in aggregation-prone conditions, which proved not to be the case. 
However, differences in the fluorescence emission spectra of ANS in the presence 
and absence of G-CSF C3 at pH 4 were identified, but upon addition of urea 
concentrations of 1 M or higher this effect was eradicated (Figure  4.15F). These 
changes in the fluorescence properties of ANS are hypothesised to be caused 
indirectly by electrostatic interactions between the negatively charged sulphonate 
group and a positively charged surface on G-CSF C3 at pH 4 that may be involved 
in reducing aggregation of G-CSF C3 at acidic pH in the absence of ANS 
(Figure  4.2). Upon addition of ANS insoluble aggregates are observable by eye, 
suggesting that this positively charged surface is neutralised and ANS is 
incorporated into the resulting aggregates, which causes the changes observed in 
its fluorescence emission spectra. Consequently, ANS binding to G-CSF C3 at pH 4 
and 7 has been further investigated by acquisition of 1H-15N HSQC spectra to 
investigate how ANS binds to the protein.           
 
In Chapter 5 10 % (v/v) D2O was added to all samples before performing NMR 
experiments. Therefore, all experiments in this chapter were carried out in pH 4 or 7 
buffers in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 
buffer or 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium 
azide, 10 % (v/v) D2O pH 7 buffer unless otherwise stated. The different pH values 
plus urea and protein concentrations used for measuring CSPs and R2 rates are 
outlined in Table  5.1. 
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Experiment pH 
Urea 
concentration / M 
G-CSF C3 
concentration / 
μM 
CSP 
7 
0 458 
0.5 81 
4 208 
4 
0 473 
0.5 103 
3 173 
R2 
7 
0 130 
0.5 135 
4 134 
4 
0 162 
0.5 151 
3 163 
Table ‎5.1 Conditions used for the measurement of CSPs and backbone 15N R2 rates. CSPs and R2 rates were 
measured at pH 4 and 7 in the presence of the urea concentrations shown using the G-CSF C3 concentrations 
shown. However, CSPs resulting from the addition of 3 or 4 M urea at pH 4 and 7, respectively were measured 
largely by urea titration of 
1
H-
15
N HSQC spectra using 103 and 81 μM 
15
N G-CSF C3 at pH 4 and 7, respectively, 
but also by acquisition of HNCA, CBCA(CO)NH and 
1
H-
15
N HSQC spectra using 173 and 208 μM 
13
C 
15
N G-CSF C3 
at pH 4 in 3 M urea and at pH 7 in 4 M urea, respectively.   
 
5.2 Results  
 
5.2.1 Characterising conformational changes of G-CSF C3 under 
aggregation-prone conditions using CSPs       
 
Conformational changes of G-CSF C3 at pH 4 and 7 resulting from the addition of 
sub-denaturing urea concentrations were determined at amino acid resolution by 
calculation of CSPs (see Section  2.9.6) relative to G-CSF C3 in the absence of urea. 
In order to calculate CSPs for G-CSF C3 at pH 7 in the presence of 4 M urea and at 
pH 4 in the presence of 3 M urea (Figure  5.2 and Figure  5.4, respectively), chemical 
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shift assignments for backbone amide proton and nitrogen nuclei of G-CSF C3 in pH 
4 and 7 buffers in the absence of urea were transferred to 1H-15N HSQC spectra of 
G-CSF C3 acquired in the presence of these urea concentrations. This was carried 
out largely by acquisition of 1H-15N HSQC spectra using 81 µM G-CSF C3 in pH 7 
buffer in the presence of 0-4 M urea with 0.5 M increments, as well as 103 µM G-
CSF C3 in pH 4 buffer in the presence of 0-3 M urea with 0.5 M increments (see 
Section  2.9.3). In addition, assignments were aided by acquisition of HNCA, 
CBCA(CO)NH and 1H-15N HSQC spectra using 208 µM G-CSF C3 in pH 7 buffer 
with 4 M urea and 176 µM G-CSF C3 in pH 4 buffer with 3 M urea (see 
Section  2.9.1). 
 
Near-UV CD and fluorescence emission spectra of G-CSF C3 at pH 4 and 7 in the 
presence of sub-denaturing urea concentrations (Figure  4.10 and Figure  4.9, 
respectively) showed that the change in the environment of one or more Tyr side 
chains occurs at low urea concentrations i.e. 1 M urea at pH 4 and 0.5 M urea at pH 
7, although at higher urea concentrations the environment of Tyr side chains 
appears to be perturbed to a greater extent. These urea concentrations have not 
been observed to cause increased aggregation of G-CSF C3 (Figure  4.3). 
Therefore, CSPs were also calculated for G-CSF C3 in the presence of 0.5 M urea 
at pH 4 and 7 (Figure  5.1 and Figure  5.3, respectively).    
 
In the absence of urea, the backbone amide proton and nitrogen atoms of 160 
residues of G-CSF C3 were assigned at pH 4 (see Section  3.2.7.2). The 
experiments above enabled assignment of the backbone amide proton and nitrogen 
atoms of 159 residues of G-CSF C3 at pH 4 in the presence of 3 M urea, with Ile96 
being the only residue that could not be assigned. For G-CSF C3 at pH 7 in the 
absence of urea, 157 residues were assigned (see Section  3.2.7.2), while in the 
presence of 4 M urea 155 residues were assigned, but Leu62 and Ile96 could not be 
assigned. For G-CSF C3 at pH 4 in the presence of 0.5 M urea, 158 residues were 
assigned, with Leu62 and Ile96 not being assigned. At pH 7 in the presence of 0.5 M 
urea, 151 residues were assigned but Leu62, Ser64, Gln68, Leu72, Ile96 and 
Phe145 could not be assigned. Consequently, any possible conformational change 
associated with these residues in the urea concentrations outlined could not be 
assessed because CSPs could not be calculated. 
 
Generally, addition of urea results in the movement of peaks in the proton dimension 
of 1H-15N HSQC spectra downfield away from the proton resonance frequency of 
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water, which is calculated to be 4.75 ppm at 25 oC at pH 5.5. Although the proton 
resonance frequency of water will vary with pH, this variation is only 0.02 ppm per 
pH unit319.  
 
Addition of urea results in reduction of the intrinsic exchange rate of amide protons 
with water protons in the solvent335. The change in hydrogen exchange rate also 
affects the amide nitrogen chemical shift, causing movement of HSQC peaks in the 
nitrogen dimension as well as proton. Urea reduces the base catalysed rate of 
hydrogen exchange by reducing the concentration of hydroxyl anions in the solution, 
which occurs as a result of urea repressing the ionisation of water to protons and 
hydroxyl anions i.e. Kw
335,400. Hydroxyl anions are predominantly involved in catalysis 
of hydrogen exchange reactions above pH 3 in the absence of urea, meaning urea 
reduces the intrinsic hydrogen exchange rate at these pH values335.  
 
The general effect of adding urea of causing peaks to be shifted downfield in the 
proton and nitrogen dimensions of the 1H-15N HSQC spectra of G-CSF C3 is greater 
at pH 7 in the presence of 4 M urea (Figure  5.2A) than at pH 4 in the presence of 3 
M urea (Figure  5.4A), which is evident from the changes in the peak position of the 
Trp119 indole side chain in Figure  5.2A and Figure  5.4A, respectively. This is 
because the intrinsic rate of base catalysed hydrogen exchange increases at higher 
pH, such that the effect of urea on reducing hydrogen exchange is more significant 
at higher pH. The effect of urea on the intrinsic hydrogen exchange rate is also 
concentration dependent, i.e. the change in the peak position of the Trp119 indole 
side chain of G-CSF C3 at pH 7 is greater in the presence of 4 M urea (Figure  5.2A) 
than in the presence of 0.5 M urea (Figure  5.1A)335.  
 
Any conformational changes of G-CSF C3 that occur in sub-denaturing urea 
concentrations should give rise to greater CSPs than the subtle changes that arise 
from changes in the intrinsic rate of hydrogen exchange, particularly as a result of 
the change in the environment of one or more Tyr side chains of G-CSF C3 as 
aromatic ring current effects cause large proton chemical shift changes332. However, 
any conformational changes of G-CSF C3 in sub-denaturing urea concentrations 
may be more easily observed at pH 4 compared with pH 7 due to the lower intrinsic 
rate of hydrogen exchange335.   
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Figure ‎5.1 CSPs for G-CSF C3 at pH 7 resulting from addition of 0.5 M urea. The 1H-15N HSQC spectra of 458 µM 
G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 
buffer (I = 72 mM) in the absence of urea (black) and 81 µM G-CSF C3 in the presence of 0.5 M urea (green) are 
shown in A, which were used for calculation of the CSPs shown in B. Extra peaks on the right hand side of the 
spectrum due to urea are labelled, along with peaks corresponding to the side chain (sc) of Trp119. CSPs were 
calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 in the presence and absence of 
0.5 M urea (B). Red arrows in A show the changes in peak position of residues that exhibit significantly large CSPs 
upon addition of 0.5 M urea, which are coloured red in B. Horizontal lines show the mean, mean + σ and mean + 2σ 
CSP values. Orange and red bars correspond to residues exhibiting CSPs greater than the mean + σ and mean + 
2σ, respectively. A secondary structure schematic is shown above for reference. Right: Residues with significant 
CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, 
constructed using PyMOL
289
. Red residues are also labelled. Spectra were acquired at 25 
o
C using a spectrometer 
operating at a proton resonance frequency of 600 MHz equipped with a room temperature probe.    
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Figure ‎5.2 CSPs for G-CSF C3 at pH 7 resulting from addition of 4 M urea. The 1H-15N HSQC spectra of 458 µM G-
CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 
buffer (I = 72 mM) in the absence of urea (black) and 208 µM G-CSF C3 in the presence of 4 M urea (purple) are 
shown in A, which were used for calculation of the CSPs shown in B. Extra peaks on the right hand side of the 
spectrum due to urea are labelled, along with peaks corresponding to the side chain (sc) of Trp119. CSPs were 
calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 in the presence and absence of 
4 M urea (B). Red arrows in A show the changes in peak position of residues that exhibit significantly large CSPs 
upon addition of 4 M urea, which are coloured red in B. Horizontal lines show the mean, mean + σ and mean + 2σ 
CSP values. Orange and red bars correspond to residues exhibiting CSPs greater than the mean + σ and mean + 
2σ, respectively. A secondary structure schematic is shown above for reference. Right: Residues with significant 
CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, 
constructed using PyMOL
289
. Red residues are also labelled. Spectra were acquired at 25 
o
C using a spectrometer 
operating at a proton resonance frequency of 600 MHz equipped with a room temperature probe. 
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Figure ‎5.3 CSPs for G-CSF C3 at pH 4 resulting from addition of 0.5 M urea. The 1H-15N HSQC spectra of 473 µM 
G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I = 39 mM) in the 
absence of urea (black) and 103 µM G-CSF C3 in the presence of 0.5 M urea (green) are shown in A, which were 
used for calculation of the CSPs shown in B. Peaks corresponding to the side chain (sc) of Trp119 are labelled. 
CSPs were calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 in the presence and 
absence of 0.5 M urea (B). Red arrows in A show the changes in peak position of residues that exhibit significantly 
large CSPs upon addition of 0.5 M urea, which are coloured in red in B. Horizontal lines show the mean, mean + σ 
and mean + 2σ CSP values. Orange and red bars correspond to residues exhibiting CSPs greater than the mean + 
σ and mean + 2σ, respectively. A secondary structure schematic is shown above for reference. Right: Residues with 
significant CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, 
constructed using PyMOL
289
. Red residues are also labelled. Spectra were acquired at 25 
o
C using a spectrometer 
operating at a proton resonance frequency of 600 MHz equipped with a room temperature probe. 
Elucidating the conformational changes that promote G-CSF C3 aggregation 
 
200 
 
 
Figure ‎5.4 CSPs for G-CSF C3 at pH 4 resulting from addition of 3 M urea. The 1H-15N HSQC spectra of 473 µM G-
CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I = 39 mM) in the 
absence of urea (black) and 173 µM G-CSF C3 in the presence of 3 M urea (purple) are shown in A, which were 
used for calculation of the CSPs shown in B. Peaks corresponding to the side chain (sc) of Trp119 are labelled. 
CSPs were calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 in the presence and 
absence of 3 M urea (B). Red arrows in A show the changes in peak position of residues that exhibit significantly 
large CSPs upon addition of 3 M urea, which are coloured in red in B. Horizontal lines show the mean, mean + σ 
and mean + 2σ CSP values. Orange and red bars correspond to residues exhibiting CSPs greater than the mean + 
σ and mean + 2σ, respectively. A secondary structure schematic is shown above for reference. Right: Residues with 
significant CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, 
constructed using PyMOL
289
. Red residues are also labelled. Spectra were acquired at 25 
o
C using a spectrometer 
operating at a proton resonance frequency of 600 MHz equipped with a room temperature probe. 
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CSPs for residues Ala60 and Leu158 are among the largest observed for G-CSF C3 
at both pH 4 and 7 in the presence of urea (coloured red in Figure  5.1B-
Figure  5.4B). Additionally, Leu79 exhibits a large CSP at pH 4 in the presence of 0.5 
and 3 M urea (Figure  5.3B and Figure  5.4B, respectively), while Leu62 also exhibits 
a large CSP at pH 4 in the presence of 3 M urea (Figure  5.4B). Leu62 of G-CSF C3 
could not be assigned at pH 4 in the presence of 0.5 M urea, making it unclear if this 
residue experiences a significant change in its chemical environment upon addition 
of 0.5 M as well as 3 M urea. Leu79 also exhibits a significant CSP at pH 7 in the 
presence of 0.5 and 4 M urea (coloured orange in Figure  5.1B and Figure  5.2B, 
respectively). Residues Leu83, His157 and Arg167 also exhibit significant CSPs at 
pH 4 and 7 in the presence of urea.  
 
Overall, the vast majority of significant and large CSPs observed for G-CSF C3 at 
pH 4 and 7 upon addition of urea are observed for residues in the AB loop or 
residues in helices B and D that are proximal spatially to regions of the latter half of 
the AB loop (Figure  5.1B-Figure  5.4B), suggesting that a conformational change in 
this region results from addition of urea at sub-denaturing concentrations. 
Surprisingly, similar residues of G-CSF C3 at pH 4 and 7 exhibit significantly large 
CSPs in the presence of 0.5 M (Figure  5.3B and Figure  5.1B, respectively) and in 
urea concentrations that promote aggregation (Figure  5.4B and Figure  5.3B, 
respectively). This suggests that the conformational change in the AB loop occurs at 
lower urea concentrations than those required to promote aggregation of G-CSF C3, 
which agrees with the results of near-UV CD (Figure  4.10) and fluorescence 
emission spectra (Figure  4.9) which also suggest a conformational change in urea 
concentrations lower than those required to promote G-CSF C3 aggregation. 
 
The program CMView401 was used to determine whether residues exhibiting large 
CSPs are clustered around a particular Tyr side chain in the structure of G-CSF wt 
(PDB 1GNC283), modelled in PyMOL289. CMView401 predicts a contact between two 
residues if there are atoms in these residues that are within 8 Å401. All of the 
residues exhibiting large CSPs (coloured red in Figure  5.1B-Figure  5.4B) were 
predicted to have contacts with Tyr86 (Figure  5.5), while none of these residues 
were predicted to have contacts with Tyr40 or Tyr166. This strongly suggests that a 
change in the environment of Tyr86 is occurring in low urea concentrations, which is 
responsible for the changes in near-UV CD (Figure  4.10) and fluorescence emission 
(Figure  4.9) spectra of G-CSF C3 in sub-denaturing urea concentrations and could 
be linked to aggregation. Moreover, many of the significant and large CSPs are 
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located on the latter half of the AB loop, supporting the notion that a conformational 
change in the AB loop is responsible for the change in the environment of the side 
chain of Tyr86.  
 
Interestingly, a conformational change in the AB loop has been suggested 
previously to be linked to aggregation of wild-type G-CSF in low GdnHCl 
concentrations at pH 7, reported by increased fluorescence emission intensity of 
Trp59142. This suggests that G-CSF C3 aggregation could be linked to the same 
conformational change that has been hypothesised to promote aggregation of wild-
type G-CSF. 
 
 
Figure ‎5.5 Proximity of the side chain of Tyr86 in G-CSF C3 to residues that exhibit large CSPs in the presence of 
urea concentrations that promote aggregation. Contacts predicted between Tyr86 (blue) and residues that exhibit 
large CSPs (red) by the program CMView
401
 are represented by green lines drawn between the Cα atoms of 
residues, although contacts are not necessarily predicted between these particular atoms. Predicted contacts are 
shown for residues of G-CSF C3 that exhibit large CSPs at pH 7 in the presence of 4 M urea i.e. Ala60 and Leu158 
(A) and at pH 4 in the presence of 3 M urea i.e. Ala60, Leu62, Leu79 and Leu158 (C). Distances between the amide 
protons of residues exhibiting large CSPs at pH 7 in the presence of 4 M urea (B) and at pH 4 in the presence of 3 
M urea (D) and the nearest atom of the side chain of Tyr86 are shown in Å connected by yellow dotted lines. This 
figure was constructed using the structure of G-CSF wt (PDB 1GNC
283
) in PyMOL
289
. 
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5.2.2 Probing for changes in the dynamics of G-CSF C3 under aggregation-
prone conditions using amide nitrogen transverse relaxation rates (R2)   
 
The effect of sub-denaturing urea concentrations on the dynamics of G-CSF C3 was 
determined next by measurement of amide nitrogen R2 rates. Transverse relaxation 
refers to decoherence of magnetisation in the xy plane324. The low gyromagnetic 
ratio of 15N nuclei coupled to the high gyromagnetic ratio of protons319 means that 
relaxation of backbone 15N nuclei is predominantly due to dipole-dipole interactions 
between amide proton and nitrogen nuclei319,340. Therefore, measurement of 
backbone 15N nuclei longitudinal and transverse relaxation rates (denoted R1 and 
R2, respectively) can be used to investigate local polypeptide fluctuations on the ps-
ns timescale. However, R2 rates are also affected by the rotational correlation time 
(τc) and chemical exchange resulting from larger amplitude protein motions on the 
µs-ms timescale e.g. conformational exchange341. A more comprehensive 
description of the theory behind transverse relaxation is given in Section  2.9.8. 
 
For measurement of R2 rates in pH 7 buffer 130, 135 and 134 µM G-CSF C3 were 
used in the presence of 0, 0.5 and 4 M urea, respectively. For R2 rate 
measurements in pH 4 buffer 162, 151 and 163 µM G-CSF C3 were used in the 
presence of 0, 0.5 and 3 M urea, respectively. R2 rates were measured in the 
presence of 0.5 M urea, as well as urea concentrations which promote aggregation, 
in order to probe for changes in the dynamics of G-CSF C3 which only occur in 
higher urea concentrations and so are more likely to relate to aggregation.       
 
R2 rates are measured using a variation of the HSQC pulse sequence (Figure  2.1), 
which contains a CPMG pulse train342,343 between the first INEPT block and the t1 
evolution period in the indirect dimension. By varying the number of repetitions of 
the CPMG block time delays of different lengths are created and 1H-15N HSQC 
spectra with different amide proton peak intensities are acquired, which are used to 
calculate R2 rates for each amide nitrogen
341. Time delays of 16.1, 32.2, 48.4, 64.5, 
80.6, 96.7, 112.8 and 129.0 ms were used for measurement of G-CSF C3 R2 rates. 
Amide proton peak intensities at each of these relaxation delays were fitted to a 
single exponential decay function, with errors being calculated from the difference of 
duplicate peak intensities from the mean intensity acquired using relaxation delays 
of 32.2 and 96.7 ms. Monte Carlo error analysis was subsequently performed to 
calculate the error in the rates obtained from fitting of peak intensities (see 
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Section ‎2.9.8). Plots of peak intensity at each relaxation delay outlined and fitting of 
these peak intensities to a single exponential decay function are shown in 
Appendices 7.9 and 7.10 respectively for G-CSF C3 at pH 4 and 7 in the absence of 
urea. Some examples of these plots are shown in Figure  5.8A-E for G-CSF C3 at 
pH 7 in the absence or presence of 4 M urea. 
 
After measurement of backbone 15N R2 rates for G-CSF C3 at pH 7 in the presence 
of 0, 0.5 and 4 M urea (Figure  5.6A and Figure  5.7A, respectively) and at pH 4 in the 
presence of 0, 0.5 and 3 M urea (Figure  5.9A and Figure  5.10A, respectively) ratios 
of R2 rates measured without urea to R2 rates measured with urea were calculated 
(Figure  5.6B-Figure  5.10B). Residues with R2 ratios significantly greater than the 
mean + σ ratio are coloured red in Figure  5.6B-Figure  5.10B, while residues with R2 
ratios significantly lower than the mean – σ ratio are coloured blue. Residues are 
only highlighted red if their R2 ratio minus the error in this calculated ratio is greater 
than the mean + σ ratio and are only highlighted blue if their R2 ratio plus the error in 
this calculated ratio is lower than the mean – σ ratio.    
 
Generally, R2 rates are lower for residues of G-CSF C3 in unstructured regions, 
such as the N- and C-termini and the AB and CD loops (Figure  5.6A-Figure  5.10A), 
suggesting that these regions of G-CSF C3 are more dynamic on the ps-ns 
timescale. Conversely, residues in helical sections of G-CSF C3 have higher R2 
rates, suggesting that these regions are more rigid. Through measurement of NMR 
relaxation rates, the N- and C- termini of wild-type G-CSF as well as the CD loop 
have been shown previously to be more dynamic than the rest of G-CSF on the sub-
nanosecond timescale283,288.   
 
Despite the fact the AB loop of G-CSF C3 is longer than the CD loop (residues 42-
71 in the AB loop compared with residues 125-144 in the CD loop), the R2 rates of 
residues in the AB loop are higher than those in the CD loop (Figure  5.6A-
Figure  5.10A), suggesting that the CD loop is more dynamic than the AB loop. This 
has been observed previously for the AB and CD loops of G-CSF wt and is most 
likely due to the short helical section in the AB loop plus the two disulphide bonds 
linking residues Cys37-Cys43 and Cys65-Cys75, which restrain the AB loop by 
linking residues at the N- and C-termini of this loop to helices A and B, respectively 
(Figure  1.11)288. 
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Figure ‎5.6 Backbone 15N R2 rates for G-CSF C3 at pH 7 in the absence or presence of 0.5 M urea. R2 rates 
measured using 130 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium 
azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) in the absence of urea (black) and 135 µM G-CSF C3 in the presence 
of 0.5 M urea (red) are shown in A with a secondary structure schematic above for reference. The ratios of R2 rates 
measured in 0 M urea to rates measured in 0.5 M urea are shown in B with a secondary structure schematic above 
for reference. Horizontal lines show the mean, mean + σ and mean - σ R2 ratios. The red bar corresponds to a 
residue exhibiting an R2 ratio significantly greater than the mean + σ value and blue bars correspond to residues 
exhibiting R2 ratios significantly lower than the mean - σ value. Right: Residues with significant R2 ratios are shown 
mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, constructed using 
PyMOL
289
. The red residue is also labelled. R2 rates were measured at 25 
o
C using a spectrometer operating at a 
proton resonance frequency of 600 MHz equipped with a room temperature probe.      
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Figure ‎5.7 Backbone 15N R2 rates for G-CSF C3 at pH 7 in the absence or presence of 4 M urea. R2 rates 
measured using 130 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium 
azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) in the absence of urea (black) and 134 µM G-CSF C3 in the presence 
of 4 M urea (red) are shown in A with a secondary structure schematic above for reference. The ratios of R2 rates 
measured in 0 M urea to rates measured in 4 M urea are shown in B with a secondary structure schematic above 
for reference. Horizontal lines show the mean, mean + σ and mean - σ R2 ratios. Red bars correspond to residues 
exhibiting R2 ratios significantly greater than the mean + σ value and blue bars correspond to residues exhibiting R2 
ratios significantly lower than the mean - σ value. Right: Residues with significant R2 ratios are shown mapped onto 
the structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, constructed using PyMOL
289
. Red 
residues are also labelled. R2 rates for residues coloured in black and labelled can only be measured reliably in the 
presence of 4 M urea. R2 rates were measured at 25 
o
C using a spectrometer operating at a proton resonance 
frequency of 600 MHz equipped with a room temperature probe. 
Elucidating the conformational changes that promote G-CSF C3 aggregation 
 
207 
 
Ratios of R2 rates measured at pH 7 in the absence of urea to rates measured in the 
presence of 0.5 M urea suggest that only one residue becomes significantly more 
dynamic in the presence of urea i.e. Leu83, which is located in helix B (Figure  5.6B). 
Conversely, ratios of R2 rates at pH 7 calculated in the presence of 4 M urea 
suggest that three residues within the AB loop become significantly more dynamic, 
these being Ser54, Arg71 and Leu83. Ser54 and Arg71 are located on the helical 
section of the AB loop and in the region between this helical section and helix B, 
respectively (Figure  5.7B).  
 
There are also some residues for which R2 rates can only be measured reliably in 
the presence of 4 M urea as the peaks in 1H-15N HSQC spectra for these residues in 
the absence of urea are too broad (Figure  5.8). This suggests that upon addition of 
4 M urea these residues become more dynamic, giving rise to narrower peaks in 1H-
15N HSQC spectra and enabling measurement of accurate R2 rates, in accordance 
with the relationship between the width of peaks at half height in NMR spectra (ν1/2) 
and the R2 rate (Equation  5.1)
324. These residues are Ser64, Gln68 and Leu72 and 
are found in the latter half of the AB loop (coloured black in Figure  5.7B), along with 
Ser54 and Arg71 (coloured red in Figure  5.7B), suggesting that increased dynamics 
of the residues in this region are observed upon addition of 4 M urea, but not in the 
presence of 0.5 M urea. Therefore, increased mobility of the latter half of the AB 
loop region of G-CSF C3 at pH 7 resulting from addition of 4 M urea could be linked 
to increased aggregation observed under the same conditions. 
 
 
ν1/2 =
R2
π
 
 
Equation ‎5.1 
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Figure ‎5.8 Backbone 15N R2 rates for residues of G-CSF C3 at pH 7 that exhibit broad 1H-15N HSQC peaks in the 
absence of urea. Plots of peak intensity over time used for calculation of R2 rates for G-CSF C3 in 18 mM sodium 
phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) in the 
absence or presence of 4 M urea are shown for residues Ser64 (A and B, respectively) and Gln68 (C and D, 
respectively). In the absence of urea, the peak for Leu72 is too broad to detect in the 
1
H-
15
N HSQC spectrum, such 
that an R2 rate could not be measured and so a plot of peak intensity over time is only shown for this residue in the 
presence of 4 M urea (F). Peak intensity is shown in arbitrary units and a horizontal dotted line is drawn at zero 
peak intensity. R2 rates were measured using 130 µM G-CSF C3 at pH 7 in the absence of urea and 134 µM G-CSF 
C3 in the presence of 4 M urea. R2 rates calculated from these plots are shown in E for residues of G-CSF C3 at pH 
7 measured in the absence or presence of 4 M urea (grey and red, respectively).  
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Ratios of R2 rates measured at pH 4 in the absence of urea to rates measured in the 
presence of 0.5 M urea suggest that two residues within the latter half of the AB loop 
become significantly more dynamic, these being Ala69 and Leu70, as well as Leu72 
which is the N-terminal residue of helix B (Figure  5.9B). Interestingly, Tyr86 on helix 
B also appears to be significantly more dynamic in the presence of 0.5 M urea, 
although this effect is not observed in 3 M urea (Figure  5.10B). 
 
In the presence of 3 M urea, residues Gly56, Arg59, Leu70 and Arg71 within the 
latter half of the AB loop of G-CSF C3 at pH 4 are significantly more dynamic. This 
could suggest that in the presence of 0.5 M urea the last few residues of the C-
terminal end of the AB loop become more dynamic, whereas upon addition of 3 M 
urea the entire latter half of the AB loop, encompassing the C-terminus of the short 
helical section to the C-terminal end of the loop becomes more dynamic. The larger 
amplitude of the protein motion suggested in 3 M compared to 0.5 M urea may 
account for the increased aggregation of G-CSF C3 observed at pH 4 in the 
presence of 3 M but not 0.5 M urea.  
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Figure ‎5.9 Backbone 15N R2 rates for G-CSF C3 at pH 4 in the absence or presence of 0.5 M urea. R2 rates 
measured using 162 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 
buffer (I = 39 mM) in the absence of urea (black) and 151 µM G-CSF C3 in the presence of 0.5 M urea (red) are 
shown in A with a secondary structure schematic above for reference. The ratios of R2 rates measured in 0 M urea 
to rates measured in 0.5 M urea are shown in B with a secondary structure schematic above for reference. 
Horizontal lines show the mean, mean + σ and mean – σ R2 ratios. Red bars correspond to residues exhibiting R2 
ratios significantly greater than the mean + σ value and blue bars correspond to residues exhibiting R2 ratios 
significantly lower than the mean – σ value. Right: Residues with significant R2 ratios are shown mapped onto the 
structure of G-CSF wt (PDB 1GNC
283
) using the same colour scheme, constructed using PyMOL
289
. Red residues 
are also labelled. R2 rates were measured at 25 
o
C using a spectrometer operating at a proton resonance frequency 
of 600 MHz equipped with a room temperature probe. 
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Figure ‎5.10 Backbone 15N R2 rates for G-CSF C3 at pH 4 in the absence or presence of 3 M urea. R2 rates 
measured using 162 µM G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 
buffer (I = 39 mM) in the absence of urea (black) and 163 µM G-CSF C3 in the presence of 3 M urea (red) are 
shown in A with a secondary structure schematic above for reference. The ratios of R2 rates measured in 0 M urea 
to rates measured in 3 M urea are shown in B with a secondary structure schematic above for reference. Horizontal 
lines show the mean, mean + σ and mean - σ R2 ratios. Red bars correspond to residues exhibiting R2 ratios 
significantly greater than the mean + σ value and blue bars correspond to residues exhibiting R2 ratios significantly 
lower than the mean – σ value. Right: Residues with significant R2 ratios are shown mapped onto the structure of G-
CSF wt (PDB 1GNC
283
) using the same colour scheme, constructed using PyMOL
289
. Red residues are also 
labelled. R2 rates were measured at 25 
o
C using a spectrometer operating at a proton resonance frequency of 600 
MHz equipped with a room temperature probe. 
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5.2.3 Probing for changes in the solvent exposure of G-CSF C3 under 
aggregation-prone conditions using hydrogen/deuterium exchange      
 
Native state hydrogen/deuterium exchange of backbone amide protons on G-CSF 
C3 was used to measure dynamics over longer timescales than accessible by R2 
rates, as well as probe for changes in solvent exposure in the presence and 
absence of urea concentrations that promote aggregation. Native state hydrogen 
exchange monitored by NMR has been used to identify partially unfolded forms 
(PUFs) of proteins that are sparsely populated402,403 and often undetectable in 
kinetic and thermodynamic studies404-408. Native state hydrogen exchange has also 
been used to identify PUFs involved in aggregation89 as well as more general 
increases in dynamics and solvent exposure that promote aggregation92,409,410. A 
more comprehensive description of the theory behind hydrogen/deuterium exchange 
is given in Section  2.9.7. 
 
Considering that the aggregation of wild-type G-CSF at pH 7 has been proposed to 
occur from a native-like species142,185,303,307,308, which has also been hypothesised to 
correspond to a late stage folding intermediate observed during kinetic folding 
studies of G-CSF wt at pH 4142,304, native state hydrogen exchange is an appropriate 
technique to probe for subtle conformational changes in the native state of G-CSF 
C3 that give rise to aggregation.   
 
Native state hydrogen exchange monitored by mass spectrometry has been carried 
out for G-CSF wt previously at pH 7 at temperatures which favour and disfavour 
aggregation i.e. 37 and 4 oC, respectively, revealing a general increase in solvent 
exposure of helices at 37 oC and increased protection of helices at 4 oC307. However, 
increased intrinsic hydrogen exchange rates335, coupled with the increased thermal 
motion of proteins at higher temperatures, make it unclear to what extent the 
general increase in solvent exposure of helices at higher temperature relates to the 
minimal conformational change needed to promote G-CSF aggregation.  
 
Native state hydrogen exchange monitored by mass spectrometry309 and infrared 
(IR) spectroscopy185,308 have also been carried out for G-CSF wt in the presence of 
sucrose and benzyl alcohol, which have been shown to discourage185,307,308 and 
promote185 wild-type G-CSF aggregation, respectively. These experiments showed a 
general increase in solvent exposure of helices in the presence of benzyl 
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alcohol185,309 and increased protection from solvent in the presence of sucrose185,307-
309. Sucrose is a commonly used excipient in protein drug formulations178 which 
causes compaction of the native conformation and destabilises partially unfolded 
states of proteins through preferential exclusion of water from the protein surface198. 
Conversely, benzyl alcohol is an antimicrobial preservative99 which has been shown 
to cause aggregation and interact with partially unfolded species of proteins186-188. 
Therefore, it is perhaps unsurprising that increased protection of helices from 
hydrogen exchange is observed for G-CSF in the presence of sucrose185,307-309, 
which causes compaction of the native conformation, while increased solvent 
exposure is observed in the presence of benzyl alcohol185,309, most likely due to 
partial unfolding186,187. Consequently, these global increases and decreases in 
solvent exposure of the native conformation may mask the minimal conformational 
fluctuation required for G-CSF aggregation.  
 
For initiation of hydrogen/deuterium exchange reactions, concentrated stocks of G-
CSF C3 in pH 7 and 4 buffers were diluted ten-fold with deuterated pD 7.8 and pD 
4.8 buffers, respectively, to a final concentration of 52 µM G-CSF C3. pD 7.8 buffer 
with or without 4.44 M urea was used for initiating hydrogen exchange in the 
presence and absence of a final concentration of 4 M urea, while pD 4.8 buffer with 
or without 3.33 M urea was used for hydrogen exchange reactions in the presence 
and absence of 3 M urea. pD 4.8 and 7.8 buffers exhibited pH meter readings of 4.4 
and 7.4, respectively338. 
 
After dilution, hydrogen exchange of amide protons was monitored by recording 1H-
15N band-selective optimised-flip-angle short-transient (SOFAST) HMQC spectra339 
every 5 mins over a 15 h period for pD 7.8 reactions and every 20 mins over a 24 h 
period for pD 4.8 reactions. Spectra with different acquisition times were taken to 
account for the increased intrinsic rate of hydrogen exchange at neutral pH335. 1H-
15N SOFAST HMQC spectra reduce the acquisition time from hours to minutes 
through band-selective excitation of amide protons, which results in faster 
longitudinal relaxation due to dipolar interactions with non-perturbed protons339. The 
longitudinal relaxation rate (R1) determines the time before nuclei can be excited 
again by a radiofrequency pulse324, meaning more scans can be carried out over a 
shorter time period by acquiring 1H-15N SOFAST HMQC spectra339 compared with 
1H-15N HSQC spectra.                 
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Changes in the amide proton peak intensities of residues over time were fitted to a 
single exponential decay function with a y-axis offset. However, many peaks in the 
1H-15N SOFAST HMQC spectrum of G-CSF C3 after dilution into deuterated pD 7.8 
buffer were not detectable at the beginning of acquisition. This is the result of 
exchange of amide protons with deuterium occurring in the dead-time between 
initiation of the hydrogen exchange reaction and beginning acquisition, which was 7-
8 mins.  
 
Of the residues for which rate constants of hydrogen exchange could be reliably 
measured for G-CSF C3 amide protons at pD 7.8, protection factors (PFs) were 
calculated (see Section  2.9.7). Plots and fits used for calculation of the PFs shown 
in Figure  5.11A are shown in Appendix  7.12 for residues of G-CSF C3 in the 
absence of urea. Protection factors are the ratio of the intrinsic hydrogen exchange 
rates, calculated using CIntX337, to the observed rates. The ratios of ln(PF) in 0 M 
urea to ln(PF) in 4 M urea were calculated to probe for regions of G-CSF C3 with 
significantly altered dynamics or solvent exposure in the presence of 4 M urea.  
 
Overall, ln(PF) for residues of G-CSF C3 at pD 7.8 are lower in the presence of 4 M 
urea (Figure  5.11A). However, there are no residues that appear to be significantly 
less protected than other residues in the presence of 4 M urea (Figure  5.11B), 
suggesting a general increase in solvent exposure of these residues in helices of G-
CSF C3. This would suggest that the effect of 4 M urea on G-CSF C3 at pD 7.8 is to 
increase the general exposure of helical residues to solvent, which is comparable to 
the reported effect of benzyl alcohol on the solvent exposure of wild-type G-
CSF185,309.  Consequently, no specific regions of G-CSF C3 could be detected to 
undergo partial unfolding or exhibit increased solvent exposure at pD 7.8 upon 
addition of 4 M urea.  
 
Additionally, ln(PF) calculated for residues in the absence of urea are close to the 
ln(PF) representing global unfolding (shown as a green line in Figure  5.11A), 
suggesting that solvent exchange of the residues detected at pD 7.8 is reporting on 
global unfolding rather than partial unfolding events that are potentially linked to 
aggregation.             
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Figure ‎5.11 PFs for G-CSF C3 calculated from hydrogen/deuterium exchange rates at pD 7.8 in the absence or 
presence of 4 M urea. The ln(PF)s shown in A are calculated as the ratio of intrinsic rates (calculated using CIntX
337
)  
to observed rates for 52 µM G-CSF C3 in 20 mM sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium 
azide, 90 % (v/v) D2O pD 7.8 buffer (I = 89 mM) in the absence or presence of 4 M urea (black and red, 
respectively) and a secondary structure schematic is shown above for reference. The theoretical maximum ln(PF) 
was calculated using a ΔG
o
UN value of 40 kJ mol
-1
, measured by equilibrium denaturation analysis of G-CSF C3 at 
pH 7 (Table  4.1) and is shown as a horizontal green line in A. The ratios of ln(PF) calculated in 0 M urea to ln(PF) 
calculated in 4 M urea are shown in B with a secondary structure schematic above for reference. Horizontal lines 
show the mean, mean + σ and mean - σ ln(PF) ratios. Hydrogen/deuterium exchange rates were measured at 25 
o
C 
using a spectrometer operating at a proton resonance frequency of 600 MHz equipped with a room temperature 
probe. 
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Hydrogen exchange rates could be calculated for more residues of G-CSF C3 at pD 
4.8 than at pD 7.8, owing to the slower exchange rate at acidic pH335. However, for 
residues in largely or entirely unstructured regions of G-CSF C3 i.e. the AB loop plus 
the N- and C-termini and CD loop, respectively, the majority of amide proton peak 
intensities were undetectable at the beginning of acquisition, having exchanged in 
the dead-time of the experiment.  
 
The only residues in these unstructured regions that could be detected in 1H-15N 
SOFAST HMQC spectra had already undergone exchange of amide protons with 
deuterium, producing plots of largely unchanged peak intensity over time that could 
not be fitted to a single exponential decay function with a y-axis offset 
(Figure  5.12B). Peaks for these residues were visible even after exchange of 90 % 
of amide protons with deuterium because the peak intensities for the remaining 10 
% of unexchanged amide protons were great enough to be observed.         
 
Conversely, many amide protons for residues of G-CSF C3 did not undergo a 
significant amount of exchange with deuterium at pD 4.8 during the 24 h acquisition 
period, again resulting in plots of largely unchanged peak intensity over time that 
could not be fitted to a single exponential decay function with a y-axis offset 
(Figure  5.12A). Residues that had undergone negligible exchange of amide protons 
with deuterium were distinguishable from residues that were detectable even after 
exchange of 90 % of amide protons by their higher relative peak intensities 
(Figure  5.12A and B, respectively).  
 
PFs were only calculated for residues for which reliable hydrogen exchange rates 
could be calculated. The reliability of exchange rates was determined from the 
amplitude of the error relative to the calculated rate as well as visual inspection of 
the plots of peak intensity over time used for fitting to a single exponential decay 
function with a y-axis offset. Plots and fits used for calculation of the PFs shown in 
Figure  5.13A can be found in Appendix  7.11 for residues of G-CSF C3 in the 
absence of urea, plus two examples of these plots are shown in Figure  5.12C and 
D. 
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Figure ‎5.12 Plots of peak intensity over time for residues of G-CSF C3 undergoing hydrogen-deuterium exchange 
at pD 4.8 in the absence of urea. Examples of hydrogen exchange curves for 52 µM G-CSF C3 are shown for a 
residue that undergoes negligible hydrogen exchange over 24 h (A), a residue that is 90 % exchanged during the 
dead-time of the experiment but can still be observed from the peak intensity of the remaining 10 % of amide 
protons (B), and residues that undergo hydrogen exchange on a timescale that allows calculation of accurate 
exchange rates and protection factors (C and D). Peak intensity is shown in arbitrary units at 20 minute intervals, as 
well as fitting of these peak intensities to a single exponential decay function with a y-axis offset. Error bars 
represent the experimental noise calculated in CCPN Analysis
321
. Hydrogen/deuterium exchange rates were 
measured at 25 
o
C using a spectrometer operating at a proton resonance frequency of 600 MHz equipped with a 
room temperature probe. 
 
Overall, a significant difference between the ln(PF) at pD 4.8 with or without 3 M 
urea could only be detected for one residue of G-CSF C3 relative to other residues 
measured (Figure  5.13B). Considering the number of other residues of G-CSF C3 
for which accurate PFs could not be calculated, it is uncertain whether the increased 
protection of Leu100 from solvent in the presence of 3 M urea is significant. 
Therefore, no specific regions of G-CSF C3 could be detected to undergo partial 
unfolding or exhibit increased solvent exposure at pD 4.8 upon addition of 3 M urea, 
similarly to the results of hydrogen exchange monitored for G-CSF C3 at pD 7.8. 
However, the ln(PF) calculated for residues at pD 4.8 are significantly lower than the 
ln(PF) representing global unfolding (shown as a green line in Figure  5.13A), 
suggesting solvent exchange of the residues detected at pD 4.8 is reporting on local 
unfolding, in contrast to the solvent exchange observed for residues at pD 7.8.            
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Figure ‎5.13 PFs for G-CSF C3 calculated from hydrogen/deuterium exchange rates at pD 4.8 in the absence or 
presence of 3 M urea. The ln(PF)s shown in A are calculated as the ratio of intrinsic rates (calculated using CIntX
337
)  
to observed rates for 52 µM G-CSF C3 in 20 mM sodium phosphate, 20 mM sodium acetate, 90 % (v/v) D2O pD 4.8 
buffer (I = 46 mM) in the absence or presence of 3 M urea (black and red, respectively) and a secondary structure 
schematic is shown above for reference. The theoretical maximum ln(PF) was calculated using a ΔG
o
UN value of 37 
kJ mol
-1
, measured by equilibrium denaturation analysis of G-CSF C3 at pH 4 (Table  4.1) and is shown as a 
horizontal green line in A. The ratios of ln(PF) calculated in 0 M urea to ln(PF) calculated in 3 M urea are shown in B 
with a secondary structure schematic above for reference. Horizontal lines show the mean, mean + σ and mean - σ 
ln(PF) ratios. The blue bar corresponds to a residue exhibiting an ln(PF) ratio significantly lower than the mean – σ 
value. Hydrogen/deuterium exchange rates were measured at 25 
o
C using a spectrometer operating at a proton 
resonance frequency of 600 MHz equipped with a room temperature probe. 
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5.2.4 Searching for aggregation interfaces of G-CSF C3 using 1H-15N HSQC 
spectra 
 
In an attempt to determine the protein-protein interaction interfaces involved in G-
CSF C3 aggregation, aggregation assays were set up and monomer depletion was 
monitored by the changes in peak intensities of 1H-15N HSQC spectra versus time. 
The peak intensities of all G-CSF C3 residues should decrease over time during 
aggregation due to the formation of soluble aggregates. These larger species will 
exhibit slower molecular tumbling according to Stokes’ Law (Equation  5.2). In 
Equation  5.2, τc is the rotational correlation time i.e. the time taken for the particle to 
rotate by one radian, η is the viscosity of the sample, Rh is the hydrodynamic radius 
of the particle, kB is Boltzmann’s constant and T is temperature
319.  
 
 
τc =
4πηRh
3
3kBT
 Equation ‎5.2 
 
As soluble aggregates are formed and the τc of these species increases, the R2 rate 
of relaxation will also increase (Figure  2.4). Consequently, the peaks in 1H-15N 
HSQC spectra will decrease in intensity exponentially due to the relationship 
between R2 rate and peak width (Equation  5.1)
324. Eventually, peaks will be 
broadened beyond detection, which is referred to as lifetime broadening, causing 
the change in peak intensity over time to reach a plateau.  
 
The R2 rate is also contributed to by chemical exchange
341, which will arise as a 
result of the amide proton of a particular residue being in different chemical 
environments. Therefore, residues at the aggregation interface will be broadened by 
chemical exchange as well as lifetime broadening and as a result of slower 
molecular tumbling, meaning that the peak intensities of these residues should 
decay faster than residues not involved with the aggregation interface. Calculating 
the decay rate of peak intensity over the course of an aggregation assay should thus 
provide an indication of residues at the aggregation interface.   
 
Assignments of backbone amide nitrogen and proton nuclei were transferred from 
25 to 37 oC by thermal titration of G-CSF C3 over these temperatures monitored 
through 1H-15N HSQC spectra. For aggregation assays monitored by 1H-15N HSQC 
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spectra, 300 µl samples of G-CSF C3 were set up in a Shigemi tube, using 66 and 
67 µM G-CSF C3 in pH 7 buffer in the presence and absence of 4 M urea, 
respectively and 83 and 85 µM G-CSF C3 in pH 4 buffer in the presence and 
absence of 3 M urea, respectively (see Section  2.9.4). These samples were 
incubated at 37 oC for 24 h and 1H-15N HSQC spectra recorded every 30 mins.  
 
The resulting decays in amide proton peak intensities during aggregation of G-CSF 
C3 at pH 7 in the absence and presence of 4 M urea were fitted to a single 
exponential decay function with a y-axis offset to calculate decay rates. Examples of 
the plots and fits used for calculation of decay rates for residues of G-CSF C3 in the 
absence or presence of 4 M urea are shown in Figure  5.14A and B, respectively. All 
of the plots and fits used for calculation of the decay rates shown in Figure  5.14C 
can be found in Appendix  7.13 for residues of G-CSF C3 in the absence of urea.  
 
The resulting decays in amide proton peak intensities during aggregation of G-CSF 
C3 at pH 4 in the absence and presence of 3 M urea could not be fitted to a single 
exponential decay function with a y-axis offset so these data are not shown. 
However, these experiments are mentioned because insoluble aggregates from all 
G-CSF C3 aggregation assay samples monitored by 1H-15N HSQC spectra were 
snap frozen and later analysed by EM in order to characterise their morphology (see 
Sections  2.8 and  4.2.5).     
 
Surprisingly, the rates of decay for amide proton peaks during aggregation of G-CSF 
C3 at pH 7 are greater in the absence of urea than in the presence of 4 M urea 
(Figure  5.14C and D, respectively), even though G-CSF C3 aggregates more readily 
in the presence of 4 M urea (Figure  4.3A and Figure  4.6). This is most likely due to 
the size of the soluble aggregates formed in the absence and presence of 4 M urea 
(Figure  4.6C and D, respectively).  
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Figure ‎5.14 Decay rates in amide proton peak intensities during aggregation assays of G-CSF C3 at pH 7 in the 
absence or presence of 4 M urea. Observed decay rates (kobs) were measured using 66 µM G-CSF C3 in 18 mM 
sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) in 
0 M urea and 67 µM G-CSF C3 in 4 M urea incubated at 37 
o
C. Examples of the plots and fits used for calculating 
kobs in the absence or presence of 4 M urea are shown in A and B, respectively. kobs rates measured in the absence 
or presence of 4 M urea are shown plotted against residue number in C and D, respectively. Horizontal lines show 
the mean, mean + σ and mean – σ kobs rates and a secondary structure schematic is shown above for reference. 
Red bars correspond to residues exhibiting kobs rates significantly greater than the mean + σ value and blue bars 
correspond to residues exhibiting kobs rates significantly lower than the mean – σ value. Right: Residues with 
significant kobs rates are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using the same colour 
scheme, constructed using PyMOL
289
. Red residues are also labelled. kobs rates were measured at 37 
o
C using a 
spectrometer operating at a proton resonance frequency of 750 MHz equipped with a cryogenic probe. 
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In the absence of urea, G-CSF C3 at pH 7 is largely monomeric before incubation at 
37 oC, as shown by analytical SEC (Figure  3.9) and DLS (Figure  4.6A, C and E). 
After incubation of G-CSF C3 at 37 oC quiescently at pH 7 in the absence of urea, 
DLS showed that there was increased deviation of the autocorrelation function from 
the fit to a single exponential decay function at early time periods (Figure  4.6A), 
which corresponded to an increase in the width of the main peak in regularisation 
analysis (Figure  4.6C and E). This is indicative of the formation of species with 
larger Rh values i.e. soluble aggregates.  
 
In the presence of 4 M urea G-CSF C3 was observed by DLS to form larger species 
than those formed in the absence of urea even before incubation at 37 oC 
(Figure  4.6B, D and F), with this incubation period simply shifting the distribution of 
species to even larger Rh values (Figure  4.6D and F). Therefore, the transition from 
soluble aggregates formed in the presence of 4 M urea to larger soluble aggregates 
formed during incubation at 37 oC may not be detectable in 1H-15N HSQC spectra, 
while the transition from largely monomeric G-CSF C3 to oilgomeric species at pH 7 
without urea can be detected, resulting in faster rates of decay for amide proton 
peak intensities.  
 
Residues of G-CSF C3 exhibiting significantly high decay rates during aggregation 
at pH 7 in the absence and presence of 4 M urea are coloured red in Figure  5.14C 
and D, respectively. The three residues that exhibit significantly high decay rates in 
the presence of 4 M urea are not clustered in a particular region (Figure  5.14D). In 
addition, the decay rates encountered in the presence of 4 M urea are lower 
generally than the rates observed in the absence of urea, suggesting that they may 
not be reporting on interactions at a possible aggregation interface. 
 
Of the six residues of G-CSF C3 that exhibit significantly high decay rates during 
aggregation at pH 7 in the absence of urea, four are located around the AB loop that 
has already been shown to exhibit increased dynamics in aggregation-prone 
conditions (see Section  5.2.2), these residues being Gly82 and Leu85 in helix B and 
Leu158 and Leu162 in helix D. Interestingly, these residues in helix B are close to 
Tyr86, the side chain of which has been shown to undergo an alteration in its 
chemical environment under aggregation-prone conditions at both pH 4 and 7 
(Figure  5.5). Moreover, Leu158 is one of the residues that exhibits a large CSP in 
sub-denaturing urea concentrations (Figure  5.1B-Figure  5.4B), again as a result of a 
change in the environment of the side chain of Tyr86.  
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This could suggest that the region around Tyr86 is acting as an aggregation 
interface, which would also agree with the changes in the near-UV CD and 
fluorescence emission spectra observed for G-CSF C3 in sub-denaturing urea 
concentrations (Figure  4.10 and Figure  4.9, respectively). Near-UV CD spectra 
showed increased negativity around 275 nm upon addition of sub-denaturing urea 
concentrations, suggesting that the side chain of Tyr86 was becoming less mobile 
(Figure  4.10). Likewise, fluorescence emission spectra showed increased emission 
intensity upon adding these same urea concentrations, suggested Tyr86 was 
becoming less solvent exposed (Figure  4.9).          
 
5.2.5 Mapping ANS binding to G-CSF C3 using 1H-15N HSQC spectra 
 
In Chapter 4 the fluorescence emission spectra of ANS in the presence and 
absence of G-CSF C3 were used to probe for exposed hydrophobic surfaces that 
could be linked to aggregation. The fluorescence emission spectra of 250 µM ANS 
at pH 7 were largely unchanged in the presence of 2.5 µM G-CSF C3 in 0-7 M urea, 
suggesting no change in the hydrophobicity of the surface detected by ANS 
(Figure  4.15A and C). Conversely, the fluorescence emission spectra of 250 µM 
ANS at pH 4 showed a significant increase in emission intensity and a blue shift in 
the emission maxima in the presence of 5 µM G-CSF C3, suggesting increased 
hydrophobicity of the surface detected by dye binding395,396 in the presence of G-
CSF C3 (Figure  4.15B and D). Intriguingly, the fluorescence emission spectra of 
ANS at pH 4 in the presence of urea concentrations of 1 M and above were similar 
with and without G-CSF C3, suggesting that this change in hydrophobicity was not 
occurring at these urea concentrations. 
 
The structural similarity of G-CSF C3 at pH 4 and 7 suggested by calculation of 
CSPs (Figure  3.19), coupled to the overall positive charge on G-CSF C3 at pH 4 
that is not apparent at pH 7 (based on a pI of 6.67 predicted from the amino acid 
sequence117), led to the hypothesis that the binding of ANS to G-CSF C3 at pH 4 
was driven by electrostatic rather than hydrophobic interactions. Previous studies 
have shown that ion pairing between the sulphonate group of ANS and positively 
charged side chains of Lys, Arg and His at acidic pH is the dominant mechanism of 
binding to protein surfaces397-399. However, such electrostatic interactions with a 
protein surface do not usually cause the characteristic increase in emission intensity 
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and blue shift in the emission maximum of ANS that are associated with an 
increased hydrophobicity of its environment398 (see Section  4.2.11). 
 
The changes in fluorescence emission spectra of ANS resulting from incubation with 
G-CSF C3 at pH 4 were attributed to aggregation because protein precipitation was 
evident in this sample and ANS has previously been shown to cause protein 
aggregation187. Moreover, no insoluble aggregate could be observed in samples of 
G-CSF C3 and ANS at pH 4 in the presence of urea concentrations of 1 M or 
greater, in-line with the similar fluorescence emission spectra of ANS observed with 
or without G-CSF C3 under these conditions. Therefore, it was postulated that ANS 
binding to G-CSF C3 at pH 4 may block a positively charged site that is involved in 
inhibiting aggregation at acidic pH and replacing this site with a hydrophobic 
naphthalene group that promotes aggregation.    
 
To elucidate the ANS binding behaviour of G-CSF C3, 1H-15N HSQC spectra were 
acquired using 85 µM G-CSF C3 at pH 4 and 65 µM G-CSF C3 at pH 7 in the 
presence of 700 µM ANS at 25 oC (see Section  2.9.5). These spectra were 
compared with spectra acquired using the same concentrations of G-CSF C3 in the 
absence of ANS at 25 oC and CSPs calculated (see Section  2.9.6). 
 
Due to the lower protein concentrations required for measuring fluorescence 
emission spectra compared to 1H-15N HSQC spectra (at least 2 and 50 µM, 
respectively), the same molar ratio of G-CSF C3 to ANS could not be used during 
acquisition of 1H-15N HSQC spectra that was used previously for acquiring 
fluorescence emission spectra. Therefore, the molar excess of ANS to G-CSF C3 
used for acquiring 1H-15N HSQC spectra was roughly nine- and ten-fold at pH 4 and 
7, respectively, compared with the fifty- and one hundred-fold molar excesses of 
ANS to G-CSF C3 at pH 4 and 7, respectively, that were used for acquiring 
fluorescence emission spectra.  
 
Upon mixing of G-CSF C3 and ANS at pH 4 aggregation could be observed, which 
meant that 1H-15N HSQC spectra were acquired immediately after brief manual 
mixing of ANS and G-CSF C3. Conversely, samples of ANS and G-CSF C3 used for 
acquisition of fluorescence emission spectra were incubated at 25 oC overnight 
before acquisition as aggregation did not significantly affect the emission intensity of 
spectra.    
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At pH 7, Arg71 of G-CSF C3 exhibits the largest CSP as a result of adding ANS, 
suggesting that ANS binds to this residue (Figure  5.15B). Additionally, residues 
neighbouring Arg71 in the amino acid sequence and proximal to this residue in the 
tertiary structure of G-CSF C3 exhibit large CSPs, coloured in red in Figure  5.15B, 
which also suggests that ANS binds in this region. Arg71 also exhibits a large CSP 
upon addition of ANS at pH 4 (Figure  5.16B), suggesting that ANS also binds Arg71 
at pH 4.  
 
The peaks for Arg71 of G-CSF C3 at pH 4 and 7 are far less intense in the presence 
of ANS, but aggregation of G-CSF C3 at pH 4 upon addition of ANS makes it 
unclear if the reduced intensity of this peak relates to ANS binding or a decrease in 
the concentration of soluble G-CSF C3 (Figure  5.16A). However, aggregation of G-
CSF C3 was not observed at pH 7 after adding ANS, yet this peak is considerably 
weaker in the presence of ANS, while other peaks appear to exhibit comparable 
intensities in the presence and absence of ANS, suggesting that broadening of the 
peak for Arg71 occurs as a result of ANS binding (Figure  5.15A).        
 
At pH 4, His157 of G-CSF C3 exhibits a large CSP as a result of adding ANS, 
suggesting that ANS also binds to this residue (Figure  5.16B). Ala60 and Ser67 also 
exhibit large CSPs, which is most likely the result of ANS binding to His157. 
Interestingly, His157 does not exhibit a significant CSP as a result of addition of 
ANS at pH 7 (Figure  5.15B), suggesting that ANS binds to this residue at pH 4 but 
not at pH 7. This is consistent with both the pKa of the His side-chain (6.0117) and 
the dominant mechanism of ANS binding being ion pairing between the sulphonate 
group of ANS and positively charged side chains397-399.  
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Figure ‎5.15 ANS binding to G-CSF C3 at pH 7. The 1H-15N HSQC spectra of 65 µM G-CSF C3 in 18 mM sodium 
phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) in the 
absence or presence of 700 µM ANS (black and pink, respectively) are shown in A, which were used for calculation 
of the CSPs shown in B. CSPs were calculated using backbone amide proton and nitrogen chemical shifts of G-
CSF C3 in the presence and absence of 700 µM ANS (B). Residues Ala60, Arg71 and His157 are shown magnified 
in A as these residues give rise to relatively large CSPs upon addition of 700 µM ANS at pH 4 (Figure ‎5.16B). Of 
these residues, only Arg71 exhibits a significantly large CSP at pH 7, which is coloured in red in B. Horizontal lines 
show the mean, mean + σ and mean + 2σ CSP values. Orange and red bars correspond to residues exhibiting 
CSPs greater than the mean + σ and mean + 2σ, respectively. A secondary structure schematic is shown above for 
reference. Residues with significant CSPs are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) using 
the same colour scheme, constructed using PyMOL
289
. Red residues are also labelled. Spectra were acquired at 25 
o
C using a spectrometer operating at a proton resonance frequency of 750 MHz equipped with a cryogenic probe. 
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Figure ‎5.16 ANS binding to G-CSF C3 at pH 4. The 1H-15N HSQC spectra of 85 µM G-CSF C3 in 18 mM sodium 
phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I = 39 mM) in the absence or presence of 700 µM 
ANS (black and pink, respectively) are shown in A, which were used for calculation of the CSPs shown in B. CSPs 
were calculated using backbone amide proton and nitrogen chemical shifts of G-CSF C3 in the presence and 
absence of 700 µM ANS (B). Peaks for residues Ala60, Arg71 and His157 are shown magnified in A as these 
residues give rise to relatively large CSPs and so are coloured in red in B. The peak for Cys75 overlaps with that of 
His157 in the absence of ANS and so is also shown magnified in A, but does not exhibit a significant CSP in B. 
Horizontal lines show the mean, mean + σ and mean + 2σ CSP values. Orange and red bars correspond to 
residues exhibiting CSPs greater than the mean + σ and mean + 2σ, respectively. A secondary structure schematic 
is shown above for reference. Residues with significant CSPs are shown mapped onto the structure of G-CSF wt 
(PDB 1GNC
283
) using the same colour scheme, constructed using PyMOL
289
. Red residues are also labelled. 
Spectra were acquired at 25 
o
C using a spectrometer operating at a proton resonance frequency of 750 MHz 
equipped with a cryogenic probe. 
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The observation of G-CSF C3 aggregation upon mixing with ANS at pH 4 but not at 
pH 7, coupled to the binding of ANS to residue His157 of G-CSF C3 at pH 4 but not 
at pH 7 possibly reveals a role for this residue in the reduced aggregation propensity 
of G-CSF C3 at pH 4 (Figure  4.2). Reduced aggregation of wild-type G-CSF has 
also been reported at acidic pH185,276,303, which has been attributed to increased 
electrostatic repulsion between monomeric G-CSF, owing to the overall positive 
charge on G-CSF wt at acidic pH303. The proposed role of His157 in inhibiting G-
CSF C3 aggregation at acidic pH is further supported by the suggested roles of the 
nearby residues Leu158 and Leu162 in the aggregation interface, which were 
identified during monitoring of G-CSF C3 aggregation at pH 7 in the absence of urea 
using 1H-15N HSQC spectra (Figure  5.14A).   
 
The binding of ANS to G-CSF C3 at pH 4 in the presence of urea was not 
investigated using 1H-15N HSQC spectra. However, fluorescence emission spectra 
of ANS with and without G-CSF C3 at pH 4 in the presence of urea concentrations 
of 1 M or higher are similar (Figure  4.15B, D and F). In addition, aggregation could 
not be observed during incubation of G-CSF C3 with ANS at these urea 
concentrations, which suggests that ANS is not able to bind His157 in urea 
concentrations higher than 1 M. This could mean that the increased dynamics of the 
AB loop of G-CSF C3 in sub-denaturing urea concentrations is hindering ANS 
binding to His157, either through steric hindrance of the side chain of this residue or 
through disruption of the proximal arrangement of the positively charged side chains 
from His53, Arg59 and His157 (Figure  3.21).  
 
The ability of ANS to bind G-CSF C3 at pH 4 has been shown to decrease gradually 
as the urea concentration is raised from 0-1 M in 0.2 M increments (Figure  4.15F). 
This may be accounted for by a gradual increase in the dynamics of the AB loop, as 
R2 measurements would suggest that part of the latter half of the AB loop becomes 
more dynamic in the presence of only 0.5 M urea at pH 4 (Figure  5.9B), which may 
partially inhibit ANS binding. However, in the presence of urea concentrations that 
promote aggregation i.e. 3 M urea the entire latter half of this loop is more dynamic 
(Figure  5.10B), which completely prevents ANS binding.   
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5.3 Discussion    
 
Characterisation of the conformational change of G-CSF C3 that occurs upon 
addition of urea concentrations that are too low to cause global unfolding at amino 
acid resolution was achieved by calculation of CSPs, revealing a change in the 
environment of residues of the AB loop and residues on helices B and D that are 
proximal to this loop. This conformational change occurred in the presence of 0.5 M 
urea (Figure  5.1B and Figure  5.3B) as well as urea concentrations that promote 
aggregation (Figure  5.2B and Figure  5.4B). Residues exhibiting the largest CSPs 
e.g. Ala60 and Leu158 have been shown to have contacts with Tyr86 (Figure  5.5), 
which shows that a change in the environment of the side chain of Tyr86 is 
responsible for changes in the near-UV CD and fluorescence emission spectra of G-
CSF C3 observed upon addition of sub-denaturing urea concentrations, as outlined 
in Chapter 4 (Figure  4.10 and Figure  4.9, respectively). 
 
The change in the environment of Tyr86 is observed in the presence of urea 
concentrations that have been shown to promote G-CSF C3 aggregation, as well as 
0.5 M urea, based on analysis of 1H-15N HSQC (Figure  5.1-Figure  5.4), near-UV CD 
(Figure  4.10) and fluorescence emission spectra (Figure  4.9). Such low urea 
concentrations do not promote aggregation (Figure  4.3), which raises the possibility 
that a change in the environment of Tyr86 may be coincidental with increased 
aggregation observed in the presence of urea. However, the observation that 0.5 M 
urea does not promote G-CSF C3 aggregation is based on formation of insoluble 
aggregates, whereas the effect of such low urea concentrations on soluble G-CSF 
C3 aggregate formation has not been tested. Considering that G-CSF C3 has been 
shown to undergo soluble aggregate formation by DLS at pH 4 and 7 in the absence 
of urea (Figure  4.7A, C and F and Figure  4.6A, C and F, respectively), it is possible 
that urea concentrations as low as 0.5 M may promote soluble G-CSF C3 aggregate 
formation. Alternatively, the concentration of the aggregation-prone species in 0.5 M 
urea may be too low to initiate aggregation as protein aggregation is concentration-
dependent41.   
 
Measurement of R2 rates for backbone amide nitrogen nuclei of G-CSF C3 allowed 
changes in the local dynamics of the polypeptide backbone to be elucidated in the 
presence of 0.5 M urea (Figure  5.6 and Figure  5.9), as well as in higher urea 
concentrations at which G-CSF C3 exhibited a higher propensity to aggregate 
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(Figure  5.7, Figure  5.8 and Figure  5.10). At pH 7, residue Leu83 in helix B was 
shown to have a significantly reduced R2 rate in both 0.5 and 4 M urea (Figure  5.6B 
and Figure  5.7B, respectively), suggesting that this residue becomes more dynamic 
in sub-denaturing urea concentrations. However, in the presence of 4 M urea 
residues Ser54 and Arg71 in the latter half of the AB loop were also shown to be 
more dynamic (Figure  5.7B). Additionally, accurate R2 rates could only be measured 
for residues Ser64, Gln68 and Leu72 in the presence of 4 M urea (Figure  5.8F), 
suggesting that these residues in the latter half of the AB loop are also more 
dynamic in the presence of 4 M urea. However, the low signal-to-noise ratio of the 
peaks for these residues in the absence of urea, resulting from their high R2 rates 
(Equation  5.1)324 makes it difficult to measure reliably the extent to which their R2 
rate had increased. 
 
At pH 4, residues Ala69 and Leu70 of the AB loop as well as Leu72 of helix B, 
located at the point of connection between the AB loop and helix B were shown to 
become significantly more dynamic in the presence of 0.5 M urea (Figure  5.9B). In 
the presence of 3 M urea, residues Gly56 and Arg59 in the latter half of the AB loop 
exhibited significantly increased dynamics, along with residues Leu70 and Arg71 
(Figure  5.10B). Overall, measurement of R2 rates for G-CSF C3 in different urea 
concentrations would suggest that in the presence of 0.5 M urea there is an 
increase in the dynamics of residues at the C-terminal end of the loop AB as well as 
the N-terminal end of helix B, whereas in the presence of urea concentrations that 
promote aggregation residues throughout the latter half of the AB loop become more 
dynamic, perhaps implying that a greater proportion of the AB loop of G-CSF C3 
becomes more dynamic in order to cause aggregation. 
 
Monitoring of G-CSF C3 aggregation at pH 7 in the absence of urea using 1H-15N 
HSQC spectra showed that residues Gly82, Leu85, Leu158 and Leu162 were 
among the six residues that exhibited significantly high rates of decay 
(Figure  5.14A). During soluble aggregate formation, the peaks of all amide protons 
of G-CSF C3 will be reduced in intensity due to the slower molecular tumbling 
exhibited by larger species (Equation  5.2)319. The faster rates of decay for the 
outlined residues results from the additional contribution of chemical exchange to 
the R2 rate
341, which is caused by these residues experiencing two different 
chemical environments i.e. in monomeric G-CSF C3 and at the aggregation 
interface of oligomeric species. 
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The proximity of residues Gly82 and Leu85 to Tyr86 suggests that the change in the 
chemical environment of the Tyr86 side chain that occurs in sub-denaturing urea 
concentrations may result from this region of helix B being involved in the 
aggregation interface. This would support the results of near-UV CD spectra 
acquired in the presence of sub-denaturing urea concentrations, which show an 
increased negativity of the absorption minimum around 275 nm (Figure  4.10), 
suggesting Tyr86 is becoming less mobile upon adding urea. Moreover, 
fluorescence emission spectra acquired in the presence of sub-denaturing urea 
concentrations show increased emission intensity (Figure  4.9), implying reduced 
solvent exposure of the Tyr86 side chain upon adding urea. Additionally, Leu158 
exhibits one of the largest CSPs in the presence of low urea concentrations 
(Figure  5.1B-Figure  5.4B), resulting from its proximity to Tyr86 (Figure  5.5), which 
supports the notion that Leu158 and possibly the nearby residue Leu162 are also 
part of the aggregation interface. 
 
Mapping the binding of ANS to G-CSF C3 using 1H-15N HSQC spectra also indicates 
that the region around Leu158 may be involved in an aggregation interface. ANS 
was shown to bind to Arg71 of G-CSF C3 at both pH 4 and 7 based on calculation of 
CSPs and broadening of this peak (Figure  5.16 and Figure  5.15, respectively). 
However, the fluorescence emission spectra of ANS at pH 7 with and without G-
CSF C3 are similar, regardless of the concentration of urea present (Figure  4.15A 
and C), suggesting that binding of ANS to Arg71 is not accompanied by a change in 
the polarity of the environment around the dye at pH 7. This agrees with previous 
studies which have demonstrated that the dominant mechanism of ANS binding to 
protein surfaces is through ion pairing interactions between the sulphonate group of 
ANS and positively charged side chains397-399.    
 
Conversely, ANS at pH 4 without urea shows a dramatic increase in fluorescence 
emission intensity and a blue shift in the wavelength at which maximum emission is 
observed in the presence of G-CSF C3 compared with the absence of G-CSF C3 
(Figure  4.15B and D). This is indicative of increased hydrophobicity of the 
environment around ANS395,396 and is attributed to insoluble aggregate formation, 
which was observed during incubation of G-CSF C3 and ANS at pH 4 before 
analysis by both 1H-15N HSQC and fluorescence emission spectra. ANS was shown 
to bind to His157 of G-CSF C3 at pH 4 but not at pH 7 based on calculation of CSPs 
(Figure  5.16B and Figure  5.15B, respectively), suggesting that the protonated side 
chain of His157 may be involved in inhibition of aggregation at pH 4 compared with 
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pH 7 (Figure  4.2) and more generally that the region of G-CSF C3 around His157 
may be involved in an aggregation interface.  
 
In the presence of urea concentrations of 0-1 M at 0.2 M increments a gradual 
decrease in the fluorescence emission intensity of ANS is observed with G-CSF C3 
(Figure  4.15F), which coincides with no formation of insoluble aggregates 
(observable by eye) at pH 4 with ANS in the presence of urea concentrations of 1 M 
or greater. This would also suggest that ANS is not able to bind His157 as 
effectively in the presence of urea concentrations that have been shown to promote 
G-CSF C3 aggregation in the absence of ANS, most likely as a result of the 
increased dynamics of the latter half of the AB loop. Moreover, ANS is able to bind 
to G-CSF C3 at pH 4 in the presence of urea concentrations below 1 M, albeit to a 
lesser extent than in the absence of urea. This supports the theory that there is an 
increase in the dynamics of the AB loop in the presence of urea concentrations that 
promote aggregation compared to lower urea concentrations that do not appear to 
affect the amount of insoluble aggregate formation.   
 
The mechanism by which this increased mobility of the AB loop would hinder ANS 
binding to His157 is uncertain, but could relate to steric hindrance of the His157 side 
chain by the loop. Alternatively, movement of the AB loop may disrupt the triad of 
positively charged side chains formed by His53, Arg59 and His157 (Figure  3.21), 
which could be involved in facilitating binding of ANS to His157. Contrary to this 
argument, the CSPs exhibited by His53 are not significantly large at pH 4 or 7 
(Figure  5.16B and Figure  5.15B, respectively), indicating that this residue is not 
directly involved ANS binding, although Arg59 does exhibit a significant CSP at both 
pH 4 and 7, suggesting a possible role of Arg59 in ANS interaction along with 
His157. 
 
Overall, the work in Chapter 5 has shown that there is a change in the environment 
of Tyr86 and increased dynamics in the latter half of the AB loop that is proximal 
spatially to this residue in aggregation-prone conditions. Aggregation assays 
monitored by NMR have also indicated that residues close to Tyr86 may be part of 
an aggregation interface, which is supported by the role of His157 in ANS binding 
and presumably inhibiting aggregation at pH 4. The experiments and key findings 
from Chapter 5 are summarised in Figure  5.17 and the theorised involvement of 
Tyr86 in G-CSF C3 aggregation is further explored in Section  5.3.1 using the 
aggregation prediction program CamSol63.    
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Figure ‎5.17 Illustrative summary of the key features of G-CSF C3 aggregation. Important residues identified from 
the experiments listed in B are shown mapped onto the structure of G-CSF wt (PDB 1GNC
283
) in A using the same 
colour scheme, constructed using PyMOL
289
. Residues exhibiting large CSPs in aggregation-prone conditions, 
resulting from a change in their chemical environment relative to Tyr86, at pH 4 and/or 7 are coloured/labelled in red 
in A and listed in B. Residues in the latter half of the AB loop that exhibit increased dynamics (decreased R2 rates) 
in urea concentrations that cause aggregation are coloured/labelled in green in A and listed in B. Residues involved 
in protein-protein interactions at the aggregation interface are coloured/labelled in orange in A and listed in B. 
Residues involved in ANS binding are coloured/labelled in pink in A and listed in B. Residues Arg71 and Leu158 
were identified in more than one experiment but are only shown in one colour.    
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5.3.1 Tyr86 is predicted to be intrinsically aggregation-prone 
 
CamSol63 was used to compare the intrinsic solubility of the amino acid sequence of 
G-CSF C3 with the structurally-corrected solubility scores (Figure  5.18A and B, 
respectively), which project these intrinsic scores onto the surface of a protein 
structure in order to correct for the solvent accessible surface area (SASA) of 
residues (see Section  4.2.1)63. Additionally, structurally corrected scores were 
calculated for a hypothetical G-CSF C3 structure that lacked the AB loop in order to 
assess the degree of protection from solvent provided by this loop to residues that 
may be intrinsically insoluble (Figure  5.18C and D). 
 
Tyr86 is predicted to significantly reduce the intrinsic solubility of G-CSF C3 at pH 4 
and 7, according to the score of this residue being below -1 (Figure  5.18A). 
Residues Gly82 and Leu85 also exhibit scores of predicted intrinsic solubility below -
1 at pH 7, with Leu85 also scoring very close to -1 at pH 4, suggesting that these 
residues are also predicted to promote general aggregation of G-CSF C3 at pH 7 
and to a lesser extent at pH 4. Whilst His157 and Leu158 are not predicted to 
significantly affect the intrinsic solubility of G-CSF C3 at pH 4 or 7, Leu162 shows a 
score more negative than -1 at pH 4 and very close to -1 at pH 7, suggesting that 
this residue is predicted to promote general aggregation.  
 
Interestingly, the scores of all of the highlighted residues are very close or equal to 
zero when corrected for the structure of G-CSF wt (Figure  5.18B), suggesting that 
these residues do not significantly contribute to the solubility of the structure of G-
CSF C3. The changes observed in the solubility scores of these residues when 
projected onto the structure of G-CSF C3 relates to their low SASA.     
 
Carrying out CamSol63 predictions of the solubility of the structure of G-CSF C3 
without the AB loop results in increased negativity of scores for residues Gly82, 
Leu85 and Tyr86 at both pH 4 and 7 (Figure  5.18C and D, respectively). The 
increases in negativity observed are of similar magnitude for these residues, 
suggesting that the AB loop shields them from solvent exposure. These predictions 
help strengthen the theory that increased dynamics of the AB loop promotes G-CSF 
C3 aggregation by exposing Tyr86 and surrounding residues such as Gly82 and 
Leu85, resulting in this region of helix B being involved in the aggregation interface. 
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Figure ‎5.18 Predictions of the intrinsic and structural solubility of G-CSF C3. CamSol63 solubility scores above 1 
indicate residues predicted to increase solubility, while scores below -1 indicate residues predicted to decrease 
solubility and so promote aggregation
63
 of G-CSF C3 at pH 4 and 7 (red and blue, respectively). Intrinsic solubility 
scores predicted from the amino acid sequence of G-CSF C3 are shown in A. Solubility scores corrected for 
structure were calculated using the G-CSF wt structure (PDB 1GNC
283
), with residues being mutated in PyMOL
289
 
for calculation of G-CSF C3 solubility scores (B-D). The solvent accessible surface area (SASA) of residues is 
plotted in B as grey bars on the right-hand y-axis with values for residues Gly82, Leu85, Tyr86, His157, Leu158 and 
Leu162 shown in green. SASAs were obtained from the DSSP
411
 file associated with the structure of G-CSF wt 
(PDB 1GNC
283
), acquired using the MRS server
412
. For calculation of solubility scores corrected for structure without 
the AB loop at pH 4 and 7 (black and pink, respectively), residues 42-71 were deleted from the G-CSF wt structure 
(PDB 1GNC
283
) in PyMOL
289
 (C and D). Scores predicted for residues Gly82, Leu85, Tyr86, His157, Leu158 and 
Leu162 with or without the AB loop are shown as filled data points. 
           
Solubility scores for residues Leu158 and Leu162 remain close to zero even after 
deletion of the AB loop, suggesting possible protection of these residues from 
solvent by a different region of G-CSF C3. However, during monitoring of G-CSF C3 
aggregation at pH 7 in the absence of urea by 1H-15N HSQC spectra peaks for the 
amide protons of these residues exhibit significantly faster rates of decay than other 
residues, along with Gly82 and Leu85 (Figure  5.14A). This could indicate a role of 
residues around Tyr86 on helix B in the early interactions that drive aggregation, 
followed by additional interactions involving Leu158 and Leu162 and possibly 
surrounding residues on helix D that help stabilise aggregates.  
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Residues Glu163 and Val164 exhibit the most negative intrinsic solubility scores at 
pH 4 and 7 (Figure  5.18A). These residues are also predicted to promote generic 
aggregation in the context of a tertiary structure of G-CSF C3 with the AB loop 
removed at pH 4 (Figure  5.18C), while Glu163 is predicted to promote aggregation 
in this same context at both pH 4 and 7. Furthermore, these residues exhibit 
increasingly negative scores in the structure of G-CSF C3 as a result of removal of 
the AB loop (Figure  5.18C and D, respectively), implying a degree of protection of 
these residues from solvent by this loop that may be disrupted in urea 
concentrations that promote aggregation. 
 
Surprisingly, the solubility score for His157 becomes more negative as a result of 
deletion of the AB loop, implying a degree of protection of His157 from solvent 
exposure by this loop. This is in contrast to decreased ANS binding by G-CSF C3 at 
pH 4 in the presence of urea concentrations that significantly increase AB loop 
dynamics, which would imply an increase in the protection of His157 from solvent as 
a result of a conformational change of the AB loop. Therefore, the reason for the 
decreased binding of ANS to His157 of G-CSF C3 at pH 4 in the presence of urea 
most likely does not relate to solvent exposure, but may be the result of disrupting 
the proximal arrangement of positively charged side chains from His53, Arg59 and 
His157 (Figure  3.21), although mapping of ANS binding using CSPs does not 
indicate any direct interaction between His53 and ANS at pH 4 or 7 (Figure  5.16B 
and Figure  5.15B, respectively). 
  
In Chapter 6, the key findings in this study relating to G-CSF C3 folding, dynamics 
and aggregation are summarised and discussed in relation to existing knowledge of 
wild-type G-CSF. Future perspectives on this work are also envisaged for further 
studying the link between G-CSF C3 folding, dynamics and aggregation, as well as 
relating these characteristics back to wild-type G-CSF and attempting to clarify the 
effects of the substitutions found in the variant C3 on recombinant expression level. 
Overall, the work in this chapter has identified a change in the environment of the 
side chain of Tyr86 and residues in and around the AB loop of G-CSF C3 in sub-
denaturing urea concentrations. The conformational change of the AB loop is due to 
increased dynamics, which exposes an intrinsically aggregation-prone segment of 
G-CSF C3 encompassing Tyr86 on helix B that is predicted to drive aggregation. 
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Chapter 6 Conclusions and future perspectives 
 
The work in Chapter 5 has identified the conformational fluctuation in the native 
state of G-CSF C3 that promotes aggregation in denaturant concentrations that are 
too low to cause global unfolding, this being increased dynamics in the latter half of 
the AB loop that changes the environment of the proximal side chain of Tyr86. This 
subtle conformational change is hypothesised to promote aggregation of G-CSF C3 
by increasing the exposure of the region around Tyr86 on helix B to solvent, which is 
predicted by CamSol63 to be intrinsically aggregation-prone (Figure  5.18A). 
Additionally, Aggrescan62, Zyggregator64 and TANGO65 also predict this region of 
the amino acid sequence of G-CSF C3 to be amongst the most significantly 
aggregation-prone (Figure  4.1A, D and E, respectively). Moreover, the predicted 
aggregation propensity of this region in the context of the structure of wild-type G-
CSF is increased upon removal of the AB loop (Figure  5.18C and D), suggesting a 
degree of protection provided by this loop.       
 
The proposed role of the region around Tyr86 in G-CSF C3 aggregation is 
supported by monitoring of G-CSF C3 aggregation at pH 7 in the absence of urea 
using 1H-15N HSQC spectra, which revealed significantly higher rates of decay for 
peak intensities of residues Gly82 and Leu85 of helix B, as well as nearby Leu158 
Leu162 of helix D (Figure  5.14A). Plus, near-UV CD spectra of G-CSF C3 in sub-
denaturing urea concentrations indicate reduced mobility of the side chain of Tyr86 
(Figure  4.10), rather than the increased mobility that would be expected from 
increased solvent exposure. Furthermore, fluorescence emission spectra under the 
same conditions point towards reduced solvent exposure of Tyr86 (Figure  4.9).  
 
The work in Chapter 4 showed that G-CSF C3 exhibits similar aggregation 
behaviour to that reported for the wild-type protein in terms of the dependence of 
aggregation on pH, protein concentration (see Section  4.2.2) and denaturant 
concentrations that are too low to cause global denaturation (see Section  4.2.3). In 
addition, analysis of the thermodynamic stability of G-CSF C3 at pH 4 and 7 in urea 
resulted in calculation of similar ΔGoUN values to those reported for the wild-type 
protein in GdnHCl at the same pH values (see Section  4.2.4).  
 
Overall, the similarities of the folding and aggregation properties of these proteins, 
as well as their structural similarity, suggest strongly that the subtle conformational 
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change elucidated for G-CSF C3 aggregation also applies to the wild-type protein. 
Indeed, aggregation of G-CSF wt in low GdnHCl concentrations at pH 7 has been 
proposed previously to be linked to a conformational rearrangement of the AB loop, 
revealed by increased fluorescence emission intensity of Trp59142, the fluorescence 
of which is quenched by Tyr86 at neutral pH in the absence of denaturant (see 
Section  3.2.6). Although calculation of CSPs from 1H-15N HSQC spectra of G-CSF 
wt and C3 in pH 4 buffer could not be used to rule out a subtle change in 
conformation around the W59R substitution of G-CSF, no differences in 
conformation beyond the local environments of the four substitutions could be 
observed (Figure  3.19). 
 
Despite the fact that the role of increased dynamics of the AB loop of G-CSF C3 in 
promoting aggregation has been established, the timescale for motions of this loop 
that affect aggregation is uncertain. R2 rates reflect the local fluctuations of 
polypeptides (ps-ns motions) but are also affected by chemical exchange and τc, 
which can result from larger amplitude motions such as conformational exchange 
(µs-ms motions). Conversely, R1 rates and heteronuclear nOe relaxation rates are 
determined by local polypeptide fluctuations only341. Therefore, measurement of 
these additional relaxation rates under the same conditions as those used for 
measuring R2 rates would allow greater definition of the timescale of these motions 
of the AB loop.   
 
A possible avenue for producing an aggregation-resistant version of G-CSF would 
be to reduce the mobility of this loop, for instance by introducing an additional 
disulphide linkage between the latter half of the loop and helix B to further restrict its 
motion. However, this could greatly reduce the yield of native G-CSF, either during 
refolding of recombinantly expressed G-CSF from insoluble inclusion bodies or 
during disulphide formation in the periplasm of E. coli, as disulphide bonds must 
also be formed between Cys37-Cys43 and Cys65-Cys75 at the N- and C-terminal 
ends of the AB loop, respectively in order for G-CSF to attain its native 
conformation. Additionally, residues in the helical section of the AB loop are involved 
in the minor site of interaction of G-CSF with its receptor in the ligand-receptor 2:2 
complex (see Section  1.6.2), which is required for cellular signal transduction. 
Consequently, attempting to fix the conformation of the AB loop of G-CSF may 
hinder its functional activity.               
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Considering no residues of helix B appear to be involved in receptor binding (see 
Section  1.6.2), there is potential for mutation of Tyr86 to a charged residue such as 
Arg or Glu to try and reduce the aggregation propensity of G-CSF C3. The functional 
activities of G-CSF wt and C3 are equivalent, demonstrated by respective EC50 
values of 6 and 2.6 µM measured in cell proliferation assays150. G-CSF wt and C3 
exhibit these equivalent functional activities even though G-CSF C3 contains the 
substitutions W59R and F84L, which are in close proximity to Tyr86, further 
supporting the notion that this local region of G-CSF is not involved in function. 
 
Although not directly involved in receptor binding, Tyr86 may be involved in the 
hydrophobic core of G-CSF, stabilising the native conformation that is required for 
receptor recognition. Tyr86 is buried within the structure of G-CSF as shown by its 
low solvent accessibility (Figure  5.18B), plus the residues around Tyr86 in the 
sequence are largely hydrophobic (GLLLYQGLL) suggesting that this residue may 
be involved in hydrophobic interactions in the core of G-CSF and this presumably 
makes this region more aggregation-prone.  
 
In order to assess whether the region encompassing Tyr86 is involved in stabilising 
the native conformation, the single-residue local frustration (srlf) index of G-CSF C3 
was calculated (Figure  6.1) using the Frustratometer413. This prediction program is 
based on the principle of minimal frustration, which states that the energy of a 
protein decreases as it assumes conformations that are more like the ground 
(native) state. The reduction in energy is of a greater magnitude than can be 
accounted for by chance and so allows an unfolded polypeptide to traverse the 
energy landscape to the native state, overcoming kinetic traps and the reduced 
entropy of the unfolded polypeptide19. However, within the ensemble of native 
conformations there may still be frustration in the energy landscape, arising from a 
particular arrangement of amino acids that is not optimal for the stability of the native 
conformation but may be essential for function. In this way, proteins are able to 
harness the roughness of their energy landscape, facilitating dynamic motions 
between different functional conformations31,32.     
 
The Frustratometer413 quantifies the degree of local frustration in a protein structure 
by assessing the contacts made by a particular residue and then how energetically 
favourable these contacts are relative to the contacts that would be made by every 
other residue occupying this position. Minimally frustrated residues exhibit scores 
greater than 0.78 and are predicted to be involved in the folding core of a protein, 
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having formed contacts that are among the most energetically favoured. On the 
other hand, maximally frustrated residues exhibit scores more negative than -1, 
having formed contacts that are energetically unfavourable and so are predicted to 
be in regions of a protein required for function413. As a result of the predicted link 
between locally frustrated regions of proteins and their function, the structure of G-
CSF C3 both free in solution and in complex with the G-CSF receptor were 
submitted for local frustration calculation.  
 
 
Figure ‎6.1 Local frustration scores for residues in the G-CSF C3 structure. Single-residue local frustration (srlf) 
scores were predicted using the Frustratometer
413
 and the G-CSF wt structure (PDB 1GNC
283
), with residues being 
mutated in PyMOL
289
 for calculation of G-CSF C3 srlf scores (black). For calculation of srlf scores of G-CSF C3 
bound to the G-CSF receptor (red) the crystal structure of G-CSF wt in complex with this receptor was used (PDB 
2D9Q
287
) after deletion of the receptor in PyMOL
289
. Scores for residues 83-90 are shown as filled data points.          
              
Although the predicted frustration score for Tyr86 appears neutral, the surrounding 
residues 83-85 and 89-90 produce scores above 0.78, suggesting that these 
residues are minimally frustrated (Figure  6.1). This means that the contacts made by 
these residues are predicted to be among the most energetically favourable that can 
be made by residues in these positions and may be important in stabilising the 
native conformation of G-CSF. Consequently, mutation of Tyr86 to a charged 
residue could affect the structure and thermodynamic stability of the native 
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conformation of G-CSF, potentially affecting its receptor binding activity or even 
counteracting the reduced propensity for aggregation hypothesised. 
 
The work in Chapter 4 showed that the substitutions found in G-CSF C3 do not 
appear to alter aggregation behaviour significantly in relation to the wild-type protein, 
but they dramatically increase the recombinant expression level of G-CSF, 
regardless of whether the protein is being expressed as soluble native protein in the 
periplasm of E. coli150 or as insoluble aggregates in the cytoplasm (Figure  3.2). This 
suggests that a change in another factor relating to the recombinant expression of 
these proteins (e.g. translation levels) is caused by one or more of these 
substitutions, which is discussed in more detail in Section  3.3.  
 
The substitutions found in G-CSF C3 were identified from screening of a randomly 
generated library of G-CSF DNA constructs150. As such, it is unknown if all four of 
these substitutions are required for the observed improvement in recombinant 
expression. Recombinant expression trials of G-CSF constructs containing only 
single substitutions would help identify the mutation and subsequently the region of 
G-CSF responsible for the observed increase in heterologous expression level, 
which is presumed to result from factors other than protein aggregation (see 
Section  3.3). In addition, this would allow removal of unnecessary mutations from G-
CSF variants, providing a system more closely related to the wild-type protein for 
further investigation of the link between G-CSF folding, dynamics, aggregation and 
recombinant expression. 
 
Aggregation of therapeutic proteins from the native state is not only observed for G-
CSF. IFN-α-2a is a four helical cytokine used in cancer and viral disease 
treatment131 that aggregates in the presence of benzyl alcohol, attributed to partial 
unfolding of the native state188. IFN-γ is another four helical cytokine that exhibits 
antitumor and anti-infective activities267 and has been shown to aggregate in low 
denaturant concentrations410,414 via partial unfolding of the native state410.  
 
Protein aggregation from native-like species is also linked to a range of diseases. 
For instance, protein aggregation from partial unfolding of the native state has been 
shown for γS-crystallin89,90, which is involved in cataract formation91. TTR has also 
been shown to aggregate from a native-like state92,93, causing a range of 
amyloidoses94,415. In addition, a variant of the protein DJ-1 has been linked to a rare 
form of inherited Parkinson’s disease and has been shown to result from transient 
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exposure of hydrophobic surfaces in the otherwise native conformation of this 
protein409. 
 
Although the factors surrounding the immunogenicity of protein drugs are wide 
ranging155, aggregates are considered to be one of the main causes156,157. Little is 
known about the mechanism of the immunological response to recombinantly 
produced human therapeutic proteins157, despite the fact that such immunogenic 
responses are potentially life-threatening156,164,416, which coupled to the difficulties in 
detecting and characterising the wide range of aggregate sizes that occur162,165,166 
and uncertainty in the aggregate species responsible for eliciting immunogenic 
responses156, means that every effort must be made to prevent aggregation in 
protein drug formulations. Currently, pharmaceutical protein preparation is based 
generally on trial-and-error exploration of a wide range of buffer conditions131,210. 
However, with a better understanding of the mechanisms of protein drug 
aggregation and the conformational substates involved, more rational approaches 
can be developed to avoid population of these states. 
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Chapter 7 Appendices 
 
7.1 DNA sequences of G-CSF constructs 
 
1   ATGACTCCTC TCGGTCCTGC ATCTAGCCTT CCGCAAAGCT TCCTGCTGAA         
51  GTGCCTTGAA CAGGTCCGCA AAATCCAGGG TGATGGCGCT GCCCTGCAGG        
101 AGAAACTGTG TGCGACCTAC AAACTGTGCC ATCCGGAAGA ACTGGTGCTG        
151 TTGGGCCACT CTCTGGGCAT TCCGTGGGCA CCCCTGAGTA GCTGTCCATC        
201 CCAAGCCCTG CAATTAGCCG GCTGCTTATC GCAGCTGCAC TCAGGACTCT        
251 TCCTGTATCA GGGCCTGTTA CAGGCGTTAG AGGGGATTTC CCCGGAACTG 
301 GGTCCCACAC TCGATACGCT TCAGTTGGAT GTTGCGGACT TTGCAACCAC        
351 CATCTGGCAG CAGATGGAGG AACTGGGGAT GGCACCAGCG TTGCAACCGA        
401 CGCAAGGTGC GATGCCGGCC TTTGCGAGTG CCTTTCAGCG TCGTGCTGGA        
451 GGTGTACTCG TGGCTTCACA TCTGCAGTCG TTCCTGGAAG TGAGCTATCG        
501 CGTTCTGCGC CATTTGGCGC AACCGTAATA A 
Appendix  7.1 DNA sequence of G-CSF wt. Start and stop codons are underlined. Codons encoding different amino 
acids in G-CSF wt and C3 are highlighted in red. All other nucleotide variations between G-CSF wt and C3 DNA 
sequences are silent and not highlighted. The nucleotide at the beginning of each line is numbered on the left. 
 
1   ATGACCCCGT TAGGCCCTGC CTCCTCTCTT CCGCAATCCT TCCTGCTGAA         
51  AGGCCTGGAA CAGGTGCGCA AAATCCAGGG TGATGGTGCA GCACTGCAAG        
101 AGAAGCTGTG TGCGACCTAC AAACTGTGCC ATCCGGAAGA GCTGGTGTTG        
151 CTCGGCCATA GCCTGGGTAT TCCGCGTGCA CCCCTCAGCA GCTGTCCGTC        
201 ACAGGCGTTA CGTCTGGCCG GTTGCCTTAG TCAGCTGCAC TCTGGACTGT        
251 TGCTGTATCA GGGGTTACTC CAAGCCCTGG AAGGCATTTC GCCGGAACTG 
301 GGTCCAACTC TGGATACGCT GCAGTTGGAC GTTGCGGATT TTGCCACGAC        
351 CATCTGGCAG CAGATGGAGG AACTTGGCAT GGCTCCAGCG CTGCAACCCA        
401 CACAAGGGGC AATGCCTGCG TTTGCTTCAG CGTTTCAACG GCGTGCGGGA        
451 GGCGTACTGG TTGCCAGTCA CTTGCAGAGC TTCCTCGAAG TCTCGTATCG        
501 CGTGTTACGC CATCTTGCTC AGCCGTAATA A 
Appendix  7.2 DNA sequence of G-CSF C3. Start and stop codons are underlined. Codons encoding different 
amino acids in G-CSF wt and C3 are highlighted in red. All other nucleotide variations between G-CSF wt and C3 
DNA sequences are silent and not highlighted. The nucleotide at the beginning of each line is numbered on the left. 
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7.2 Plasmid map of G-CSF constructs 
 
 
Appendix  7.3 Plasmid map of G-CSF in pET23a. 
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7.3 Amino acid sequences of G-CSF proteins 
 
1   MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 
51  LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL         
101 GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGAMPA FASAFQRRAG        
151 GVLVASHLQS FLEVSYRVLR HLAQP 
Appendix  7.4 Amino acid sequence of G-CSF wt. Mutated residues in G-CSF wt and C3 amino acid sequences are 
highlighted in red. Cys residues linked by disulphide bonds are highlighted in the same colour (blue or green). The 
amino acid at the beginning of each line is numbered on the left.  
 
1   MTPLGPASSL PQSFLLKGLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL         
51  LGHSLGIPRA PLSSCPSQAL RLAGCLSQLH SGLLLYQGLL QALEGISPEL        
101 GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGAMPA FASAFQRRAG        
151 GVLVASHLQS FLEVSYRVLR HLAQP 
Appendix  7.5 Amino acid sequence of G-CSF C3. Mutated residues in G-CSF wt and C3 amino acid sequences 
are highlighted in red. Cys residues linked by disulphide bonds are highlighted in the same colour (blue or green). 
The amino acid at the beginning of each line is numbered on the left. 
 
7.4 Backbone assignments of G-CSF proteins 
 
7.4.1 Backbone assignments of G-CSF wt at pH 4 
 
Residue Number Amino acid 1H / ppm 15N / ppm 
2 Thr 8.68 121.12 
4 Leu 8.33 122.56 
5 Gly 8.22 109.69 
7 Ala 8.45 123.42 
8 Ser 8.19 114.26 
9 Ser 8.04 116.37 
10 Leu 8.4 122.09 
12 Gln 9.1 125.53 
13 Ser 8.84 112.46 
14 Phe 7.06 122.95 
15 Leu 7.71 121.48 
16 Leu 8.47 117.22 
17 Lys 7.53 120.85 
18 Cys 8.12 116.72 
19 Leu 8.14 118.98 
20 Glu 7.63 118.43 
21 Gln 8.03 121.23 
22 Val 8.36 119.82 
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23 Arg 7.57 117.84 
24 Lys 7.96 122.17 
25 Ile 8.25 119.59 
26 Gln 8.84 119.99 
27 Gly 8.01 107.72 
28 Asp 8.43 124.18 
29 Gly 9.29 109.54 
30 Ala 8.23 125.73 
31 Ala 7.91 121.18 
32 Leu 7.59 118.69 
33 Gln 8.46 118 
34 Glu 8.69 120.4 
35 Lys 8.07 120.52 
36 Leu 8.59 122.09 
37 Cys 7.96 118.2 
38 Ala 8.81 123.3 
39 Thr 8.17 110.37 
40 Tyr 7.12 115.7 
41 Lys 7.68 114.49 
42 Leu 6.98 121.48 
43 Cys 8.03 118.63 
44 His 8.53 117.12 
46 Glu 10.11 118.66 
47 Glu 7.65 117.43 
48 Leu 7.7 118.46 
49 Val 7.16 119.42 
50 Leu 8.52 121.96 
51 Leu 7.97 122.31 
52 Gly 8.31 105.52 
53 His 8.04 118.63 
54 Ser 8.5 116.9 
55 Leu 8.09 119.71 
56 Gly 7.6 107.02 
57 Ile 7.41 119.62 
59 Trp 7.82 120.19 
60 Ala 7.25 126.21 
62 Leu 8.55 120.78 
63 Ser 7.52 116.35 
64 Ser 9.74 118.51 
65 Cys 7.95 118.2 
67 Ser 8.31 113.29 
68 Gln 7.87 118.14 
69 Ala 8.35 123.55 
70 Leu 7.77 120.69 
71 Gln 8.75 125.67 
72 Leu 8.66 126.25 
73 Ala 8.86 120.22 
74 Gly 7.88 105.95 
75 Cys 8.24 120.51 
76 Leu 8.78 117.72 
77 Ser 8.18 112.15 
78 Gln 8.06 122.86 
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79 Leu 8.99 124.53 
80 His 8.97 116.6 
81 Ser 9.15 115 
82 Gly 8.62 111.3 
83 Leu 8.12 121.4 
84 Phe 8.15 119.44 
85 Leu 7.97 123.04 
86 Tyr 8.12 116.86 
87 Gln 8.87 120.18 
88 Gly 7.71 107.38 
89 Leu 8.44 123.72 
90 Leu 8.44 115.69 
91 Gln 7.97 119.67 
92 Ala 7.88 121.75 
93 Leu 7.24 115.92 
94 Glu 7.92 115.39 
95 Gly 8.98 107.38 
96 Ile 7.59 110.76 
99 Glu 8.95 115.4 
100 Leu 7.77 121.3 
101 Gly 7.91 108.34 
103 Thr 7.56 114.41 
104 Leu 8.23 124.9 
105 Asp 9.06 120.46 
106 Thr 7.9 117.02 
107 Leu 7.2 120.51 
108 Gln 8.71 116.97 
109 Leu 8.2 121.32 
110 Asp 8.43 119.78 
111 Val 8.61 122.73 
112 Ala 8.37 122.92 
113 Asp 8.67 117.97 
114 Phe 7.89 121.82 
115 Ala 8.87 121.49 
116 Thr 8.73 116.46 
117 Thr 8.44 121.41 
118 Ile 8.24 120.42 
119 Trp 8.77 122 
120 Gln 8.95 116.05 
121 Gln 7.58 119.5 
122 Met 8.25 118.38 
123 Glu 8.23 118.62 
124 Glu 7.86 120.66 
125 Leu 7.39 116.27 
126 Gly 7.72 108.22 
127 Met 7.97 116.26 
128 Ala 7.71 123.52 
130 Ala 8.24 122.42 
131 Leu 7.94 119.9 
132 Gln 8.36 122.77 
134 Thr 8.19 114.94 
135 Gln 8.67 124.34 
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136 Gly 8.32 111.29 
137 Ala 8.11 122.85 
138 Met 8.35 121.83 
140 Ala 7.91 122.31 
141 Phe 8.4 120.57 
142 Ala 8.2 124.93 
143 Ser 7.85 111.65 
144 Ala 9.03 124.64 
145 Phe 8.72 117.16 
146 Gln 7.89 116.06 
147 Arg 7.97 117.47 
148 Arg 7.85 118.12 
149 Ala 8.29 120.12 
150 Gly 8.28 106.44 
151 Gly 7.92 109.01 
152 Val 7.36 121.06 
153 Leu 8.12 120.01 
154 Val 9.41 119.95 
155 Ala 8.25 119.77 
156 Ser 8.09 112.39 
157 His 8.15 120.97 
158 Leu 8.7 122.55 
159 Gln 8.2 117.76 
160 Ser 7.66 115.68 
161 Phe 8.39 124.7 
162 Leu 9.08 120.29 
163 Glu 8.13 121.42 
164 Val 7.48 119.48 
165 Ser 8.13 115.96 
166 Tyr 8.79 121.8 
167 Arg 7.52 117.24 
168 Val 8.22 120.27 
169 Leu 8.37 119.62 
170 Arg 8.56 117.8 
171 His 7.72 116.83 
172 Leu 7.78 118.09 
173 Ala 7.67 120.15 
174 Gln 7.76 118.79 
Appendix  7.6 Backbone assignments of G-CSF wt at pH 4. Assignments of backbone amide proton and nitrogen 
nuclei were carried out using previous assignments
283,288
. The 
1
H-
15
N HSQC spectrum used for assignments was 
acquired using 111 µM 
15
N G-CSF wt in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 (I = 
39 mM) buffer at 25 
o
C, using a spectrometer operating at a proton resonance frequency of 600 MHz equipped with 
a room temperature probe.  
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7.4.2 Backbone assignments of G-CSF C3 at pH 4 
 
Residue Number Amino acid 
1H / 
ppm 
15N / 
ppm 
13C / 
ppm 
13Cα / 
ppm 
13Cβ / 
ppm 
1 Met - - 172.23 55.12 32.65 
2 Thr 8.61 121.2 174.03 60.15 - 
3 Pro - - 176.66 63.2 32.11 
4 Leu 8.27 122.64 177.63 55.25 42.61 
5 Gly 8.14 109.76 - 44.77 - 
6 Pro - - 177.04 63.37 32.11 
7 Ala 8.37 123.68 177.69 52.67 19.16 
8 Ser 8.13 114.35 174.02 58.56 64.13 
9 Ser 7.99 116.56 173.63 57.97 - 
10 Leu 8.28 122.58 174.21 52.35 - 
11 Pro - - 177.99 62.79 32.05 
12 Gln 8.92 124.43 177.95 59.12 28.42 
13 Ser 8.6 112.5 177.01 60.93 61.51 
14 Phe 7.12 122.49 176.55 60.21 39.28 
15 Leu 7.43 120.02 178.23 57.93 41.9 
16 Leu 8.26 116.92 180.26 58.02 41.34 
17 Lys 7.54 120.29 178.92 58.95 32.11 
18 Gly 8.54 107.96 174.8 47.18 - 
19 Leu 8.12 121.15 179.32 58.66 41.52 
20 Glu 7.4 118.66 179.41 59.04 28.41 
21 Gln 8.37 121.16 178.9 59.36 27.97 
22 Val 8.34 120.1 177.58 67.45 31.38 
23 Arg 7.53 118.3 179.83 58.89 29.98 
24 Lys 7.89 122.11 179.08 59.29 32.59 
25 Ile 8.15 119.42 178.8 65.14 37.9 
26 Gln 8.77 119.88 180.34 59.52 28.86 
27 Gly 8.03 107.83 177.01 47.37 - 
28 Asp 8.4 124.36 179.38 56.01 39.38 
29 Gly 9.19 109.54 175.15 46.9 - 
30 Ala 8.2 125.7 180.44 54.91 17.67 
31 Ala 7.86 121.45 180.45 55.09 17.76 
32 Leu 7.5 118.79 177.87 58.39 41.59 
33 Gln 8.35 117.99 179.23 60.16 29.26 
34 Glu 8.63 120.45 179.04 59.41 28.05 
35 Lys 8.04 120.58 180.34 59.36 32.89 
36 Leu 8.48 121.9 179 59.13 41.66 
37 Cys 7.87 118.19 176.96 57.2 37.99 
38 Ala 8.75 123.4 179.47 55.34 18.88 
39 Thr 8.1 110.46 175.3 65.62 69.94 
40 Tyr 7.05 115.82 174.71 57.04 39.68 
41 Lys 7.61 114.53 176.22 57.66 28.68 
42 Leu 6.92 121.55 175.4 53.55 42.2 
43 Cys 7.96 118.58 173.62 57.11 47.8 
44 His 8.39 116.96 173.55 52.46 - 
45 Pro - - 177.95 65.53 31.86 
46 Glu 9.96 118.65 177.98 59.21 27.64 
47 Glu 7.59 117.62 177.18 57.17 29.62 
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48 Leu 7.62 118.64 177 54.26 42.46 
49 Val 7.14 119.54 178.06 65.62 32.04 
50 Leu 8.34 122.13 179.59 57.83 40.98 
51 Leu 7.93 122.27 179.21 57.18 41.32 
52 Gly 8.3 106.16 175.68 47.97 - 
53 His 7.94 118.65 176.82 57.54 28.25 
54 Ser 8.32 116.73 175.71 60.8 63.07 
55 Leu 8.12 120.15 177.27 55.54 42.98 
56 Gly 7.61 107.05 174.78 46.69 - 
57 Ile 7.74 120.12 174.3 58.96 - 
58 Pro - - 175 62.72 32.54 
59 Arg 8.2 118.07 175.15 54.52 31.84 
60 Ala 8.16 126.65 175 49.51 - 
61 Pro - - 176.92 63.12 32.8 
62 Leu 8.38 121.85 179.32 54.38 43.18 
63 Ser 7.26 115.65 176.08 60.3 - 
64 Ser 10 118.9 173.69 59.38 63.04 
65 Cys 7.87 118.73 171.4 54.01 - 
66 Pro - - 176.84 64.42 31.36 
67 Ser 8.28 114.89 175.18 61.18 62.11 
68 Gln 8.07 117.92 175.05 56.03 29.11 
69 Ala 7.98 124.25 175.17 52.11 17.95 
70 Leu 7.59 121.91 177.29 56.72 42.24 
71 Arg 8.52 127.78 176.22 54.62 29.8 
72 Leu 8.58 125.96 177.61 59.82 42.02 
73 Ala 8.83 120.19 180.71 56.22 17.86 
74 Gly 7.76 105.76 175.78 47.18 - 
75 Cys 8.45 120.71 176.32 58.23 38.99 
76 Leu 8.75 118.06 178.83 58.75 40.5 
77 Ser 7.92 112.09 177.57 62.38 62.75 
78 Gln 8.09 122.55 180.94 59.75 28.53 
79 Leu 9.13 124 178.65 58.63 42.16 
80 His 8.85 117.11 176.11 62.44 28.83 
81 Ser 9.03 114.02 177.62 62.25 62.51 
82 Gly 8.59 111.17 174.53 47.74 - 
83 Leu 8 121.89 178.54 58.43 41.88 
84 Leu 7.46 118.53 180.46 58 40.81 
85 Leu 7.79 123.78 179.19 58.3 40.65 
86 Tyr 8.03 116.87 177.87 64.4 37.55 
87 Gln 8.83 120.61 178.59 60.56 29.1 
88 Gly 7.87 106.53 177.11 47.47 - 
89 Leu 8.45 124.1 178.1 58.02 43.19 
90 Leu 8.42 116.08 180.36 57.83 41.8 
91 Gln 8.03 119.79 179.03 59.18 28.3 
92 Ala 7.79 121.67 178.06 54.13 17.96 
93 Leu 7.24 116.11 176.8 55.79 41.14 
94 Glu 7.84 115.59 176.74 56.57 26.62 
95 Gly 8.93 107.57 173.85 46.4 - 
96 Ile 7.54 111.27 - - - 
98 Pro - - 179.08 65.82 31.67 
99 Glu 8.86 115.49 177.55 58.81 28.51 
100 Leu 7.71 121.11 177.09 54.51 42.73 
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101 Gly 7.81 108.36 - 49.45 - 
102 Pro - - 179.3 65.9 32.01 
103 Thr 7.47 114.68 177.05 66.71 67.09 
104 Leu 8.15 124.87 178.5 58.04 41.22 
105 Asp 8.94 120.86 178.33 57.15 38.93 
106 Thr 7.87 117.4 174.93 66.94 - 
107 Leu 7.25 120.72 177.88 57.99 42.37 
108 Gln 8.53 116.78 178.37 60.52 29.51 
109 Leu 8.02 121.5 179.28 58.25 41.69 
110 Asp 8.32 119.72 180.02 57.13 38.92 
111 Val 8.49 122.6 177.04 67.58 - 
112 Ala 8.18 122.92 180.7 55.49 18.34 
113 Asp 8.53 118.01 178.66 56.9 39.76 
114 Phe 7.86 121.41 177.34 57.35 39.79 
115 Ala 8.73 121.76 180.2 56.35 17.34 
116 Thr 8.49 116.24 176.08 66.93 67.43 
117 Thr 8.26 121.14 177.47 67.01 - 
118 Ile 8.26 120.96 177.16 65.2 32.69 
119 Trp 8.61 121.86 177.48 60.63 29.77 
120 Gln 8.71 116.43 178.87 58.98 28.22 
121 Gln 7.54 119.18 178.52 57.83 29.1 
122 Met 8.19 118.64 178.45 60.15 32.98 
123 Glu 8.13 118.6 180.28 58.82 28.13 
124 Glu 7.85 120.63 177.78 58.75 28.15 
125 Leu 7.3 116.52 177.05 54.61 42.42 
126 Gly 7.65 108.32 175.18 46.54 - 
127 Met 7.85 116.85 174.34 55.24 33.75 
128 Ala 7.86 124.34 174.74 50.31 - 
129 Pro - - 175.98 62.52 31.96 
130 Ala 8.19 123.09 177.75 52.67 19.25 
131 Leu 8.04 120.94 176.75 54.8 42.78 
132 Gln 8.36 123.27 173.84 53.45 - 
133 Pro - - 176.73 62.92 32.13 
134 Thr 8.17 115.63 174.41 61.94 69.94 
135 Gln 8.46 124 176.07 55.8 29.87 
136 Gly 8.22 110.5 172.78 44.78 - 
137 Ala 8.06 123.21 177.66 52.18 19.23 
138 Met 8.33 121.65 174.16 52.27 - 
139 Pro - - 174.25 62.27 31.48 
140 Ala 7.85 122.48 176.71 50.91 19.52 
141 Phe 8.34 120.49 175.51 56.53 39.37 
142 Ala 8.19 125.03 177.32 53.99 20.08 
143 Ser 7.76 111.62 174.32 56.08 66.8 
144 Ala - - 179.9 55.94 17.64 
144 Ala 8.97 124.76 - - - 
145 Phe 8.63 117.27 176.97 61.87 38.88 
146 Gln 7.79 116.16 178.44 59.83 28.54 
147 Arg 7.88 117.55 177.35 59.81 30.58 
148 Arg 7.75 118.14 176.92 59.63 30.36 
149 Ala 8.14 120.15 179.94 54.71 18.54 
150 Gly 8.18 106.15 175.16 47.28 - 
151 Gly 7.82 109.03 173.96 48.14 - 
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152 Val 7.29 121.05 178.89 66.52 31.55 
153 Leu 7.85 120.35 178.94 58.3 43.17 
154 Val 9.12 119.33 177.49 67.79 31.67 
155 Ala 8.14 119.8 179.25 55.97 17.45 
156 Ser 8 112.83 178.09 61.64 62.38 
157 His 8.46 120.88 177.65 57.96 - 
158 Leu 8.76 122.74 177.97 57.82 41.28 
159 Gln 8.15 118.15 179.65 59.54 27.77 
160 Ser 7.69 115.83 176.48 62.25 62.45 
161 Phe 8.12 125.01 178.7 61.38 39.53 
162 Leu 9.03 120.75 178.64 57.03 41.45 
163 Glu 7.98 121.06 179.48 59.63 28.54 
164 Val 7.33 119.77 178.11 66.69 31.11 
165 Ser 7.97 115.48 174.84 63.41 - 
166 Tyr 8.65 121.36 176.13 62.14 38.48 
167 Arg 7.57 117.74 179.73 59.92 30.01 
168 Val 8.37 120.6 178.03 66.37 32.27 
169 Leu 8.02 118.64 178.88 58.5 40.95 
170 Arg 8.49 117.46 178.75 58.74 29.24 
171 His 7.85 117 176.57 58.1 28.12 
172 Leu 7.7 117.93 177.39 56.46 42.4 
173 Ala 7.62 120.56 177.2 52.88 19.12 
174 Gln 7.66 118.91 172.2 53.54 - 
Appendix  7.7 Backbone assignments of G-CSF C3 at pH 4. Assignments of backbone amide proton and nitrogen 
nuclei plus alpha, beta and carbonyl carbon atoms were carried out using an 
1
H-
15
N HSQC spectrum in combination 
with HNCA, HN(CO)CA, CBCA(CO)NH, HNCO and HN(CA)CO triple-resonance spectra. Spectra were acquired 
using 473 µM 
13
C 
15
N G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I 
= 39 mM) at 25 
o
C, using a spectrometer operating at a proton resonance frequency of 600 MHz equipped with a 
room temperature probe. 
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7.4.3 Backbone assignments of G-CSF C3 at pH 7 
 
Residue Number Amino acid 
1H / 
ppm 
15N / 
ppm 
13C / 
ppm 
13Cα / 
ppm 
13Cβ / 
ppm 
3 Pro - - 176.71 63.24 32.1 
4 Leu 8.26 122.34 177.62 55.24 42.7 
5 Gly 8.13 109.61 - 44.77 - 
6 Pro - - 177.04 63.38 32.08 
7 Ala 8.38 123.57 177.66 52.69 19.34 
8 Ser 8.11 114.26 174.02 58.57 64.19 
9 Ser 8.01 116.48 173.65 57.99 64.37 
10 Leu 8.26 122.63 174.28 52.41 - 
11 Pro - - 177.89 62.8 - 
12 Gln 8.87 123.98 177.75 59.05 29.01 
13 Ser 8.58 112.53 176.91 60.91 61.42 
14 Phe 7.17 122.45 176.44 60.3 - 
15 Leu 7.42 119.74 178.22 57.87 - 
16 Leu 8.23 116.61 180.24 57.97 - 
17 Lys 7.55 120.35 178.92 58.98 - 
18 Gly 8.56 107.77 174.83 47.18 - 
19 Leu 8.08 121.07 179.25 58.72 - 
20 Glu 7.34 118.64 179.8 59.18 - 
21 Gln 8.34 120.9 178.73 59.4 - 
22 Val 8.36 119.75 177.55 67.48 - 
23 Arg 7.51 118.02 179.76 58.79 - 
24 Lys 7.88 121.96 179.16 59.48 - 
25 Ile 8.15 119.45 178.74 65.09 - 
26 Gln 8.78 119.75 180.48 59.58 - 
27 Gly 8.01 107.49 176.94 47.36 - 
28 Asp 8.35 124.43 179.41 56.21 39.67 
29 Gly 9.2 109.61 175.07 46.86 - 
30 Ala 8.19 125.37 180.44 54.9 17.67 
31 Ala 7.86 121.39 180.49 55 17.69 
32 Leu 7.52 119.09 177.83 58.4 - 
33 Gln 8.3 118.01 179.22 60.14 - 
34 Glu 8.59 120.79 179.2 59.78 29.26 
35 Lys 8.02 120.11 180.5 59.44 - 
36 Leu 8.49 121.86 179.11 59.19 - 
37 Cys 7.85 118.23 177.06 57.12 37.91 
38 Ala 8.79 123.28 179.57 55.33 18.9 
39 Thr 8.1 110.33 175.32 65.7 69.34 
40 Tyr 7.08 115.74 174.52 57.05 - 
41 Lys 7.63 114.56 176.03 57.61 28.75 
42 Leu 6.86 121.27 175.38 53.53 - 
43 Cys 8.11 118.87 - 57.61 - 
45 Pro - - 178.19 65.59 - 
46 Glu 9.97 118.26 178.5 59.63 - 
47 Glu 7.52 117.22 177.59 57.55 - 
48 Leu 7.6 117.81 177.17 54.48 - 
49 Val 7.14 119.53 178.24 65.97 32.01 
50 Leu 8.25 120.96 179.62 57.91 42.54 
Appendices 
 
254 
 
51 Leu 7.75 121.34 179.02 57.12 41.71 
52 Gly 8.18 106.32 175.76 48.02 - 
53 His 7.82 119.94 177.98 58.39 30.9 
54 Ser 8.2 116.18 176.01 60.78 - 
55 Leu 8.13 120.01 177.34 55.62 - 
56 Gly 7.68 107.1 174.85 46.58 - 
57 Ile 7.69 120.07 173.98 59.23 38.22 
58 Pro - - - 62.49 - 
59 Arg 8.01 116.67 175.79 54.04 32.01 
60 Ala 8.02 127.08 175.19 49.72 19.5 
61 Pro - - - 63 - 
62 Leu 8.35 121.54 179.3 54.38 - 
63 Ser 7.26 115.38 - 60.35 - 
64 Ser 10 118.87 173.66 59.5 - 
65 Cys 7.87 118.87 - 54.13 - 
66 Pro - - 177.08 64.66 - 
67 Ser 8.26 115.36 175.29 61.22 62.27 
68 Gln 8.1 117.78 175.09 56.4 28.89 
69 Ala 7.91 124.24 175.22 52.01 18.02 
70 Leu 7.58 122.2 177.31 56.72 - 
71 Arg 8.45 127.71 - 54.65 - 
72 Leu 8.57 125.74 177.45 59.97 - 
73 Ala 8.79 119.97 180.6 56.06 17.95 
74 Gly 7.73 105.4 175.65 47.3 - 
75 Cys 8.5 120.45 176.2 58.32 - 
76 Leu 8.68 118 178.52 58.82 - 
77 Ser 7.78 111.6 177.47 62.27 62.73 
78 Gln 8.01 122.69 180.66 59.63 - 
79 Leu 9.05 123.96 178.43 58.56 - 
80 His 8.63 118.76 176.6 63.24 - 
81 Ser 8.68 111.93 178.05 61.94 62.62 
82 Gly 8.49 110.45 174.23 47.59 - 
83 Leu 8.04 122.28 178.81 58.49 - 
84 Leu 7.67 118.46 180.67 58.02 - 
85 Leu 7.79 123.76 179.09 58.35 - 
86 Tyr 8.05 116.87 177.9 64.13 - 
87 Gln 8.84 120.55 178.49 60.51 29.05 
88 Gly 7.85 106.28 177.16 47.45 - 
89 Leu 8.52 124.12 178.09 58.05 - 
90 Leu 8.45 115.98 180.63 57.88 - 
91 Gln 8.04 119.8 179.12 59.32 28.18 
92 Ala 7.83 121.75 177.78 54.07 17.93 
93 Leu 7.19 115.72 176.7 55.87 - 
94 Glu 7.87 116.09 176.78 57.21 27.76 
95 Gly 9.07 107.71 173.64 46.59 38.22 
96 Ile 7.53 110.3 - - - 
98 Pro - - 179 65.9 - 
99 Glu 8.93 115.16 177.69 58.99 - 
100 Leu 7.73 121.29 177.14 54.54 42.64 
101 Gly 7.81 108.46 - 49.59 - 
102 Pro - - 179.35 65.79 - 
103 Thr 7.47 114.69 176.89 66.76 67.33 
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104 Leu 8.05 125.16 178.74 58.04 - 
105 Asp 8.86 121.66 178.77 57.91 40.59 
106 Thr 7.78 116.7 175.05 66.87 - 
107 Leu 7.31 120.71 177.92 58.01 - 
108 Gln 8.49 116.46 178.39 60.48 29.08 
109 Leu 7.98 121.34 179.37 58.19 41.54 
110 Asp 8.31 119.82 179.76 57.24 - 
111 Val 8.51 122.54 176.99 67.55 - 
112 Ala 8.1 122.51 180.64 55.41 18.39 
113 Asp 8.42 118.62 179 57.43 41.23 
114 Phe 7.89 121.17 177.34 57.4 - 
115 Ala 8.65 121.87 179.86 56.25 17.24 
116 Thr 8.42 115.58 176.14 67.02 67.85 
117 Thr 8.15 120.47 177.49 66.94 67.95 
118 Ile 8.24 121.46 176.83 65.26 42.8 
119 Trp 8.82 121.83 177.77 61.5 - 
120 Gln 8.67 115.91 178.83 59.08 - 
121 Gln 7.62 119.21 178.48 57.78 - 
122 Met 8.13 118.55 178.42 60.43 - 
123 Glu 8.14 119.82 180.69 59.62 29.57 
124 Glu 7.94 121.33 178.28 59.54 29.63 
125 Leu 7.31 116.08 177.09 54.66 42.34 
126 Gly 7.76 108.48 175.33 46.62 - 
127 Met 7.91 116.48 174.38 55.26 33.96 
128 Ala 7.9 123.8 174.94 50.78 17.26 
129 Pro - - 175.73 62.49 - 
130 Ala 8.22 122.59 177.53 52.51 19.67 
131 Leu 8.04 120.52 176.85 54.64 43.12 
132 Gln 8.42 123 173.99 53.59 29.02 
133 Pro - - 176.68 63.03 32.07 
134 Thr 8.13 115.19 174.46 61.77 69.98 
135 Gln 8.46 123.65 176.2 55.86 29.91 
136 Gly 8.22 110.21 172.8 44.78 - 
137 Ala 8.04 123.02 177.66 52.19 19.37 
138 Met 8.31 121.54 174.17 52.26 33.7 
139 Pro - - 174.11 62.29 31.4 
140 Ala 7.81 122.29 176.63 50.74 19.83 
141 Phe 8.4 120.47 175.52 56.7 39.7 
142 Ala 8.22 124.73 177.17 53.72 19.98 
143 Ser 7.7 111.26 174.35 56.12 66.84 
145 Phe 8.67 117.2 179.72 61.9 - 
146 Gln 7.81 115.91 178.4 59.81 - 
147 Arg 7.83 117.51 177.27 59.82 - 
148 Arg 7.74 118.02 176.88 59.69 - 
149 Ala 8.12 119.94 179.73 54.7 18.31 
150 Gly 8.19 105.74 175.02 47.27 - 
151 Gly 7.82 108.67 173.78 48.07 - 
152 Val 7.27 120.98 178.89 66.51 - 
153 Leu 7.83 119.94 178.32 58.23 - 
154 Val 9.06 118.4 177.45 67.44 - 
155 Ala 8.05 119.22 179.21 56 17.34 
156 Ser 7.75 113.34 177.92 61.63 62.07 
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157 His 8.61 123.52 178.95 58.53 - 
158 Leu 8.74 121.93 178.28 57.92 - 
159 Gln 8.22 118.12 176.8 59.68 - 
160 Ser 7.81 115.91 176.61 62.13 62.44 
161 Phe 8.21 125 178.65 61.27 - 
162 Leu 9.08 121.04 178.53 57.11 41.4 
163 Glu 7.96 121.18 179.61 59.8 - 
164 Val 7.27 119.62 178.04 66.66 - 
165 Ser 8.02 115.45 174.81 63.31 - 
166 Tyr 8.63 121.12 176.13 62.12 - 
167 Arg 7.54 117.48 179.59 59.86 - 
168 Val 8.35 120.42 177.57 66.46 - 
169 Leu 7.97 118.43 178.79 58.49 - 
170 Arg 8.37 117.04 178.86 58.8 - 
171 His 7.92 119.04 177.71 59.1 30.21 
172 Leu 7.74 117.47 177.5 56.4 42.77 
173 Ala 7.62 120.47 177.12 52.69 19.35 
174 Gln 7.6 119.25 172.51 53.85 29.11 
Appendix  7.8 Backbone assignments of G-CSF C3 at pH 7. Assignments of backbone amide proton and nitrogen 
nuclei plus alpha, beta and carbonyl carbon atoms were carried out using an 
1
H-
15
N HSQC spectrum in combination 
with HNCA, HN(CO)CA, CBCA(CO)NH, HNCO and HN(CA)CO triple-resonance spectra. Spectra were acquired 
using 458 µM 
13
C 
15
N G-CSF C3 in 18 mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 
10 % (v/v) D2O pH 7 buffer (I = 72 mM) at 25 
o
C, using a spectrometer operating at a proton resonance frequency of 
600 MHz equipped with a room temperature probe. 
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7.5 R2 curves for G-CSF C3 at pH 4 
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Appendix  7.9 Plots of peak intensity over time used for calculation of backbone 15N R2 rates for G-CSF C3 at pH 4. 
Peak intensity is shown in arbitrary units after relaxation delays of 16.1, 32.2, 48.4, 64.5, 80.6, 96.7, 112.8 and 
129.0 ms, as well as fitting of these peak intensities to a single exponential decay function. Error bars represent the 
difference of duplicate measurements from the mean peak intensity at relaxation delays of 32.2 and 96.7 ms. A 
horizontal dotted line is drawn at zero peak intensity. R2 rates were measured using 162 µM 
15
N G-CSF C3 in 18 
mM sodium phosphate, 18 mM sodium acetate, 10 % (v/v) D2O pH 4 buffer (I = 39 mM) at 25 
o
C, using a 
spectrometer operating at a proton resonance frequency of 600 MHz equipped with a room temperature probe.   
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7.6 R2 curves for G-CSF C3 at pH 7 
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Appendix  7.10 Plots of peak intensity over time used for calculation of backbone 15N R2 rates for G-CSF C3 at pH 
7. Peak intensity is shown in arbitrary units after relaxation delays of 16.1, 32.2, 48.4, 64.5, 80.6, 96.7, 112.8 and 
129.0 ms, as well as fitting of these peak intensities to a single exponential decay function. Error bars represent the 
difference of duplicate measurements from the mean peak intensity at relaxation delays of 32.2 and 96.7 ms. A 
horizontal dotted line is drawn at zero peak intensity. R2 rates were measured using 130 µM 
15
N G-CSF C3 in 18 
mM sodium phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 buffer (I = 72 
mM) at 25 
o
C, using a spectrometer operating at a proton resonance frequency of 600 MHz equipped with a room 
temperature probe. 
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7.7 Hydrogen/deuterium exchange curves for G-CSF C3 at pD 4.8 
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Appendix  7.11 Plots of peak intensity over time used for calculation of amide proton hydrogen exchange rates for 
G-CSF C3 at pD 4.8. Peak intensity is shown in arbitrary units at 20 minute intervals, as well as fitting of these peak 
intensities to a single exponential decay function with a y-axis offset. Error bars represent the experimental noise 
calculated in CCPN Analysis
321
. Hydrogen exchange rates were measured using 52 µM 
15
N G-CSF C3 in 20 mM 
sodium phosphate, 20 mM sodium acetate, 90 % (v/v) D2O pD 4.8 buffer (I = 46 mM) at 25 
o
C, using a spectrometer 
operating at a proton resonance frequency of 600 MHz equipped with a room temperature probe. 
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7.8 Hydrogen/deuterium exchange curves for G-CSF C3 at pD 7.8 
 
 
Appendix  7.12 Plots of peak intensity over time used for calculation of amide proton hydrogen exchange rates for 
G-CSF C3 at pD 7.8. Peak intensity is shown in arbitrary units at 5 minute intervals, as well as fitting of these peak 
intensities to a single exponential decay function with a y-axis offset. Error bars represent the experimental noise 
calculated in CCPN Analysis
321
. Hydrogen exchange rates were measured using 52 µM 
15
N G-CSF C3 in 20 mM 
sodium phosphate, 20 mM sodium acetate, 0.02 % (w/v) sodium azide, 90 % (v/v) D2O pD 7.8 buffer (I = 89 mM) at 
25 
o
C, using a spectrometer operating at a proton resonance frequency of 600 MHz equipped with a room 
temperature probe. 
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7.9 Aggregation assay curves for G-CSF C3 at pH 7 
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Appendix  7.13 Plots of peak intensity over time used for calculation of amide proton decay rates during G-CSF C3 
aggregation at pH 7. Peak intensity is shown in arbitrary units at 30 minute intervals, as well as fitting of these peak 
intensities to a single exponential decay function with a y-axis offset. Error bars represent the experimental noise 
calculated in CCPN Analysis
321
. Decay rates were measured using 66 µM 
15
N G-CSF C3 in 18 mM sodium 
phosphate, 18 mM sodium acetate, 0.018 % (w/v) sodium azide, 10 % (v/v) D2O pH 7 buffer (I = 72 mM) at 37 
o
C, 
using a spectrometer operating at a proton resonance frequency of 750 MHz equipped with a cryogenic probe. 
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